

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

210496Orig1s000

MULTI-DISCIPLINE REVIEW

Summary Review

Office Director

Cross Discipline Team Leader Review

Clinical Review

Non-Clinical Review

Statistical Review

Clinical Pharmacology Review

NDA Multi-Disciplinary Review and Evaluation

Application Type	NDA (Original-1)
Application Number	210496
Priority or Standard	Standard
Submit Date	June 30, 2017
Received Date	June 30, 2017
PDUFA Goal Date	June 30, 2018
Division/Office	DOP2/OHOP
Established Name	Encorafenib
(Proposed) Trade Name	BRAFTOVI™
Pharmacologic Class	Kinase inhibitor
Code Name	LGX818
Applicant	Array BioPharma Inc.
Formulation	50 mg and 75 mg capsules
Dosing Regimen	450 mg orally once daily in combination with binimetinib
Applicant Proposed Indication/Population	In combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation as detected by an FDA-approved test
Recommendation on Regulatory Action	Regular approval
Recommended Indication/Population	In combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test

Table of Contents

Reviewers of Multi-Disciplinary Review and Evaluation.....	14
Additional Reviewers of Application	15
Glossary	16
1 Executive Summary	19
1.1. Product Introduction.....	19
1.2. Conclusions on the Substantial Evidence of Effectiveness.....	19
1.3. Benefit-Risk Assessment	21
1.4. Patient Experience Data.....	24
2 Therapeutic Context.....	25
2.1. Analysis of Condition.....	25
2.2. Analysis of Current Treatment Options	25
3 Regulatory Background	29
3.1. U.S. Regulatory Actions and Marketing History.....	29
3.2. Summary of Presubmission/Submission Regulatory Activity	29
4 Significant Issues from Other Review Disciplines Pertinent to Clinical Conclusions on Efficacy and Safety	32
4.1. Office of Scientific Investigations (OSI)	32
4.2. Product Quality	32
4.3. Clinical Microbiology	33
4.4. Devices and Companion Diagnostic Issues	33
5 Nonclinical Pharmacology/Toxicology	34
5.1. Executive Summary.....	34
5.2. Referenced NDAs, BLAs, DMFs	36
5.3. Pharmacology	36
5.4. ADME/PK.....	45
5.5. Toxicology	47
5.5.1. General Toxicology	47
5.5.2. Genetic Toxicology.....	52
5.5.3. Carcinogenicity	53

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

5.5.4. Reproductive and Developmental Toxicology	54
5.5.5. Other Toxicology Studies	63
6 Clinical Pharmacology	64
6.1. Executive Summary	64
6.2. Summary of Clinical Pharmacology Assessment	67
6.2.1. Pharmacology and Clinical Pharmacokinetics	67
6.2.2. General Dosing and Therapeutic Individualization	68
6.3. Comprehensive Clinical Pharmacology Review	71
6.3.1. General Pharmacology and Pharmacokinetic Characteristics	71
6.3.2. Clinical Pharmacology Questions	75
7 Sources of Clinical Data and Review Strategy	87
7.1. Table of Clinical Studies	87
7.2. Review Strategy	91
8 Statistical and Clinical and Evaluation	92
8.1. Review of Relevant Individual Trials Used to Support Efficacy	92
8.1.1. COLUMBUS – Trial Design	93
8.1.2. LOGIC2 – Trial Design	103
8.1.3. COLUMBUS – Study Results	105
8.1.4. LOGIC2 – Study Results	129
8.1.5. Assessment of Efficacy Across Trials	133
8.1.6. Integrated Assessment of Effectiveness	137
8.2. Review of Safety	139
8.2.1. Safety Review Approach	139
8.2.2. Adequacy of Applicant’s Clinical Safety Assessments	144
8.2.3. Safety Results	146
8.2.4. Analysis of Submission-Specific Safety Issues	173
8.2.5. Clinical Outcome Assessment (COA) Analyses Informing Safety/Tolerability	203
8.2.6. Safety Analyses by Demographic Subgroups	203
8.2.7. Specific Safety Studies/Clinical Trials	205
8.2.8. Additional Safety Explorations	205
8.2.9. Safety in the Postmarket Setting	206
8.2.10. Integrated Assessment of Safety	206

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

SUMMARY AND CONCLUSIONS.....	208
8.3. Statistical Issues	208
8.4. Conclusions and Recommendations	208
9 Advisory Committee Meeting and Other External Consultations	210
10 Pediatrics.....	211
11 Labeling Recommendations	212
11.1. Prescription Drug Labeling	212
12 Risk Evaluation and Mitigation Strategies (REMS)	217
13 Postmarketing Requirements and Commitment	218
14 Division Director (DHOT)	219
15 Division Director (OCP).....	220
16 Division Director (OB).....	221
17 Associate Division Director (Clinical).....	222
18 Office Director	223
19 Appendices.....	224
19.1. Financial Disclosure	224
19.2. OCP Appendices (Technical documents supporting OCP recommendations).....	226
19.2.1. Population PK Analysis	226
19.2.1.1 Encorafenib	226
19.2.1.2 Binimetinib	235
19.2.2. Dose-Response Analyses	242
19.2.2.1 Dose-Response Analyses for Efficacy	243
19.2.2.2 Dose-Response Analyses for Safety	248
19.2.3. Exposure Response Analyses.....	254
19.2.3.1 Encorafenib Exposure and Efficacy	254
19.2.3.2 Encorafenib Exposure and Safety	258
19.2.3.3 Binimetinib Exposure and Efficacy	261
19.2.3.4 Binimetinib Exposure and Safety	266
19.2.4. Physiological-based Pharmacokinetic Modeling Review.....	270

Multi-Disciplinary Review and Evaluation NDA 210496

BRAFTOVI™ (encorafenib)

19.2.4.1. Objectives	270
19.2.4.2. Background	270
19.2.4.3. Method	271
19.2.4.4. Result	274
19.2.4.5. Conclusion.....	278
19.2.4.6. Information Requests	278
19.2.4.7. Appendix	278
19.3. Statistical Appendix	280

Table of Tables

Table 1: Available FDA-Approved Therapies Indicated for the Treatment of Patients with Unresectable or Metastatic Melanoma.....	25
Table 2: LGX818 inhibition of ligand binding.....	36
Table 3: LGX818 and PLX4032 inhibition of cell viability.....	37
Table 4: EC ₅₀ values for LGX818 inhibition of pMEK.....	37
Table 5: Duration of pMEK inhibition after removal of RAF inhibitors.....	38
Table 6: Tumor growth inhibition, partial responses, and stable disease in mice bearing A375 or MEL13B4 tumors after treatment with LGX818 and MEK162 as single agents and in combination.....	41
Table 7: Tumor regression in mice bearing HMEX1906 tumors after treatment with LGX818 or MEK162 as single agents or in combination.....	42
Table 8. Encorafenib Exposures after a Single Dose and Repeat Doses as a Single Agent in Study CLGX818X2101.....	70
Table 9. Encorafenib Exposures after a Single Dose and Repeat Doses in Combination with Binimetinib in Study CMEK162X2110.....	71
Table 10. Summary of General Pharmacology and Pharmacokinetic Characteristics of Encorafenib.....	71
Table 11: Summary of Efficacy Comparison Between Combo 300 and Combo 450 in Study CMEK162B2301.....	75
Table 12. PK Parameters of a Single Dose of Encorafenib after a High-Fat Meal as Compared with a Fasted State.....	78
Table 13. Comparative Analysis of Encorafenib PK Parameters on Day 1 (Without Posaconazole) and Day 7 (With Posaconazole).....	80
Table 14. Comparative Analysis of Encorafenib PK Parameters on Day 1 (Without Diltiazem) and Day 7 (With Diltiazem).....	81
Table 15. Comparative Analysis of Encorafenib PK Parameters on Day 1 (Without Rabeprazole) and Day 8 (With Rabeprazole).....	82
Table 16. IC ₅₀ and Calculated R ₁ values for Encorafenib Inhibition of CYP activities in Human Liver Microsomes.....	83
Table 17. Encorafenib Induction of Mean mRNA and Activity Levels of CYP Enzymes.....	84
Table 18. Comparison of Encorafenib and Binimetinib Exposures Following Combination Treatment and Single Agents.....	85
Table 19: Clinical Trials Included in the NDA Submission.....	87
Table 20: Studies Reviewed for Efficacy.....	91
Table 21: COLUMBUS Key Trial Dates.....	92
Table 22: COLUMBUS Study Objectives and Endpoints.....	93
Table 23: Dose Reductions for Encorafenib.....	97
Table 24: Dose Reductions for Binimetinib.....	97
Table 25: Expected Number of OS Events and Cumulative Power at Expected Analysis Time Points.....	100
Table 26: Summary of Major Protocol Amendments: COLUMBUS.....	100
Table 27: Patient Disposition in Part 1 of COLUMBUS.....	106

Multi-Disciplinary Review and Evaluation NDA 210496
 BRAFTOVI™ (encorafenib)

Table 28: Patient Disposition in Part 2 of COLUMBUS	107
Table 29: Summary of Deviations from Eligibility Criteria for COLUMBUS Part 1	108
Table 30: Reasons Leading to Exclusion of Patients from Per-protocol Set: Columbus Part 1...109	
Table 31: Patient Demographics in COLUMBUS	112
Table 32: Patient and Disease Characteristics in COLUMBUS	113
Table 33: Prior Therapy, Including Immunotherapy (starting amendment 2).....	114
Table 34: Prior Immunotherapy Any Setting: Columbus Part 1.....	114
Table 35: Progression-Free Survival in the ITT Population for Part 1 of COLUMBUS (Combo 450 vs. Vemurafenib)	115
Table 36: Progression-Free Survival in the ITT Population for Part 1 of COLUMBUS (Combo 450 vs. Encorafenib)	117
Table 37: Progression-Free Survival in the ITT Population for COLUMBUS (Combo 300 vs. Pooled Encorafenib Group)	118
Table 38: Overall Survival, as Reported by the DMC, in the ITT Population for Part 1 of COLUMBUS (Combo 450 vs. Vemurafenib)	120
Table 39: Confirmed ORR and DOR Results from Part 1 of COLUMBUS.....	121
Table 40: Confirmed ORR and DOR Results from Part 2 of COLUMBUS.....	121
Table 41: Confirmed ORR and DOR Results for the Encorafenib Arms in Parts 1 and 2 of COLUMBUS	122
Table 42: FACT-M Compliance Summary by Time Window and Treatment (Part 1).....	123
Table 43: FACT-M Compliance Summary by Time Window and Treatment (Part 2).....	125
Table 44: Progression-Free Survival in the ITT for Part 1 of COLUMBUS using “Backdated” Assessments (Combo 450 vs. Encorafenib)	127
Table 45: Sensitivity Analysis for Progression-Free Survival in the ITT Population for Part 2 of COLUMBUS (Combo 300 vs. Encorafenib).....	128
Table 46: Patient Disposition in Group A of Part 1 of LOGIC2	129
Table 47: Patient Demographics in Group A of Part 1 of LOGIC2	130
Table 48: Patient and Disease Characteristics in LOGIC2	131
Table 49: Confirmed ORR and DOR Results for Group A of Part 1 of LOGIC2	132
Table 50: Comparisons of Combo 450 vs. Vemurafenib in Part 1 by Subgroup	134
Table 51: Comparisons of Combo 450 vs. Encorafenib in Part 1 by Subgroup.....	135
Table 52: Comparisons of Combo 300 vs. Encorafenib in Part 2 by Subgroup.....	136
Table 53: Trials Submitted in Support of Safety Assessment of Combo 450 Regimen.....	139
Table 54: Trials Contributing to Pooled Single Agent Safety Data.....	140
Table 55: Duration of Exposure to Study Treatment: COLUMBUS Part 1 and Combo $\geq$ 400	142
Table 56: Primary Cause of Treatment Emergent Deaths: COLUMBUS Part 1	145
Table 57: Summary of Applicant Narratives for Patients in COLUMBUS Part 1 Who Died $\leq$ 30 days of Treatment for Cause Other than Disease Progression.....	146
Table 58: Incidence of Past Medical History of Psychiatric Disorders and Treatment Emergent Psychiatric Disorders and Depression: COLUMBUS Part 1 and Pooled Datasets	151
Table 59: Serious Treatment Emergent Adverse Events: COLUMBUS Part 1 and Pooled Combination Dataset.....	152
Table 60: Fatal Treatment Emergent Serious Adverse Events.....	153

Multi-Disciplinary Review and Evaluation NDA 210496
 BRAFTOVI™ (encorafenib)

Table 61: SAEs Occurring in at Least 2 patients ($\geq 1\%$) in the Combo 450 Arm: COLUMBUS Part 1	155
Table 62: Incidence of Serious Adverse Event All Grades and Grades 3-4 by SOC: COLUMBUS Part 1 and Combo ≥ 400 Pool	156
Table 63: Discontinuations prior to cutoff by Investigator and Reviewer Assessed Reason: COLUMBUS Part 1 and Combo ≥ 400 Pool	157
Table 64: TEAEs at the SOC Level Leading to Discontinuation $\geq 1\%$ of patients in Combo 450 arm: COLUMBUS Part 1 and Combo ≥ 400 Pool	158
Table 65: Frequency of Adverse Events leading to Dose interruptions/reductions: COLUMBUS Part 1	159
Table 66: TEAEs by PT leading to dose interruption and/or dose reduction in $\geq 2\%$ of patients in Combo 450 arm: COLUMBUS Part 1	160
Table 67: Incidence GRADE 3 and 4 TEAEs occurring in $\geq 1\%$ of Patients in Combo 450 arm: COLUMBUS Part 1	161
Table 68: INCIDENCE OF GRADE 3 and 4 TEAEs by SOC occurring in $\geq 1\%$ of Patients in Combo 450 arm: COLUMBUS Part 1	162
Table 69: TEAE Occurring in $\geq 10\%$ All Grades or $\geq 2\%$ Grade 3-4 in Combo 450 Arm: COLUMBUS Part 1	164
Table 70: Incidence of TEAEs at the SOC level: COLUMBUS Part 1	165
Table 71: Incidence of Treatment-Emergent Laboratory Abnormalities (Changes from Baseline) Occurring in $\geq 10\%$ (All Grades) or $\geq 2\%$ (Grade3-4) of Patients with Combo 450: COLUMBUS Part 1	166
Table 72: Patients with Newly Occurring Notably Abnormal Vital Signs by: COLUMBUS Part 1	168
Table 73: Patients with Notable ECG Value Changes: COLUMBUS Part 1	169
Table 74: Incidence Worst Post-baseline LVEF Grade: COLUMBUS Part 1	171
Table 75: Incidence of AESI All Grades and Grades 3-4: Columbus Part 1	173
Table 76: Adverse Drug Reactions Groupings	174
Table 77: Incidence of ADR by General Organ System: COLUMBUS Part 1	175
Table 78: Frequency of Treatment Discontinuations, Reductions, and Interruptions by Adverse Drug Reaction: COLUMBUS Part 1 COMBO 450 and Encorafenib Monotherapy	180
Table 79: Important Safety Issues with Related Drugs in Patients with BRAF Mutated Melanoma	183
Table 80: Applicant Proposed Labeled Safety Issues: Encorafenib and Binimetinib	185
Table 81: ADRs Decreased ($\geq 5\%$) in Combo 450 arm compared to Encorafenib monotherapy arm: COLUMBUS Part 1	200
Table 82: Summary of Deaths and Adverse Events Combo 450 versus Combo 300: COLUMBUS	201
Table 83: ADRs increased ($\geq 5\%$) in Combo 450 arm versus Combo 300 arm: COLUMBUS	202
Table 84: Overall Summary of Adverse Events by Age Group: COLUMBUS Part 1	203
Table 85: Overall Summary of Adverse Events by Sex: COLUMBUS Part 1	203
Table 86: Summary of Safety Events: COLUMBUS Part 1	206
Table 87: Final Population PK Parameters of Full model of Encorafenib.	227
Table 88: Summary of Steady-State Exposure Metrics of Encorafenib Administered as Monotherapy or in Combination with Binimetinib in COLUMBUS study.	233

Table 89: Final Population PK Parameters of Full model of Binimetinib.	235
Table 90: Summary of Exposure Metrics of Binimetinib Administered in Combination with Encorafenib in COLUMBUS study.	240
Table 91: Baseline Characteristics in Part 1 and Part 2 of Study CMEK162B2301.....	242
Table 92: HRs of Dose Comparison and Significant Baseline Covariates of Final D-R Model of PFS.	244
Table 93: HRs of Dose Comparison and Significant Baseline Covariates of Final D-R Model of OS.	247
Table 94: Parameter Estimates of Final D-R Model of General Safety Events Comparing Combo 450 to Mono (P1), Combo 400 to Mono (P2) and Combo 450 to Combo 300.	249
Table 95: Parameter Estimates of Final Encorafenib E-R Model of ORR.	253
Table 96: Crude ORR Rates in Patients with Different Encorafenib Exposure Quartiles.	254
Table 97: Parameter Estimates of Final Encorafenib E-R Model of Time to PFS.	254
Table 98: Parameter Estimates of Final Encorafenib E-R Model of Time to OS.	256
Table 99: Parameter Estimates of Final Encorafenib E-R Model of Time to Evaluated General Safety Event.....	258
Table 100: Parameter Estimates of Final Encorafenib E-R Model of Time to Evaluated Safety Event of Special Interest.....	259
Table 101: The Rates of Evaluated Safety Events in Patients with Low or High Encorafenib Exposure and the HR in Risks Comparing Patients with Low Exposure to Patients with High Exposure.	260
Table 102: Parameter Estimates of Final Binimetinib E-R Model of ORR.	261
Table 103: Crude ORR Rates in Patients with Different Binimetinib Exposure Quartiles.	261
Table 104: Parameter Estimates of Final Binimetinib E-R Model of Time to PFS.	262
Table 105: Parameter Estimates of Final Binimetinib E-R Model of Time to OS.	264
Table 106: Parameter Estimates of Final Binimetinib E-R Model of Time to Evaluated General Safety Event.....	266
Table 107: Parameter Estimates of Final Binimetinib E-R Model of Time to Evaluated Safety Event of Special Interest.....	267
Table 108: The Rates of Evaluated Safety Events in Patients with Low or High Binimetinib Exposure and the HR in Risks Comparing Patients with Low Exposure to Patients with High Exposure.	268
Table 109. Summary of the predicted vs. observed AUC and Cmax ratios with or without the presence of posaconazole, a strong CYP3A4 inhibitor. PE: prediction error.....	275
Table 110. Summary of the predicted vs. observed AUC and Cmax ratios with or without the presence of diltiazem, a moderate CYP3A4 inhibitor. PE: prediction error.	276
Table 111. Predicted effect of CYP3A4 inhibitors on encorafenib exposures in cancer patients	276
Table 112. Key physicochemical and biopharmaceutical parameters for encorafenib used in GastroPlus simulations	277
Table 113. Predicted versus observed DDI effects of posaconazole on midazolam.....	279
Table 114. Predicted versus observed DDI effects of diltiazem on midazolam.....	279
Table 115: Patient Disposition in Part 2 of COLUMBUS, including pooled Encorafenib Group..	280

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

Table 116: Patient Demographics in Part 2 of COLUMBUS, including Pooled Encorafenib Group	281
Table 117: Protocol Deviations in Part 2 of COLUMBUS, including pooled Encorafenib Group.	282
Table 118: Confirmed ORR and DOR Results from Part 2 of COLUMBUS (Combo 450 vs. Pooled Encorafenib Group)	282
Table 119: Progression-Free Survival in the Per-Protocol Population for Part 1 of COLUMBUS (Combo 450 vs. Encorafenib).....	283

Table of Figures

Figure 1: Anti-proliferative and pERK inhibitory activity of LGX818 and its active metabolite LHY746.....	39
Figure 2: Anti-proliferative activity of the combination of encorafenib and binimetinib in melanoma and colorectal cancer derived cell lines.....	40
Figure 3: Pharmacokinetic activity of LGX818 in mice A375 tumors.....	40
Figure 4: Anti-tumor activity of LGX818 in mice bearing A375 tumors.....	41
Figure 5: Anti-tumor activity of LGX818 in mice bearing Malme-3M tumors (right panel) or mice bearing HMEX1906 tumors (left panel).....	41
Figure 6: Anti-tumor activity of LGX818 and MEK162 as single agents and in combination in mice bearing A375 and MEL13B4 tumors.....	42
Figure 7: Tumor volume and body weight in mice bearing HMEX1906 tumors after treatment with LGX818 or MEK162 as single agents or in combination.....	44
Figure 8: The HRs Comparison of Combination Therapy to the Randomized Monotherapy and HR Comparison of Combo 450 to Combo 300 after Adjusting for Baseline Covariates for Evaluated General Safety Event in Study CMEK162B2301.....	77
Figure 9: Study Schema of COLUMBUS.....	94
Figure 10: Timing of Testing of Primary and Key Secondary Endpoints.....	100
Figure 11: Study Design for Study LOGIC2.....	104
Figure 12: Kaplan-Meier Plot of Progression-Free Survival in the ITT Population for Part 1 of COLUMBUS (Combo 450 vs. Vemurafenib).....	117
Figure 13: Kaplan-Meier Plot of Progression-Free Survival in the ITT Population for COLUMBUS (Combo 450 vs. Encorafenib).....	118
Figure 14: Kaplan-Meier Plot of Progression-Free Survival in the ITT Population for COLUMBUS (Combo 300 vs. Pooled Encorafenib Group).....	120
Figure 15: Kaplan-Meier Plot of Overall Survival in the ITT Population for Part 1 of COLUMBUS (Combo 450 vs. Vemurafenib).....	121
Figure 16: Time to Definitive 10% Deterioration in the FACT-M Subscale – Combo 450 vs. Vemurafenib (Part 1).....	125
Figure 17: Time to Definitive 10% Deterioration in the FACT-M Subscale – Combo 450 vs. Encorafenib (Part 1).....	126
Figure 18: Time to Definitive 10% Deterioration in the FACT-M Subscale – Combo 300 vs. Encorafenib (Part 2).....	127
Figure 19: Goodness-of-fit Plots of Encorafenib in Patients with Rich PK Profile in Study ARRAY-162-105, CLGX818X2101 and CMEK162X2110.....	229
Figure 20: Prediction corrected Visual Predictive Check for Encorafenib PK profile at Cycle 1 Day 1 and Cycle 1 Day 15 in Study CLGX818X2101 and CMEK 162X2110.....	230
Figure 21: Goodness-of-fit Plots of Encorafenib in All Patients in Study ARRAY-162-105, CLGX818X2101, CMEK162X2110, CLGX818X2109 and CMEK162B2301 Part 1.....	231
Figure 22: Covariate Effects on Encorafenib PK Parameters.....	232
Figure 23: Goodness-of-fit Plots of Encorafenib in Patients from Part 1 and Part 2 in Study CMEK162B2301.....	233

Figure 24: Prediction-corrected Visual Predictive Check for Encorafenib PK profile in Study CMEK162B2301	234
Figure 25: Covariate Effects on Binimetinib PK Parameters	237
Figure 26: Goodness-of-fit Plots of Binimetinib in All Patients in Study ARRAY-162-105, CMEK162X2110, CLGX818X2109 and CMEK162B2301 Part 1.	238
Figure 27: Prediction-corrected Visual Predictive Check for Binimetinib PK profile at Cycle 1 Day 1 and Cycle 1 Day 15.	239
Figure 28: Goodness-of-fit Plots of Binimetinib in Patients from Part 1 and Part 2 in Study CMEK162B2301	240
Figure 29: Prediction-corrected Visual Predictive Check for Binimetinib PK profile in Study CMEK162B2301	241
Figure 30: The Kaplan-Meier (KM) Curve of PFS for Monotherapy and Combination Therapy in Part 1 and Part 2 of Study CMEK162B2301.	245
Figure 31: The Kaplan-Meier (KM) Curve of Preliminary OS for Monotherapy and Combination Therapy in Part 1 and Part 2 of Study CMEK162B2301.	247
Figure 32: The Kaplan-Meier (KM) Curve of Time to Evaluated General Safety Event in Part 1 and Part 2 of Study CMEK162B2301.	250
Figure 33: The HRs Comparing Combination Therapy to the Randomized Monotherapy and HR Comparing Combo 450 to Combo 300 after Adjusting for Baseline Covariates for Evaluated Special Safety Event of Interest in Study CMEK162B2301.	253
Figure 34: The Kaplan-Meier (KM) Curve of Time to PFS Stratified by Predicted Encorafenib Exposure Metrics.	256
Figure 35: The Kaplan-Meier (KM) Curve of Time to OS Stratified by Predicted Encorafenib Exposure Metrics.	258
Figure 36: The Kaplan-Meier (KM) Curve of Time to PFS Stratified by Predicted Binimetinib Exposure Metrics.	264
Figure 37: The Kaplan-Meier (KM) Curve of Time to OS Stratified by Predicted Binimetinib Exposure Metrics.	266
Figure 38: Observed (points) and PBPK-predicted (lines) plasma-time profiles of encorafenib in healthy subjects taking a single dose of encorafenib.	275
Figure 39: Observed (points) and PBPK-predicted (lines) plasma-time profiles of encorafenib in cancer patients receiving QD doses of encorafenib as capsule.	275
Figure 40: Observed (points) and PBPK-predicted (lines) plasma-time profiles of encorafenib in healthy subjects taking a single dose of 100 mg encorafenib the fasted (left) and fed (right) status.	276
Figure 41: Observed (points) and PBPK-predicted (lines) plasma-time profiles of encorafenib in healthy subjects taking a single dose of 50 mg encorafenib with posaconazole.	276
Figure 42: Mean FACT-M Overall Score by Treatment Arm and Visit in Part 1	284
Figure 43: Mean FACT-M Overall Score by Treatment Arm and Visit in Part 1 (Combo 450 vs. Vemurafenib).....	285
Figure 44: Mean FACT-M Overall Score by Treatment Arm and Visit in Part 1 (Combo 450 vs. Encorafenib)	286
Figure 45: Mean Change from Baseline FACT-M Overall Score by Treatment Arm and Visit in Part 1	287

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

Figure 46: Mean Change from Baseline FACT-M Overall Score by Treatment Arm and Visit in Part 1 (Combo 450 vs. Vemurafenib) 288

Figure 47: Mean Change from Baseline FACT-M Overall Score by Treatment Arm and Visit in Part 1 (Combo 450 vs. Encorafenib) 289

Figure 48: Mean FACT-M Overall Score by Treatment Arm and Visit in Part 2 (Combo 300 vs. Encorafenib) 290

Figure 49: Mean Change from Baseline FACT-M Overall Score by Treatment Arm and Visit in Part 2 (Combo 300 vs. Encorafenib) 291

Figure 50: FACT-M Compliance Summary by Time Window and Treatment (Part 1) 292

Figure 51: FACT-M Compliance Summary by Time Window and Treatment (Part 2) 292

Reviewers of Multi-Disciplinary Review and Evaluation

Regulatory Project Manager	Anuja Patel
Nonclinical Reviewer	Stephanie Aungst
Nonclinical Team Leader	Whitney Helms
Office of Clinical Pharmacology Reviewers	Youwei Bi, Ruby Leong
Office of Clinical Pharmacology Team Leaders	Jiang Liu, Hong Zhao
Clinical Reviewer	Margaret Thompson
Clinical Team Leader	Ashley Ward
Statistical Reviewer	Jonathan Vallejo
Statistical Team Leader	Lisa Rodriguez
Cross-Disciplinary Team Leader	Ashley Ward
Division Director (DHOT)	John Leighton
Division Director (OCP)	Nam Atiqur Rahman
Division Director (OB)	Rajeshwari Sridhara
Associate Division Director (OHOP)	Steven Lemery
Office Director (or designated signatory authority)	Richard Pazdur

Additional Reviewers of Application

OPQ	Steven Kinsley, RHBPM, OPRO Anamitro Banerjee, Drug Product (DP) Branch Chief, ONDP/ Branch 2 Rohit Tiwari, Application Technical Lead (ATL), DP/Drug Substance (DS) Reviewer, DNDPAPI/Branch 1 Ben Stevens, DS Branch Chief, DNDPAPI/Branch 1 Diane Goll, Process Reviewer, OPF/DPA1/Branch 2 Ying Zhang, Quality Assessment Lead, OPF/DPA1/Branch 2 Rakhi Shah, Process Branch Chief, OPF/DPA1/Branch 2 Joan (Zhuojun) Zhao, Biopharmaceutics Reviewer, OPF/DIA/ Branch 2 Okpo Eradiri, Quality Assessment Lead, OPF/DIA/ Branch 2 Angelica Dorantes, Branch Chief, OPF/DIA/ Branch 2 Ruth Moore, Facility Reviewer, OPF/DIA/Branch 2 Viviana Matta, Facility Reviewer, OPF/DIA/Branch 2 Derek Smith, Branch Chief, OPF/DIA/Branch 2
OPDP	Nazia Fatima, Reviewer
OSI	Navid Homayouni, Reviewer Lauren Iacono-Connor, Reviewer Susan Thompson, Team Leader
OSE/DEPI	Shaily Arora, Reviewer Afrouz Nayernama, Team Leader
OSE/DMEPA	Janine Stewart, Reviewer Alice (Chi-Mi) Tu, Team Leader
OSE/DRISK	Naomi Redd, Reviewer Elizabeth Everhard, Team Leader
Other	Monica Hughes, Chief of Project Management Staff, DOP2 Stacy Short, Acting Associate Director for Labeling, DOP2 Ann Marie Trentacosti, Labeling Development Team, OND Marathe Dhananjay, QT Reviewer Shawna Hutchins, Patient Labeling Reviewer Latonia Ford, OSE Regulatory Project Manager Sue Kang, OSE Team Leader Caryl Guiliano, Center for Devices and Radiologic Health Reviewer

OPQ=Office of Pharmaceutical Quality
 OPDP=Office of Prescription Drug Promotion
 OSI=Office of Scientific Investigations
 OSE= Office of Surveillance and Epidemiology
 DEPI= Division of Epidemiology
 DMEPA=Division of Medication Error Prevention and Analysis
 DRISK=Division of Risk Management

Glossary

ADaM	Analysis Data Model
ACAT™	Advanced Compartmental Absorption and Transit Model
ADME	absorption, distribution, metabolism, excretion
ADR	adverse drug reaction
AE	adverse event
AESI	adverse event of special interest
AJCC	American Joint Committee on Cancer
ALP	alkaline phosphatase
ALT	alanine aminotransferase
AR	adverse reaction
AST	aspartate aminotransferase
AUC	area under the curve
BID	twice daily
BIRC	blinded independent review committee
BLA	biologics license application
BORR	best objective response rate
BP	blood pressure
BPM	beats per minute
CDRH	Center for Devices and Radiological Health
CDTL	Cross-Discipline Team Leader
CFR	Code of Federal Regulations
CI	confidence interval
C _{max}	maximum concentration
CMC	chemistry, manufacturing, and controls
CNS	central nervous system
CORR	confirmed objective response rate
CP	cross point
CPK	creatine phosphokinase
CR	complete response
CRF	case report form
CRO	contract research organization
CSR	clinical study report
CuSCC	cutaneous squamous cell carcinoma
DCR	disease control rate
DDI	drug-drug Interaction
DHOT	Division of Hematology Oncology Toxicology
DMC	data monitoring committee
DOR	duration of response
D-R	dose-response
ECG	electrocardiogram
ECHO	echocardiography

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)


ECOG PS	Eastern Cooperative Oncology Group Performance Status
eCRF	electronic case report form
eCTD	electronic common technical document
EFT	embryo-fetal toxicity
EOT	end of therapy
E-R	exposure-response
FACT-M	Functional Assessment of Cancer Therapy - Melanoma
FAS	full analysis set
FDA	Food and Drug Administration
FPFV	first patient's first visit
GCP	good clinical practice
GGT	gamma-glutamyl transferase
GLP	good laboratory practice
HLGT	higher level group term
HLT	higher level term
HR	hazard ratio
IC ₅₀	half maximal effective concentration
IEC	independent ethics committee
ILD	interstitial lung disease
IND	Investigational New Drug
IRB	Institutional Review Board
ISE	integrated summary of effectiveness
ISS	integrated summary of safety
ITT	intent to treat
KM	Kaplan-Meier
Km	substrate concentration at half the maximum velocity
Kps	drug tissue:plasma partition coefficients
LVEF	left ventricular ejection fraction
MAED	MedDRA-based Adverse Event Diagnostics
mDOR	mean duration of response
MedDRA	Medical Dictionary for Regulatory Activities
mmHg	millimeters of mercury
MMRM	mixed effect model for repeated measures
mOS	median overall survival
MTD	maximum tolerated dose
MUGA	multi-gated acquisition (scan)
NCI-CTCAE	National Cancer Institute-Common Terminology Criteria for Adverse Event
NDA	new drug application
NME	new molecular entity
OCT	ophthalmic coherence T
OPQ	Office of Pharmaceutical Quality
ORR	objective response rate
OS	overall survival
OSE	Office of Surveillance and Epidemiology

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

OSI	Office of Scientific Investigation
PBPK	physiologically based pharmacokinetic
PD	progressive disease
PD	pharmacodynamics
PEAR	population estimates for age-related
PFS	progression free survival
PI	prescribing information
PK	pharmacokinetics
PMA	premarket approval
PMC	postmarketing commitment
PMR	postmarketing requirement
popPK	population PK
PP	per protocol
PPI	patient package insert
PPS	per protocol set
PREA	Pediatric Research Equity Act
PRO	patient reported outcome
PT	Preferred Term
QD	once daily
RECIST	Response Evaluation Criteria in Solid Tumors
REMS	risk evaluation and mitigation strategy
RPED	retinal pigment epithelium detachment
RVO	retinal vein occlusion
SAE	serious adverse event
SAP	statistical analysis plan
SAS	Statistical Analysis Software
SD	stable disease
SDTM	study data tabulation model
SMQ	Standardized MedDRA Query
SOC	system organ class
TEAE	treatment emergent adverse event
TGI	tumor growth inhibition
TK	toxicokinetics
Tmax	time drug is present at maximum concentration
TTD	time to 10% deterioration
TTR	time to objective response
ULN	upper limit of normal
VAI	voluntary action indicated

1 Executive Summary

1.1. Product Introduction

Proprietary Name:	BRAFTOVI™	
Established Name:	encorafenib	
Also Known As:	LGX818	
Chemical Name:	Methyl N-((2S)-1-[(4-{3-[5-chloro-2-fluoro-3-(methanesulfonamido)phenyl]-1-(propan-2-yl)-1Hpyrazol-4-yl}pyrimidin-2-yl)amino]propan-2-yl)carbamate	
Molecular Formula:	C ₂₂ H ₂₇ ClFN ₇ O ₄ S	Chemical Structure:
Molecular Weight:	540.0 g/mol	
Dosage Forms:	Capsules, 50 mg and 75 mg	
Therapeutic Class:	Antineoplastic	
Chemical Class:	Small molecule	
Pharmacologic Class:	BRAF inhibitor	

Mechanism of Action: Inhibition of mutant and wild-type BRAF enzyme by encorafenib prevents activation of MEK1, leading to reduced cellular proliferation.

Encorafenib (BRAFTOVI™) is a new molecular entity. NDA 210496 was submitted for the proposed indication of treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation using a dose of 450 mg daily, in combination with binimetinib 45 mg twice daily.

1.2. Conclusions on the Substantial Evidence of Effectiveness

The review team recommends regular approval of encorafenib and binimetinib under 21 CFR 314.105 for the indication, "Treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test," using a dose of encorafenib 450 mg daily and binimetinib 45 mg twice daily. The recommendation is based on the finding of increased progression-free survival (PFS) compared to vemurafenib in Study CMEK162B2301 (COLUMBUS, NCT01909453).

A more complete description of efficacy that includes overall survival, determination of an appropriate encorafenib dose for patients with concomitant use of a moderate CYP3A4 inhibitor, and dose adjustment guidelines for patients with comedICATIONS of CYP substrates whose PK may be affected by encorafenib remain to be determined in postmarketing studies.

COLUMBUS was an open-label, randomized, multicenter, two-part clinical trial of encorafenib in combination with binimetinib for adults with unresectable or metastatic melanoma harboring a V600E or V600K mutation. In Part 1, patients were randomized 1:1:1 to receive either

encorafenib (450 mg daily) in combination with binimetinib (45 mg twice daily) (“Combo 450”), encorafenib alone (300 mg daily), or vemurafenib (960 mg twice daily). The Combo 450 regimen used in the pivotal study and proposed for marketing authorization were based on results from dose-finding Study CMEK162X2110, and was supported by dose-response and exposure-response analyses contained in this review. Higher doses of encorafenib resulted in dose limiting kidney toxicity.

The primary endpoint of COLUMBUS was PFS, determined based on tumor assessment (RECIST version 1.1 criteria) as per blinded independent central review (BIRC). The Combo 450 arm had significantly longer PFS compared to the vemurafenib arm, with a stratified log-rank test p-value of <0.0001. The estimated median PFS times were 14.9 months (95% CI: [11.0, 18.5]) for the Combo 450 arm and 7.3 (95% CI: [5.6, 8.2]) for the vemurafenib arm. The stratified hazard ratio of PFS for the Combo 450 arm compared to the vemurafenib arm was 0.54 (95% CI: [0.41, 0.71]).

A key secondary endpoint of COLUMBUS, intended by the applicant to assess the contribution of binimetinib to the efficacy of the combination, was PFS in the Combo 450 arm versus the encorafenib monotherapy arm. The Combo 450 arm did not demonstrate a significant improvement in PFS when compared to the encorafenib arm, with a two-sided stratified log-rank test p-value of 0.0513. The estimated median PFS times were 14.9 months (95% CI: [11.0, 18.5]) for the Combo 450 arm and 9.6 (95% CI: [8.7, 14.8]) for the encorafenib arm. The stratified hazard ratio of PFS for the Combo 450 arm compared to the encorafenib arm was 0.75 (95% CI: [0.56, 1.00]).

However, in presubmission meetings and correspondence with the applicant, FDA noted that the trial design for Part 1 of COLUMBUS, which employs a higher dose of encorafenib in the combination arm than in the single-agent arm, would not allow an adequate assessment of the contribution of binimetinib treatment effect in the combination. The applicant responded that the dose of encorafenib as monotherapy could not be increased for reasons of unacceptable toxicity, as the addition of binimetinib mitigates some of the encorafenib-associated toxicities. Part 2 was thus added to the study to respond to the FDA’s concern. In Part 2, patients were randomized 3:1 to receive either encorafenib (300 mg daily) in combination with binimetinib (45 mg twice daily) (“Combo 300”) or encorafenib alone (300 mg daily).

The Combo 300 arm exhibited a numerical improvement in progression-free survival when compared to encorafenib monotherapy, though no formal test was performed due to hierarchical testing rules. The estimated median PFS times were 12.9 months (95% CI: [10.1, 14.0]) for the Combo 300 arm and 9.2 (95% CI: [7.4, 11.0]) in the encorafenib group. The stratified hazard ratio of PFS for the Combo 300 arm compared to the encorafenib group was 0.77 (95% CI: [0.61, 0.97]).

The review team concluded that the clinically and statistically significant PFS advantage seen with encorafenib and binimetinib compared to vemurafenib constitutes substantial evidence of

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

effectiveness, and that, based on the totality of the data generated by COLUMBUS, both encorafenib and binimetinib are required to yield the observed efficacy.

1.3. Benefit-Risk Assessment

The applicant has proposed that encorafenib (BRAFTOVI™), a RAF inhibitor, in combination with binimetinib (MEKTOVI™), a MEK inhibitor, be approved for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation based on a prolongation of progression-free survival compared to a standard of care agent (vemurafenib). The review team recommends regular approval of encorafenib and binimetinib for the proposed indication, at the proposed doses of 450 mg daily and 45 mg twice daily, respectively.

Patients with untreated unresectable or metastatic melanoma have a dismal prognosis, with a 5-year overall survival of <10%. BRAF mutations are associated with several high risk features of melanoma including truncal primary, earlier age of onset, lack of chronic skin damage, and shortened survival. Since 2011, the FDA has approved 7 new therapies for unresectable or metastatic melanoma. Standard of care treatment options now include immunotherapeutic agents (ipilimumab, nivolumab, pembrolizumab) given alone or in combination, which prolong median survival but are associated with immune-related adverse reactions that can be life-threatening or fatal, or, for patients with BRAF V600 mutations, RAF and MEK inhibitor combinations (vemurafenib with cobimetinib and dabrafenib with trametinib), which also prolong median survival but are associated with serious toxicities including secondary skin malignancies, cardiac failure, and ocular toxicities. None of these agents are curative, and thus an unmet medical need persists.

In the COLUMBUS study, patients treated with encorafenib in combination with binimetinib had a median progression-free survival of 14.9 months, compared to 7.3 months in patients treated with vemurafenib (hazard ratio 0.54 (95% CI: [0.41, 0.71]), p-value <0.0001). Patients treated with encorafenib in combination with binimetinib also had a trend toward improved overall survival compared to patients treated with vemurafenib, but survival data is not yet mature, and statistical testing will not be performed on this endpoint. While limitations in study design prevented a statistically robust demonstration of the contribution of each individual drug to the overall treatment effect, the totality of the data generated on COLUMBUS, which incorporated an encorafenib monotherapy arm, supported the FDA's conclusion that both drugs are required to maximize clinical benefit. There is no identified advantage for encorafenib and binimetinib over other available RAF and MEK inhibitor combinations, but it is acknowledged that modest differences in side effect profiles may provide options for individualized treatment selection for specific patients.

Important toxicities observed on clinical trials of encorafenib and binimetinib include new primary malignancies, tumor promotion in BRAF wild-type tumors, ocular toxicities (serious retinopathy, retinal vein occlusion, and uveitis), hemorrhage, QT prolongation, cardiomyopathy, venous thromboembolism, interstitial lung disease, hepatotoxicity, and rhabdomyolysis. However, these toxicities were generally manageable with dose interruption or reduction, and only 9% of subjects on COLUMBUS terminated therapy due to

an adverse reaction. These results provide substantial evidence that the combination of encorafenib and binimetinib is tolerable for most patients.

Given the tolerability of encorafenib in combination with binimetinib, the clinical benefit of the combination appears to outweigh the risks for patients with unresectable or metastatic melanoma harboring a BRAF V600 mutation.

	Evidence and Uncertainties	Conclusions and Reasons
Analysis of Condition	- Patients with unresectable or metastatic melanoma have a 5-year overall survival of <10%. - Patients whose disease harbors a BRAF V600 mutation have a worse prognosis.	Unresectable or metastatic melanoma is a fatal disease.
Current Treatment Options	- FDA-approved therapies for unresectable or metastatic melanoma include immunotherapy agents (ipilimumab, nivolumab, pembrolizumab), BRAF inhibitors (vemurafenib, dabrafenib), and MEK inhibitors (cobimetinib, trametinib). - PD-1 inhibitors prolong median survival, but are associated with immune-related adverse reactions which can be life-threatening. - BRAF and MEK inhibitors prolong median survival in patients with BRAF V600 mutations, but serious toxicities, including secondary skin cancers, left ventricular dysfunction, and ocular toxicities can occur.	There is a need for additional effective therapies for the treatment of unresectable or metastatic melanoma. Differences in activity and side effect profiles among therapies approved for this disease provide options for individualization of therapy.
Benefit	- In COLUMBUS, patients treated with encorafenib in combination with binimetinib had a median progression-free survival of 14.9 months, compared to 7.3 months in patients treated with vemurafenib. - In COLUMBUS, patients treated with encorafenib in combination with binimetinib had a trend toward improved overall survival compared to patients treated with vemurafenib, but survival data is not yet mature, and statistical testing will not be performed on this endpoint.	There is substantial evidence of effectiveness for encorafenib and binimetinib in the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. A more complete description of survival needs to be determined.

	Evidence and Uncertainties	Conclusions and Reasons
Risk	• The most common adverse reactions (≥25%) included fatigue, nausea, vomiting, abdominal pain, and arthralgia. • Important toxicities of encorafenib include new primary malignancies, tumor promotion in BRAF wild-type tumors, hemorrhage, uveitis, and QT prolongation. • Important toxicities of binimetinib include cardiomyopathy, venous thromboembolism, ocular toxicities (serious retinopathy, retinal vein occlusion, and uveitis), interstitial lung disease, hepatotoxicity, rhabdomyolysis, and hemorrhage. • Nonclinical data suggest that encorafenib and binimetinib may cause embryo-fetal toxicity (EFT). • An appropriate dose for patients with concomitant use of a moderate CYP3A4 inhibitor has not been established. • Dose adjustment guidelines for patients who require concomitant use of CYP3 substrates have not been established.	The overall safety profile of encorafenib and binimetinib is acceptable for patients with unresectable or metastatic melanoma. Dose adjustment guidelines for certain drug-drug interactions need to be clarified.
Risk Management	• The protocol included monitoring for risks and instructions for intervention. With this in place, serious toxicities could be mitigated by dose interruption or reduction. • The proposed labeling includes warnings, dose modifications and management guidelines for serious toxicities.	A patient medication guide is recommended for encorafenib and a patient package insert is recommended for binimetinib to inform and educate patients of the risks and when to seek medical attention. Labeling should include warnings for important toxicities, and instructions for monitoring and dose modifications for toxicities.

1.4. Patient Experience Data

Patient Experience Data Relevant to this Application (check all that apply)

X	The patient experience data that was submitted as part of the application include:	Section where discussed
	☐ Clinical outcome assessment (COA) data, such as	
	☒ Patient reported outcome (PRO)	Section 8.1.3
	☐ Observer reported outcome (ObsRO)	
	☐ Clinician reported outcome (ClinRO)	
	☐ Performance outcome (PerFO)	
	☐ Qualitative studies (e.g., individual patient/caregiver interviews, focus group interviews, expert interviews, Delphi Panel, etc.)	
	☐ Patient-focused drug development or other stakeholder meeting summary reports	
	☐ Observational survey studies designed to capture patient experience data	
	☐ Natural history studies	
	☐ Patient preference studies (e.g., submitted studies or scientific publications)	
	☐ Other: (Please specify)	
	☐ Patient experience data that was not submitted in the application, but was considered in this review.	

Ashley Ward, MD
 Cross-Disciplinary Team Leader

2 Therapeutic Context

2.1. Analysis of Condition

The American Cancer Society reports there will be approximately 91,270 new cases of melanoma in 2018, with approximately 9,320 people expected to die of the disease. Approximately 84% of cases will be localized or confined to the primary site, 9% will have spread to regional lymph nodes, and 4% will have metastasized to distant sites. Melanoma is more frequent in men (60% of cases) than women (40% of cases). Median age at diagnosis is 64 years, with approximately 70% of cases occurring in patients $\geq$ 55 years of age. The incidence of melanoma of the skin by race reported in the SEER data for 2014 (cases per 100,000 people) is: White: 31.4, Black: 1.0, Asian/Pacific Islander:1.6, American Indian/Alaska Native: 3.1, and Hispanic: 5.4. The 5-year overall survival for all-comers with melanoma is 92%; however, once melanoma is metastatic to distant sites, the 5-year overall survival is less than 10%.

Approximately 40-60% of melanomas contain a mutation in the BRAF gene that leads to constitutive activation of downstream signalling in the MAP kinase pathway. In 80-90% of these cases, the activating mutation consists of the substitution of glutamic acid for valine at amino acid 600 (V600E). BRAF mutations are associated with several high risk features of melanoma including truncal primary, earlier age of onset, lack of chronic skin damage, and shortened survival. The most important prognostic factors in metastatic melanoma are site(s) of metastases and the presence of elevated serum lactate dehydrogenase (LDH). Prognosis is particularly poor in patients with the American Joint Committee on Cancer (AJCC) stage IV M1c melanoma in which the tumor has metastasized to visceral organs (other than the lung) or when there are any distant metastases accompanied by elevated LDH.

2.2. Analysis of Current Treatment Options

Table 1 summarizes FDA approved therapies for use in advanced or metastatic melanoma. Current standard of care consists of either a CTLA-4 inhibitor (ipilimumab), a PD-1 inhibitor (pembrolizumab or nivolumab) or, for patients whose disease harbors a BRAF V600 mutation, a BRAF inhibitor, typically in combination with a MEK inhibitor. Ipilimumab and pembrolizumab are approved for patients regardless of BRAF mutation status, while nivolumab has regular approval for BRAF wild-type patients and accelerated approval for patients with BRAF V600 mutations. PD-1 inhibitors are associated with relatively modest response rates (33-34%, mostly partial responses), but responding patients do well, with survival curves having a long “tail.” However, ipilimumab and the PD-1 inhibitors are associated with immune-related adverse reactions, which can be life-threatening or fatal (see Table 1). BRAF and MEK inhibitors are typically associated with higher response rates (66-70%, mostly partial responses), but relapse due to acquired resistance mutations is inevitable, and these agents are associated with other important toxicities, including skin neoplasia, left ventricular dysfunction, and ocular toxicities. There are no curative therapies for patients with advanced or metastatic melanoma.

Table 1: Available FDA-Approved Therapies Indicated for the Treatment of Patients with Unresectable or Metastatic Melanoma

Drug	Approval Year	Trial Design	Endpoint(s)	Clinical Benefit/Effect	Notable Toxicities
Chemotherapy¹					
DTIC (dacarbazine) ²	1975	Single-Arm	ORR	ORR 5-20%	- Leukopenia, thrombocytopenia, anemia - Anorexia, nausea, vomiting, fever, myalgias, malaise - Hepatic vein thrombosis, hepatocellular necrosis
General Immune Therapy					
Proleukin (aldesleukin) ²	1998	Multicenter Single Arm	ORR	ORR 16% (CR 6%); DOR CR: 59+ m (3 to 122+ m) CR or PR: 59+ m (1 to 22+m)	- Fever, hypotension, chills, dyspnea, rash, malaise, confusion - Nausea, vomiting, diarrhea, acute kidney failure - Ventricular tachycardia, myocardial infarction - Immune-related organ inflammation
Checkpoint Inhibitor					
Yervoy (Ipilimumab) ²	2011	Multicenter, randomized, blinded, active-controlled three-arm	OS ORR	Ipilimumab vs. gp100: OS: HR 0.66 (95% CI: 0.51, 0.87) median 10 vs. 6 m BORR: 10.9% vs. 1.5% mDOR: not reached in either arm	Severe/fatal immune-mediated adverse events (including hepatitis, endocrinopathies, pneumonitis, nephritis and renal dysfunction, encephalitis, and infusion reactions)
Keytruda (pembrolizumab)	2014	Multicenter, randomized, blinded, active-controlled three-arm	ORR PFS OS	Pembrolizumab vs. Ipilimumab: OS: HR 0.69 (95% CI: 0.52, 0.90) Median OS not reached mPFS: 4.1m vs 2.8m HR 0.58 (95% CI: 0.47, 0.72) ORR: 33% vs 12% CR: 6% vs 1%, PR: 27% vs 10%	Severe/fatal immune-mediated adverse events (including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis and renal failure, skin reactions including SJS and TEN, infusion-related reactions, organ transplant rejection, and complications of allogeneic stem cell transplant)
Opdivo (nivolumab)	2014	Multicenter, randomized, blinded, active-controlled three-arm	ORR PFS OS	Nivolumab vs. Dacarbazine: OS: HR 0.42 (95% CI: 0.30, 0.60) Median OS not reached mPFS: 5.1m vs 2.2m HR 0.43 (95% CI: 0.34, 0.56) ORR: 34% vs 9% CR: 4% vs 1%, PR: 30% vs 8%	Severe/fatal immune-mediated adverse events (including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis and renal dysfunction, skin reactions, encephalitis, infusion-related reactions, and complications of allogeneic stem cell transplant)

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

Drug	Approval Year	Trial Design	Endpoint(s)	Clinical Benefit/Effect	Notable Toxicities
Opdivo and Yervoy (nivolumab and ipilimumab)	2015 ³	Randomized, double-blind, active controlled, three-arm study	PFS OS ORR	<u>Nivolumab+Ipilimumab vs. Ipilimumab</u> mPFS: 11.5 vs. 2.9 m HR: 0.42 (95% CI: 0.34, 0.51) mOS: NR vs. 17.7m cORR: 50% (95% CI: 44, 45) vs 14% (95% CI: 10, 18) CR: 8.9% vs 1.9%, PR: 41% vs 12% mDOR: NR (range 1.2+, 15.8+m)	Immune-mediated adverse events occurring at increased severity and frequency compared to either agent alone
BRAF/MEK inhibitors					
Zelboraf (vemurafenib) ⁵	2011	Randomized, open-label, active controlled, two arm	OS PFS ORR	<u>Vemurafenib vs. DTIC</u> mOS: NR vs. 7.9 m HR: 0.44 (95% CI: 0.33, 0.59) mPFS: 5.3 vs. 1.6 m HR: 0.26 (95% CI: 0.20, 0.33) cORR: 48% (95% CI: 42, 55) vs 6% (95% CI: 3, 9) CR: 0.9% vs 0%, PR: 48% vs 6%	- Cutaneous and non-cutaneous malignancies (squamous cell carcinomas, keratoacanthomas) - Ocular toxicity (retinal vein occlusion, iritis, uveitis) - Hypersensitivity reactions and serious skin toxicity (SJS, TEN) - Hepatotoxicity, renal failure, QT prolongation - Radiation sensitivity and recall, photosensitivity - Dupuytren's contracture and plantar fascial fibromatosis
Tafinlar (dabrafenib) ⁵	2013	Randomized, open label, active controlled, two arm	PFS ORR	<u>Dabrafenib vs. Dacarbazine</u> mPFS: 5.1 vs. 2.7 m HR: 0.33 (95% CI: 0.20, 0.54) cORR: 52% (95% CI: 44, 59) vs 17% (95% CI: 9, 29) CR: 3% vs 0%, PR: 48% vs 17%	- Cutaneous and non-cutaneous malignancies (squamous cell carcinomas, keratoacanthomas) - Cardiomyopathy, uveitis, serious febrile reactions - Hypersensitivity reactions and serious skin toxicity (SJS, TEN) - Hemorrhage, hemolytic anemia, hyperglycemia
Mekinist (trametinib) ⁶ ≤ 1 prior therapy; no prior BRAF or MEK inhibitor	2013	Randomized, open-label, active-controlled, two arm	PFS ORR	<u>Trametinib vs. Chemotherapy</u> mPFS: 4.8 vs. 1.5 m HR: 0.47 (95% CI: 0.34, 0.65) cORR: 22% (95% CI: 17, 28) vs 8% (95% CI: 4, 15) CR: 2% vs 0%, PR: 20% vs 9%	- Cutaneous and non-cutaneous malignancies (squamous cell carcinomas, keratoacanthomas) - Hemorrhage, colitis, GI perforation, venous thromboembolism, cardiomyopathy - Ocular toxicities (uveitis, retinal vein occlusion) - Interstitial lung disease, serious febrile reactions, serious skin toxicity (SJS, TEN), hyperglycemia

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

Drug	Approval Year	Trial Design	Endpoint(s)	Clinical Benefit/Effect	Notable Toxicities
Tafinlar and Mekinist (dabrafenib and trametinib) ⁶	2014	Randomized, open-label, active-controlled, two arm portion of dose-escalation study	ORR PFS OS	<u>Dabrafenib+Trametinib vs.Dabrafenib</u> ORR 66% vs. 51% mDOR 9.2m vs. 10.2m mPFS: 9.3m vs. 8.8m HR: 0.75 (95% CI: 0.57, 0.99) mOS: 25.1m vs. 18.7m HR: 0.71 (95% CI: 0.55, 0.92)	• See toxicities associated with individual agents. • Pyrexia, hemorrhagic events and thromboembolic events occurred at a higher incidence and cutaneous malignancies at a lower incidence with the combination compared to single-agent dabrafenib
Cotellic and Zelboraf (cobimetinib and vemurafenib) ⁶	2015	Randomized, double-blind, active controlled, two-arm study	PFS OS ORR	<u>Cobimetinib+Vemurafenib vs. Vemurafenib</u> mPFS: 12.3 vs. 7.2 m HR: 0.56 (95% CI: 0.45, 0.70) mOS: NR vs. 17 m cORR: 70% (95% CI: 64, 75) vs 50% (95% CI: 44, 56) CR: 16% vs 10%, PR: 54% vs 40% mDOR: 13 vs. 9.2 m	• See toxicities associated with vemurafenib • Also hemorrhage, cardiomyopathy, rhabdomyolysis • Alopecia, hyperkeratosis and erythema occurred at a lower incidence with the combination compared to single-agent vemurafenib

Source: Cotellic USPI; Dacarbazine USPI; Keytruda USPI; Mekinist USPI; Opdivo USPI; Proleukin USPI; Tafinlar USPI; Yervoy USPI; Zelboraf USPI

Abbreviations in Table: m, months; BORR, best objective response rate; CR, complete response; cORR, confirmed objective response rate; DOR, duration of response; HR, hazard ratio; mDOR, median duration of response; mOS, median overall survival; mPFS, median progression-free survival; NR, not reached; ORR, objective response rate; OS, overall survival; PR, partial response; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis; +, response is ongoing.

¹ Hydroxyurea is also FDA-approved for treatment of melanoma but is of historical interest only and not clinically used for this indication.

² BRAF V600 mutation status unknown.

³ Accelerated approval as per 21 CFR 601, subpart E.

⁴ Accelerated approval as per 21 CFR 314.510 of subpart H.

⁵ Patient selection based on BRAF V600E mutation-positive tumors.

⁶ Patient selection based on BRAF V600E or V600K mutation-positive tumors.

3 Regulatory Background

3.1. U.S. Regulatory Actions and Marketing History

Encorafenib and binimetinib are new molecular entities (NME) and neither is currently marketed in the United States.

3.2. Summary of Presubmission/Submission Regulatory Activity

On January 24, 2012, Novartis submitted an IND for the development of binimetinib with encorafenib for treatment of patients with unresectable or metastatic melanoma harboring BRAF V600 mutations. IND 113850 opened in DOP2, and the two trials contributing to the efficacy analysis portion of this application, (CMEK162B2301 and CMEK162X2110), were eventually conducted under this IND.

On April 29, 2013, a Type B, End of Phase 2 (EOP2) meeting was held to discuss Novartis' proposed trial, Study CMEK162B2301, entitled, "A Phase III randomized, 3-arm, partially blinded, placebo controlled, multicenter, study of the Combination of LGX818 plus MEK162 compared with vemurafenib, and of LGX818 compared with vemurafenib for the treatment of patients with unresectable stage IIIB, IIIC or Stage IV melanoma with BRAF V600 mutation." Key agreements and comments:

- FDA agreed progression-free survival (PFS) was an acceptable primary endpoint for the proposed trial and may support a request for regular approval provided a statistically significant, robust and clinically meaningful effect on PFS that is large in magnitude is observed.
- FDA noted that a companion diagnostic test would be required for approval of encorafenib and recommended that Novartis stratify patients based on BRAF V600 mutation type (i.e., V600E vs. V600K).
- FDA did not object to the proposed statistical analysis methods for independent comparisons of both the LGX818/MEK162 combination versus vemurafenib and LGX818 versus vemurafenib. FDA noted that the Bayesian analysis for estimating the contribution of MEK162 to the combination of LGX818 plus MEK162 would be considered exploratory.
- FDA recommended that the primary analyses of PFS and OS be conducted at a prespecified number of events, that the O'Brien-Fleming method be used for alpha adjustment for interim analysis of overall survival (OS), and that given the proposal to ignore or group strata, the primary analysis should be unstratified.
- FDA strongly recommended that Novartis submit a Pre-Submission to CDRH to discuss the analytical validation necessary to support premarket approval (PMA) for the companion diagnostic test.

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

On June 14, 2013, a new clinical protocol for Study CMEK162B2301 was submitted to IND 113850. CMEK162B2301 was proposed as a prospective, randomized (1:1:1) open-label, multi-center study comparing LGX818 in combination with MEK162 (450 mg once daily and 45 mg twice daily, respectively) to LGX818 monotherapy (300 mg once daily) and vemurafenib (approved dose) in patients with locally advanced unresectable or metastatic melanoma with BRAF V600 mutation.

On October 22, 2013, FDA issued an Advice/Information Request letter, which included the following advice:

- “Please be advised that you will need to demonstrate the relative contribution of each investigational product to the effect of the combination in an NDA submission seeking initial approval of two previously unapproved investigational products for use in combination. Data that is limited to clinical outcomes evaluating only LGX818 and MEK162 as single agents would not be sufficient to demonstrate the contribution of each component of the combination. Please refer to the FDA Guidance for Industry “Codevelopment of Two or More Unmarketed Investigational Drugs for Use in Combination.”

On April 9, 2014, a Type C teleconference was held between representatives of FDA and Novartis, to discuss proposed changes to the ongoing Phase 3 Study CMEK162B2301 with an emphasis on FDA’s statements that the trial design, which employs a higher dose of encorafenib in the combination arm than the single-agent arm, would not allow an adequate assessment of the contribution of binimetinib treatment effect in the combination, that the proposal to present results from the primary efficacy analysis and immature results from the key secondary analysis without overall survival information would not provide sufficient information to file an NDA, and that the proposed Bayesian analysis was not acceptable to assess the treatment effects of the combination. Novartis stated that the dose of encorafenib could not be increased for reasons of unacceptable toxicity; FDA agreed to review this information.

On July 23, 2014, a Type C teleconference was held between representatives of FDA and Novartis, to discuss the ongoing going study, CMEK162B2301 and to obtain feedback on the encorafenib dosing rationale and the proposed modifications to the analysis plan. FDA reiterated the need for Novartis to demonstrate the relative contribution of each investigational product to the effect of the combination and that the proposed Bayesian analysis for estimating the contribution would be considered exploratory. The FDA further stated that an application in which substantial evidence of effectiveness has not been demonstrated would not be fileable. FDA recommended that Novartis add a treatment arm consisting of encorafenib 300 mg daily in combination with binimetinib 45 mg twice daily and compare that arm to the encorafenib single-agent arm to establish the contribution of binimetinib.

On November 20, 2014, Novartis submitted an amended protocol CMEK162B2301, Version 3, intended to address the FDA’s concerns. In this amendment, Novartis added a Part 2 to the trial, in which additional patients would be randomized 3:1 to either encorafenib 300 mg daily in combination with binimetinib 45 mg twice daily or to encorafenib 300 mg daily as

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

monotherapy. In an advice letter, FDA stated that based on separate randomizations of patients in the single-agent encorafenib arm (Part 1 and Part 2) and the encorafenib 300 mg plus binimetinib 45 mg arm (Part 2 only), there may be some imbalance in important patient characteristics with potential introduction of bias.

On March 2, 2015, Novartis stated that Array BioPharma, Inc. (Array) regained worldwide rights to encorafenib and binimetinib from Novartis, and on September 15, 2015, Novartis transferred sponsorship of IND 113850, and all rights and responsibilities related to the IND application to Array.

On January 22, 2016, Array submitted a Type C, Written Responses Only meeting request to reach agreement on the clinical data plan, including the presentation of efficacy data and the pooling and presentation of clinical safety data, to support a planned NDA for encorafenib for use in combination with binimetinib for the treatment of patients with BRAF V600 mutation-positive melanoma. (FDA final written responses issued on April 7, 2016.)

On February 12, 2016, Array submitted a Type C, Written Responses Only meeting request to reach agreement with the Agency on the clinical pharmacology program and the presentation of clinical pharmacology data to support a planned NDA for encorafenib, for use in combination with binimetinib for the treatment of patients with BRAF V600 mutation positive melanoma. (FDA final written responses issued on April 26, 2016.)

On November 21, 2016, Array and FDA held an informal teleconference in response to a November 15, 2016, e-mail communication from Array requesting a meeting to discuss recent DMC recommendations to modify Part 2 of Study CMEK162B2301 and to determine whether the data are sufficient to support the encorafenib and binimetinib NDA filings. FDA stated that the higher dose of encorafenib in the combination arm as compared to the encorafenib single-agent arm confounds the assessment of the contribution of binimetinib to the effect of the combination.

On February 20, 2017, a Pre-NDA meeting was held with Array to discuss and reach agreement on the content and presentations of data for the NDAs to support the use of encorafenib in combination with binimetinib and binimetinib in combination with encorafenib in patients with BRAF V600 mutation-positive melanoma. The key points were:

- FDA did not agree that efficacy data from Part 1 of study CMEK 162B2301 would be adequate to demonstrate the contribution of binimetinib to the treatment effect of binimetinib when administered with encorafenib. In response, Array agreed to provide Part 2 data.
- FDA stated that based on the information available at the time of the pre-NDA meeting, FDA did not believe that a REMS would be necessary.
- FDA generally agreed with the proposed population PK analysis plan but noted that using population PK analysis to assess the impact of uncontrolled concomitant medication exposure is challenging.

On February 21 2017, a Pre-NDA meeting CMC only was held with Array to reach agreement with the FDA on the content and presentations of data for the NDAs to support the use of

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

encorafenib in combination with binimetinib and binimetinib in combination with encorafenib in patient with BRAF V600 mutation-positive melanoma.

On June 30, 2017, the NDAs were submitted electronically.

4 Significant Issues from Other Review Disciplines Pertinent to Clinical Conclusions on Efficacy and Safety

4.1. Office of Scientific Investigations (OSI)

The Division of Oncology Products 2 (DOP2) consulted the Office of Scientific Investigation (OSI) to perform an audit to support the review of the NDA applications. The focus of the inspection was Part 1 of COLUMBUS, and clinical investigator site selection was based accordingly. Four clinical sites were audited: Dr. Ivana Krajsova (clinical site 2013), Dr. Caroline Dutriaux (clinical site 3046), Dr. Ralf Gutzmer (clinical site 4015), and Dr. Thaddeus Beck (clinical site 5048). The Division selected these sites, in consultation with OSI, based on enrollment characteristics, patterns of protocol violations reported for the sites, patterns of efficacy reporting, and patterns of serious adverse event (SAE) reporting. The Contract Research Organization (CRO) responsible for some aspects of the clinical trial, (b) (4) was also audited.

The overall conclusion for the OSI inspection is that the data submitted to the FDA in support of COLUMBUS appear reliable based on available information from the inspection of the four clinical sites and the CRO.

There were no significant inspectional observations for clinical investigators Dr. Krajsova, Dr. Dutriaux, Dr. Gutzmer, and the CRO. The final classification for the inspections of these sites is No Action Indicated (NAI). Regulatory violations were observed during the inspection of Dr. Beck. For this site, a Form FDA-483 was issued for, "Failure to prepare or maintain adequate and accurate case histories with respect to observations and data pertinent to the investigations." Specifically, case histories, including the case report forms and supporting data, were not properly retained for the patients enrolled at the site, although the records were scanned and imported into ARIA and OncoEMR electronic medical records system. These violations were considered by OSI to be unlikely to significantly impact the determination of efficacy and safety, and the final classification for the inspection is Voluntary Action Indicated (VAI). OSI recommended that a sensitivity analysis with and without data from Site 5048 be performed; however, the clinical reviewer determined that as Site 5048 enrolled only 7 patients across three treatment arms of COLUMBUS, any impact of data from this site on the primary efficacy or safety analyses would be minimal.

4.2. Product Quality

Novel excipients: No

Any impurity of concern: No

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

Encorafenib drug product (BRAFTOVI™) is presented as 50 mg and 75 mg hard gelatin capsules for oral use. The 50 mg capsule is size 0 with a (b) (4) orange opaque cap and flesh opaque body, printed with a stylized “A” on the cap and “LGX 50 mg” on the body. The 75 mg capsule is size 00 with a flesh colored opaque cap and white opaque body, printed with a stylized “A” on the cap and “LGX 75 mg” on the body.

The encorafenib capsule drug product formulations for both strengths include the following compendial excipients: copovidone, poloxamer 188, microcrystalline cellulose, succinic acid, crospovidone, colloidal silicon dioxide, and magnesium stearate. The levels of the excipients in the proposed drug product formulation are below the IIG database for oral administration. The clinical trial formulation was the same as the proposed to-be-marketed formulation. Therefore, the levels of excipients in the proposed drug products are acceptable. No formulation bridging is needed, as the formulation of the proposed commercial 50 mg capsules is the same as the clinical batch. The Applicant’s biowaiver request of the proposed commercial 75 mg capsules is granted based on 21 CFR 320.22(b).

The primary commercial container closure systems consist of HDPE, white, opaque bottles with induction seal, (b) (4) cap, and 2 g desiccant soft packet. Bottle sizes are 325 cc (for 90 count 75 mg capsules) and 175 cc (for 60 count 50 mg capsules). The drug product is labeled for storage at USP controlled room temperature. The provided stability data summarized above supports the above storage conditions in the working range of 20°C to 25°C with short term excursions down to 15°C and up to 30°C. The applicant proposed the initial shelf life of 15 months is acceptable based on the data provided in the application.

There were no outstanding safety issues identified for the manufacturing process or from the facilities inspections. The Applicant claimed a categorical exclusion from the requirement for an environmental assessment, and the claim was accepted under 21 CFR 25.31(b). Approval of the NDA was recommended by the Product Quality review team.

4.3. **Clinical Microbiology**

Not applicable.

4.4. **Devices and Companion Diagnostic Issues**

The applicant is seeking an indication for patients with unresectable or metastatic melanoma limited to those who have a BRAF V600E or V600K mutation, which is the target of encorafenib. In COLUMBUS, patients were selected based on detection of a BRAF V600E and/or V600K mutation in tumor tissue prior to enrollment as determined by a sponsor designated central laboratory utilizing a bioMerieux ThxID™ BRAF assay. It was determined that a device to select patients for therapy would be required for the safe use of this drug when marketed. The applicant cross-referenced supplemental PMA application P120014 (S008) for the ThxID™ BRAF Assay Kit. At the time of completion of this review, the Center for Devices and Radiologic Health (CDRH) had not yet made a final regulatory determination for the PMA.

5 Nonclinical Pharmacology/Toxicology

5.1. Executive Summary

Encorafenib (LGX818) is an ATP-competitive small molecule kinase inhibitor that has activity against BRAFV600E, and wild type (wt) BRAF and CRAF. In non-cellular biochemical assays, encorafenib prevented BRAFV600E, and wt BRAF and CRAF-mediated activation of MEK1 with inhibitory concentrations (IC₅₀) of approximately 0.35, 0.47, and 0.30 nM, respectively. In cellular anti-proliferation assays, encorafenib inhibited growth of cell lines expressing BRAFV600E with EC₅₀ values of approximately 4 nM, and inhibited phosphorylation of downstream targets ERK1/2 and MEK1/2 with EC₅₀ values of approximately 3 and 2 nM, respectively, greater than 1000-fold lower than the average peak total (bound + unbound) maximum concentration (C_{max}) of 3760 ng/mL (6963 nM) in patients treated at the once daily oral dose of 450 mg when used in combination with binimetinib, and ≥ 300-fold lower than the C_{max} of approximately 1 μM accounting for 86% human plasma protein binding. Incubation with encorafenib also reduced cellular proliferation in cell lines with BRAF(V600) D and K mutations. In mouse tumor models expressing BRAF(V600E), encorafenib in combination with binimetinib inhibited tumor growth at a greater rate compared to encorafenib or binimetinib alone. In addition, treatment with the combination of encorafenib and binimetinib in a mouse model of implanted BRAFV600E tumors resulted in longer term inhibition of tumor growth compared to either drug alone.

To assess the safety of encorafenib, the applicant conducted GLP-compliant toxicology studies of up to 13-weeks in Wistar Hannover rats and cynomolgus monkeys. In general, the target organs and toxicities observed in rats and monkeys during the one month and chronic toxicity studies were similar. In the long-term (13-week) rat study, animals received encorafenib once daily by oral gavage at doses of 6, 20, and 60 mg/kg. No test article related deaths occurred. Clinical observations included skin abnormalities (scabbed, dry, flaking, red/white spots, swelling of hind and forepaws and tail) at all dose levels, including the lowest dose of 6 mg/kg (approximately 11 times the clinical exposure of 13.9 μg*h/mL achieved clinically at the 450 mg encorafenib dose in combination with binimetinib). These findings were also present in the 60 mg/kg recovery animals after 4-weeks off encorafenib. Skin toxicity is the most common adverse event noted clinically with encorafenib treatment. Minor increases in hematology parameters and clinical chemistry parameters occurred in the 20 and 60 mg/kg doses. The largest change was limited to increased ALT and AST in the 60 mg/kg group of 125-165% compared to controls; liver function test abnormalities were also observed clinically. The male reproductive organs (testis and epididymis) were targets of encorafenib with findings of tubular degeneration, oligospermia, and cellular debris with a trend towards increased severity at the 20 and 60 mg/kg doses. The nonglandular stomach was another target organ with epithelial hyperplasia and hyperkeratosis that persisted during the recovery period observed in both male and female animals, at the 60 mg/kg dose. This finding was added to Section 13.2 of the label.

In the 13-week monkey study, animals received encorafenib once daily by oral gavage at doses of 20 and 60 mg/kg. No deaths occurred during this study. Emesis was common in monkeys at the high dose level. Other findings in both sexes were limited to the eyes, with granular substances and blister like findings at the 60 mg/kg dose (approximately 1.5 times the clinical exposure by AUC at the 450 mg dose of encorafenib).

While some QTc prolongation has been reported in clinical trials of encorafenib in combination with binimetinib, nonclinical studies with encorafenib did not clearly predict this effect. Neither encorafenib nor its metabolite inhibited the hERG potassium current at clinically achievable concentrations. Similarly, encorafenib did not significantly inhibit sodium or calcium channels included in a panel of 143 receptors, transporters, and ion channels screened in a secondary pharmacology assay. Encorafenib did not induce QTc prolongation in cynomolgus monkeys in either a single-dose safety pharmacology study at doses up to 200 mg/kg or in the 13-week repeat-dose study at doses up to 60 mg/kg/day. An additional safety pharmacology study indicated that a single oral administration of 100 mg/kg encorafenib to Sprague-Dawley rats resulted in a 28% decrease in forelimb grip strength compared to controls at 24 hours post dose, with no other central nervous system findings, and had no effect on respiratory parameters up to 24 hours post dose. Encorafenib did have phototoxic potential in an in vitro assay; this quality may contribute to the skin and ocular effects observed clinically.

Carcinogenicity studies were not conducted with encorafenib and are not required to support the use of a drug intended to treat patients with advanced cancer. Encorafenib showed no genotoxic potential in the standard genetic toxicology battery.

Dedicated studies to assess fertility were not conducted or required to support the development of a drug intended to treat patients with advanced cancer. Histopathological findings in male rats suggest the potential for transient decreases in male fertility. To assess the potential developmental and reproductive toxicity of encorafenib, the applicant conducted embryo-fetal development studies in Sprague-Dawley rats and New Zealand White Hra:(NZW)SPF rabbits. Rats were administered 0, 0.5, 5, or 20 mg/kg of encorafenib by oral gavage, once daily from Gestation Day 6 to 17. In pregnant rats, administration of encorafenib at the 20 mg/kg dose (approximately 26 times the clinical encorafenib exposure of 13.9 $\mu\text{g}\cdot\text{hr}/\text{mL}$ at the 450 mg dose) caused decreased maternal body weight gain (11% compared to controls); pups from these dams showed decreased body weights, delayed ossifications, and visceral malformations of anasarca, micrognathia, and microphthalmia. Rabbits received 0, 5, 25, or 75 mg/kg of encorafenib by oral gavage, once daily from gestation Days 7 to 20. In pregnant rabbits, maternal toxicity occurred at the 75 mg/kg dose (approximately 178 times the clinical exposure at 450 mg) resulting in 4 deaths due to significant signs of toxicity as well as increases in post-implantation loss. Skeletal variations, primarily delayed ossification, occurred in pups from dams at doses $\geq$ 25 mg/kg (approximately 72 times the clinical exposure at 450 mg), and visceral malformations occurred in pups from dams dosed with 75 mg/kg, including multiple cardiac malformations. Given the high dose multiples for fetal findings, data from the embryo-fetal development studies alone might not warrant a warning for embryofetal

toxicity; however, in knockout models alterations in the BRAF signaling cascade have been associated with serious embryo-fetal toxicity including embryoletality, severe growth retardation, and post-natal death and congenital mutations of *BRAF* in humans have been associated with serious genetic disorders. With these considerations in mind, along with the facts that an assessment of post-natal development is not required for drugs intended for the treatment of patients with advance cancer and that encorafenib is being approved in combination with binimetinib (an inhibitor of MEK with more significant findings in embryo-fetal development studies), the drug's mechanism of action warrants a warning for embryo-fetal toxicity in the BRAFTOVI label.

Females are also advised to use non-hormonal contraception (due to a potential for drug-drug interactions rendering hormonal contraception ineffective determined by the clinical pharmacology review team) for at least 2 weeks after the last dose of BRAFTOVI due to the potential for embryo-fetal toxicity in the absence of genotoxicity. No studies were conducted or required to investigate the presence or encorafenib in milk. Because many drugs are secreted in milk, the label includes a warning not to breastfeed during treatment with BRAFTOVI for 2 weeks after the final dose based on a half-life of 2-4 hours. There are no outstanding issues from a pharmacology/toxicology perspective that would prevent the approval of BRAFTOVI, with an established pharmacological class of kinase inhibitor, in combination with binimetinib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation as detected by an FDA-approved test.

5.2. Referenced NDAs, BLAs, DMFs

IND 111003 for encorafenib held by Array Biopharma Inc.

5.3. Pharmacology

Primary pharmacology

A. In Vitro Studies

The Applicant evaluated the selectivity of LGX818 (encorafenib) against a panel of 386 kinases using a competition binding assay (Study report # NVR020-01-P-00001). Briefly, the test article competed with immobilized ligands for binding to a panel of DNA-tagged kinases. Competition was assessed by qPCR of eluates, representing the percent of kinase unbound to immobilized cognate ligand at the tested concentration and normalized to qPCR measurements of positive control competitors. Results were reported as percent of negative control normalized to positive control, with lower numbers representing high levels of binding by LGX818 preventing binding of the listed kinase to its ligand. In the first assay, the concentration of LGX818 was 10,000 nM (10 μM). Targets with less than 5% binding to the cognate ligand in the presence of LGX818 at this concentration included BRAF, BRAF (V600E), ADCK4, CDKL2, CSNK1E, CSNK1G2, CIT, GCN2, GSK3B, HIPK4, IRAK1, JNK1,2,3, LIMK2, MEK4, MEK5, MLK2, p38-alpha, P38-beta, PFCDPK1, PIK4CB, RAF1, RIPK2, SRMS, STK36, TAOK3, TESK1, ZAK. In an additional study

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

(#NVR021-01-P-00001), the Applicant conducted the same assay using 4 concentrations of LGX818 (10, 100, 1000, and 10,000 nM). Ten nM LGX818 led to between 97.8 and 78% inhibition of ligand binding for the following kinases: BRAF wt, BRAF(V600E), RAF1, and STK36 (Table 2).

Table 2: LGX818 inhibition of ligand binding

Kinase Target	NVP-LGX818-NX-4			
Ambit Gene Symbol	%Ctrl @ 10nM	%Ctrl @ 100nM	%Ctrl @ 1000nM	%Ctrl @ 10000nM
ADCK3	100	100	79	8.4
ADCK4	92	59	11	0.1
BRAF	4.4	0.25	0	0
BRAF(V600E)	3.7	0.45	0	0
BRK	100	100	63	8
CDKL2	100	67	50	2.2
CIT	88	100	69	3
CSNK1A1	100	100	54	3.4
CSNK1D	83	98	54	3.6
CSNK1E	79	63	60	3
CSNK1G2	98	74	29	0.4
GCN2(Kin.Dom.2.S600G)	71	67	24	0.95
GSK3B	100	93	11	0.35
HIPK4	69	67	46	6.6
IRAK1	100	84	20	0.5
JNK1	64	25	1	0
JNK2	69	11	0.1	0
JNK3	65	26	0.95	0
LIMK1	67	10	0.15	0.1
LIMK2	73	30	2	0.15

Kinase Target	NVP-LGX818-NX-4			
Ambit Gene Symbol	%Ctrl @ 10nM	%Ctrl @ 100nM	%Ctrl @ 1000nM	%Ctrl @ 10000nM
MAP4K5	89	64	69	12
MEK4	77	44	1.6	0
MEK5	100	65	6.3	0.65
MLK1	100	93	54	5.5
MLK2	100	97	28	4.0
MLK3	87	94	43	17
NLK	71	26	7.9	9.7
p38-alpha	99	85	36	2.4
p38-beta	100	100	35	1.2
PFCDPK1(P.falciparum)	81	16	1	0.1
PIK4CB	97	96	69	4.1
PIP5K1C	70	62	75	10
RAF1	21	2.5	0	0
RIPK2	95	45	4.4	0.55
SRMS	77	50	2.0	0.1
STK36	13	1.2	0.5	0.45
TAOK3	100	98	56	3.2
TESK1	75	67	31	3.2
TNNSK	100	100	47	5.4
ZAK	83	40	4.3	1.8

%Ctrl Legend: 0.5x<1 1.5x<10 10.5x<35 x235

(Excerpted from Study # NVR021-01-P-00001)

The applicant conducted additional biochemical studies to determine IC₅₀ values for LGX818 against intended targets, BRAF(V600E), BRAF, and CRAF, using the AlphaScreen enzymatic assay (Study #RD-2011-50048). Briefly, human RAF enzymes BRAF(V600E), BRAF, and CRAF were incubated with serial dilutions of LGX818 in the presence of ATP and biotinylated MEK1, as the protein substrate, in 384-well plates for 3 hours at room temperature, after which Protein A and streptavidin beads were added and incubated for an additional hour. IC₅₀ values for inhibition of MEK1 phosphorylation were 0.35, 0.47, and 0.30 nM for BRAF(V600E), BRAF, and CRAF, respectively. In Study #LGX818-Enz-1, the Applicant determined the activity of the largest circulating metabolite (approximately 15.5% of AUC), LHY746 (AR00492720), on the RAF enzymes using the same method. The IC₅₀ values for LHY746 mediated inhibition of MEK1 phosphorylation by BRAF(V600E), BRAF, and CRAF were 9.3, 15.5, and 9.1 nM, respectively.

In Study # RD-2011-50435, the applicant examined and compared the effects of the RAF inhibitors LGX818 and PLX4032 (vemurafinib) against a large panel of genetically characterized cell lines. Briefly, the Applicant incubated cells from 512 cell lines for 72 hours with LGX818 or PLX4032 at concentrations ranging from 0.003 to 8 μM, then determined cell growth using the CellTiter Glo assay. Results are normalized as cross point (CP) values defined as the concentration required to achieve cell viability half way between the positive and negative control. Cell lines carrying the BRAFV600E mutation had CPs < 1 μM, while cell lines lacking this allele were predominately insensitive to both compounds (see Table 3 for examples). LGX818 inhibited more cell lines with the V600E allele compared to PLX4032 (74% vs. 40%, respectively of total cell lines tested).

Table 3: LGX818 and PLX4032 inhibition of cell viability

Cell line	BRAF mutation	LGX818 CP (μM)	PLX4032 CP (μM)
A375 (skin)	V600E	0.009	0.56
C32 (skin)	V600E	0.021	8.0
COLO-679 (skin)	V600E	0.011	0.56
MDST8 (large intestine)	V600K	0.143	6.7
WM-115 (skin)	V600D	0.08	5.14
WM-266-4 (skin)	V600D	0.005	0.8
22Rv1	L597R	3.5	3.0
COLO 792 (skin)	None	8.0	8.0
CHL-1 (skin)	None	2.9	4.9

To further determine the inhibitory activity of LGX818 and PLX4032 on cancer cell lines with activating mutations in BRAF at position 600 (E/D/K), the applicant examined six colorectal and 26 melanoma-derived cell lines with V600 mutations. LGX818 inhibited 4/6 (67%) of the colorectal, and 19/26 (73%) of the melanoma cell lines with CP < 1 μM, while PLX4032 inhibited 2/6 colorectal (33%) and 13/26 (50%) melanoma cell lines with CP < 1 μM. LGX818 had greater activity against cancer cell lines harboring BRAFV600 alterations compared to wild type.

In Study # RD-2011-50039, the applicant conducted a cellular proliferation assay to determine inhibitory effects of LGX818 on cellular proliferation, and western and immunosorbant assays to measure inhibition of downstream substrates of the targeted receptor (i.e. phosphorylation of ERK and MEK) (Table 4). Briefly, in the proliferation assay, A375 cells (BRAF(V600E) melanoma cell line), were incubated with serial dilutions of LGX818 for 72 hours (h) after which CellTiter Glo reagent was added to detect ATP, which is proportional to the number of live cells remaining (n=5 experiments). The EC₅₀ for inhibition of proliferation of A375 cells was 4 nM. In the In-Cell Western assay, A375 cells were incubated with serial dilutions of LGX818 for 3 hours after which media was removed and cells were fixed with paraformaldehyde for 30 minutes then washed, followed by immunodetection using anti-pERK1/2 (n=4). The EC₅₀ for pERK inhibition was 3 nM. In the ECL immunosorbant assay, A375 cells were incubated with serial dilutions of LGX818 for 3 hours, and analyzed for pMEK1/2 using ECL. The EC₅₀ for pMEK inhibition was 2 nM.


Table 4: EC₅₀ values for LGX818 inhibition of pMEK

Inhibition	EC ₅₀
Inhibition of A375 cell proliferation	4 nM
pERK1/2	3 nM
pMEK1/2	2 nM

In Study # 818-CBiology-0117, the applicant evaluated the activity of LGX818 and its active metabolite LHY746 on proliferation and inhibition of pERK in the melanoma cell line Malme-3M (BRAF(V600E) mutant) using methods previously described. LGX818 had 32-fold more activity

than LHY746 at inhibiting proliferation of Malme-3M cells (3.9 vs. 125 nM), and 2-fold more activity at inhibiting pERK in Maleme-3M cells (34 vs. 73 nM) (Figure 1).

Figure 1: Anti-proliferative and pERK inhibitory activity of LGX818 and its active metabolite LHY746



(Excerpted from Study # 818-CBiology-0117)

Because RAF inhibitors differ significantly in off rates in biochemical assays, the applicant utilized a wash-out protocol to track the duration of pMEK inhibition after removal of RAF inhibitors using the ECL assay (Study # RD-2011-50039) (Table 5). Briefly, A375 cells were incubated with serial dilutions of LGX818 or PLX4032 (vemurafinib) for 3 hours at 37°C, media removed, cells washed, and ECL performed at 0, 1, or 3 hours post wash for pMEK. Shifts in EC₅₀ values were assessed. The EC₅₀ value for LGX818 inhibition of pMEK increased by 1.75-fold 3 h post wash-out of test article compared to time 0, while, the EC₅₀ for PLX4032 increased by 23-fold, indicating a slower off rate for LGX818, thus a longer inhibition of the target.

Table 5: Duration of pMEK inhibition after removal of RAF inhibitors


Compound	0 Time post wash	1 h post wash	3 h post wash
LGX818	2.4 nM	3 nM	4.2 nM
PLX4032	30 nM	192 nM	685 nM

In vitro encorafenib/binimetinib combination data

The applicant determined the activity of the combination of LGX818 (encorafenib) and MEK162 (binimetinib) compared to single-agent activity in a panel of melanoma and colorectal cancer derived cell lines with either the T1799A allele, which encodes the BRAFV600E protein, or the wild type (wt) BRAF allele (Study #RD-2011-50576). Briefly, using the CellTiter Glo kit, the applicant measured cell viability based on ATP concentrations after incubation of cells for 72 hours with serial dilutions of LGX818 and MEK162 either alone or in combination. IC₅₀ values were calculated. Synergistic activity of the combination was assessed using the Excess Inhibition 2D matrix according to the Loewe additivity model and were reported either as a Synergy Score or a combination index (CI) which was derived from the lowest value on the graphs at 50% inhibition. LGX818 alone had a 3.2-fold greater anti-proliferative activity against cell lines containing mutated BRAF compared to cell lines containing wt BRAF (mean across cell lines 770 nM vs 2533 nM, respectively). Similarly, BRAF mutated cell lines were more sensitive to MEK162 compared to cell lines with wt BRAF with a 2-fold difference in IC₅₀ values (990 nM vs.

1932 nM). Synergy score measurements for the LGX818 and MEK162 combination indicated that the combination was more active in BRAF mutants than wt cell lines (median synergy scores of 1.94 vs. 0.91, respectively).

Figure 2: Anti-proliferative activity of the combination of encorafenib and binimetinib in melanoma and colorectal cancer derived cell lines




(Excerpted from Study # RD-2011-50576)

B. In Vivo Studies

In Study # RD-2011-50045, the applicant evaluated the anti-tumor, pharmacokinetic (PK), and pharmacodynamic (PD) activity of LGX818 in mice bearing human melanoma tumors with BRAF(V600E) mutations. Briefly, female adult nude mice bearing A375 tumors were treated with single oral LGX818 doses of 0.6, 6, or 60 mg/kg then analyzed for both plasma exposure and activity in tumor tissue including levels of pMEK, pERK, and mRNA of downstream transcriptional targets DUSP6 and SPRY4, at different time points. Maximum target inhibition occurred approximately 6 hours post-dose.

Figure 3: Pharmacokinetic activity of LGX818 in mice A375 tumors




(Excerpted from Study #RD-2011-50045)

In an anti-tumor activity study, female nude mice bearing subcutaneous A375 tumors were treated twice daily with LGX818 at 0.6, 6, 60, or 300 mg/kg for 14 days. No mortalities or significant changes in body weight occurred during the study. Tumor regression occurred at all

but the lowest dose tested (0.6 mg/kg). The 6 mg/kg dose resulted in 51% tumor regression which did not increase with increased dose, indicating that LGX818 achieved maximum anti-tumor activity in this model at the 6 mg/kg dose. Taken with the data from the PK/PD summarized above, the data suggests that prolonged inhibition of downstream signaling of at least 75% is needed to achieve tumor regression.


Figure 4: Anti-tumor activity of LGX818 in mice bearing A375 tumors



(Excerpted from Study # RD-2011-50045)

The applicant further determined the anti-tumor activity in a second xenograft model using Malme-3M and HMEX1906 tumors (both BRAF(V600E) mutants) in nude female mice. Malme-3M tumors were generated via subcutaneous implantation of tumor cells grown in vitro, and HMEX1906 tumors were generated using subcutaneous implant of a fresh human melanoma tumor biopsy previously established in nude mice. Mice bearing Malme-3M tumors were treated with LGX818 once daily (QD) at doses of 0.5, 3, or 20 mg/kg for 14 days, and mice bearing HMEX1906 tumors were treated twice daily (BID) with 1, 5, or 20 mg/kg for 14 days. Similar to data in the A375 model, LGX818 induced tumor regression in both Malme-3M and HMEX1906 tumors at doses as low as 3 mg/kg once daily and 1 mg/kg twice daily, respectively.

Figure 5: Anti-tumor activity of LGX818 in mice bearing Malme-3M tumors (right panel) or mice bearing HMEX1906 tumors (left panel)



(Excerpted from Study # RD-2011- 50045)


In vivo encorafenib/binimetinib combination data

In two xenograft studies (#060304-1513 and #060304-1547), the applicant investigated the effect of oral MEK162 (binimetinib) and LGX818 (encorafenib) either as single agents or in combination in adult female nu/nu NCr mice (n=7/group) bearing subcutaneous malignant

melanoma tumors from A375 (BRAF(V600E)) cells or MEL13B4 (BRAF(V600E)) cells. Animals received the following doses for 14 consecutive days in both studies; MEK-162 alone 3.5 mg/kg BID; LGX818 alone 6, 20, 60 mg/kg QD; or MEK-162 at 3.5 mg/kg BID with LGX818 at doses of 6, 20, or 60 mg/kg QD. Dosing started when A375 tumors reached approximately 240 mm³ and MEL13B4 reached approximately 229 mm³. The doses and schedules employed in these studies did not lead to overt toxicity: there were no deaths and body weight gain decreases of <7% decrease in all groups for A375 bearing mice and of <10% for MEL13B4 bearing mice.

MEK-162 as a single agent had slight activity on tumor growth inhibition (TGI) leading to 40% TGI in A375 tumors and 31% TGI in MEL13B4 tumors compared to vehicle controls. LGX818 as a single agent at 6 mg/kg had no effect on tumor growth; however, 20 and 60 mg/kg LGX818 doses led to 78 and 90% TGI in A375 tumors and 48 and 44% TGI in MEL13B4 tumors, respectively. While the lowest dose of LGX818 was not effective as a single agent, in combination with 3.5 mg/kg of MEK162, treatment with 6 mg/kg LGX818 led to TGIs of 78 and 52% in A375 and MEL13B4 tumors, respectively. At the higher LGX818 doses, the combination with MEK-162 did not have a large impact on TGI compared to single agent values in A375 tumors. In MEL13B4 tumors, the combination with MEK-162 increased the TGI to 71 and 63% for the 20 and 60 mg/kg doses, respectively. No complete responses occurred in this study. Partial responses (PR) and stable disease (SD) occurrences are listed in Table 6.

Figure 6: Anti-tumor activity of LGX818 and MEK162 as single agents and in combination in mice bearing A375 and MEL13B4 tumors



(Excerpted from Study # 060304-1513 for A375 tumors and #060304-1547 for MEL13B4 tumors)

Table 6: Tumor growth inhibition, partial responses, and stable disease in mice bearing A375 or MEL13B4 tumors after treatment with LGX818 and MEK162 as single agents and in combination

Test Articles	A375 tumors		MEL13B4 tumors	
	%TGI	PR/SD	%TGI	PR/SD
Vehicle	0	0/0	na	1/0
MEK-162 3.5 mg/kg BID	40.2	0/0	31	0/2

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

LGX818 6 mg/kg QD	8.3	0/0	-4	0/0
LGX818 20 mg/kg QD	77.5	1/3	48	0/1
LGX818 60 mg/kg QD	90	3/4	44	1/2
MEK-162 3.5 mg/kg BID + LGX818 6 mg/kg QD	78.2	0/5	52	1/0
MEK-162 3.5 mg/kg BID + LGX818 20 mg/kg QD	89.9	3/4	71	1/3
MEK-162 3.5 mg/kg BID + LGX818 60 mg/kg QD	90	4/3	63	0/1


TGI= tumor growth inhibition; PR= partial response; SD= stable disease; na= not applicable as vehicle control tumors exceeded recommended limits for tumor growth.

In Study # RD-2011-50693, the applicant investigated whether the combination of LGX818 and MEK162 can prevent or delay the emergence of treatment resistance, which occurs in melanoma patients that relapse after treatment with BRAF inhibitors. The HMEX1906 BRAF(V600E) melanoma cell line is sensitive to BRAF and MEK inhibitors and, similarly to the clinical situation, develops resistance to treatment with BRAF inhibitors alone over the course of several weeks, thus HMEX1906 cells were used in a mouse xenograft model. Briefly, nude female mice (n=8) bearing subcutaneous HMEX1906 tumors (approximately 400 mm³) were treated with vehicle, MEK162 (3 or 10 mg/kg, BID oral), LGX818 (3 mg/kg, BID oral), or the combination of MEK162 and LGX818 (3 + 3 mg/kg or 10 + 3 mg/kg; BID oral). Tissue was harvested after 17 weeks of dosing. Tumor growth measurements halted after 2 mice/group were euthanized due to tumor burden. Body weight changes in treated animals compared to control animals did not occur in any dose group over the course of the study. Tumor regression occurred in all treatment groups; however, the response was transient in the 3 mg/kg MEK162 single agent dose group with a nadir around 14 days (Table 7). MEK162 as a single agent at 10 mg/kg led to a 60% tumor regression by Day 50, but tumor growth recurred and mice were euthanized due to tumor burden before the Day 104 analysis. The anti-tumor activity of LGX818 alone did not continue past Day 50, with tumor regression going from 77% to 36% on Day 104. Tumor regression of the MEK162/ LGX818 (3+3 mg/kg) combination was maintained through Day 104 but some growth occurred by Day 117. The MEK162/LGX818 combination of 10 + 3 mg/kg, led to tumor regression throughout the course of the study suggesting that the combination at appropriate doses could lead to longer responses to treatment.

Table 7: Tumor regression in mice bearing HMEX1906 tumors after treatment with LGX818 or MEK162 as single agents or in combination

Drug	Dose	% regression compared to control TV 1309 mm ³		
		Day 50	Day 104	Day 117
Vehicle (0.5% CMC, 0.5% T-80)	-	-	-	-
MEK162	3	0.4	-	-
MEK162	10	60	-	-
LGX818	3	77	36	-
MEK162 + LGX818	3 + 3	82	82	77
MEK162 + LGX818	10 + 3	88	92	93

Figure 7: Tumor volume and body weight in mice bearing HMEX1906 tumors after treatment with LGX818 or MEK162 as single agents or in combination



(Excerpted from Study #RD-2011-50693)

Secondary Pharmacology

Off-target activity of LGX818 was assessed using 143 GPCRs, transporters, ion channels, nuclear receptors, and enzymes (Study #RD-2016-00386). Off-target activity of the main metabolite, LHY746, was assessed on 56 GPCRs, transporters, ion channels, nuclear receptors, and enzymes (Study #RD-2015-00327). LGX818 activity leading to greater than 50% inhibition or activation at the concentration of 10 μ M, was limited to the PDE4D enzyme with an IC_{50} of 4.4 μ M. Several targets identified as being potentially involved in suicidality were also tested and IC_{50} values were all greater than 30 μ M. LHY746 activity leading to greater than 50% inhibition at 10 μ M was limited to the KDR kinase and phosphodiesterase PDE4D, with IC_{50} values of 1.8 and 4.2 μ M. LHY746 was found to be an agonist of the pregnane X receptor (PXR), with an EC_{50} value of 3.8 μ M.

Safety Pharmacology

In non-GLP Study #PCS-R 0970564, HEK293 cells stably expressing human hERG potassium channel were incubated with encorafenib (10, 30, 100 μ M), 0.3% DMSO (negative control), or 90 nM Cisapride (positive control) followed by measurement of potassium current using the patch-clamp technique. Negative and positive controls behaved as expected. Encorafenib inhibited the hERG potassium current with an IC_{50} value of 73.4 μ M (n=3), suggesting minimal risk of QT prolongation in humans given encorafenib. The LHY746 (AR00492720) metabolite demonstrated similar activity in a separate study.

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

In GLP-compliant Study #PCS-R1170383, radiotelemetry-instrumented male cynomolgus monkeys received single oral doses of LGX818 at 50, 100, and 200 mg/kg using a 4x4 crossover paradigm and a 7-day washout between each dose to assess the effects of LGX818 on cardiovascular parameters. Clinical signs, mortality, systemic blood pressures, heart rate, body temperature, and ECG duration/intervals (PR, RR, QRS, QT, and QTc) were measured prior to each dose and at approximately 30 minutes, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, and 24 hours post dose. Consistent with the in vitro hERG data, treatment with LGX818 at dose levels up to 200 mg/kg did not result in QT or QTc prolongation. In addition, doses up to 200 mg/kg did not affect QRS, body temperature, or systemic blood pressure. There were no mortalities and clinical signs were limited to salivation in 2 out of 4 animals at the 200 mg/kg high dose level. Post-dose heart rate increases with maximum differences of 75 bpm (73%) at 11 hours, 82 bpm (82%) at 12.5 hours, and 68 bpm (68%) at 12.75 hours occurred in animals at the 50, 100, and 200 mg/kg dose levels, respectively, relative to the concurrent controls, with no dose relationship.

In GLP-compliant Study #PCS-R1170382, the applicant assessed LGX818 for the potential to induce CNS and respiratory toxicity by administering a single LGX818 dose of 100 mg/kg to male Sprague-Dawley rats followed by completing functional observation battery (FOB) testing (n=10) and respiratory minute volume (RMV) testing (n=5). The FOB was conducted pre-dose, 1, 3, and 24 hours post dose. RMV assessment was conducted for 30 minutes pre-dose, continuously from immediate post dose to 1 hour post dose, and for a 30 minute period at 3, 7, and 24 hours post dose. Forelimb grip strength was reduced by 28% 24 hours post dose in LGX818 treated animals compared to controls (p<0.01, t-test), but not at any other time point. A single oral dose of LGX818 at 100 mg/kg did not affect other FOB parameter or any respiratory function measures up to 24 hours post dose.

5.4. ADME/PK

Type of Study	Major Findings						
Absorption							
Study #R1000227: Absorption, metabolism, and excretion in intact and bile duct-cannulated rats after a single intravenous (5 mg/kg) or oral dose (50 mg/kg) of [¹⁴ C]LGX818	• LGX818 elimination occurred primarily through oxidative metabolism and parent drug excretion after IV or oral dosing • LGX818 accounted for 85% of the total plasma AUC • Oral bioavailability was 40-50% in the mouse, rat, and dog and 22% in monkey						
	LGX818 in plasma <table border="1" style="margin-left: 20px;"> <thead> <tr> <th>Parameter</th> <th>Intravenous</th> <th>Oral</th> </tr> </thead> <tbody> <tr> <td>Cmax (ng/mL)</td> <td>43500</td> <td>36400</td> </tr> </tbody> </table>	Parameter	Intravenous	Oral	Cmax (ng/mL)	43500	36400
Parameter	Intravenous	Oral					
Cmax (ng/mL)	43500	36400					

Type of Study	Major Findings																			
Study #R1000210: In vitro binding of [¹⁴ C]LGX818 to blood cells, and serum and plasma proteins in the mouse, rat, dog, monkey and human	AUC _{inf} (h*ng/mL)	58900	24500 0																	
	Tmax (h)	0.083	2-4																	
	T _{1/2} (h)	62	7.6																	
	% dose radioactivity recovery 0-168 h	99	97.4																	
	Plasma protein binding																			
<table border="1"> <thead> <tr> <th data-bbox="662 537 813 569">Parameter</th> <th data-bbox="821 537 1036 569">Mean % binding</th> <th data-bbox="1044 537 1258 569">Range % binding</th> </tr> </thead> <tbody> <tr> <td data-bbox="662 579 813 604">Mouse</td> <td data-bbox="821 579 1036 604">98.6</td> <td data-bbox="1044 579 1258 604">98.5-98.7</td> </tr> <tr> <td data-bbox="662 615 813 640">Rat</td> <td data-bbox="821 615 1036 640">98.1</td> <td data-bbox="1044 615 1258 640">96.4-99</td> </tr> <tr> <td data-bbox="662 651 813 676">Dog</td> <td data-bbox="821 651 1036 676">82.7</td> <td data-bbox="1044 651 1258 676">79.3-85.8</td> </tr> <tr> <td data-bbox="662 686 813 711">Monkey</td> <td data-bbox="821 686 1036 711">74.6</td> <td data-bbox="1044 686 1258 711">65.4-82.2</td> </tr> <tr> <td data-bbox="662 722 813 747">Human</td> <td data-bbox="821 722 1036 747">86.1</td> <td data-bbox="1044 722 1258 747">84.4-86.8</td> </tr> </tbody> </table>			Parameter	Mean % binding	Range % binding	Mouse	98.6	98.5-98.7	Rat	98.1	96.4-99	Dog	82.7	79.3-85.8	Monkey	74.6	65.4-82.2	Human	86.1	84.4-86.8
Parameter	Mean % binding	Range % binding																		
Mouse	98.6	98.5-98.7																		
Rat	98.1	96.4-99																		
Dog	82.7	79.3-85.8																		
Monkey	74.6	65.4-82.2																		
Human	86.1	84.4-86.8																		
Distribution																				
Study #R1100588: Tissue distribution following a single oral (50 mg/kg) or intravenous (5 mg/kg) dose of [¹⁴ C]LGX818 in the rat	Oral • Little to no distribution to the CNS • LGX818 rapidly and extensively distributed to the tissues • Cmax was 0.25-2 hours post dose • Highest exposures occurred in bile and liver • All other tissue was below or close to blood values • At 168 h post dose most tissue were below the lower limit of detection except the liver Intravenous • Tissue distribution patten was similar to that observed in oral administration Cmax ~0.05 hours																			
Metabolism																				
Study #R1000081: In vitro metabolism of [¹⁴ C]LGX818 in rat, dog, monkey, and human hepatocytes	• Two predominant metabolites occurred in rat and dog: 1) M32.7 (loss of the isopropyl group via N dealkylation); 2) M23.8 (loss of the isopropyl group and the isopropyl-carbamic acid methyl ester side chains via N-dealkylations) • Additional metabolites occurred in monkey: 1) M36.5 (monohydroxylated LGX818); 2) M42.5A (LHY746, AR00492720) (loss of the isopropyl-carbamic acid methyl ester side chain via N-dealkylation); 3) M30.6 (further oxidation of monohydroxylated LGX818 to a carboxylic acid) 5 unique human metabolites identified: Significant amounts (<7% of total radioactivity used in the assay) of metabolites M46.3 (monohydroxy LGX818), M38																			

Type of Study	Major Findings
	(glucuronide of M46.3); Trace amounts (<1%) of M12.8 (a glucuronide), M31A (glucuronide of M44), and M39.4 (glucuronide of LGX818); because these metabolites were present at low levels, additional qualification is not needed for a drug intended for the treatment of patients with cancer
Excretion	
Study #R1000227: Absorption, metabolism, and excretion in intact and bile duct-cannulated rats after a single intravenous (5 mg/kg) or oral dose (50 mg/kg) of [¹⁴ C]LGX818	• Following a single 100 mg/kg oral dose, fecal and urinary excretion accounted for 85 and 12% of administered dose, respectively, within the first 24 hours with unchanged parent accounting for 57.8% and 0.04%, respectively • Following a single intravenous dose of 5 mg/kg, fecal and urinary excretion accounted for 74 and 24% of the administered dose, respectively, within the first 24 hours with unchanged parent accounting for 5.5% and 0.08%, respectively
TK data from general toxicology studies	TK data from long-term studies was incorporated in review of general toxicology studies in section 5.5.1
TK data from reproductive toxicology studies	TK data from embryofetal toxicity studies was incorporated in review of reproductive toxicology studies in section 5.5.4

5.5. Toxicology

5.5.1. General Toxicology

Study title/ number: A 13-week oral (gavage) toxicity study with a 4-week recovery period in rats / Study no. 8000058

Key Study Findings

- Oral gavage administration of LGX818 to rats at doses up to 60 mg/kg did not cause mortalities
- Dose-related microscopic findings in the testis, epididymis, skin, and stomach.

Conducting laboratory and location:



GLP compliance:

Yes

Methods

Dose and frequency of dosing:

6, 20, and 60 mg/kg/day

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

Route of administration:	Once daily for 13-weeks
Formulation/Vehicle:	Oral gavage 0.5% (w/v) sodium carboxymethylcellulose, type 7HF, aqueous solution containing 0.5% (v/v) Tween 80, NF, in ultra-pure water
Species/Strain:	Wistar Hannover Crl:WI (Han) rats
Number/Sex/Group:	Main: 10/sex/group Recovery: 6/sex/vehicle and 60 mg/kg groups
Age:	8 weeks
Satellite groups/ unique design:	None
Deviation from study protocol affecting interpretation of results:	No

Observations and Results: changes from control

Parameters	Major findings
Mortality	60 mg/kg/day: 1 Male euthanized on Day 82 in deteriorating clinical condition due to gavage accident; not related to LGX818 administration
Clinical Signs	<u>Main toxicity groups</u> All dose levels: Skin abnormalities: scabbed, dry, flaking, red and/or white skin, slight to moderate firm swelling of hind and forepaws and tail; findings started first week of dosing and continued through dosing period <u>Recovery animals</u> 60 mg/kg/day: All findings listed above still present at end of recovery period
Body Weights	<u>Decreases in body weight gain</u> 6 mg/kg/day: Males (↓ 3.9%), Females (↓ 3.6%) vs. controls 20 mg/kg/day: Males (↓ 8.7%), Females (↓ 5.1%) vs. controls correlated with an overall 7.5% decrease in food consumption 60 mg/kg/day: Males (↓ 11.2%), Females (↓ 7.9%) vs. controls correlated with an overall 11.1% decrease in food consumption Body weight changes recovered in all groups by end of recovery period.
Ophthalmoscopy	Unremarkable
Hematology	Percent Differences in Mean Values vs. Concurrent Controls

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

	Sex	Males			Females			
		Dose (mg/kg/day)	6	20	60	6	20	60
WBC	Week 5	-	-	+14	-	+22	+14	
	Week 11	-	-	+14	-	+12	+13	
	Recovery	-	-	+18	-	-	+19	
	Neutrophil	Week 5	-	-	+37	-	-	+13
		Week 11	-	-	+61	-	-	+35
	Eosinophil	Week 5	-	+77	+135	-	+67	+67
		Week 11	-	+47	+126	-	+37	+54
		Recovery	-	-	-	-	-	+58
	Reticulocyte	Week 5	-	-	-	-	-	-
Week 11		-	-	-	-	+24	+21	
‘-‘= no findings.								
Clinical Chemistry	Percent Differences in Mean Values vs. Concurrent Controls							
		Sex	Males			Females		
			Dose (mg/kg/day)	6	20	60	6	20
	ALT	Recovery	-	-	+133	-	-	+165
	AST	Recovery	-	-	+125	-	-	+134
	Urea	Week 5	-	+15	-	-	-	-
		Week 11	-	+15	+16	-	-	-
	Glucose	Week 5	-	-	+11	-	-	-
		Week 11	-	-	+16	-	+12	+11
	Cholesterol	Week 5	+20	+29	+30	-	-	-
		Week 11	-	+29	+27	-	-	-
	Triglycerides	Week 5	-	-	-27	-	-	-
		Week 11	-	-	-29	-	+35	+17
	‘-‘= no findings							
	Urinalysis	Unremarkable						
Gross Pathology	<u>Main toxicity groups</u> 20 mg/kg/day: (2/10 Males) abnormal consistency/soft/small testis (1/10 Males) epididymis (correlates with microscopic findings of tubular degeneration, cellular debris, oligo/aspermia) 60 mg/kg/day: - abnormal consistency/soft/small testis (4/10 Males) - epididymis (4/10 Males) (correlates with microscopic findings of tubular degeneration, cellular debris, oligo/aspermia) ; (3/10 Males) thickness and yellow discoloration in hind paw (correlates with hyper keratosis of the skin) <u>Recovery groups</u> 60 mg/kg/day: (2/5 Males) increased stomach wall thickness (correlates with hyperplasia and hyperkeratosis of the stomach)							
Organ Weights	Unremarkable							

Multi-Disciplinary Review and Evaluation NDA 210496
 BRAFTOVI™ (encorafenib)

Histopathology Adequate battery: Yes	Sex	Males			Females			
	Dose (mg/kg/day)	6	20	60	6	20	60	
	# main group, # recovery	10,-	10,-	10,5	10,-	10,-	10,6	
<i>Testis</i>								
Tubular degeneration	Minimal	1	-	1	na	na	na	
	Mild	1	-	-	na	na	na	
	Moderate	-	-	1,3R	na	na	na	
	Marked	-	1	1	na	na	na	
	Severe	-	-	3	na	na	na	
<i>Epididymis</i>								
Oligo/aspermia	Mild	-	-	1	na	na	na	
	Moderate	-	-	2	na	na	na	
	Marked	-	1	-	na	na	na	
	Severe	1	-	1	na	na	na	
Cellular debris	Moderate	-	-	-	na	na	na	
	Marked	1	1	3	na	na	na	
<i>Skin (hind paws)</i>								
Epithelial hyperplasia	Minimal	9	5	2,1R	7	3	4,1R	
	Mild	1	3	1	1	3	2	
	Moderate	-	2	3	-	1	-	
	Marked	-	-	3	-	-	-	
Hyperkeratosis	Minimal	7	7	2,1R	8	7	6,1R	
	Mild	3	1	1	-	-	2	
	Moderate	-	2	5	-	-	-	
	Marked	-	-	1	-	-	-	
<i>Stomach</i>								
Epithelial hyperplasia, non-glandular	Minimal	-	1	3,2R	-	-	4,1R	
Hyperkeratosis	Minimal	-	1	2,2R	-	-	4,1R	
There were no findings in control animals. 'na' = not applicable. '-'= no findings.								
Toxicokinetics	- Exposure increased in a dose-dependent manner - Exposure in females was approximately 2-fold higher compared to males at all dose levels							
	Dose (mg/kg/day)	6		20		60		
	Sex	M	F	M	F	M	F	
	Day 1							
	Cmax (ng/mL)	9820	16800	27500	48300	57800	102000	
	AUC0-24h (ng*h/mL)	40900	96800	141000	288000	303000	879000	
	Tmax(h)	1	1	1	1	0.5	1	
	Day 90							
	Cmax (ng/mL)	10400	18600	42100	54500	100000	150000	
	AUC0-24h (ng*h/mL)	45200	114000	178000	414000	614000	1110000	
	Tmax(h)	1	1	1	0.5	1	1	

Study title/ number: 13-week oral (gavage) toxicity study in monkeys with a 10-week recovery period / Study no. 1370471

Key Study Findings

- Oral treatment with LGX818 did not cause mortalities in monkeys at doses up to 60 mg/kg
- Findings were limited to eyes with granular substances and blister like findings

Conducting laboratory and location: Novartis Pharmaceuticals Corporation
 East Hanover, NJ, USA

GLP compliance: Yes

Methods

Dose and frequency of dosing: 20 and 60 mg/kg/day*
 Once daily for 13-weeks

Route of administration: Oral gavage

Formulation/Vehicle: Purified water

Species/Strain: Cynomolgus monkeys, Asian origin

Number/Sex/Group: Main: 4/sex/group
 Recovery: 2/sex/vehicle and 60 mg/kg groups

Age: 3-5 years

Satellite groups/ unique design: None

Deviation from study protocol affecting interpretation of results: No

*While higher doses might be tolerated in monkeys based on data from 1-month studies, the dose appears justified based on an exposure in monkeys that is 1.6 times the human exposure at the proposed 450 mg clinical dose.

Parameters	Major findings
Mortality	None
Clinical Signs	Main toxicity animals 60 mg/kg/day: sporadic emesis (4/6 Males; 5/6 Females), emesis with apparent drug in emesis (3/6 Males; 1/6 females): Salivation, occasional (2/6 females)
	Recovery animals 20 mg/kg/day: emesis with apparent drug (1/4 Females, Day 70)
Body Weights	Females at all dose levels had body weight decreases of ≤ 8.9% compared to controls throughout dosing period. Fully recovered to control levels during recovery period.
Ophthalmoscopy	60 mg/kg/day: Day 85 (2 animals/bilateral findings) displayed granular substance, circular in shape covered fovea, with ventral aspect of lesion yellow: Days 92 and 94 blister like lesion over fovea with yellow spotting increased in size from Day 85, newly formed blister on fovea with yellow fluid, blister like lesion dorsal of optic nerve; Recovery was partial to full.

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

Hematology	Unremarkable				
ECG	Unremarkable				
Clinical Chemistry	Unremarkable				
Urinalysis	Unremarkable				
Gross Pathology	Unremarkable				
Organ Weights	Unremarkable				
Histopathology Adequate battery: Yes	Dose (mg/kg/day)	60 mg/kg Males	60 mg/kg Females		
	# main group, # recovery	4,2	4,2		
	Eyes				
	Retinal separation or detachment	Minimal	-,1R	1	
There were no findings in control animals. '-'= no findings.					
Toxicokinetics	- Exposure was highly variable among individuals - Exposure increased with an increase in dose				
	Dose (mg/kg/day)	20		60	
	Sex	M	F	M	F
	Day 1				
	Cmax (ng/mL)	3590	8270	10400	12700
	AUC0-24h (ng*h/mL)	5830	11100	24200	43000
	Tmax (h)	1	0.75	0.917	1
	Day 86				
	Cmax (ng/mL)	1640	2930	9760	7790
	AUC0-24h (ng*h/mL)	3120	4280	20300	23900
Tmax (h)	0.875	1.13	1.67	2	

General toxicology; additional studies

One month GLP-compliant oral toxicology studies were conducted in Sprague-Dawley rats and cynomolgus monkeys and reviewed under IND 111003 to support first-in-human dosing. Drug induced mortality occurred in rats dosed at 400 mg/kg/day (exposure greater than 50-fold the clinical exposure at the recommended dose of 450 mg) due to toxicities, and the same target organ observations occurred as those observed in the 13-week study. No mortalities occurred in the monkey study dosed up to 100 mg/kg/day with minimal toxicity in the bone marrow and spleen.

5.5.2. Genetic Toxicology

In Vitro Reverse Mutation Assay in Bacterial Cells (Ames)

Study title/ number: Reverse Mutation in Five Histidine-Requiring Strains of Salmonella typhimurium / (b) (4) study number 8229996

Key Study Findings:

- LGX818 did not show genotoxic activity in five strains of Salmonella in the presence or absence of S9 activation
- Standard positive controls confirm the sensitivity and validity of the assay.

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

GLP compliance: Yes

Test system: Salmonella strains TA1535, TA97a, TA98, TA100, TA102; no bacterial toxicity up to 5000 µg/plate; +/- S9

Study is valid: Yes

In Vitro Assays in Mammalian Cells

Study title/ number: Induction of Chromosome Aberrations in Cultured Human Peripheral Blood Lymphocytes / (b) (4) study number 8229997

Key Study Findings:

- LGX818 did not show any evidence of genotoxic activity in the absence or presence of S9.
- Positive controls caused substantial increases in the proportion of aberrations confirming the sensitivity and validity of the study.

GLP compliance: Yes

Test system: human peripheral blood lymphocytes; LGX818 up to 550 µg/mL; +/- S9

Study is valid: Yes

In Vivo Clastogenicity Assay in Rodent (Micronucleus Assay)

Study title/ number: Induction of Micronuclei in the Bone Marrow of Treated Rats / (b) (4) study number 8265568

Key Study Findings:

- Oral administration of LGX818 at ≤ 2000 mg/kg/day (200, 1000, and 2000 mg/kg/day) for 2 days did not induce micronuclei in polychromatic erythrocytes of the bone marrow of male rats with numbers falling within the range of the negative controls.
- Positive control material induced a significant increase in the frequency of micronucleated polychromatic erythrocytes confirming the sensitivity and validity of the study.

GLP compliance: Yes

Test system: rat, bone marrow micronuclei; two oral doses of 200, 100, and 2000 mg/kg/day administered 24 hours apart

Positive control: 20 mg/kg cyclophosphamide

Study is valid: Yes

Other Genetic Toxicity Studies: None

5.5.3. Carcinogenicity

None submitted or required for the proposed indication.

5.5.4. Reproductive and Developmental Toxicology

Fertility and Early Embryonic Development

Neither submitted nor required

Embryo-Fetal Development

Study title/ number: An oral gavage study of embryo-fetal development in the rat / 9000201

Key Study Findings

- 20 mg/kg/day treated females had decreased body weight (11% compared to controls)
- Pups from 20 mg/kg/day treated mothers showed malformations of anasarca, micrognathia, and microphthalmia

Conducting laboratory and location:



GLP compliance:

Yes

Methods

Dose and frequency of dosing:

0.5, 5, and 20 mg/kg/day
Daily from Days 6 to 17 post coitum

Route of administration:

Oral gavage

Formulation/Vehicle:

0.5% (w/v) sodium carboxymethylcellulose (Na CMC), type 7HF, containing 0.5% (v/v) Tween 80, NF, in ultra pure water

Species/Strain:

Wistar Hannover Crl:WI (Han) rats

Number/Sex/Group:

20/group

Satellite groups:

Yes; 3 animals/control; 5 animals/treatment group

Study design:

Time-mated rats were treated once daily oral gavage from Days 6 to 17 post coitum

Deviation from study protocol

No

affecting interpretation of results:

Observations and Results

Parameters	Major findings
Mortality	No test article related deaths
Clinical Signs	Unremarkable
Body Weights	Decreased mean body weight (11% vs. controls) occurred during dosing period Days 6-18 in the 20 mg/kg animals

Multi-Disciplinary Review and Evaluation NDA 210496
 BRAFTOVI™ (encorafenib)

Necropsy findings Cesarean Section Data		0	0.5 mg/kg	5 mg/kg	20 mg/kg	
	Pregnancy index (%)	100	92	96	96	
	Number of females with viable fetuses for examination on GD20	24	22	23	23	
	Number pregnant	24	22	23	23	
	Number not pregnant	0	2	1	1	
	Gravid uterine weight	80.6	-	↓3%	↓4%	
	Mean corporate lutea	12.8	12.1	12.5	12.3	
	Mean implantation sites	11.9	11.3	11	11.2	
	Mean % preimplantation loss	6.83	7.71	11.41	8.84	
	Mean% postimplantation loss	4.61	3.47	2.59	3.17	
	Mean litter size	11.3	10.9	10.8	10.9	
	Mean early resorptions	0.6	0.4	0.3	0.3	
	Mean late resorptions	0	0	0	0.1	
	Fetal weight change relative to controls					
	Male	5.419 g	↑2.2%	↓0.4%	↓4.3%	
	Female	5.128g	↑2.2%	↓0.6%	↓3.5%	

'-' = change of less than 0.01%.

Multi-Disciplinary Review and Evaluation NDA 210496
 BRAFTOVI™ (encorafenib)

Necropsy findings Offspring	Dose	0	0.5 mg/kg	5 mg/kg	20 mg/kg
	Visceral Malformations				
Number of Fetuses/Litters Evaluated		272/24	239/22	248/23	250/23
# of fetuses affected (%) / # of litters affected (%)					
Anasarca		0	0	0	1 (0.4) / 1 (4.3)
Mandibular micrognathia		0	0	0	1 (0.4) / 1 (4.3)
Maxillary micrognathia		0	0	0	1 (0.4) / 1 (4.3)
Microphthalmia		0	0	0	1 (0.4) / 1 (4.3)
Small lens		0	1 (0.8) / 1 (4.5)	0	1 (0.8) / 1 (4.3)
Vitreous body, discoloration dark		0	1 (0.8) / 1 (4.5)	0	1 (0.8) / 1 (4.3)
Omphalocele		0	0	2 (0.8) / 1 (4.3)	0
Abnormal flexure of hindlimbs		1 (0.4) / 1 (4.2)	0	1 (0.4) / 1 (4.3)	3 (1.2) / 2 (8.7)
Total Visceral Malformations					
Number of fetuses (%) / number of litters (%)		1 (0.4) / 1 (4.2)	2 (0.8) / 2 (9.1)	3 (1.2) / 2 (8.7)	3 (1.2) / 2 (8.7)
Visceral Variations					
Number of Fetuses/Litters Evaluated		136/24	118/22	123/23	125/23
Lens, misshapen		0	0	0	1 (0.8) / 1 (4.3)
Liver lob vestigial		1 (0.7) / 1 (4.2)	0	0	1 (0.8) / 1 (4.3)
Ureters dilated		0	1 (0.8) / 1 (4.5)	0	0
Total Visceral Variations					
Number of fetuses (%) / number of litters (%)		1 (0.4) / 1 (4.2)	1 (0.4) / 1 (4.5)	0	2 (0.8) / 2 (8.7)
Skeletal Variations					
Number of Fetuses/Litters Evaluated		137/24	122/22	125/23	125/23
Nasal bone incomplete ossification		1 (0.7) / 1 (4.2)	0	0	0
Parietal bone incomplete ossification		5 (3.6) / 4 (16.7)	11 (9.0) / 6 (27.3)	9 (7.2) / 6 (26.1)	25 (20) / 13 (56.5)
Frontal bone incomplete ossification		2 (1.5) / 2 (8.3)	0	0	3 (2.4) / 1 (4.3)
Interparietal bone incomplete ossification		6 (4.4) / 6 (25)	10 (8.2) / 6 (27.3)	16 (12.8) / 10 (43.5)	29 (23.2) / 14 (60.9)
Supraoccipital bone incomplete ossification		4 (2.9) /	1 (0.8) /	3 (2.4) /	3 (2.4) /

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

		2 (8.3)	1 (4.5)	3 (13)	3 (13)
	Hyoid bone unossified	0	1 (0.8)/ 1 (4.5)	0	0
	Hyoid bone incomplete ossification	0	1 (0.8)/ 1 (4.5)	1 (0.8)/ 1 (4.3)	2 (1.6)/ 1 (4.3)
	Zygomatic temporal incomplete ossification	1 (0.7)/ 1 (4.2)	0	0	1 (0.8)/ 1 (4.3)
	Zygomatic maxilla process incomplete ossification	0	0	0	1 (0.8)/ 1 (4.3)
	Extra presacral vertebra	2 (1.5)/ 2 (8.3)	2 (1.6)/ 2 (9.1)	4 (3.2)/ 4 (17.4)	2 (1.6)/ 2 (8.7)
	Cervical vertebral arch fused	0	0	1 (0.8)/ 1 (4.3)	0
	Cervical vertebral centrum absent	0	0	1 (0.8)/ 1 (4.3)	0
	Lumbar centrum semi-bipartite	0	3 (2.5)/ (13.6)	0	1 (0.8)/ 1 (4.3)
	Ossification center on 1 st lumbar or 14 th thoracic vertebra	56 (40.9)/ 22 (91.7)	45 (36.9)/ 17 (77.3)	45 (36)/ 20 (87)	37 (29.6)/ 17 (73.9)
	Thoracic vertebral arches fused	0	0	1 (0.8)/ 1 (4.3)	0
	Thoracic vertebral centrum displaced	0	0	1 (0.8)/ 1 (4.3)	0
	Thoracic centrum variants (unossified/incomplete/semi-bipartite/bipartite)	12 (8.8)/ 10 (41.7)	24 (19.7)/ 12 (54.5)	21(16.8)/ 15 (65.2)	31 (24.8)/ 16 (69.6)
	Reduced number of caudal vertebrae	0	1 (0.8)/ 1 (4.5)	0	0
	Sternebrae 1 to 4 (unossified/incomplete/semi-bipartite/bipartite)	2 (1.5)/ 2 (8.3)	2 (1.6)/ 2 (9.1)	2 (1.6)/ 2 (8.7)	4 (3.2)/ 2 (8.7)
	Sternebrae 5 and xiphisternum (unossified/incomplete/semi-bipartite/bipartite)	10 (7.3)/ 5 (20.8)	14 (11.5)/ 7 (31.8)	4 (3.2)/ 4 (17.4)	3 (2.4)/ 3 (13)
	Wavy ribs	0	0	1 (0.8)/ 1 (4.3)	0
	Notched ribs	0	0	0	1 (0.8)/ 1 (4.3)
	Ribs incomplete ossification	0	0	2 (1.6)/ 2 (8.7)	1 (0.8)/ 1 (4.3)
	Rudimentary 14 th rib	15 (10.9)/ 12 (50)	17 (13.9)/ 11 (50)	10 (8)/ 9 (39.1)	13 (10.4)/ 9 (39.1)
	Extra 14 th rib	5 (3.6)/ 5 (20.8)	2 (1.6)/ 2 (9.1)	7 (5.6)/ 5 (21.7)	3 (2.4)/ 2 (8.7)
	Ossification center on 7 th cervical vertebra	1 (0.7)/ 1 (4.2)	3 (2.5)/ 2 (9.1)	1 (0.8)/ 1 (4.3)	4 (3.2)/ 3 (13)
	Rudimentary 14 th rib with contralateral ossification center	1 (0.7)/ 1 (4.2)	0	2 (1.6)/ 2 (8.7)	1 (0.8)/ 1 (4.3)
	Extra 14 th rib with contralateral rudimentary rib	1 (90.7)/ 1 (4.2)	1 90.8)/ 1 (4.5)	3 (2.4)/ 3 (13)	1 (0.8)/ 1 (4.3)
	Total Skeletal Variations				
	Number of fetuses (%) / number of litters (%)	98 (71.5) / 23 (95.8)	74 (60.7) / 19 (86.4)	80 (64) / 22 (95.7)	84 (67.2) / 23 (100)
Toxicokinetics	- The AUC exposures in rats at doses of 0.5, 5, and 20 mg/kg were 1x, 6x, and 26x those achieved in patients given the 450 mg encorafenib dose - Fetal exposures were approximately 1-2% of the concentrations in maternal plasma				

Maternal Exposure			
Dose (mg/kg/day)	0.5	5	20
Day 16 post coitum-maternal			
Cmax (ng/mL)	2040	12700	36400
AUC0-24h (ng*h/mL)	13700	90200	370000
Tmax (h)	0.5	0.7	1
Fetal Exposure			
Dose (mg/kg/day)	0.5	5	20
Day 16 post coitum-fetal exposure 1 hour post dose			
Cmax (ng/mL)	27.5	237	583

Study title/ number: An oral gavage study of embryo-fetal development in the rabbit / 9000203

Key Study Findings

- 4 females dosed at 75 mg/kg/day euthanized between Days 20 and 23 post coitum due to significant clinical signs of toxicity
- Skeletal variations occurred in pups from dams dosed at 25 and 75 mg/kg/day
- Malformations occurred in pups from dams dosed at 75 mg/kg/day, including multiple cardiac malformations

Conducting laboratory and location:



GLP compliance:

Yes

Methods

Dose and frequency of dosing:

5, 25, and 75 mg/kg/day
 Daily from Days 7 to 20 post coitum

Route of administration:

Oral gavage

Formulation/Vehicle:

0.5% (w/v) sodium carboxymethylcellulose (Na CMC), type 7HF, containing 0.5% (v/v) Tween 80, NF, in ultra pure water

Species/Strain:

New Zealand White rabbits

Number/Sex/Group:

20/group

Satellite groups:

Yes; 3 animals/control; 5 animals/treatment group for TK

Study design:

Time-mated rabbits were treated once daily oral gavage from Days 7 to 20 post coitum

Deviation from study protocol affecting interpretation of results:

No

Observations and Results

Parameters	Major findings																																																																																										
Mortality	4 main study animals dosed with the highest dose of 75 mg/kg euthanized between Days 20 and 23 post coitum																																																																																										
Clinical Signs	Decreased fecal output/reduced fecal size, liquid feces, mucoid material in feces, partially closed eyes, prominent backbone and thinness noted in 4/20 animals dosed with the highest dose of 75 mg/kg (euthanized early)																																																																																										
Body Weights	Unremarkable																																																																																										
Necropsy findings Cesarean Section Data	<table border="1"> <thead> <tr> <th></th> <th>0</th> <th>5 mg/kg</th> <th>25 mg/kg</th> <th>75 mg/kg</th> </tr> </thead> <tbody> <tr> <td>Pregnancy index (%)</td> <td>100</td> <td>95</td> <td>95</td> <td>100</td> </tr> <tr> <td>Number of females with viable fetuses for examination on GD20</td> <td>20</td> <td>19</td> <td>19</td> <td>15</td> </tr> <tr> <td>Number pregnant</td> <td>20</td> <td>19</td> <td>19</td> <td>20</td> </tr> <tr> <td>Number not pregnant</td> <td>0</td> <td>1</td> <td>1</td> <td>0</td> </tr> <tr> <td>Number with total resorptions</td> <td>0</td> <td>0</td> <td>0</td> <td>1</td> </tr> <tr> <td>Number euthanized on study</td> <td>0</td> <td>0</td> <td>0</td> <td>4</td> </tr> <tr> <td>Gravid uterine weight</td> <td>534.6</td> <td>↑3%</td> <td>↓2%</td> <td>↓7%</td> </tr> <tr> <td>Mean corpora lutea</td> <td>10.3</td> <td>10.4</td> <td>10.2</td> <td>10.9</td> </tr> <tr> <td>Mean implantation sites</td> <td>9.6</td> <td>9.7</td> <td>9.4</td> <td>9.8</td> </tr> <tr> <td>Mean % preimplantation loss</td> <td>6.87</td> <td>6.17</td> <td>7.81</td> <td>10.88</td> </tr> <tr> <td>Mean% postimplantation loss</td> <td>4.83</td> <td>1.17</td> <td>6.18</td> <td>8.46</td> </tr> <tr> <td>Mean litter size</td> <td>9.1</td> <td>9.6</td> <td>8.8</td> <td>9</td> </tr> <tr> <td>Mean early resorptions</td> <td>0.3</td> <td>0.1</td> <td>0.3</td> <td>0.5</td> </tr> <tr> <td>Mean late resorptions</td> <td>0.2</td> <td>0</td> <td>0.3</td> <td>0.3</td> </tr> <tr> <td colspan="5">Fetal weight change relative to controls</td> </tr> <tr> <td>Male</td> <td>42.7 g</td> <td>-</td> <td>-</td> <td>↓7%</td> </tr> <tr> <td>Female</td> <td>41.7 g</td> <td>↓3%</td> <td>-</td> <td>↓9%</td> </tr> </tbody> </table>		0	5 mg/kg	25 mg/kg	75 mg/kg	Pregnancy index (%)	100	95	95	100	Number of females with viable fetuses for examination on GD20	20	19	19	15	Number pregnant	20	19	19	20	Number not pregnant	0	1	1	0	Number with total resorptions	0	0	0	1	Number euthanized on study	0	0	0	4	Gravid uterine weight	534.6	↑3%	↓2%	↓7%	Mean corpora lutea	10.3	10.4	10.2	10.9	Mean implantation sites	9.6	9.7	9.4	9.8	Mean % preimplantation loss	6.87	6.17	7.81	10.88	Mean% postimplantation loss	4.83	1.17	6.18	8.46	Mean litter size	9.1	9.6	8.8	9	Mean early resorptions	0.3	0.1	0.3	0.5	Mean late resorptions	0.2	0	0.3	0.3	Fetal weight change relative to controls					Male	42.7 g	-	-	↓7%	Female	41.7 g	↓3%	-	↓9%
	0	5 mg/kg	25 mg/kg	75 mg/kg																																																																																							
Pregnancy index (%)	100	95	95	100																																																																																							
Number of females with viable fetuses for examination on GD20	20	19	19	15																																																																																							
Number pregnant	20	19	19	20																																																																																							
Number not pregnant	0	1	1	0																																																																																							
Number with total resorptions	0	0	0	1																																																																																							
Number euthanized on study	0	0	0	4																																																																																							
Gravid uterine weight	534.6	↑3%	↓2%	↓7%																																																																																							
Mean corpora lutea	10.3	10.4	10.2	10.9																																																																																							
Mean implantation sites	9.6	9.7	9.4	9.8																																																																																							
Mean % preimplantation loss	6.87	6.17	7.81	10.88																																																																																							
Mean% postimplantation loss	4.83	1.17	6.18	8.46																																																																																							
Mean litter size	9.1	9.6	8.8	9																																																																																							
Mean early resorptions	0.3	0.1	0.3	0.5																																																																																							
Mean late resorptions	0.2	0	0.3	0.3																																																																																							
Fetal weight change relative to controls																																																																																											
Male	42.7 g	-	-	↓7%																																																																																							
Female	41.7 g	↓3%	-	↓9%																																																																																							

Multi-Disciplinary Review and Evaluation NDA 210496
 BRAFTOVI™ (encorafenib)

Necropsy findings Offspring	Dose	0	5 mg/kg	25mg/kg	75 mg/kg
	External and Visceral Malformations				
Number of Fetuses/Litters Evaluated		181/20	183/19	167/19	135/15
# of fetuses affected (%) / # of litters affected (%)					
Cleft in skin at sacral region		2 (1.1)/ 1 (5)	0	2 (1.2)/ 2 (10.5)	4 (3)/ 4 (26.7)
Microphthalmia		0	0	1 (0.6)/ 1 (5.3)	0
Gastroschisis		0	0	1 (0.6)/ 1 (5.3)	0
Diaphragmatic hernia		0	0	0	1 (0.7)/ 0.67)
Lung lobes small/reduced		0	0	0	1(0.7)/ 1 (6.7)
Accessory lung lob absent		11 (6.1)/ 3 (15)	7 (3.8)/ 5 (26.3)	4 (2.4)/ 3 (15.8)	7 (5.3)/ 3 (20)
Heart misshapen, globular		0	0	0	1 (0.7)/ 1 (6.7)
Dilatation of ascending aorta		0	0	0	2 (1.5)/ 2 (13.3)
Stenosis of pulmonary trunk		0	0	0	1 (0.7)/ 1 (6.7)
Interventricular septum absent		0	0	0	1 (0.7)/ 1 (6.7)
Aortic arch dilated		0	0	0	2 (1.5)/ 2 (13.3)
Heart innominate artery absent		0	0	1 (0.6)/ 1 (5.3)	0
Heart extra vessels-minor vessel		8 (4.4)/ 4 (20)	3 (1.6)/ 1 (5.3)	4 (2.4)/ 2 (10.5)	9 (6.7)/ 4 (26.7)
Subclavian retroesophageal		0	0	0	1 (0.7)/ 1 (6.7)
Heart cyst		0	0	0	1 (0.7)/ 1 (6.7)
Membranous ventricular septum defect		0	0	0	1 (0.7)/ 1 (6.7)

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

Spleen absent	0	0	0	1 (0.7)/ 1 (6.7)
Eye circumcorneal hemorrhage	0	0	0	1 (0.7)/ 1 (6.7)
Eye discoloration dark	0	0	1 (0.6)/ 1 (5.3)	0
Gallbladder absent	0	1 (0.5)/ 1 (5.3)	0	0
Ureter retrocaval	3 (1.7)/ 3 (15)	0	4 (2.4)/ 4 (21.1)	0
Total External and Visceral Malformations				
Number of fetuses (%) / number of litters (%)	22 (12.2)/ 9 (45)	11 (6)/ 6 (31.6)	14 (8.4)/ 7 (36.8)	16 (11.9)/ 6 (40)
Skeletal Variations				
Number of Fetuses/Litters Evaluated	181/20	183/19	167/19	135/15
Nasal bone incomplete ossification	3 (1.7)/ 2 (10)	0	2 (1.2)/ 2 (10.5)	2 (1.5)/ 1 (6.7)
Parietal bone incomplete ossification	0	0	0	1 (0.7)/ 1 (6.7)
Frontal bone incomplete ossification	33 (18.2)/ 13 (65)	28 (15.3)/ 13 (68.4)	41 (24.5)/ 17 (89.5)	42 (31.1)/ 13 (86.7)
Interparietal bone incomplete ossification	3 (1.7)/ 2 (10)	2 (1.1)/ 2 (10.5)	9 (5.4)/ 6 (31.6)	2 (1.5)/ 1 (6.7)
Interparietal bone unossified	0	0	0	1 (0.7)/ 1 (6.7)
Supraoccipital bone incomplete ossification	4 (2.2)/ 3 (15)	2 (1.1)/ 2 (10.5)	5 (3)/ 4 (21.1)	2 (1.5)/ 2 (13.3)
Hyoid bone unossified	1 (0.6)/ 1 (5)	1 (0.5)/ 1 (5.3)	1 (0.6)/ 1 (5.3)	1 (0.7)/ 1 (6.7)
Hyoid bone incomplete ossification	22 (12.2)/ 15 (75)	47 (25.7)/ /14 (73.7)	38 (22.8)/ 11 (57.9)	34 (25.2)/ 11 (73.3)
Hyoid bone ala incomplete ossification	2 (1.1)/ 2 (10)	1 (0.5)/ 1 (5.3)	1 (0.6)/ 1 (5.3)	1 (0.7)/ 1 (6.7)
Hyoid bone ala misshapen	2 (1.1)/ 1 (5)	3 (1.6)/ 2 (10.5)	4 (2.4)/ 3 (15.8)	4 (3)/ 4 (26.7)
Hyoid bone ala bent	9 (5)/ 6 (30)	5 (2.7)/ 4 (21.1)	7 (4.2)/ 6 (31.6)	6 (4.4)/ 4 (26.7)
Extra presacral vertebra	1 (0.6)/ 1 (5)	0	5 (3)/ 3 (15.8)	6 (4.4)/ 4 (26.7)
Cervical vertebral centrum semi-bipartite	0	0	1 (0.6)/ 1 (5.3)	0
Cervical vertebral centrum bipartite	0	0	1 (0.6)/ 1 (5.3)	0
Cervical vertebral centrum fused	0	0	1 (0.6)/ 1 (5.3)	0

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

	Cervical vertebral centrum ossification center	0	0	0	1 (0.7)/ 1 (6.7)
	Cervical vertebral centrum incomplete ossification	0	0	1 (0.6)/ 1 (5.3)	0
	Cervical vertebra arches incomplete ossification	0	0	1 (0.6)/ 1 (5.3)	0
	Lumbar centrum displaced	0	0	1 (0.6)/ 1 (5.3)	1 (0.7)/ 1 (6.7)
	Lumbar vertebral arches absent	0	0	1 (0.6)/ 1 (5.3)	1 (0.7)/ 1 (6.7)
	Thoracic vertebral centrum absent	0	0	1 (0.6)/ 1 (5.3)	0
	Thoracic vertebral centrum semi-bipartite	7 (3.9)/ 4 (20)	12 (6.6)/ 7 (36.8)	18 (10.8)/ 12 (63.2)	24 (17.8)/ 10 (66.7)
	Thoracic vertebral centrum displaced	0	0	0	2 (1.5)/ 2 (13.3)
	Thoracic vertebral arches absent	0	0	1 (90.6)/ 1 (5.3)	0
	Reduced number of caudal vertebrae	2 (1.1)/ 2 (10)	1 (0.5)/ 1 (5.3)	1 (0.6)/ 1 (5.3)	1 (0.7)/ 1 (6.7)
	Sternebrae fused	3 (1.7)/ 2 (10)	0	1 (0.6)/ 1 (5.3)	8 (5.9) /6 (40)
	Extra sternebrae	1 (09.6)/ 1 (5)	2 (1.1)/ 2 (10.5)	1 (0.6)/ 1 (5.3)	4 (3)/ 3 (20)
	Sternebrae (unossified/incomplete/semi0bipartite/bipartite)	82 (45.3)/ 18 (90)	68 (37.2)/ 17 (89.5)	67 (40.1)/ 18 (94.7)	73 (54.1)/ 14 (93.3)
	Fused ribs	0	0	0	1 (0.7)/ 1 (6.7)
	Irregular ossification of ribs	0	0	0	1 (0.7)/ 1 (6.7)
	Ribs absent	0	0	1 (0.6)/ 1 (5.3)	0
	Ossification center on 7 th cervical vertebra	3 (1.7)/ 3 (15)	3 (1.6)/ 1 (5.3)	1 (0.6)/ 1 (5.3)	3 (2.2)/ 3 (20)
	Ribs on 7 th cervical vertebra	0	1 (0.5)/ 1 (5.3)	4 (2.4)/ 2 (10.5)	0
	Extra 13 th rib with contralateral rudimentary rib	46 (25.4)/ 15 (75)	46 (25.1)/ 14 (73.7)	37 (22.2)/ 12 (63.2)	56 (41.5)/ 14 (93.3)
	Pubic bone incomplete ossification	6 (3.3)/ 5 (25)	10 (5.5)/ 7 (36.8)	9 (5.4)/ 6 (31.6)	38 (28.1)/ 10 (66.7)
	Pubic bone unossified	0	0	0	1 (0.7)/ 1 (6.7)
	Reduced number of phalanges in forepaw	0	1 (0.5)/ 1 (5.3)	0	0
	Reduced number of phalanges in pollex	0	0	0	1 (0.7)/
					1 (6.7)
	Reduced number of phalanges in tarsal bone	0	1 (0.5)/ 1 (5.3)	0	1 (0.7)/ 1 (6.7)
	Total Skeletal Variations				
	Number of fetuses (%)/number of litters (%)	77(42.5)/ 20 (100)	90 (49.2)/ 18 (94.7)	100(59.9)/ 19 (100)	97 (71.9)/ 15 (100)
Toxicokinetic s	The AUC exposures in rabbits at doses of 5, 25, and 75 mg/kg were 22x, 73x, and 178x those achieved in patients given the 450 mg encorafenib dose				

Fetal exposures were less than 1% of the maternal plasma concentrations																				
Maternal Exposures <table border="1"> <thead> <tr> <th>Dose (mg/kg/day)</th> <th>5</th> <th>25</th> <th>75</th> </tr> </thead> <tbody> <tr> <td colspan="4">Day 19 post coitum-maternal</td> </tr> <tr> <td>Cmax (ng/mL)</td> <td>23800</td> <td>83800</td> <td>213000</td> </tr> <tr> <td>AUC0-24h (ng*h/mL)</td> <td>302000</td> <td>1010000</td> <td>2480000</td> </tr> <tr> <td>Tmax (h)</td> <td>4</td> <td>1.8</td> <td>1</td> </tr> </tbody> </table>	Dose (mg/kg/day)	5	25	75	Day 19 post coitum-maternal				Cmax (ng/mL)	23800	83800	213000	AUC0-24h (ng*h/mL)	302000	1010000	2480000	Tmax (h)	4	1.8	1
Dose (mg/kg/day)	5	25	75																	
Day 19 post coitum-maternal																				
Cmax (ng/mL)	23800	83800	213000																	
AUC0-24h (ng*h/mL)	302000	1010000	2480000																	
Tmax (h)	4	1.8	1																	
Fetal Exposures <table border="1"> <thead> <tr> <th>Dose (mg/kg/day)</th> <th>5</th> <th>25</th> <th>75</th> </tr> </thead> <tbody> <tr> <td colspan="4">Day 19 post coitum-fetal exposure 3 hours post dose</td> </tr> <tr> <td>Cmax (ng/mL)</td> <td>7304</td> <td>357</td> <td>1400</td> </tr> </tbody> </table>	Dose (mg/kg/day)	5	25	75	Day 19 post coitum-fetal exposure 3 hours post dose				Cmax (ng/mL)	7304	357	1400								
Dose (mg/kg/day)	5	25	75																	
Day 19 post coitum-fetal exposure 3 hours post dose																				
Cmax (ng/mL)	7304	357	1400																	

Prenatal and Postnatal Development

Neither submitted nor required.

5.5.5. Other Toxicology Studies

A non-GLP (Study #VH090801) in vitro screen for phototoxicity, the 3T3 NRU assay, indicated a phototoxic potential for LGX818, with a Photo Irritation Factor (PIF) of 84. A GLP-compliant contact hypersensitivity screen (Study # R501817) in mice using the murine local lymph node assay indicated that LGX818 has no sensitizing potential, but weak irritating potential was revealed for skin contact. An addition primary skin irritation/corrosion study in rabbits (Study #R501816, GLP-compliant), indicated that LGX818 does not cause skin irritation up to 72 hours post exposure after a 4 hour direct exposure to the skin.

Stephanie Aungst, PhD
 Nonclinical Pharmacology/Toxicology
 Primary Reviewer

Whitney Helms, PhD
 Nonclinical Pharmacology/Toxicology
 Team Leader

6 Clinical Pharmacology

6.1. Executive Summary

The applicant seeks approval of encorafenib (BRAFTOVI), in combination with binimetinib (MEKTOVI), for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation as detected by an FDA-approved test. The proposed encorafenib dosing regimen is 450 mg orally once daily (QD), with or without food.

The Clinical Pharmacology Section of the NDA is supported by single and repeat dose pharmacokinetics (PK) studies of encorafenib in cancer patients and the following evaluations and analyses: dose-response (D-R) and exposure-response (E-R) relationships, population pharmacokinetics (popPK), potential QT/QTc prolongation, effect of mild hepatic impairment and food on encorafenib systemic exposure, and potential PK drug-drug interactions (DDI) between encorafenib and a strong CYP3A4 inhibitor, moderate CYP3A4 inhibitor, and proton pump inhibitor. The popPK analyses did not identify clinically important covariates influencing encorafenib PK. Dose-dependent QTc prolongation was observed with encorafenib. The DDI study results indicated that dose adjustment is necessary for encorafenib when it is coadministered with strong or moderate CYP3A4 inhibitors.

The D-R and E-R relationships for efficacy and safety support the proposed encorafenib dosing regimen. There is insufficient evidence suggesting that Combo 300 is as effective as Combo 450 based on clinical observation and E-R relationships for efficacy. A comparison of safety profiles between Combo 450 (Encorafenib 450 mg QD plus Binimetinib 45 mg BID) and Combo 300 (Encorafenib 300 mg QD plus Binimetinib 45 mg BID) did not indicate a clinically significant safety concern for Combo 450 relative to Combo 300 which would outweigh the potential for improved efficacy at the higher dose. The overall efficacy and safety profiles support the use of the proposed encorafenib dosing regimen, 450 mg QD in combination with binimetinib with dose modification in the event of adverse reactions to the lowest dose of 200 mg QD.

Recommendations

The proposed encorafenib dosing regimen of 450 mg QD in combination with binimetinib with the dose reduction schema in the event of adverse reactions is acceptable given the D-R and E-R relationships for efficacy and for safety. From a Clinical Pharmacology standpoint, the NDA is approvable provided the applicant and the FDA reach agreement regarding labeling language.

Review Issue	Recommendations and Comments
Pivotal or supportive evidence of effectiveness[†]	Proposed dosing regimen is supported by D-R and E-R relationships for objective response rate (ORR), progression-free survival (PFS) and preliminary overall survival (OS).
General dosing instructions	Encorafenib 450 mg QD in combination with binimetinib 45 mg twice daily (BID) without regards to food.

Dosing in patient subgroups (intrinsic and extrinsic factors)	• Based on the observed D-R relationship for safety, the observed 2.8-fold and 1.8-fold increases in exposure when coadministered with a strong and a moderate CYP3A inhibitor, respectively, are clinically meaningful. Avoidance of concomitant use of BRAFTOVI with strong or moderate CYP3A inhibitors is recommended. • If concomitant use of a strong CYP3A inhibitor cannot be avoided, reduce the encorafenib daily dose by approximately two-thirds (i.e., from 450 mg to 150 mg, from 300 mg to 100 mg, or from 200 mg to 75 mg). • If concomitant use of a moderate CYP3A inhibitor cannot be avoided, reduce the encorafenib daily dose by approximately one-half (i.e., from 450 mg to 225 mg, from 300 mg to 150 mg, or from 200 mg to 100 mg).
Labeling	• Avoid concomitant administration of strong or moderate CYP3A inhibitors. If concomitant administration of strong or moderate CYP3A4 inhibitors is unavoidable, reduce the BRAFTOVI dose (b) (4) (b) (4)
Bridge between the to-be-marketed and clinical trial formulations	The registration trial (CMEK162B2301) utilized the 50 and 100 mg capsules. The applicant submitted a biowaiver for the 75 mg capsule strength that is bracketed by the 50 and 100 mg capsule strengths, and plans to have the 50 and 75 mg capsules commercially available.

Postmarketing Requirements and Commitments

The applicant is requested to conduct the following clinical pharmacology studies as postmarketing commitments (PMC). The PMC studies will be included in the Approval Letter with milestones agreed upon after negotiation with the Applicant.

PMC or PMR	Key Issue(s) to be Addressed	Rationale	Key Considerations for Design Features
☒ PMC ☐ PMR	Determination of an appropriate encorafenib dose for patients with concomitant use of a moderate CYP3A4 inducer.	Physiologically-based pharmacokinetic (PBPK) modeling was used to predict the effect of rifampin (a strong CYP3A4 inducer) on encorafenib steady-state AUC. There was no adequate data to validate this drug-drug interaction model. Labeling recommendation is to avoid concomitant administration of strong or moderate CYP3A4 inducers. The magnitude of decrease in encorafenib systemic exposures by strong CYP3A4 inducers is predicted to be too large to allow for a feasible dose adjustment; therefore, avoidance of coadministration with strong CYP3A4 inducers with encorafenib is recommended. The PMC study results will determine dosage modification when coadministration of a moderate CYP3A4 is unavoidable.	Multiple dose encorafenib with and without coadministration of repeat doses of a moderate CYP3A4 inducer in patients.
☒ PMC ☐ PMR	Dose adjustment in patients with comedICATIONS of CYP substrates whose PK may be affected by encorafenib.	Based on in vitro studies, encorafenib is an inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2D6, and CYP3A and an inducer of CYP2B6, CYP2C9, and CYP3A at clinically relevant plasma concentrations.	Repeat doses of encorafenib in patients with and without coadministration of sensitive CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A substrates.

6.2. Summary of Clinical Pharmacology Assessment

6.2.1. Pharmacology and Clinical Pharmacokinetics

After a single dose administration of encorafenib, systemic exposure was dose proportional over the dose range of 50 mg to 800 mg. After repeat once a day (QD) doses, systemic exposure was less than dose proportional over the dose range of 50 mg to 800 mg QD. Following encorafenib 450 mg QD, the geometric mean (%CV) steady-state $AUC_{0-\tau}$ was 13.1 (35%) mcg·h/mL and C_{max} was 4.0 (49%) mcg/mL with accumulation ratio of 0.4 (52%).

Absorption

The median t_{max} is 2 hours (range: 0.5-2 hours) following administration of encorafenib 450 mg QD. A standard high-fat meal did not affect encorafenib AUC and C_{max} .

Distribution

Encorafenib is 86% bound to human plasma proteins and binding is not concentration-dependent. The blood-to-plasma concentration ratio is 0.6. The geometric mean (%CV) apparent volume of distribution (V_d/F) at steady-state is 157 (39%) L.

Elimination

The geometric mean (CV%) apparent clearance of encorafenib is 14 (54%) L/h after a single dose and increases to 32 (59%) L/h at steady-state. The mean terminal half-life ($t_{1/2}$) is 3.5 (17%) hours.

Metabolism

Encorafenib is primarily metabolized by CYP3A4 (83%) and to a lesser extent by CYP2C19 (16%) and CYP2D6 (1%) in vitro. N-dealkylation was the major metabolic pathway for encorafenib. Following a single 100 mg oral dose of ^{14}C -encorafenib, unchanged encorafenib (27.5%) and its metabolite M42.5A (15.5%) were the major circulating radioactive components. M42.5A inhibited BRAF V600E, wild-type BRAF, and CRAF with 30-fold lower potency than encorafenib in vitro.

Excretion

Following a single 100 mg oral dose of ^{14}C -encorafenib, 39% of the administered dose (5% as unchanged) was recovered in the feces and 47% of the administered dose (1.8% as unchanged) was recovered in the urine.

Dose Selection Rationale and Dose- and Exposure-Response Relationships

Encorafenib 450 mg QD in combination with binimetinib 45 BID (Combo 450) was selected as the recommended Phase 2 dose (RP2D) in the dose escalation trial (Study CMEK162X2110). At encorafenib 600 mg QD with binimetinib 45 mg BID, 3 cases of drug-related grade 3 serum

creatinine increase occurred and 52% of patients required a dose reduction. The maximum tolerated dose (MTD) for encorafenib as a single agent was 450 mg QD; 300 mg QD was selected as the recommended dose for encorafenib as a single agent due to Grade 3 AEs and AEs requiring early dose reduction at the 450 mg dose (Study CLGX818X2101). From a mechanistic basis, the reduction in BRAF inhibitor-related toxicities is hypothesized to be due to binimetinib as a MEK inhibitor blocking paradoxical activation of the mitogen-activated protein kinase pathway when encorafenib as a BRAF inhibitor is administered alone. The proposed labeling recommends reduction of BRAFTOVI from 450 mg to 300 mg QD if binimetinib is temporarily interrupted or discontinued, which is supported by the mechanism of toxicity and D-R relationships for safety (APPEARS THIS WAY ON ORIGINAL Figure 8), and preservation of activity/efficacy and safety results from Studies CMEK162X2110 and CLGX818X2101.

D-R relationships for efficacy suggest comparable objective response rate (ORR) and progression-free survival (PFS) between Combo 450 mg and Combo 300 mg QD (Encorafenib 300 mg QD in combination with binimetinib 45 BID); however, overall survival (OS) appears to be better with Combo 450 compared to Combo 300 mg based on preliminary analyses. Combo 450 had a (nominally) statistically significantly higher risk of having adverse events of special interest and Grade 3/4 adverse events (AEs) compared to Combo 300. However, when looking at the risks of individual safety events of special interest, no difference was detected between Combo 450 and Combo 300 except for Grade 1+ retinopathy excluding retinal vein occlusion (RVO). No consistent relationships between encorafenib or binimetinib exposure and efficacy endpoints were identified. The E-R relationships for safety were consistent with D-R relationships. In summary, there is insufficient evidence suggesting that Combo 300 is as effective as Combo 450 based on clinical observations and D-R relationships for efficacy. A comparison of safety profiles between Combo 450 and Combo 300 did not indicate a clinically significant safety concern for Combo 450 relative to Combo 300 which would outweigh the potential for improved efficacy at the higher dose. The overall efficacy and safety profiles and D-R/E-R relationships support the use of the proposed encorafenib 450 mg QD in combination with binimetinib 45 mg BID with dose modification in the event of adverse reactions to the lowest dose of encorafenib 200 mg QD.

6.2.2. General Dosing and Therapeutic Individualization

General Dosing

The proposed dosing regimen of encorafenib is 450 mg QD in combination with binimetinib 45 mg BID, orally with or without food.

Therapeutic Individualization

Results of a DDI study showed that coadministration of repeat doses of posaconazole (a strong CYP3A4 inhibitor) with a single dose encorafenib 50 mg increased encorafenib AUC by 2.8-fold (90% CI: 2.5, 3.2) and C_{max} by 1.7-fold (90% CI: 1.5, 1.8) as compared with encorafenib administered alone. Based on the dose-response for safety (

Figure 8), a 2.8-fold increase in exposure is clinically meaningful; therefore, strong CYP3A inhibitors should be avoided. When concomitant use of a strong CYP3A inhibitor is unavoidable, the encorafenib once daily dose should be reduced by approximately two-thirds (i.e., 450 mg to 150 mg, 300 mg to 100 mg, or 200 mg to 75 mg).

Coadministration of repeat doses of diltiazem (a moderate CYP3A4 inhibitor) with a single dose encorafenib 50 mg increased encorafenib AUC by 1.8-fold (90% CI: 1.6, 2.0) and C_{max} by 1.4-fold (90% CI: 1.2, 1.7) as compared with encorafenib administered alone. Based on the D-R relationship for safety (

APPEARS THIS WAY ON ORIGINAL

Figure 8), a 1.8-fold increase in encorafenib exposure is clinically meaningful; therefore, moderate CYP3A inhibitors should also be avoided. When concomitant use of a moderate CYP3A inhibitor is unavoidable, the encorafenib QD dose should be reduced by approximately one-half (i.e., 450 mg to 225 mg, 300 mg to 150 mg, or 200 mg to 100 mg).

Outstanding Issues

The PK and potential decrease in efficacy of encorafenib in patients requiring concomitant use of a strong or moderate CYP3A4 inducer have not been studied clinically. PBPK modeling was used to predict the effect of rifampin (a strong CYP3A4 inducer) on encorafenib steady-state AUC; however, there was no adequate data to validate this DDI model. Given the likelihood that coadministration of strong CYP3A4 inducers would need to be avoided due to the expected magnitude of exposure decrease, a PMC clinical trial is requested to determine dosing recommendations in patients requiring concomitant use of a moderate CYP3A4 inducer. Before the PMC study results become available, the labeling recommends avoidance of both strong and moderate CYP3A inducers.

Based on in vitro studies, encorafenib is an inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2D6, and CYP3A and an inducer of CYP2B6, CYP2C9, and CYP3A at clinically relevant plasma concentrations. A PMC clinical trial is requested to assess the effect of encorafenib on the magnitude of decreased exposures of sensitive CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A substrates.

Summary of Labeling Recommendations

Drug-Drug Interactions

Coadministration of repeat doses of posaconazole (a strong CYP3A4 inhibitor) with a single dose encorafenib 50 mg increased encorafenib AUC by 2.8-fold (90% CI: 2.5, 3.2) and C_{max} by 1.7-fold (90% CI: 1.5, 1.8) as compared with encorafenib administered alone. Coadministration of repeat doses of diltiazem (a moderate CYP3A4 inhibitor) with a single dose encorafenib 50 mg increased encorafenib AUC by 1.8-fold (90% CI: 1.6, 2.0) and C_{max} by 1.4-fold (90% CI: 1.2, 1.7) as compared with encorafenib administered alone. Based on the D-R for safety (Figure 8), both 2.8-fold and 1.8-fold increase in exposure are clinically meaningful; therefore, avoidance of concomitant use of BRAFTOVI with strong or moderate CYP3A inhibitors is

recommended. If concomitant administration of a strong CYP3A inhibitor is unavoidable, the recommended dose reduction is by approximately two-thirds of the once daily BRAFTOVI dose (i.e., 450 mg to 150 mg, 300 mg to 100 mg, or 200 mg to 75 mg). If concomitant administration of a moderate CYP3A inhibitor is unavoidable, the recommended dose reduction is by approximately one-half of the once daily BRAFTOVI dose (i.e., 450 mg to 225 mg, 300 mg to 150 mg, or 200 mg to 100 mg). Following discontinuation of a strong or moderate CYP3A inhibitor and after 3-5 half-lives of the CYP3A inhibitor, resume the BRAFTOVI dose that was used before starting the CYP3A4 inhibitor.

Based on in vitro studies, encorafenib may inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2D6, and CYP3A and induce CYP2B6, CYP2C9, and CYP3A at clinically relevant plasma concentrations. Coadministration of BRAFTOVI with sensitive CYP3A substrates may result in increased toxicity or decreased efficacy of these agents.

Contraception

Given that encorafenib has teratogenic potential and BRAFTOVI may cause decreased exposure and efficacy of hormonal contraceptives (primarily metabolized by CYP3A4 and to a lesser extent by CYP2C9/CYP2C19), females of reproductive potential should be advised to use effective non-hormonal contraception during treatment with BRAFTOVI and for 2 weeks after the last dose of BRAFTOVI.

Organ Impairment

Following oral administration of a single 100 mg dose of radiolabeled encorafenib to healthy subjects, 47% of the administered dose (5% as unchanged encorafenib) was recovered in the feces and 47% of the administered dose (1.8% as unchanged encorafenib) was recovered in the urine, indicating that encorafenib is eliminated by both hepatic and renal elimination pathways. Encorafenib AUC following a single 50 mg dose was 25% higher in otherwise healthy subjects with mild hepatic impairment (Child-Pugh Class A, n=6) as compared with that in healthy subjects with normal hepatic function (n=6); this magnitude of change in AUC is not considered clinically meaningful. Based on a popPK analysis, encorafenib exposures were similar between 59 patients with mild hepatic impairment (total bilirubin within ULN and AST >ULN or total bilirubin >1 and up to 1.5 × ULN and any AST) and 640 patients with normal hepatic function (total bilirubin and AST within ULN), suggesting that no dose adjustment is necessary in patients with mild hepatic impairment. The PK and safety of encorafenib in patients with moderate (total bilirubin >1.5 and up to 3 × ULN and any AST) or severe (total bilirubin >3 × ULN and any AST) hepatic impairment have not been studied.

Based on a popPK analysis, encorafenib exposures were similar among 159 patients with mild (CLCr 60 to 89 mL/min) renal impairment, 33 patients with moderate renal impairment (CLCr 30 to 59 mL/min), and 508 patients with normal renal function (≥90 mL/min), suggesting that no dose adjustment is necessary in patients with mild to moderate renal impairment. The PK and

safety of encorafenib in patients with severe renal impairment (CLcr <30 mL/min) have not been studied.

6.3. Comprehensive Clinical Pharmacology Review

6.3.1. General Pharmacology and Pharmacokinetic Characteristics

Over the range of 50 mg to 800 mg, encorafenib (molecular weight of 540 g/mol) exhibits dose proportional exposure after a single dose and less than dose proportional following repeat QD doses. Encorafenib exposures after single and repeat dose are shown in Table 8 and Table 9. A summary of general pharmacology and PK characteristics of encorafenib is shown in Table 10.

Table 8. Encorafenib Exposures after a Single Dose and Repeat Doses as a Single Agent in Study CLGX818X2101

	Single Dose		Repeat Doses	
	Geometric Mean AUC _{0-24h} , ng·h/mL (%CV)	Geometric Mean C _{max} , ng/mL (%CV)	Geometric Mean AUC _{0-24h} ^{ss} , ng·h/mL (%CV)	Geometric Mean C _{max} ^{ss} , ng/mL (%CV)
50 mg	5360 n=1	970 n=1	2660 n=1	465 n=1
100 mg	7610 (83%) n=5	1630 (42%) n=5	5330 (37%) n=4	959 (25%) n=4
150 mg	9400 (20%) n=5	1570 (29%) n=5	4750 (12%) n=5	1300 (29%) n=5
200 mg	9860 (26%) n=4	1850 (28%) n=4	5060 (36%) n=3	1300 (31%) n=3
300 mg	20300 (29%) n=5	3310 (42%) n=5	10100 (53%) n=4	2920 (34%) n=4
450 mg	32800 (69%) n=6	5970 (56%) n=6	13100 (35%) n=6	3950 (49%) n=6
550 mg	31700 (45%) n=5	5360 (37%) n=5	15300 (36%) n=3	4170 (49%) n=3
700 mg	63900 (1.4%) n=2	8980 (14%) n=2	Not studied	Not studied

Source: CLGX818X2101 Study Report; Tables 11-10 and 11-11; Pages 129-132.

Table 9. Encorafenib Exposures after a Single Dose and Repeat Doses in Combination with Binimetinib in Study CMEK162X2110

	Single Dose		Repeat Doses	
	Geometric Mean AUC _{0-24h} , ng·h/mL (%CV)	Geometric Mean C _{max} , ng/mL (%CV)	Geometric Mean AUC _{0-24h/SS} , ng·h/mL (%CV)	Geometric Mean C _{max/SS} , ng/mL (%CV)
50 mg	2890 (105%) n=6	704 (88%) n=6	2340 (59%) n=6	498 (76%) n=6
100 mg	10400 (55%) n=5	1850 (33%) n=5	5370 (27%) n=5	1140 (34%) n=5
200 mg	20500 (43%) n=4	3580 (44%) n=4	4470 (38%) n=4	1050 (18%) n=4
400 mg	35500 (64%) n=5	6740 (27%) n=5	10100 (21%) n=5	3610 (35%) n=5
450 mg	32200 (54%) n=13	7040 (42%) n=13	13900 (59%) n=13	3760 (63%) n=13
600 mg	52200 (46%) n=8	9880 (32%) n=8	23200 (69%) n=8	6970 (123%) n=8
800 mg	34300 (42%) n=6	5840 (58%) n=6	23800 (28%) n=6	6110 (47%) n=6

Source: CMEK162X2110 Study Report; Table 12; Page 116.

Table 10. Summary of General Pharmacology and Pharmacokinetic Characteristics of Encorafenib

Pharmacology	
Mechanism of Action	- Targets kinases in the RAS/RAF/MEK/ERK pathway. - Encorafenib inhibited BRAF V600E, wild-type BRAF, and CRAF with IC₅₀ of 0.35, 0.47 and 0.30 nM, respectively.
Active Moieties	Unchanged encorafenib (27.5%) and its active metabolite M42.5A (15.5%) were the major circulating radioactive components following a single 100 mg oral dose of ¹⁴ C-encorafenib; however, M42.5A inhibited BRAF V600E, wild-type BRAF, and CRAF with approximately 30-fold lower potency than encorafenib in vitro.
QT Prolongation	Encorafenib is associated with dose-dependent QTc interval prolongation. In Study CLGX818X2101, 2 hours post-dose on day 15, the mean QTcF change from baseline (ΔQTcF) was 13 ms (90% CI: 7, 19 ms) in patients administered encorafenib 300 mg QD as a single agent (n=13); 20 ms (90% CI: 13, 26 ms) in patients administered encorafenib 450 mg QD as a single agent (n=19). Following administration of encorafenib 450 mg QD in combination with binimetinib 45 mg BID (n=66, Study CLGX818X2109), the mean QTcF change from baseline (ΔQTcF) on day 1 of week 6, 1.5 hours post-dose was 18 ms (90% CI: 14, 22 ms).
General Information	
Bioanalysis	Encorafenib was measured using validated LC-MS/MS assay methods over the range of 1 to 5000 ng/mL [Report DMPK R1300047]. Accuracy (%RE) and precision (%CV) of the quality controls (QCs) for the runs used in measuring encorafenib were ≤15%, which are acceptable based on the current Bioanalytical Method Validation Draft FDA Guidance for Industry.

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

Healthy vs. Patients	Based on a popPK analysis, PK between healthy subjects and the target patient population were similar (14% lower clearance in patients).		
Drug Exposure at Steady State Following the Therapeutic Dosing Regimen	Coadministration of binimetinib has no effect of encorafenib exposure. The geometric mean (%CV) steady-state AUC _{0-tau} was 13100 (35%) ng·h/mL following encorafenib 450 mg QD as a single agent, and the AUC _{0-tau} was 13900 (59%) ng·h/mL following encorafenib 450 mg QD in combination with binimetinib.		
Range of Effective Dose or Exposure	The minimally effective encorafenib dose resulting in mean steady-state trough concentrations that exceed the IC ₅₀ for inhibition of BRAF V600E is 50 mg.		
Maximally Tolerated Dose or Exposure	The maximum tolerated dose (MTD) of encorafenib as a single agent is 300 mg QD. The MTD of encorafenib in combination with binimetinib is 450 mg QD.		
Dose Proportionality	After a single dose of 50 to 800 mg of encorafenib as a single agent, encorafenib exposures were approximately dose proportional with an estimated slope of 0.96 (90% CI: 0.80, 1.12) for AUC _{0-24h} and 0.90 (90% CI: 0.76, 1.04) for C _{max} using a power model. After repeat doses of 50 to 800 mg QD, exposures were less than dose proportional with an estimated slope of 0.75 (90% CI: 0.52, 0.99) for AUC _{ss} and 0.85 (90% CI: 0.54, 1.15) for C _{max,ss} .		
Accumulation	The geometric mean (%CV) accumulation ratio following encorafenib 450 mg QD was 0.4 (52%).		
Variability	- Following encorafenib 450 mg QD as a single agent in patients, the inter-subject variability (CV%) of steady-state AUC_{0-tau} was 35% and C_{max} was 49%. - Following encorafenib 450 mg QD in combination with binimetinib in patients, the inter-subject variability (CV%) of steady-state AUC_{0-tau} was 59% and C_{max} was 63%.		
Absorption			
Bioavailability	The extent of oral absorption of encorafenib was 86% based on the radioactive dose recovered in the urine (47%) and the total radioactive dose recovered in the feces as metabolites (39%).		
T_{max}	Following encorafenib 450 mg QD, the median t _{max} is 2 hours (range: 0.5-2 hours).		
Food effect ^a (Fed/fasted)	The food effect study showed that administration of a single 100 mg dose of encorafenib with a high-fat meal does not affect the AUC of encorafenib, supporting the labeling recommendation of taking encorafenib without regards to food.		
	AUC_{0-∞}	C_{max}	T_{max}
	Geometric Mean Ratio [90% CI] 0.959 [0.916, 1.0]	Geometric Mean Ratio [90% CI] 0.64 [0.577, 0.701]	Increased by a median of 2 hours
	^a After a high-fat meal consisting of approximately 1000 calories (150 calories from protein, 350 calories from carbohydrates, and 500 calories from fat).		
Distribution			
Volume of Distribution	Following encorafenib 450 mg QD, the geometric mean (%CV) apparent volume of distribution (V _d /F) of encorafenib at steady-state was 157 (39%) L.		

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

Plasma Protein Binding	Encorafenib is 86% bound to human plasma proteins and the binding is not concentration-dependent.
As Substrate of Transporters	Encorafenib is a substrate of p-glycoprotein (P-gp), not breast cancer resistance protein (BCRP) or multidrug resistance-associated protein 2 (MRP2).
Elimination	
Terminal Elimination Half-Life	Following oral administration of encorafenib 450 mg, the geometric mean (CV%) apparent clearance of encorafenib is 14 (54%) L/h after a single dose and increases to 32.4 (59%) L/h at steady-state after QD doses. The mean (CV%) terminal half-life ($t_{1/2}$) is 3.5 (17%) hours.
Effective Elimination Half-Life	Not applicable as the half-life of encorafenib is short (3.5 hours) and repeat dosing does not result in accumulation of encorafenib.
Metabolism	
Fraction Metabolized (% dose)	Based on the mean percentage of the dose recovered as metabolites in the excreta, the fraction metabolized is approximately 90%.
Primary Metabolic Pathway(s)	The major metabolic pathway of encorafenib is N-dealkylation. CYP3A4 (83%), CYP2C19 (16%), and CYP2D6 (1%) contributed to the metabolism of encorafenib.
Excretion	
Primary Excretion Pathways (% dose) ±SD	- Feces: 47% ± 1.8% (5% unchanged encorafenib). - Urine: 47% ± 1.3% (1.8% unchanged encorafenib).
Interaction liability (Drug as Victim)	
Inhibition/Induction of Metabolism	- Substrate of CYP3A4 (83%), CYP2C19 (16%), and CYP2D6 (1%). - Coadministration of posaconazole (a strong CYP3A4 inhibitor) 400 mg BID with a single dose of 50 mg encorafenib increased encorafenib AUC by 2.8-fold (90% CI: 2.5, 3.2) and C_{max} by 1.7-fold (90% CI: 1.5, 1.8) as compared with encorafenib alone. - Coadministration of diltiazem (a moderate CYP3A4 inhibitor) 240 mg (XR × 2 doses on days 1 and 7) with a single dose of 50 mg encorafenib increased encorafenib AUC by 1.8-fold (90% CI: 1.6, 2.0) and C_{max} by 1.4-fold (90% CI: 1.2, 1.7) as compared with encorafenib alone.
Inhibition/Induction of Transporter Systems	- Substrate of P-gp. - Not a substrate of BCRP, MRP2, organic anion transporting polypeptide (OATP1B1, OATP1B3) and organic cation transporter (OCT1).
Effect on Absorption	Coadministration of rabeprazole (a proton pump inhibitor) 20 mg QD for 5 days with a single dose of 100 mg encorafenib did not change encorafenib AUC or C_{max}.
Interaction liability (Drug as Perpetrator)	
Inhibition/Induction of Metabolism	- Inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2D6, CYP3A, and UGT1A1. - Inducer of CYP2B6, CYP2C9, and CYP3A at clinically relevant plasma concentrations.
Inhibition/Induction of Transporter Systems	- Inhibitor of P-gp, BCRP, OCT2, OAT1, OAT3, OATP1B1, and OATP1B3. - Not an inhibitor of OCT1 or MRP2.

* PK parameters are presented as geometric mean (%CV) or median (minimum, maximum) unless otherwise noted.

6.3.2. Clinical Pharmacology Questions

Does the clinical pharmacology program provide supportive evidence of effectiveness?

Dose-response (D-R) and exposure-response (E-R) relationships for efficacy provide supportive evidence of effectiveness for the proposed encorafenib dosing regimen, 450mg QD in combination with binimetinib 45mg BID. D-R relationships for efficacy suggest that Combo 450 and Combo 300 have a comparable ORR and PFS (Table 11). The hazard ratio (HR) of 0.56 (95% CI: 0.41, 0.77) comparing Combo 300 to Mono 300 in part 2, is numerically lower than the HR comparing Combo 450 to Mono 300 in part 1, 0.75 (95% CI: 0.56, 0.99) after adjusting for significant baseline covariates. However, OS appears to be better in Combo 450 compared to Combo 300 based on preliminary analyses. The patients treated with Combo 450 had a (nominally) statistically significantly lower risk of death compared to Mono 300 after adjusting for baseline covariates, but the difference in time to death between Combo 300 and Mono 300 in part 2 was not statistically significant. It should be noted that the results from D-R analyses for OS are preliminary and should be interpreted with caution as both arms are immature and patients treated in Part 2 are followed approximately 10 months shorter than the patients treated in Part 1.

The safety profiles between Combo 450 and Combo 300 were also compared, and showed that patients in Combo 450 had a (nominally) statistically significantly higher risk of having special interest adverse events (AEs) and grade 3/4 AEs compared to Combo 300. Patients in Combo 450 also tended to have higher risks of experiencing serious AE (SAE) and dose adjustment/reduction compared to Combo 300, but the difference was not statistically significant (Figure 8). However, when looking at the risks of developing individual safety events of special interest, no difference was detected between Combo 450 and Combo 300 except for grade 1+ retinopathy excluding retinal vein occlusion.

In addition, the relationships between encorafenib or binimetinib exposure and efficacy and safety endpoints were evaluated. No clear association was found between encorafenib exposure and ORR, PFS or OS, although the median PFS and OS was numerically longer in patients with lower exposure. Patients with low encorafenib exposure had significantly lower risks of having grade 3/4 AE, safety events of special interest for encorafenib, and grade 1+ retinopathy compared to patients with high encorafenib exposure (Figure 33 in appendix). Similarly, no clear association was found between binimetinib exposure and ORR or PFS. A (nominally) statistically significant relationship was found between time to OS and binimetinib C_{max} , but such relationships were not observed with C_{min} and AUC. Patients with low binimetinib exposure had significantly lower risks of experiencing dose adjustment/ reduction compared to patients with higher binimetinib exposure. On the other hand, they have significantly higher risks of experiencing serious adverse events and grade 2+ hand-foot syndrome compared to patients with higher binimetinib exposure.

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)


In summary, D-R relationships for efficacy suggest that there is insufficient evidence that Combo 300 is as effective as Combo 450. Cross-part comparison of safety profile between Combo 300 and Combo 450 did not indicate a clinically significant safety concern for Combo 450 relative to Combo 300 which would outweigh the potential for improved efficacy in higher dose. The ER relationships were consistent with DR relationships, and they both support the use of the proposed encorafenib dose of 450 mg QD in combination with binimetinib 45 mg BID with dose modification in the event of adverse reactions to the lowest dose of encorafenib 200 mg.

Table 11: Summary of Efficacy Comparison Between Combo 300 and Combo 450 in Study CMEK162B2301

Part	Arm	ORR (95% CI)	
1	Combo 450	63.0 (55.8, 69.9)	
1	Mono 300	50.5 (43.3, 57.7)	
2	Combo 300	65.9 (59.8, 71.7)	
2	Mono 300	50.0 (39, 61)	
Part	Arm	Median PFS	HR _{Combo vs Mono} (95% CI)
1	Combo 450	15.5 months	0.75 (0.56, 0.99)
1	Mono 300	9.56 months	
2	Combo 300	12.9 months	0.56 (0.41, 0.77)
2	Mono 300	7.4 months	
Part	Arm	Median OS	HR _{Combo vs Mono} (95% CI)
1	Combo 450	31.2 months	0.66 (0.49, 0.89)
1	Mono 300	23.1 months	
2	Combo 300	NA	0.82 (0.54, 1.26)
2	Mono 300	19.5 months	

Source: Reviewer's analysis based on dataset "adtte.xpt"

Figure 8: The HRs Comparison of Combination Therapy to the Randomized Monotherapy and HR Comparison of Combo 450 to Combo 300 after Adjusting for Baseline Covariates for Evaluated General Safety Event in Study CMEK162B2301



* AER: Time to first AE leading to discontinuation; AESPLGX: Time to first AEs of special interest- Encorafenib; DADJINT: Time to first dose adjustment/reduction; GRADE34: Time to first Grade 3/4 AE; SAEW: Time to first SAE

Source: Reviewer's analysis based on dataset "adttes.xpt"

Is the proposed dosing regimen appropriate for the general patient population for which the indication is being sought?

The proposed dosing regimen of 450 mg encorafenib orally QD in combination with 45 mg binimetinib BID is appropriate for the general patient population with the proposed indication, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation as detected by an FDA-approved test. The proposed dose reduction strategy in the event of adverse reactions to 300 mg and subsequently to the lowest acceptable dose of 200 mg encorafenib QD is reasonable as the minimally effective encorafenib dose resulting in mean steady-state trough concentrations that exceed the IC₅₀ for inhibition of BRAF V600E is 50 mg.

Dose re-escalation is not recommended for encorafenib due to lack of supporting clinical data. The Applicant's proposed labeling allows for dose re-escalation from 300 to 450 mg QD or 200

to 300 mg QD if the adverse event that resulted in dose reduction has improved to baseline and there are no other concomitant BRAFTOVI-related toxicities that would prevent re-escalation and treatment continues with binimetinib. Although the protocol for Study CMEK162B2301 allowed for dose re-escalation, there was only one patient who was dose reduced to 200 mg QD due to an AE, and eventually re-escalated to 450 mg QD.

The proposed labeling recommends reduction of BRAFTOVI from 450 mg to 300 mg QD if binimetinib is temporarily interrupted or discontinued, which is supported by mechanism of toxicity, D-R relationships for safety (APPEARS THIS WAY ON ORIGINAL Figure 8), and preservation of activity/efficacy and safety results from Studies CMEK162X2110 and CLGX818X2101. In approximately 50% of cutaneous melanomas, activating mutations in *BRAF* drive tumor survival and proliferation through the RAS/RAF/MEK/ERK mitogen-activated protein kinase pathway. *RAS* mutations pre-exist in epidermal keratinocytes and *BRAF* inhibitors have been associated with increased risk of developing neoplasia, including cutaneous squamous cell carcinoma, as a result of hyperactivation of MAPK signaling by *BRAF* inhibition in *BRAF* wild-type cells. Coadministration with MEK inhibitors has been shown to reduce the incidence of these hyperproliferative lesions by blocking paradoxical MAPK activation. Encorafenib 450 mg QD in combination with binimetinib 45 BID was selected as the recommended Phase 2 dose in the dose escalation trial (Study CMEK162X2110). At the higher dose of encorafenib 600 mg QD with binimetinib 45 mg BID, 3 cases of drug-related grade 3 serum creatinine increase occurred and 52% of patients required a dose reduction. The MTD for encorafenib as a single agent was 450 mg QD; 300 mg QD was selected as the recommended dose for encorafenib as a single agent due to Grade 3 AEs and AEs requiring early dose reduction at the 450 mg dose (Study CLGX818X2101). There were 45% of patients at 450 mg QD requiring a dose reduction due to an AE compared with 12% of the patients at 300 mg QD. During the first cycle, 28% of patients at 450 mg QD required a dose reduction for AEs compared with 8% of patients at 300 mg QD.

Is an alternative dosing regimen or management strategy required for subpopulations based on intrinsic patient factors?

A comparative popPK analysis showed that encorafenib exposures were similar between patients (N=59) with mild hepatic impairment (total bilirubin within upper limit of normal [ULN] and AST > ULN or total bilirubin > 1 and up to 1.5 times ULN and any AST) and patients (N=640) with normal hepatic function (total bilirubin and AST within ULN) according to NCI criteria. Encorafenib exposures were similar among patients (N=159) with mild (CLcr 60 to 89 mL/min) renal impairment, patients (N=33) with moderate renal impairment (CLcr 30 to 59 mL/min), and patients (N=508) with normal renal function (CLcr ≥ 90 mL/min). No dose adjustment is necessary in patients with mild hepatic impairment or in patients with mild and moderate renal impairment. Dedicated studies in patients with severe hepatic or renal impairment will not be requested, to be consistent with advice that has been provided for other approved *BRAF* inhibitors.

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

Based on a popPK analysis, age (19 to 89 years), sex, body weight (41.9 to 167.9 kg), mild hepatic impairment (Child-Pugh Class A), and mild or moderate renal impairment (CLcr 30 to 89 mL/min) do not have a clinically meaningful effect on the exposure of encorafenib; therefore, dose adjustments based on these intrinsic factors are not necessary. The effects of race/ethnicity, moderate or severe hepatic impairment (Child-Pugh Class B or C), and severe renal impairment (CLcr ≤ 29 mL/min) on encorafenib PK have not been studied.

Are there clinically relevant food-drug or drug-drug interactions, and what is the appropriate management strategy?

Food-Drug Interactions

The effect of food on encorafenib PK was evaluated in a single 100 mg dose, randomized, two period crossover study with a 7-day washout period in 30 healthy subjects who received the 100 mg to-be-marketed capsule formulation (Study ARRAY-818-102). The composition of the high-fat meal was consistent with the recommendations in the FDA Food Effect Guidance for Industry (approximately 150 calories from protein, 350 calories from carbohydrates, and 500 calories from fat). PK samples were collected from pre-dose to 72 hours post-dose. Administration of a single encorafenib 100 mg dose with a high-fat, high-calorie meal in healthy subjects resulted in no change in AUC and 36% decrease in C_{max} and a 2-hour increase in median T_{max} as compared to fasted conditions (Table 12). These results support the labeling recommendation of administering encorafenib with or without food.

Table 12. PK Parameters of a Single Dose of Encorafenib after a High-Fat Meal as Compared with a Fasted State

Exposure Parameter	Geometric Mean (%CV)		Geometric Mean Ratio* (90% CI)
	High-Fat Meal	Fasted State	
AUC _{0-72h} (ng·hr/mL)	3129 (42%) n=31	3018 (39%) n=31	0.96 (0.92, 1.0)
AUC _{0-inf} (ng·hr/mL)	3121 (42%) n=30	3034 (38%) n=31	0.96 (0.916, 1.0)
C _{max} (ng/mL)	961.5 (33%) n=31	621.0 (45%) n=31	0.64 (0.57, 0.70)

* Encorafenib 100 mg (to-be-marketed capsule formulation) administered with a high-fat meal (test) vs. a fasted state (reference)

Source: ARRAY-818-102 Final Study Report; Tables 11-2, 11-3; Pages 43, 44.

Drug-Drug Interactions (DDI)

Effects of Other Drugs on Encorafenib

Binimetinib: In vitro studies did not indicate potential for binimetinib to be a DDI perpetrator of encorafenib. Comparison of PK data from Study CMEK162X2110 with those obtained in Study CLGX818X2101 showed that coadministration of encorafenib with binimetinib has no effect on encorafenib exposure (Table 18).

Strong and Moderate CYP3A Inhibitors: The effects of posaconazole (a strong CYP3A4 inhibitor) and diltiazem (a moderate CYP3A4 inhibitor) on encorafenib PK were evaluated in a single dose, randomized, crossover study with a washout period of 7 days in healthy subjects (Study ARRAY-818-105). PK samples for encorafenib were collected from pre-dose to 72 hours post-dose. Of note, subjects received posaconazole oral suspension within 30 minutes of a meal as recommended in the posaconazole labeling with the exception of the day when posaconazole was coadministered with encorafenib in the fasted state. The results showed that coadministration of posaconazole 400 mg BID for 7 days with a single dose of 50 mg encorafenib increased encorafenib AUC by 2.8-fold (90% CI: 2.5, 3.2) and C_{max} by 1.7-fold (90% CI: 1.5, 1.8) as compared with encorafenib administered alone (Table 13). Clearance (CL/F) of encorafenib was decreased by 65% from 26 L/h to 9 L/h with coadministration of posaconazole. Based on the dose-response for safety (APPEARS THIS WAY ON ORIGINAL Figure 8), a 2.8-fold increase in encorafenib exposure is clinically significant; therefore, concomitant strong CYP3A inhibitors should be avoided. For patients requiring concomitant use of a strong CYP3A inhibitor, reduce the encorafenib once daily dose by approximately two-thirds (i.e., 450 mg to 150 mg, 300 mg to 100 mg, or 200 mg to 75 mg).

Table 13. Comparative Analysis of Encorafenib PK Parameters on Day 1 (Without Posaconazole) and Day 7 (With Posaconazole)

Exposure parameter	Geometric Mean (%CV)		Geometric Mean Ratio* (90% CI)
	Encorafenib alone (50 mg) n=16	Encorafenib (50 mg) with posaconazole (400 mg BID for 7 days) n=16	
AUC _{0-72h} (ng·hr/mL)	2035 (40%) n=16	5785 (38%) n=16	2.84 (2.55, 3.17)
AUC _{0-inf} (ng·hr/mL)	2051 (40%) n=16	5812 (38%) n=16	2.83 (2.54, 3.16)
C _{max} (ng/mL)	553.5 (33%) n=16	932.1 (31%) n=16	1.68 (1.54, 1.85)

* Posaconazole 400 mg BID for 7 days and a single encorafenib 50 mg dose vs. a single encorafenib 50 mg dose alone.

Source: ARRAY-818-105 Final Study Report; Tables 11-3, 11-4; Pages 53, 54.

Coadministration of diltiazem XR 240 mg (2 doses on days 1 and 7) with a single dose of 50 mg encorafenib increased encorafenib AUC by 1.8-fold (90% CI: 1.6, 2.0) and C_{max} by 1.4-fold (90% CI: 1.2, 1.7) as compared with encorafenib administered alone (Table 14). Clearance (CL/F) of encorafenib was decreased by 45% from 29 L/h to 16 L/h with coadministration of diltiazem. Based on the dose-response for safety (APPEARS THIS WAY ON ORIGINAL Figure 8), a 1.8-fold increase in exposure is clinically significant; therefore, moderate CYP3A inhibitors should also be avoided. For patients requiring concomitant use of a moderate CYP3A inhibitor, reduce the encorafenib once daily dose by approximately one-half (i.e., 450 mg to 225 mg, 300 mg to 150 mg, or 200 mg to 100 mg).

Table 14. Comparative Analysis of Encorafenib PK Parameters on Day 1 (Without Diltiazem) and Day 7 (With Diltiazem)

Exposure parameter	Geometric Mean (%CV)		Geometric Mean Ratio* (90% CI)
	Encorafenib alone (50 mg) n=16	Encorafenib (50 mg) with diltiazem (240 mg × 2 doses on days 1 and 7) n=16	
AUC _{0-72h} (ng·hr/mL)	1895 (40%) n=16	3495 (47.9%) n=16	1.84 (1.68, 2.03)
AUC _{0-inf} (ng·hr/mL)	1882 (42%) n=14	3511 (49.5%) n=15	1.83 (1.64, 2.03)
C _{max} (ng/mL)	482.3 (38%) n=16	697.7 (40.5%) n=16	1.45 (1.24, 1.68)

* Diltiazem XR 240 mg × 2 doses on days 1 and 7 and a single encorafenib 50 mg dose alone vs. a single encorafenib 50 mg dose alone.
 Source: ARRAY-818-105 Final Study Report; Tables 11-5, 11-6; Pages 57, 58.

Acid Reducing Agents: The effect of rabeprazole (a proton pump inhibitor) on encorafenib PK were evaluated in a single dose, randomized, crossover study with a washout period of 7 days in 10 healthy subjects (Study ARRAY-162-105). Coadministration of rabeprazole 20 mg QD for 5 days with a single dose of 100 mg encorafenib did not change encorafenib AUC or C_{max} (Table 15).

Table 15. Comparative Analysis of Encorafenib PK Parameters on Day 1 (Without Rabeprazole) and Day 8 (With Rabeprazole)

Exposure parameter	Geometric Mean (%CV)		Geometric Mean Ratio* (90% CI)
	Encorafenib alone (100 mg)	Encorafenib (100 mg) with rabeprazole (20 mg QD for 5 days)	
AUC _{0-72h} (ng·hr/mL)	4119 (33%) n=10	3991 (35.9%) n=11	0.965 (0.764, 1.22)
AUC _{0-inf} (ng·hr/mL)	4137 (33.4%) n=10	4014 (35.7%) n=11	0.966 (0.766, 1.22)
C _{max} (ng/mL)	1041 (36.9%) n=10	974.0 (70.0%) n=11	0.942 (0.593, 1.50)
* Encorafenib 100 mg alone vs. encorafenib 100 mg and rabeprazole 20 mg QD for 5 days Source: ARRAY-162-105 Final Study Report; Tables 11-7, 11-8; Pages 73, 74.			

Strong and Moderate CYP3A Inducers: In vivo DDI studies have not been conducted with encorafenib and CYP3A inducers. A physiologically-based pharmacokinetic (PBPK) analysis was conducted by the Applicant to evaluate the effect of a strong CYP3A inducer on the steady-state PK of encorafenib. There was no adequate clinical data to validate this DDI model. Refer to the PBPK review in Appendix 19.2. Avoidance of coadministration of BRAFTOVI with strong or moderate CYP3A inducers is recommended. Given the lack of clinical data or a validated PBPK model to inform the magnitude of a potential decrease in exposure with coadministration of moderate CYP3A inducers, the Applicant is requested to assess the effect of moderate CYP3A4 inducers on encorafenib PK by conducting a dedicated DDI study under a PMC to determine dosing recommendations.

Transporters: In vitro studies indicate that encorafenib is a substrate of P-gp with net flux ratio ≥ 2 in Caco-2 cells, and a known inhibitor decreased encorafenib efflux ratio to $< 50\%$ of that in the absence of the inhibitor. Encorafenib is not a substrate of BCRP or MRP2 nor OATP1B1, OATP1B3, or OCT1 as known inhibitors did not decrease encorafenib efflux ratio to $< 50\%$ of that in the absence of the inhibitors, and also did not decrease encorafenib hepatic uptake to $\leq 50\%$.

Effects of Encorafenib on Other Drugs

CYP Substrates: Encorafenib inhibits CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2D6, and CYP3A at clinically relevant unbound concentrations (R_1 values ≥ 1.02 , Table 16). The $R_{1,gut}$ for CYP3A is

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

calculated to be 445, which is greater than the cutoff of 11. M42.5A (LHY746) does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4.

A DDI cocktail study is planned to evaluate the effect of encorafenib in combination with binimetinib on the PK of caffeine (CYP1A2 substrate), losartan (CYP2C9 substrate), omeprazole (CYP2C19), dextromethorphan (CYP2D6 substrate), midazolam (CYP3A4 substrate), and rosuvastatin (OATP1B1 substrate) in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma or other advanced solid tumors (Study ARRAY-818-103). It is recommended to include a CYP2B6 substrate in Study ARRAY-818-103 given its unbound R_1 value of 3.1.

Table 16. IC_{50} and Calculated R_1 values for Encorafenib Inhibition of CYP activities in Human Liver Microsomes

CYP Enzyme	Substrate	Encorafenib IC_{50} (μ M)	R_1 value (1+I/ K_i)	Unbound IC_{50} μ M	Unbound R_1 value (1+ I_u / K_i)
CYP1A2	Phenacetin	22	1.6	16.5	1.1
CYP2A6	Coumarin	> 100	1.1	> 97.1	1.0
CYP2B6	Bupropion	1	15	0.94	3.1
CYP2C8	Paclitaxel	30	1.5	22.5	1.1
CYP2C8	Amodiaquine	20	1.7	19.4	1.1
CYP2C9	Diclofenac	5	3.8	4.9	1.4
CYP2C19	S-Mephenytoin	> 100	1.1	> 100	1.0
CYP2D6	Bufuralol	25	1.6	23.6	1.1
CYP2E1	Chlorzoxazone	> 100	1.1	94.3	1.0
CYP3A4/5	Midazolam	8	2.8	7.8	1.2
CYP3A4/5	Testosterone	15	1.9	14.6	1.1
Calculation of encorafenib R_1 values based on maximal steady-state concentration of 3760 ng/mL or 7 μ M [I_{max}] Calculation of encorafenib unbound R_1 values based on unbound maximal steady-state concentration of 526 ng/mL or 0.97 μ M [$I_{max,u}$] K_i assumed to be $IC_{50}/2$ for competitive inhibition for those CYP enzymes without an experimental K_i value Source: DMPK R1000039 Final Study Report, Table on Page 7.					

Encorafenib may induce CYP2B6, CYP2C9 and CYP3A4 (R_3 value < 0.9) at clinically relevant concentrations (7 μ M) based on the in vitro human hepatocytes study (Table 17). The PXR activation study showed that the maximum activation was 38% at encorafenib 50 μ M relative to rifampin and the EC_{50} was 9.7 μ M. A PMC clinical trial is requested to assess the magnitude of decreasing exposures of sensitive CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A substrates

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

due to enzymatic induction by encorafenib. An in vitro pharmacology study indicated that M42.5A is an agonist of PXR (EC₅₀ of 3.8 μM).

Table 17. Encorafenib Induction of Mean mRNA and Activity Levels of CYP Enzymes

Encorafenib (μM)	CYP1A2		CYP2B6		CYP2C9		CYP3A4	
	mRNA	Activity ^b	mRNA	Activity ^b	mRNA	Activity ^b	mRNA	Activity ^b
1	1.09	1.50	1.96	1.45	1.46	1.64	8.09	2.02
10	2.72	1.85	8.79	1.96	3.07	2.13	51.6	3.94
50	17.5	2.60	7.31	1.53	3.56	1.38	95.5	1.96
100	21.2	2.96	3.24	0.996	2.97	1.26	88.5	1.12
Known positive inducer ^a	38.3	22.1	7.85	2.95	1.76	2.34	29.8	5.16

^a Omeprazole 50 μM for CYP1A2, phenobarbital 1000 μM for CYP2B6, rifampin 10 μM for CYP2C9/CYP3A4
^b Mean fold change relative to vehicle control (DMSO 0.1%) from three human hepatocyte lots

Source: DMPK R1200539 Final Study Report, Tables 6-5 to 6-20, Pages 24-37.

Due to potential of encorafenib to induce CYP3A at clinically relevant concentrations, coadministration of encorafenib with CYP3A substrates can result in decreased concentrations and loss of efficacy of CYP3A substrates, including hormonal contraceptives. Estrogen and progestin hormonal contraceptives (including ethinyl estradiol, drospirenone, norgestimate, levonorgestrel, desogestrel, norethindrone, gestodene, norgestrel, ethynodiol diacetate, estradiol valerate, dienogest, ulipristal, etonogestrel, medroxyprogesterone acetate, norelgestromin), administered orally or by other non-oral routes (e.g., vaginal ring, intramuscular injection, transdermal patch, subdermal implant, hormone-releasing intrauterine devices), are primarily metabolized by CYP3A4 and to a lesser extent by CYP2C9/CYP2C19. Given that encorafenib has teratogenic potential and may decrease concentrations and efficacy of hormonal contraceptives, females of reproductive potential should be advised to use effective non-hormonal contraception during treatment with encorafenib and for 2 weeks after the last dose of encorafenib.

UGT Substrates: Encorafenib is an inhibitor of UDP-glucuronosyl transferase 1A1 (UGT1A1) (IC₅₀ 4 μM) in vitro (C_{max}/IC₅₀ ≥ 0.1).

Transporter Substrates: In vitro, encorafenib is an inhibitor of P-glycoprotein (P-gp, IC₅₀ >50 μM) and breast cancer resistance protein (BCRP, IC₅₀ 10-25 μM) based on I_{gut}/IC₅₀ ≥ 10 μM; organic cation transporter 2 (OCT2, IC₅₀ 2.05 μM), organic anion transporters 1 (OAT1, IC₅₀ 4.2 μM) and 3 (OAT3, IC₅₀ 0.92 μM) based on I_{max,u}/IC₅₀ ≥ 0.1; organic anion transporting polypeptide 1B1 (OATP1B1, IC₅₀ 5.35 μM) and 1B3 (OATP1B3, IC₅₀ 6.16 μM) based on R value ≥ 1.1. Therefore, encorafenib may have the potential to increase concentrations of coadministered substrates of these transporters. Encorafenib is not an inhibitor of OCT1 (IC₅₀ 12.7 μM) or multidrug resistance-associated protein 2 (MRP2, IC₅₀ >50 μM). M42.5A appears to be an inhibitor of BCRP.

Drug Interactions Associated with Combination Treatment

Binimetinib is primarily metabolized (61%) by glucuronidation (UGT1A1, UGT1A3, UGT1A9) and to a lesser extent by CYP1A2 and CYP2C19. Encorafenib is an inhibitor of UGT1A1, CYP1A2 and CYP2C19 in vitro. The PK of encorafenib and binimetinib administered in combination in Study CMEK162X2110 were compared with those obtained in the respective single agent studies (Study CLGX818X2101 for encorafenib and Study CMEK162X2201 for binimetinib). Binimetinib steady-state AUC was 15% higher following combination treatment as compared with binimetinib alone, which is not considered clinically meaningful. Binimetinib does not affect the PK of encorafenib.

Table 18. Comparison of Encorafenib and Binimetinib Exposures Following Combination Treatment and Single Agents

	Single Dose		Repeat Doses	
	Geometric Mean AUC _{tau} , ng·h/mL (%CV)	Geometric Mean C _{max} , ng/mL (%CV)	Geometric Mean AUC _{tau,ss} , ng·h/mL (%CV)	Geometric Mean C _{max,ss} , ng/mL (%CV)
Encorafenib Exposures				
Encorafenib 450 QD + Binimetinib 45 mg BID (Study CMEK162X2110)	32200 (54%) n=13	7040 (42%) n=13	13900 (59%) n=13	3760 (63%) n=13
Encorafenib 450 mg QD (Study CLGX818X2101)	32800 (69%) n=6	5970 (56%) n=6	13100 (35%) n=6	3950 (49%) n=6
Binimetinib Exposures				
Binimetinib 45 mg BID + Encorafenib 450 mg QD (Study CMEK162X2110)	2390 (48%) n=13	735 (45%) n=13	2420 (34%) n=13	595 (39%) n=13
Binimetinib 45 mg BID (Study CMEK162X2201)	1648 (35%) n=7	458 (46%) n=23	2103 (38%) n=7	438 (54%) n=22

Source: CMEK162X2110 Study Report; Tables 12 and 13; Pages 116 and 117; CLGX818X2101 Study Report; Tables 11-10 and 11-11; Pages 129-132; CMEK162X2201 Study Report; Table 11-11, Page 101.

Youwei Bi, PhD
Ruby Leong, PharmD
Clinical Pharmacology
Primary Reviewers

Jiang Liu, PhD
Hong Zhao, PhD
Clinical Pharmacology
Team Leaders

7 Sources of Clinical Data and Review Strategy

7.1. Table of Clinical Studies

Table 19 lists the clinical trials included in the NDA submission. The primary evidence to support the clinical of efficacy of encorafenib and binimetinib when given together in patients with BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma is from the randomized clinical trial CMEK162B2301 (hereafter referred to as COLUMBUS). In addition, Array submitted data from 158 patients with advanced unresectable or metastatic BRAF V600-mutated melanoma from trial CLGC818X2109 (hereafter referred to as LOGIC2) to support the efficacy of the combination.

The primary safety data used to characterize the safety profiles of encorafenib and binimetinib when given together is derived from 192 patients treated with encorafenib 450 mg by mouth daily given with binimetinib 45 mg by mouth twice daily (hereafter referred to as Combo 450) treated on COLUMBUS Part 1. The safety experience is supported by safety data from 158 patients with locally advanced or metastatic BRAF V600 mutation-positive melanoma treated with Combo 450 on LOGIC2, 83 patients with BRAF V600 mutation-positive melanoma who received Combo 450 on Trial CMEK162X2110, and 257 patients with BRAF V600 mutation-positive melanoma who received encorafenib 300 mg by mouth once daily and binimetinib 45 mg by mouth twice daily (hereafter referred to as Combo 300) treated on COLUMBUS Part 2. Single-agent safety data for encorafenib and binimetinib was also considered.

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

Table 19: Clinical Trials Included in the NDA Submission

Trial	Design	Regimen/ schedule/ route	Study Efficacy Endpoints	No. of patients enrolled	Study Population	No. of Centers and Countries
<i>Randomized Trial of Efficacy and Safety</i>						
CMEK162B2391 (COLUMBUS)	Phase 3, 2-part, randomized, open-label, multi-center, active control	Combo 450: binimetinib 45 mg BID + encorafenib 450 mg QD per 21 day cycle	<u>Primary:</u> PFS of Combo 450 vs. vemurafenib	192	Advanced unresectable or metastatic BRAF V600E or V600K mutation-positive melanoma	162 clinical sites in 28 countries
		encorafenib 300 mg QD per 21 day cycle	<u>Key Secondary:</u> PFS of Combo 450 vs. encorafenib 300	194		
Part 1	vemurafenib 960 mg BID per 21 day cycle	<u>Other Secondary:</u> ORR, TTR, DOR, DCR, QoL, OS	191			
Part 2	Combo 300: binimetinib 45 mg BID + encorafenib 300 mg QD per 21 day cycle	<u>Key Secondary:</u> PFS of Combo 300 vs. encorafenib 300 (Parts 1+)	258			
	encorafenib 300 mg QD per 21 day cycle	<u>Other Secondary:</u> ORR, TTR, DOR, DCR, QoL, OS	86			
<i>Non-randomized Trial to Support Efficacy and Safety</i>						
CLGX818X2109 (LOGIC2)	Multicenter, nonrandomized, 2-part study of sequential encorafenib/binimetinib combination followed by a rational combination with targeted agents after progression to overcome resistance	Combo 450: binimetinib 45 mg BID + encorafenib 450 mg QD per 21 day cycle	<u>Primary:</u> ORR <u>Other Secondary:</u> PFS, DOR, TTR, DCR	75: BRAF/MEK naïve ¹ 83: non-naïve	Locally advanced or metastatic BRAF V600 melanoma	16 clinical sites in 9 countries

Multi-Disciplinary Review and Evaluation NDA 210496
 BRAFTOVI™ (encorafenib)

Trial	Design	Regimen/ schedule/ route	Study Efficacy Endpoints	No. of patients enrolled	Study Population	No. of Centers and Countries
<i>Non-randomized trials to support safety</i>						
CMEK162X2110	Phase 1b/2, multicenter, open-label, dose-escalation	Phase 1: binimetinib 45 mg BID + encorafenib at the following dose levels: 50 mg QD 100 mg QD 200 mg QD 400 mg QD 450 mg QD 600 mg QD 800 mg QD Phase 2: binimetinib 45 mg BID + encorafenib 450 mg QD	<u>Primary:</u> ORR, DCR (Phase 2 only) <u>Secondary:</u> Phase 1: ORR Phase 2: DOR, TTR, OS	binimetinib 45 mg BID + encorafenib 400 mg QD: 4 450 mg QD: 21 600 mg QD: 62	BRAF dependent advanced solid tumors	
<i>Single-agent encorafenib trials included in the encorafenib pooled safety analysis</i>						
CMEK162B2301 Part 1	Phase 3, 2-part, randomized, open-label, multi-center, active control	encorafenib 300 mg QD	N/A	192	Advanced unresectable or metastatic BRAF V600K mutation-positive melanoma	
CLG818X2101	A Phase 1, multicenter, open-label, dose escalation study of oral encorafenib	encorafenib 300 mg QD	N/A	10	Locally advanced or metastatic BRAF mutation-positive melanoma	
CLGX818X2102	Phase 2, open-label, multicenter, 2-part study with a dose escalation phase with encorafenib alone in BRAF inhibitor naïve	encorafenib 300 mg QD	N/A	15	Locally advanced or metastatic BRAF V600 mutation-positive melanoma	

Multi-Disciplinary Review and Evaluation NDA 210496
 BRAFTOVI™ (encorafenib)

Trial	Design	Regimen/ schedule/ route	Study Efficacy Endpoints	No. of patients enrolled	Study Population	No. of Centers and Countries
	patients until PD, followed by a second phase with encorafenib in combination with targeted agents based on tumor biopsy analysis					
<i>Single-agent binimetinib trials included in the binimetinib pooled safety analysis</i>						
CMEK162A2301	Randomized, open-label, multicenter Phase 3 study	Binimetinib 45 mg BID	N/A	269	Advanced, unresectable or metastatic NRAS mutation-positive melanoma	
CMEK162X2201	Phase 2 open-label				Advanced, unresectable or metastatic NRAS mutation-positive melanoma	
Source: Summary of Clinical Safety Tables 1-2, 1-2, and 1-3 ¹ data only from BRAF/MEK naïve patients used in primary efficacy analysis						

7.2. Review Strategy

The key materials used for the review of efficacy and safety included:

- Review of the current literature on BRAF-mutant melanoma epidemiology and treatment.
- Review of COLUMBUS, including CSR, protocol, protocol amendments, SAP, and SAP amendments.
- Review and assessment of applicant analysis of encorafenib and binimetinib safety and efficacy in the clinical study report.
- Review of datasets submitted as SAS transport files.
- Review of patient narratives of serious adverse events and deaths.
- Review of minutes of key meetings conducted during encorafenib with binimetinib development for melanoma.
- Review and assessment of Module 2 summaries including the Summary of Clinical Efficacy, Summary of Clinical Safety, Integrated Summary of Efficacy, Integrated Summary of Safety, and proposed labeling modifications for encorafenib and for binimetinib.
- Review of Consultation reports of the Office of Scientific Investigations, QT-IRT, and Ophthalmology.
- Formulation of the benefit-risk analysis and recommendations.
- Review and evaluation of proposed labeling.

Data Sources

The electronic submission including Protocols, SAP, CSRs, SAS transport datasets in SDTM (Study Data Tabulation Model) and ADaM (Analysis Data Model) format, and SAS codes for the NDA submission are located in the following network paths:

- NDA 210496 original submission (encorafenib):
 - <\\CDSESUB1\evsprod\NDA210496\210496.enx>
- NDA 210498 original submission (binimetinib):
 - <\\CDSESUB1\evsprod\NDA210498\210498.enx>

Submissions related to the encorafenib and binimetinib used in combination were submitted to NDA 210496 (encorafenib), and a cross reference to NDA210496 was submitted to NDA 210498 (binimetinib). Submissions related to encorafenib as a single agent were submitted to NDA 210496, and submissions related to binimetinib as a single agent were submitted to NDA 201498.

Data and Analysis Quality

The data submitted with this application were in ADaM and SDTM formats. The data were of good quality and the applicant's analyses were reproducible. Requests for additional information from the applicant through the review process were addressed in a timely fashion. The applicant submitted information regarding their quality assurance plan including their site inspections, the use of central laboratory for hematology and serum chemistry labs, and a certificate of audit.

8 Statistical and Clinical and Evaluation

8.1. Review of Relevant Individual Trials Used to Support Efficacy

Table 20 lists the studies included in this review of efficacy.

Table 20: Studies Reviewed for Efficacy

Study	Design	Treatment Regimens Included in Review	Number of Patients Included in Review	Patient Population
COLUMBUS (Part 1)	Phase 3, 2-part randomized, open label, multicenter study	Per 28-day cycle: encorafenib 450 mg QD plus binimetinib 45 mg BID Encorafenib 300 mg QD Vemurafenib 960 mg BID	Part 1 (577 total randomized): 192: Combo 450 194: encorafenib 191: vemurafenib	Patients with locally advanced unresectable or metastatic melanoma with BRAF V600 mutation
COLUMBUS (Part 2)	Phase 3, 2-part randomized, open label, multicenter study	Per 28-day cycle: encorafenib 300 mg QD plus binimetinib 45 mg BID Encorafenib 300 mg QD	Part 2: (344 patients randomized): 258: Combo 300 86: encorafenib	Patients with locally advanced unresectable or metastatic melanoma with BRAF V600 mutation
LOGIC2 (Part 1)	Multicenter, nonrandomized, 2-part study	Per 21-day cycle: encorafenib 300 mg QD binimetinib 45 mg BID	Part 1 (158 total): 75: BRAF-inhibitor naïve 83: BRAF-inhibitor non-naïve	Patients with BRAF-mutant locally advanced unresectable or metastatic BRAF V600 melanoma

Source: Adapted from Tabular Listing of Clinical Studies.

8.1.1. COLUMBUS – Trial Design

Overview

Trial CMEK162B2301 (COLUMBUS, Protocol Version 4) was titled **CO**mbined **LGX818 Used with MEK162** in **BRAF** mutant **Unresectable Skin Cancer**, A 2-part phase III randomized, open label, multicenter study of LGX818 plus MEK162 versus vemurafenib versus LGX818 monotherapy in patients with unresectable or metastatic BRAF V600 mutant melanoma (Table 21).

Table 21: COLUMBUS Key Trial Dates

	Part 1	Part 2
First patient randomized	30 Dec 2013	19 Mar 2015
Last patient randomized	10 Apr 2015	10 Nov 2015
Data cutoff (original submission)	19 May 2016	09 Nov 2016
Minimum follow-up time	~ 13 months	~ 12 months
Number of patients	577	344
Trial Sites	162 in 28 countries	116 in 24 countries

Source: FDA Analysis

Part 1 was designed to compare encorafenib in combination with binimetinib to encorafenib alone and to vemurafenib alone. Patients were randomized in a 1:1:1 ratio to one of the three treatment arms:

- 1) Encorafenib 450 mg by mouth daily plus binimetinib 45 mg by mouth twice daily continuously in 28-day cycles (Combo 450 arm)
- 2) Encorafenib 300 mg by mouth once daily continuously in 28-day cycles (Encorafenib arm)
- 3) Vemurafenib 960 mg by mouth twice daily continuously in 28-day cycles (Vemurafenib arm)


Part 2 was designed to estimate the contribution of binimetinib to the effect of the combination. As discussed in “Protocol Amendments,” FDA stated in a meeting that the design of Part 1 was insufficient to determine the contribution of binimetinib to the effect of the combination because the combination arm uses a higher dose of encorafenib (450 mg) than the encorafenib arm alone (300 mg).

Part 2: Patients were randomized in a 3:1 ratio to one of the two treatment arms:

- 1) Encorafenib 300 mg by mouth once daily plus binimetinib 45 mg by mouth twice daily continuously in 28-day cycles (Combo 300 arm)
- 2) Encorafenib 300 mg by mouth once daily continuously in 28-day cycles (Encorafenib arm)

Figure 9 shows the study schema of COLUMBUS, with planned sample sizes.

Figure 9: Study Schema of COLUMBUS



Source: Adapted from Figure 1 of the CSR for Part 1 of COLUMBUS, dated 24-Feb-2017

Randomization was stratified by American Joint Committee on Cancer (AJCC) stage (IIIB + IIIC + VM1a + IV1b vs. IVM1c), ECOG performance status (0 vs. 1), and prior first line immunotherapy (yes vs. no).

Treatment continued until progression, unacceptable toxicity, withdrawal of consent to continue study treatment, death, physician decision or early termination of the study.

All response endpoints were evaluated according to blinded independent review committee (BIRC) central review per RECIST v1.1.

Reviewer's comment: The study was not designed to compare the efficacy or safety of Combo 450 vs. Combo 300.

Study Endpoints

Study objectives and related endpoints are described in Table 22.

Table 22: COLUMBUS Study Objectives and Endpoints

Objective	Endpoint
Primary	
Part 1: To determine whether treatment with Combo 450 prolongs progression free survival (PFS) compared with vemurafenib in patients with BRAF V600 mutant locally advanced unresectable or metastatic melanoma	PFS, defined as the time from the date of randomization to the date of the first documented disease progression or death due to any cause, whichever occurs first. PFS will be determined based on tumor assessment (RECIST version 1.1 criteria) as per BIRC and survival information.
Key secondary	
Part 1	
To determine the contribution of binimetinib to the regimen of binimetinib plus encorafenib using the PFS comparison Combo 450 vs. LGX818PFS per BIRC as above	PFS per BIRC (as above)

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

Part 2	
To further quantify the contribution of binimetinib to the regimen of binimetinib plus encorafenib using PFS comparison of Combo 300 vs. LGX818	PFS per BIRC (as above)
Other Secondary	
Part 1 only:	
To compare the treatment effect of Combo 450 vs. vemurafenib in terms of overall survival (OS)	OS, calculated as the time from the date of randomization to date of death due to any cause.
To estimate the treatment effect of Combo 450 vs. LGX818 in terms of overall survival (OS)	OS (as above)
To determine the safety and tolerability of Combo 450 and LGX818 in this patient population	Safety: Adverse events and serious adverse events, changes in laboratory values, vital signs, ECGs, MUGAS/echocardiogram and assessment of physical dermatological and ocular examinations graded according to the NCI CTCAE c4.03
Part 2 only	
To estimate the safety and tolerability of Combo 300 vs. LGX818 in this patient population	Safety (as above)
To estimate the safety and tolerability of Combo 300 vs. Combo 450 in this patient population	Safety (as above)
To estimate the treatment effect of Combo 300 vs. LGX818 in terms of overall survival (OS)	OS (as above)
To estimate the treatment effect of Combo 300 vs. vemurafenib in terms of PFS and OS	PFS per BIRC and OS (as above)
To estimate the treatment effect of Combo 300 vs. Combo 450 in terms of PFS and OS	PFS per BIRC and OS (as above)
Part 1 and 2	
To estimate the treatment effect of LGX818 vs. vemurafenib in terms of PFS and OS	PFS per BIRC and OS (as above)
To assess objective response rate (ORR) by treatment arms	ORR, calculated as the proportion of patient with a best overall response of complete response (CR) or partial response (PR). ORR will be calculated for confirmed and unconfirmed responses separately.
To describe the time to objective response (TTR)	TTR, calculated as the time from date of randomization until first documented CR or PR
To assess disease control rate (DCR) by treatment arms	DCR, calculated as the proportion of patient with a best overall response of CR, PR or stable disease (SD)
To evaluate duration of response (DOR)	DOR, calculated as the time from the date of first documented CR or PR to the first documented progression or death due to underlying cancer
To compare the patient-reported outcomes (PRO) between the treatment arms	Time to definitive 10% deterioration in the FACT-M melanoma subscale and global health status score of the EORTC QLQ-C30. Change from baseline in the FACT-M melanoma subscale, EQ-5D-5L, and global health status score of the EORTC QLQ-C30. Change from baseline in the other EORTC QLQ-C30 subscales.
To compare the ECOG PS between the treatment arms	Time to definitive 1 point deterioration in ECOG PS Change from baseline in ECOG PS

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

To characterize the pharmacokinetics of Plasma concentration-profiles of LGX818 and MEK162 and
LGX818 and MEK162 in this patient population model based PK parameters

Source: Protocol No. CMEK162B2301 Version 04 Table 3-1 dated 13-Jul-2015.

Endpoints Included in Review

FDA's review of efficacy is limited to analysis of PFS, OS, ORR, and duration of response. The clinical data cutoff date for the final PFS analysis in Part 1 of COLUMBUS was May 19, 2016. The clinical data cutoff date for the final PFS analysis in Part 2 of COLUMBUS was November 9, 2016.

Eligibility Criteria

Key inclusion criteria for COLUMBUS (excerpted from Protocol CMEK162B2301 Version 04) were:

- Age $\geq$ 18 years
- Histologically confirmed diagnosis of locally advanced, unresectable or metastatic cutaneous melanoma or unknown primary melanoma AJCC Stage IIIB, IIIC or IV;
- Presence of BRAF V600E and/or V600K mutation in tumor tissue prior to enrollment, as determined by a designated central laboratory;
- Naive untreated patients or patients who have progressed on or after prior first-line immunotherapy for unresectable locally advanced or metastatic melanoma; Note: Prior adjuvant therapy is permitted (e.g. IFN, IL-2 therapy, any other immunotherapy, radiotherapy or chemotherapy), except the administration of BRAF or MEK inhibitors.
- Evidence of at least one measurable lesion as detected by radiological or photographic methods according to guidelines based on RECIST version 1.1; **Note:** A previously irradiated lesion is eligible to be considered as a measurable lesion provided that there is objective evidence of progression of the lesion since discontinuation of therapy and prior to starting study drug.
- ECOG performance status of 0 or 1;
- Adequate bone marrow, organ function and laboratory parameters:
 - Absolute neutrophil count (ANC) $\geq$ $1.5 \times 10^9/L$,
 - Hemoglobin (Hgb) $\geq$ 9 g/dL without transfusions,
 - Platelets (PLT) $\geq$ $100 \times 10^9/L$ without transfusions,
 - AST and/or ALT $\leq$ $2.5 \times$ upper limit of normal (ULN); patient with liver metastases $\leq$ $5 \times$ ULN,
 - Total bilirubin $\leq$ $2 \times$ ULN,

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

- Creatinine $\leq$ 1.5 mg/dL, or calculated creatinine clearance (determined as per Cockcroft-Gault) $\geq$ 50mL/min;
- Adequate cardiac function:
 - left ventricular ejection fraction (LVEF) $\geq$ 50% as determined by a multigated acquisition (MUGA) scan or echocardiogram,
 - triplicate average baseline QTc interval $\leq$ 480 ms;

Key Exclusion criteria for COLUMBUS are:

- Any untreated central nervous system (CNS) lesion. However, patients are eligible if: a) all known CNS lesions have been treated with radiotherapy or surgery, b) patient remained without evidence of CNS disease progression $\geq$ 4 weeks and c) patients must be off corticosteroid therapy for $\geq$ 3 weeks;
- Uveal and mucosal melanoma;
- History of leptomeningeal metastases;
- History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO (e.g. uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes);
- History of allogeneic bone marrow transplantation or organ transplantation;
- History of Gilbert's syndrome;
- Previous or concurrent malignancy with the following exceptions:
 - adequately treated basal cell or squamous cell carcinoma of the skin (adequate wound healing is required prior to study entry),
 - in situ carcinoma of the cervix, treated curatively and without evidence of recurrence for at least 3 years prior to the study,
 - or other solid tumor treated curatively, and without evidence of recurrence for at least 3 years prior to study entry; (note: based on mechanism of action, BRAF inhibitors may cause progression of cancers associated with RAS mutations. Thus, benefits and risks should be carefully considered before administering a BRAF inhibitor to patients with a prior cancer associated with RAS mutation).
- Prior therapy with a BRAF inhibitor (including but not limited to vemurafenib, dabrafenib, LGX818, and XL281/BMS-908662) and/or a MEK inhibitor (including but not limited to trametinib, AZD6244, MEK162, GDC-0973 and RDEA119);
- Any previous systemic chemotherapy treatment, extensive radiotherapy or investigational agent other than immunotherapy, or patients who have received more than one line of immunotherapy for locally advanced unresectable or metastatic melanoma; **Note:** Ipilimumab or other immunotherapy treatment must have ended at

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

least 6 weeks prior to randomization. Chemotherapy given as part of isolated limb perfusion, regional or intralesional treatment will not be considered systemic treatment;

- Impaired cardiovascular function or clinically significant cardiovascular diseases, including any of the following:
 - History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) <6 months prior to screening,
 - Symptomatic chronic heart failure, history or current evidence of clinically significant cardiac arrhythmia and/or conduction abnormality <6 months prior to screening except atrial fibrillation and paroxysmal supraventricular tachycardia;
- Uncontrolled arterial hypertension despite medical treatment;
- Patients who have neuromuscular disorders that are associated with elevated CPK (e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy).

Dose Modification and Management Guidelines

Dose reduction was allowed for patients who did not tolerate encorafenib or binimetinib. Table 23 shows the dose reduction levels for encorafenib for patients on the Combo 450 arm, the Combo 300 arm, and the encorafenib monotherapy arm. A dose reduction for encorafenib below 50 mg QD was not allowed. Table 24 shows the levels for dose reductions for binimetinib for patients on the Combo 450 arm. A dose reduction for binimetinib below 15 mg BID was not allowed. Dose reductions for a drug were to be based on the highest AE grade.

Table 23: Dose Reductions for Encorafenib

Dose Level	Combo 450 Arm	Combo 300 or Encorafenib Monotherapy Arm
0 (starting dose)	300 mg QD	450 mg QD
-1	200 mg QD	300 mg QD
-2	100 mg QD	200 mg QD
-3	50 mg QD	100 mg QD
-4	Not Allowed	50 mg QD

Source: Columbus Protocol Version 4 Table 6-7, dated 13-Jul-2015

Table 24: Dose Reductions for Binimetinib

Dose Level	Combo 450 or Combo 300 Arm
0 (starting dose)	45 mg BID
-1	30 mg BID
-2	15 mg BID

Source: Columbus Protocol Version 4 Table 6-8, dated 13-Jul-2015

Detailed guidelines for dose adjustments, including interruption, reduction, and permanent discontinuation for encorafenib and binimetinib were specified in the protocol for the following toxicities: the eye disorders of retinal event (including retinal detachment) and/or posterior uveitis, retinal vein occlusion, other eye disorders, liver toxicity based on AST/AST and bilirubin laboratory values, left ventricular systolic dysfunction based on measured LVEF (dose adjustment for binimetinib only), QTcF prolongation, CPK elevation, rash, hand foot skin reaction (dose adjustment for encorafenib only), squamous cell carcinoma/ keratoacanthoma / other suspicion skin lesion (dose adjustment for encorafenib only), diarrhea, nausea/vomiting, and other adverse events suspected to be related to study drug(s).

If a patient on a combination arm discontinued treatment with binimetinib, the patient was allowed to continue treatment with encorafenib; however, because of the limited efficacy of binimetinib monotherapy in the study population, if a patient on a combination arm discontinued treatment with encorafenib, they were also required to discontinue treatment with binimetinib.

For both encorafenib and binimetinib, when the toxicity that resulted in a dose reduction improves to $\leq$ Grade 1, the dose could be re-escalated at the investigator's discretion provided there were no other concomitant toxicities. The following exceptions applied: binimetinib reduced due to left ventricular dysfunction or prolonged QTc, or encorafenib reduced for prolonged QTc.

Statistical Analysis Plan

The stratified log-rank test was used for PFS and OS endpoints in all analyses, with an overall significance level of 5% (two-sided). The Kaplan-Meier method was used to estimate the PFS and OS curves for each treatment arm, and the Cox proportional hazards model was used for


the estimation of hazard ratios for comparisons between arms. Overall type I error was controlled among these endpoints by a hierarchical testing procedure, where the order of testing was

- Test 1: PFS (Combo 450 vs. vemurafenib)
- Test 2: PFS (Combo 450 vs. encorafenib)
- Test 3: PFS (Combo 300 vs. encorafenib)
- Test 4: OS (Combo 450 vs. vemurafenib).

Tests that included the Combo 450 arm were performed on the ITT population from Part 1. In the comparison of the Combo 300 arm and the encorafenib arm (Test 3), the log-rank test was performed using a pooled population for the encorafenib arm, in which all patients randomized to encorafenib monotherapy in either Part 1 or Part 2 were combined, and the ITT population from Part 2 for the Combo 300 arm.

All analyses were event driven, and the estimated times at which they were to take place relative to the first patient's first visit (FPFV) are shown in Figure 10 below. The primary analysis of PFS was planned to occur when Part 1 enrollment completed, and a sufficient number of PFS events for both the primary and key secondary comparisons were available. This was expected to occur around 22 months after first treatment of the first patient.

Figure 10: Timing of Testing of Primary and Key Secondary Endpoints



C450=Combo 450; C300=Combo 300; E=Encorafenib 300; V=Vemurafenib

⇒ Hierarchical testing sequence

Source: Adapted from Figure 2 of the CSR for Part 1 of COLUMBUS, dated 24-Feb-2017

The sample size for Part 1 of this study was estimated using the assumption that the median PFS was 7 months for the vemurafenib arm and 8 months for the encorafenib arm. A total of 577 patients (using a 1:1:1 randomization) were randomized. The study was designed to detect an improvement in median PFS from 8 months in the encorafenib arm to 12 months in the Combo 450 arm. This improvement corresponds to a hazard ratio of 0.667 with 80% power

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

while maintaining an overall significance level of 5% (two-sided). This sample size also provided 90% power to detect a hazard ratio 0.58 for the Combo 450 vs. vemurafenib comparison while maintaining the overall significance level. The study utilized a staggered 25-month enrollment period (8% of total enrollment in months 1 to 7, 22% in months 8 to 14, and 70% in months 15 to 25), a 7-month follow-up period after the last subject is enrolled, and a 10% drop-out rate, yielding a 32-month study.

The sample size for Part 2 of this study was estimated using the assumption that the median PFS was 8 months for the encorafenib arm. A total of 344 patients (using a 3:1 randomization) were randomized in Part 2. Combining the patients randomized to encorafenib in part 1 (194) with those randomized in Part 2, a total of 538 patients were included in the analysis of Test 3. The study was designed to detect an improvement in median PFS from 8 months in the encorafenib arm to 11 months in the Combo 300 arm. This improvement corresponds to a hazard ratio of 0.667 with 80% power while maintaining an overall significance level of 5% (two-sided). Based on accrual assumptions, this was anticipated to occur approximately 37 months after first treatment of the first patient.

The trial was also designed to test OS, using the assumption that the median OS would be 17 months in the vemurafenib arm and 22 months in the Combo 450 arm. One interim analysis was planned for OS after 75% of deaths had occurred. The power and alpha spent at each expected analysis time are shown in Table 25. Overall type I error was controlled for the interim analysis with the α -spending function using a Gamma function with parameter 1. This spending function had an alpha allocation of 0.042 to the interim analysis and 0.008 to the final analysis.

Table 25: Expected Number of OS Events and Cumulative Power at Expected Analysis Time Points

Combo 450 versus vemurafenib	Cumulative number of OS events	Boundary to reject H0	Conditional cumulative power to reject H0 (%)*	Cumulative α spent
Part 2 PFS analysis (~37 months)	232	0.7654	46.53	0.021
OS update (~62 months)	309	0.7729	56.64	0.025

*Obtained via EAST5.4 simulations under H1.

Source: COLUMBUS SAP v4 Table 3-1, dated 28-Mar-2017

Reviewer's comment: The power for the OS analysis is low relative to the power for the PFS analyses.

Protocol Amendments

As of the cutoff date for the clinical study report, the original protocol dated 13-May-2013 was amended four times. Table 26 summarizes the major protocol revision for COLUMBUS.

Table 26: Summary of Major Protocol Amendments: COLUMBUS

Version	Version Date	Major Changes
1	03-Oct-2013	- Eligibility criteria changed to allow patients with brain metastases to enroll if they have received standard local treatment with surgery and/or radiotherapy and remain progression free for at least 4 weeks. - Frequency of ophthalmic examinations increased; required Day 1 of every cycle for patients receiving binimetinib and patients in the encorafenib and vemurafenib arms with baseline retinal abnormalities. - Eligibility criteria clarified to allow patients with BRAF V600E and V600K mutations to enroll.
2	20-Dec-2013	- Eligibility criteria changed to allow enrollment of patients who have progressed on or after a first-line immunotherapy. - Stratification factors for randomization amended to add prior first-line immunotherapy (yes versus no) and to remove the stratification for BRAF mutation status (V600E vs. V600K). - Prior first-line immunotherapy (yes versus no) added as a stratification factor for primary analyses. - Frequency of routine ophthalmic examinations for patients on encorafenib monotherapy and vemurafenib arms without baseline retinal abnormalities changed to screening, cycle 4, Day 1, every 12 weeks thereafter, end of therapy (EOT), and 30-day post EOT. In addition, dose modification guidelines for eye disorders were updated. These changes were based on preclinical data.
3	04-Nov-2014	- The study was amended to add part 2, addressing a request from the FDA to compare 300mg QD LGX818 plus 45mg BID MEK162 with the LGX818 monotherapy arm. - Testing strategy in Part 1 modified to a hierarchical testing of PFS for Combo 450 vs. vemurafenib (primary endpoint) and Combo 450 vs. encorafenib 300 monotherapy. The analysis of encorafenib 300 monotherapy vs. vemurafenib was changed to a secondary endpoint. - Due to the expected low size for the prior immunotherapy “yes” strata, both prior immunotherapy strata (yes and no) were combined and the analysis was stratified by cancer stage and ECOG PS. - Eligibility criteria amended to allow enrollment of patients with melanoma of unknown primary origin. - Renal failure, hemorrhage, and thrombotic events added to the list of notable AEs for encorafenib and/or encorafenib with binimetinib based on new safety information.
4	13-Jul-2015	- Documented a change in study sponsorship from Novartis to Array BioPharma - Study design and procedures not affected

Source: COLUMBUS Part 1 Protocol and Protocol amendments submitted to Application 30-Jun-2017.

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

Protocol v2 added prior first-line immunotherapy (yes vs. no) as a stratification factor for randomization, and removed BRAF mutation status (V600E vs. V600K) as a stratification factor for randomization. BRAF mutation status was not specified as a stratification factor in the primary analyses. As stated in protocol v0:

“Due to the relatively low expected prevalence of V600K mutation (around 10 - 15%), the two types of mutations will be combined at the time of the analysis to avoid small or empty strata. The log-rank test will therefore be stratified by the two randomization strata variables cancer stage and ECOG PS.”

When prior first-line immunotherapy was added as stratification factor for randomization in protocol v2, it was also added as a stratification factor for the primary analyses. In protocol v3, this stratification factor for the primary analyses was removed. As stated in protocol v3:

“Due to the relatively low expected prevalence of patients with prior immunotherapy (around 15%), the two prior immunotherapy strata (yes and no) will be combined at the time of the analysis to avoid small or empty strata. The log-rank test will therefore be stratified by the two randomization strata variables cancer stage and ECOG PS.”

On April 28, 2014, FDA communicated the following concern to the Applicant about the design of the trial:

“...comparing encorafenib plus binimetinib to encorafenib alone will also not allow FDA to determine the contribution of binimetinib to the combination because the combination arm uses a higher dose of encorafenib (450 mg) than the encorafenib alone arm (300 mg)...the encorafenib alone arm should use the same or higher dose than the dose of encorafenib as used in the combination arm. Otherwise, the contribution of binimetinib to the effect of the combination therapy may not be interpretable.”

Protocol v3 added a second part (Part 2) to COLUMBUS, with the intention of isolating the effect of binimetinib in the combination. The proposed test to address this isolation was a test which pooled patient data from Parts 1 & 2 in an encorafenib group, which was to be compared to patients randomized in Part 2 to Combo 300. A review of protocol v3 yielded the following comment from FDA which was conveyed to the sponsor on February 18, 2015:

“In general, we have no objections to the revised study design and the statistical analysis plan (Protocol CMEK162B2301, Version 03) which is intended to assess the contribution of binimetinib to the effect of the combination. We note, however, that patients may be randomized to the single-agent encorafenib arm at a dose of 300 mg daily in both Part 1 and Part 2, whereas patients may be randomized to the low-dose combination (encorafenib 300 mg plus binimetinib) arm in Part 2 only. Since there are separate randomizations for Parts 1 and 2, there may be some imbalance in important patient characteristics with potential introduction of bias in the analyses of these data. Therefore, the interpretation of analyses comparing the low-dose combination arm (encorafenib 300 mg), which is limited to patients enrolled in Part 2 of the trial to the

single-agent encorafenib arm, which includes patients enrolled in Parts 1 and 2 of the trial, will depend, in part, on the results of the trial. The adequacy of the revised study design and statistical analysis plan to demonstrate the contribution of binimetinib to the effect of the combination, as supported by the data, should be discussed in a pre-NDA meeting, and will be a review issue.”

8.1.2. LOGIC2 – Trial Design

Overview


LOGIC2 was a two-part, multicenter, multi-cohort, non-comparative, open-label study in patients with BRAF mutant locally advanced unresectable or metastatic melanoma. Three populations of patients were eligible for participation in Part 1:

- Group A: Patients naïve to treatment with BRAF inhibitors.
- Group B: Patients who had progressed after single-agent BRAF or MEK inhibitors; patients who had progressed after receiving a BRAF inhibitor in combination with a MEK inhibitor (other than encorafenib/binimetinib); patients who were receiving encorafenib and/or binimetinib who had not yet progressed; or, in consultation with the Sponsor, patients who had received any BRAF and/or MEK inhibitor other than encorafenib and/or binimetinib who had not yet progressed.
- Group C: Patients who progressed after encorafenib/binimetinib combination therapy.

In Part 1, 75 patients naïve to selective BRAF and MEK inhibitors (Group A) were treated with the encorafenib/binimetinib combination at the RP2D of 450 mg once daily (QD) and 45 mg twice daily (BID) until disease progression (as defined per RECIST v1.1).

Based on the genetic assessment of a tumor biopsy obtained at disease progression, patients who relapsed after encorafenib/binimetinib combination therapy could enter Part 2 of the study for tailored combination treatment in 1 of 4 arms. Figure 11 shows the study design.

Figure 11: Study Design for Study LOGIC2



*Single agents: i.e. Vemurafenib, Dabrafenib, LGX818, Trametinib, MEK162; Combos: i.e. Dabrafenib/Trametinib, LGX818/MEK162 combination

**Patients who progressed on a previous BRAFi and/or MEKi regimen will continue on LGX818/MEK162 if PR is observed, followed by new Biopsy at progression. Patients who did not progress on their prior BRAFi/MEKi regimen may continue LGX818/MEK162 combination until evidence of disease progression at which point a tumor biopsy will be taken and analyzed to guide assignment to a triple combination arm in Part II.

***LEE011 cohort might start directly at the RP2D established in CMEK162X2110, if available.

Note: As of 10 July 2015, the triple combination of LGX818/MEK162 + BKM120 is no longer being explored.

Source: LOGIC2 CSR Figure 1, dated 31-Jul-2014.

Study Endpoints

The primary objective of LOGIC2 was to assess the anti-tumor activity of encorafenib + binimetinib in combination with a third targeted agent after progression on encorafenib + binimetinib combination therapy in Part 2. A primary efficacy endpoint for Part 1 was not defined in the study protocol. The primary efficacy endpoint for Part 2 of the study was ORR as determined by Investigator-assessed tumor evaluations per RECIST v1.1. Array performed an evaluation of this endpoint for Part 1 of the study, which is presented in this review.

PFS as determined by investigator was listed as a secondary endpoint.

Statistical Analysis Plan

ORR was provided with a corresponding 95% confidence interval (CI) based on Clopper and Pearson's method for all patients. The sample size was estimated based on power calculations for Part 2 of this study. It was expected that approximately 140 patients would enroll in Part 2 of the study to address the primary objective of the study. Descriptive statistics using Kaplan-Meier methods were provided for PFS.

8.1.3. COLUMBUS – Study Results

Compliance with Good Clinical Practices

The applicant stated that the clinical trial protocol, informed consent form (ICF), and printed patient information materials were reviewed and approved by the independent ethics committee (IEC) and/or institutional review boards (IRB) for each site before any study procedures were performed. Any subsequent protocol amendments or informed consent revisions were approved by the IRB or IEC before any changes were initiated.

According to the applicant, the study was conducted according to International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guidelines concerning Good Clinical Practice (GCP), the European Union Clinical Trials Directive (2001/20/EC), Title 21 of the US Code of Federal Regulations (21 CFR) and the practices and regulations of each participating nation. Written informed consent to participate in the study was obtained from each patient before any study-specific procedures were performed.

Financial Disclosure

Novartis Pharmaceuticals Corporation transferred to Array Biopharma Inc. all development and commercial rights to binimetinib and encorafenib under a set of asset transfer and related agreements in March 2015. Financial disclosure information was obtained for interest in both Novartis and Array.

At the Pre-NDA meeting of 06 February 2017, the Applicant agreed to submit financial information for the following clinical trials:

- CMEK162B2301 (COLUMBUS)
- CLGX818X2109 (LOGIC2)
- CLGX818X2101

In accordance with 21 CFR 54.2, the applicant submitted a list investigators for these trials attached to FDA form 3454 certifying that the Principal Investigators and Sub-investigators had no financial information to disclose as defined in 21 CFR 54.2(a, b, and f) that could affect the outcome of the study. The Applicant states all information submitted was current as of end of March 2017. John R. Moore, Vice President and General Counsel, Array BioPharma Inc, certified this disclosure information for the applicant.

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

Financial disclosure information was missing for some investigators. By study, the percentage of investigators for which disclosure was missing is as follows: CMEK162B2301 (COLUMBUS): 3%, CLGX818X2109 (LOGIC2): 2%, CLGX818X2101: 4%. No reporting investigators had disclosable financial interests and/or arrangements.

This reviewer concludes the impact of potential bias due to the missing financial disclosure information is minimized by the small number of patients treated at any single site compared to the total number of patients treated in each trial.

Data Quality and Integrity

Data, statistical programs, and study reports of this application were submitted electronically. The overall quality of the submission is acceptable, and the reviewer was able to perform all analyses using the submitted data. Derivations for key variables were verified, as well as demographic variables. No inconsistencies were found in the reported efficacy results or patient baseline characteristics.

Patient Disposition

Table **27** summarizes the disposition of patients in Part 1 of COLUMBUS. A higher percentage (53%) of patients discontinued treatment due to progression on the vemurafenib arm than on the Combo 450 and encorafenib arms (43% and 45%, respectively). The Combo 450 arm had the highest percentage (35%) of patients with treatment ongoing at the time of data cutoff, followed by encorafenib (24%) and vemurafenib (14%).

Table 27: Patient Disposition in Part 1 of COLUMBUS

	Combo 450 N=192 n (%)	Encorafenib (Part 1) N=194 n (%)	Vemurafenib N=191 n (%)
Treatment received (%)			
YES	192 (100)	192 (99)	186 (97)
NO	0 (0)	2 (1)	5 (3)
Primary reason for treatment discontinuation (%)			
ADVERSE EVENT	16 (8)	24 (12)	26 (14)
DEATH	7 (4)	1 (1)	4 (2)
LOST TO FOLLOW-UP	1 (1)	1 (1)	0 (0)
PHYSICIAN DECISION	8 (4)	19 (10)	13 (7)
PROGRESSIVE DISEASE	83 (43)	87 (45)	101 (53)
PROTOCOL DEVIATION	2 (1)	1 (1)	0 (0)
SUBJECT/GUARDIAN DECISION	7 (4)	13 (7)	15 (8)
UNTREATED	0 (0)	2 (1)	5 (3)
TREATMENT ONGOING	68 (35)	46 (24)	27 (14)
Treatment ongoing (%)			
YES	68 (35)	46 (24)	27 (14)
NO	124 (65)	146 (75)	159 (83)
UNTREATED	0 (0)	2 (1)	5 (3)

Source: FDA Analysis.

Table 28 summarizes the disposition of patients in Part 2 of COLUMBUS. A higher percentage (45%) of patients discontinued treatment for progressive disease on the encorafenib arm than on the Combo 300 arm (37%). The Combo 300 arm had a higher percentage of patients (39%) with treatment ongoing at the time of the data cutoff than the encorafenib (Part 2) arm (26%).

Table 28: Patient Disposition in Part 2 of COLUMBUS

	Encorafenib (Part 2) N=86 n (%)	Encorafenib 300mg + Binimetinib N=258 n (%)
Treatment received (%)		
YES	84 (98)	257 (100)
NO	2 (2)	1 (0)
Primary reason for treatment discontinuation (%)		
ADVERSE EVENT	6 (7)	22 (9)
DEATH	1 (1)	8 (3)
LOST TO FOLLOW-UP	1 (1)	0 (0)
PHYSICIAN DECISION	8 (9)	22 (9)
PROGRESSIVE DISEASE	39 (45)	96 (37)
PROTOCOL DEVIATION	0 (0)	0 (0)
SUBJECT DECISION	7 (8)	8 (3)
UNTREATED	2 (2)	1 (0)
TREATMENT ONGOING	22 (26)	101 (39)
Treatment ongoing (%)		
YES	22 (26)	101 (39)
NO	62 (72)	156 (60)
UNTREATED	2 (2)	1 (0)

Source: FDA Analysis

Protocol Violations/Deviations

The incidence of patients with at least one protocol deviation was similar among the 3 treatment arms (62% Combo 450, 66% encorafenib monotherapy, 64% vemurafenib). Most protocol deviations were due to key procedures not performed as per protocol (48% Combo 450, 53% encorafenib monotherapy, 55% vemurafenib). Deviations due to eligibility criteria not met were reported for patients in each treatment arm (9% Combo 450, 11% encorafenib, 5% vemurafenib). Table 29 summarizes selection criteria protocol deviations by specific criteria not met. Of note, 1% of patients across arms did not meet laboratory parameters indicating adequate organ function. This was more prevalent in the encorafenib monotherapy arm compared to the other arms, but the overall frequency was low for all arms. In addition, 1.2% of patients across arms were enrolled despite having untreated CNS lesion(s). This was balanced between the Combo 450 (2.1%) and encorafenib monotherapy (1.5%) arms; no patients with untreated CNS lesion(s) were enrolled in the vemurafenib monotherapy arm.

Table 29: Summary of Deviations from Eligibility Criteria for COLUMBUS Part 1

	COLUMBUS Part 1			Total across arms
	Combo 450	Enc 300	Vem	
	N=192	N=194	N=191	
	n (%)	n (%)	n (%)	
Selection criteria not met¹	17 (8.9)	21 (10.8)	10 (5.2)	47 (8.1)
Inadequate bone marrow, organ function and/or laboratory parameters	1 (0.5)	4 (2.1)	1 (0.5)	6 (1.0)
Previous or concurrent malignancy	1 (0.5)	0	0	1 (0.2)
Previous treatment for unresectable locally advanced or metastatic melanoma ² or other than first line immuno therapy ³	1 (0.5)	0	1 (0.5)	1 (0.2)
Prior therapy with a BRAF and/or MEK inhibitor	0	1 (0.5)	0	1 (0.2)
History of retinal degenerative disease ²	0	0	1 (0.5)	1 (0.2)
Inadequate cardiac function	0	1 (0.5)	0	1 (0.2)
No adequate pregnancy test at study entry	7 (3.6)	8 (4.1)	5 (2.6)	20 (3.5)
No central confirmation of BRAF V600E and/or V600K mutation	0	2 (1.0)	0	2 (0.3)
No evidence of measurable lesion	1 (0.5)	0	1 (0.5)	2 (0.3)
No histologically confirmed diagnosis of melanoma ⁴	1 (0.5)	1 (0.5)	0	2 (0.3)
Uncontrolled arterial hypertension	3 (1.6)	1 (0.5)	1 (0.5)	5 (0.9)
Untreated CNS lesion	4 (2.1)	3 (1.5)	0	7 (1.2)
Uveal or mucosal melanoma	2 (1.0)	1 (0.5)	0	3 (0.5)

Source: CSR COLUMBUS Part 1 Table 14.1-1.8a submitted to application 30-Jun-2017: Note Reviewer corrected Applicant's table for Previous treatment for unresectable locally advanced or metastatic melanoma or other than first line immuno therapy to include patient in vemurafenib arm who received dacarbazine.

¹ Patients with more than one criteria not met is counted once. A patient, however, may be included in more than one specific selection criteria (row)

² Under initial protocol

³ After Amendment 1

⁴ After Amendment 3 (cutaneous melanoma prior to Amendment 3)

All patients who were randomized were evaluated in the full analysis set (FAS). The per protocol set (PPS) comprised all patients from the FAS without a major protocol deviation and who

received at least one dose of study. Twenty-one patients (3.6%) overall were excluded from the per protocol set. The reasons for exclusion are summarized by arm in Table 30 below. The most common reason that patients were excluded from the PPS was failure to receive at least one dose of study medication (0% Combo 450, 1% encorafenib, 3% vemurafenib).

Table 30: Reasons Leading to Exclusion of Patients from Per-protocol Set: Columbus Part 1

Reason	Combo 450 N=192 n (%)	Enc 300 N=194 n (%)	Vem N=191 n (%)
Patient excluded from Per-protocol set	4 (2.1)	10 (5.2)	7 (3.7)
Patient did not receive at least one dose of study medicine	0	2 (1.0)	5 (2.6)
No histologically confirmed diagnosis of unresectable or metastatic cutaneous melanoma or unknown primary melanoma (Stage IIIB, IIIC to IV per AJCC) ¹	1 (0.5)	1 (0.5)	0
Not positive for BRAF V600 mutation ¹	0	2 (1.0)	0
Prior treatment for unresectable or metastatic cutaneous melanoma other than immunotherapy ¹	1 (0.5)	0	0
Prior treatment with a RAF and/or MEK inhibitor ¹	0	1 (0.5)	0
No measurable lesion as detected by local review of radiological or photographic methods based on RECIST version 1.1 ¹	1 (0.5)	0	1 (0.5)
New anti-neoplastic therapy administered after start of treatment and prior to first tumor assessment	1 (0.5)	4 (2.1)	1 (0.5)

Source: CSR COLUMBUS Part 1 Table 15 submitted to application 30-Jun-2017, Reviewer verified.

¹ Major protocol deviation

Additional details regarding patients who were excluded from per-protocol set for reasons other than patient did not receive at least one dose of study medication are summarized as follows:

- No histologically confirmed diagnosis of unresectable or metastatic cutaneous melanoma or unknown primary melanoma (Stage IIIB, IIIV to IV per AJCC)
 - Patient ██████████^{(b) (6)} (Combo 450 arm): The patient was noted to have skin melanoma Stage M1C at study entry and a positive BRAF mutation test result that was conducted on melanoma tissue; however, there was no histologically confirmed diagnosis of unresectable or metastatic cutaneous melanoma or unknown primary. The patient was randomized to and treated with Combo 450. The patient was discontinued from treatment on study day 225 due to progressive disease and was evaluated in the FAS.
 - Patient ██████████^{(b) (6)} (encorafenib arm): The patient was noted to have skin melanoma Stage IV M1C at study entry and a positive BRAF mutation test result that was

conducted on melanoma tissue; however, there was no histologically confirmed diagnosis of unresectable or metastatic cutaneous melanoma or unknown primary. The patient was randomized to and treated with encorafenib monotherapy. The patient was still receiving study treatment as of the cutoff state and was evaluated in the FAS.

- Not positive for BRAF V600 mutation
 - Patient (b) (6) (encorafenib arm): The central laboratory did not confirm the BRAF mutation-positive status of the patient (indeterminate). It is unknown if the patient had a local BRAF mutation-positive result. The patient was treated with encorafenib and discontinued treatment on study day 208 due to an AE. The patient was evaluated in the FAS.
 - Patient (b) (6) (encorafenib arm): The central laboratory did not confirm the BRAF mutation-positive status of the patient (indeterminant). The patient was randomized based on local BRAF-mutation testing. The patient was treated with encorafenib and discontinued treatment on study day 103 due to physician decision. The patient was evaluated in the FAS.
- Prior treatment for unresectable or metastatic cutaneous melanoma other than immunotherapy:
 - Patient (b) (6) (Combo 450 arm): The patient received prior therapy in the metastatic setting with ipilimumab which was prohibited by the protocol. In addition, the minimum 6-week washout period for prior therapies was not followed. The patient was treated with Combo 450 and discontinued treatment on Study day 154 due to progressive disease. The patient was evaluated in the FAS.
- Prior treatment with a RAF and/or MEK inhibitor
 - Patient (b) (6) (encorafenib arm): The patient received prior therapy with the BRAF inhibitor vemurafenib. The patient was treated with encorafenib and discontinued treatment on Study day 87 due to the protocol deviation. The patient was evaluated in the FAS.
- No measurable lesion as detected by local review of radiological or photographic methods based on RECIST v 1.1
 - Patient (b) (6) (Combo 450): The patient was specified as not having a measurable lesion by local review. The patient had a dermatological lesion that was the target lesions (11 X 10 mm); however, this lesion was removed during the screening phase, prior to randomization. The patient was treated with encorafenib and discontinued treatment on Study day 87 due to the protocol deviation. The patient was evaluated in the FAS.
 - Patient (b) (6) (vemurafenib): The patient was specified as not having a measurable lesion by local review; however, the BIRC review showed subcutaneous non-nodal lesions on CT. The patient was treated with vemurafenib and discontinued from treatment on Study day 311 due to PD. The patient was evaluated in the FAS.

- New anti-neoplastic therapy administered after start of study treatment and prior to first tumor assessment
 - Patient (b) (6) (Combo 450): During treatment, the patient received palliative radiotherapy to the bone prior to the first tumor assessment. Because the radiotherapy was not administered due to evidence of progression, it was not considered a reason to discontinue study treatment per protocol. The patient was still receiving study treatment as of the cutoff date. The patient was evaluated in the FAS.
 - Patient (b) (6) (encorafenib arm): The patient initiated treatment with encorafenib but discontinued on Study Day 9 due to an adverse event. The patient received subsequent antineoplastic therapy with dabrafenib/trametinib starting on Study Day 15. The patient was evaluated in the FAS.
 - Patient (b) (6) (encorafenib): The patient initiated treatment but discontinued on Study Day 1 due to subject/guardian decision with the reason of “swallowing trouble” specified. The patient then received subsequent antineoplastic therapy with vemurafenib starting on Study day 22. The patient was evaluated in the FAS.
 - Patient (b) (6) (encorafenib): The patient initiated treatment but discontinued on Study day 15 due to an adverse event. The patient received subsequent antineoplastic therapy with dabrafenib starting on Study day 18. The patient was evaluated in the FAS.
 - Patient (b) (6) (encorafenib): The patient initiated treatment but discontinued on Study day 22 due to an adverse event. The patient received subsequent antineoplastic therapy with vemurafenib starting on Study day 34. The patient was evaluated in the FAS.
 - Patient (b) (6) (vemurafenib): The patient initiated treatment but discontinued on Study day 8 due to an adverse event. The patient received subsequent antineoplastic therapy with dabrafenib starting on Study Day 26 and then pembrolizumab starting on study day 64. The patient was evaluated in the FAS.

Demographic Characteristics

Part 1 of COLUMBUS was conducted at 162 centers in 28 countries and Part 2 was conducted at 116 clinical sites in 24 countries, with some sites used in both study parts. A total of 921 patients were randomized (Part 1: 577 patients in a 1:1:1 allocation to Combo 450, Encorafenib, and Vemurafenib; Part 2: 344 patients in a 3:1 allocation to Combo 300 and Encorafenib). In Part 1, the Combo 450 arm had the highest percentage of patients aged 65 and older (31%), followed by Vemurafenib (27%), and Encorafenib (21%). The mean age was similar across these arms. Otherwise, the demographics of the patients in Part 1 appear to be balanced as summarized in Table 31. In Part 2, there was a higher percentage of women (49%) in the encorafenib arm than the Combo 300 arm (41%). Otherwise, the demographics appear to be generally balanced over the two arms.

Table 31: Patient Demographics in COLUMBUS

	Part 1			Part 2	
	Combo 450	Encorafenib	Vemurafenib	Combo 300	Encorafenib
N	192	194	191	258	86
Age (mean (sd))	56.2 (13.6)	54.6 (12.6)	55.2 (14.2)	57.4 (14.0)	55.8 (14.7)
Age Category (%)					
<65	132 (69)	154 (79)	140 (73)	175 (68)	60 (70)
>=65	60 (31)	40 (21)	51 (27)	83 (32)	26 (30)
Sex (%)					
F	77 (40)	86 (44)	80 (42)	107 (41)	42 (49)
M	115 (60)	108 (56)	111 (58)	151 (59)	44 (51)
Race (%)					
MISSING	1 (1)	1 (1)	1 (1)	0 (0)	1 (1)
AMERICAN INDIAN OR ALASKA NATIVE	0 (0)	2 (1)	2 (1)	0 (0)	0 (0)
ASIAN	5 (3)	6 (3)	8 (4)	15 (6)	7 (8)
BLACK OR AFRICAN AMERICAN	0 (0)	0 (0)	0 (0)	1 (0)	0 (0)
OTHER	3 (2)	2 (1)	2 (1)	2 (1)	0 (0)
UNKNOWN	2 (1)	9 (5)	11 (6)	4 (2)	0 (0)
WHITE	181 (94)	174 (90)	167 (87)	236 (91)	78 (91)
ECOG¹ (%)					
0	139 (72)	143 (74)	140 (73)	191 (74)	62 (72)
1	53 (28)	51 (26)	51 (27)	67 (26)	24 (28)

Source: FDA Analysis

¹ One patient from Part 2 who had an ECOG status of 2 has been omitted.

Baseline Disease Characteristics

Table 32 summarizes the baseline disease characteristics of patients randomized on COLUMBUS. Baseline disease characteristics were generally well-balanced across arms within Part 1 and within Part 2.

Table 32: Patient and Disease Characteristics in COLUMBUS

	Part 1			Part 2	
	Combo 450	Encorafenib	Vemurafenib	Combo 300	Encorafenib
N	192	194	191	258	86
Primary site of cancer (%)					
SKIN MELANOMA	191 (99)	192 (99)	190 (99)	239 (93)	79 (92)
OTHER	1 (1)	2 (1)	1 (1)	18 (7)	7 (8)
MISSING	0 (0)	0 (0)	0 (0)	1 (0)	0 (0)
Stage at time of study entry (%)					
STAGE IIIB	0 (0)	2 (1)	1 (1)	0 (0)	0 (0)
STAGE IIIC	9 (5)	4 (2)	10 (5)	8 (3)	5 (6)
STAGE IV M1A	26 (14)	29 (15)	24 (13)	31 (12)	13 (15)
STAGE IV M1B	34 (18)	39 (20)	31 (16)	47 (18)	10 (12)
STAGE IV M1C WITH ELEVATED LDH	50 (26)	50 (26)	36 (19)	73 (28)	32 (37)
STAGE IV M1C WITH NORMAL LDH	73 (38)	70 (36)	89 (47)	99 (38)	26 (30)
Number of organs involved at baseline (%)					
1	47 (24)	56 (29)	45 (24)	78 (30)	23 (27)
2	58 (30)	52 (27)	59 (31)	66 (26)	22 (26)
3	45 (23)	42 (22)	42 (22)	59 (23)	19 (22)
>3	42 (22)	44 (23)	45 (24)	55 (21)	22 (26)
LDH at baseline (%)					
<=ULN	137 (71)	147 (76)	139 (73)	178 (69)	54 (63)
>ULN	55 (29)	47 (24)	52 (27)	80 (31)	32 (37)

Source: FDA Analysis

Prior Antineoplastic Therapy

Table 33 summarizes the proportion of patients who received prior antineoplastic therapy. The percentage of patients who had received any prior antineoplastic therapies was similar across the three treatment arms. For a specific therapy type, the percentage of patients who received prior systemic treatment or who had prior surgery was similar across arms, but a higher

percentage of patients in the encorafenib monotherapy arm (22%) received prior radiotherapy as compared with either the Combo 450 (16%) or vemurafenib (13%) arms.

Prior to Amendment 2, prior chemotherapy was allowed only in the adjuvant setting or as local-regional treatment. Two patients previously treated with chemotherapy in the metastatic setting were enrolled, one in the Combo 450 arm and one in the vemurafenib arm. Both patients received dacarbazine.

Protocol Amendment 2 permitted enrollment of patients who progressed on or after first-line treatment with immunotherapy for unresectable locally advanced or metastatic melanoma. Eleven patients (1.9%) overall received prior chemotherapy in the adjuvant setting: 3 patients in the Combo 450 arm (1.6%), 4 patients in the encorafenib monotherapy arm (2.1%), and 4 patients in the vemurafenib arm (2.1%).

For any disease setting (adjuvant or advanced/metastatic disease), a similar percentage of patients (30% Combo 450, 30% encorafenib monotherapy, 30% vemurafenib) received prior immunotherapy (based on the eCRF and not IRT stratification data) (Table 34). Prior use of interferons/interleukins was most common. Few patients received prior ipilimumab or anti-PD1/PDL1 inhibitors (0.5% overall).

Table 33: Prior Therapy, Including Immunotherapy (starting amendment 2)

	COLUMBUS Part 1		
	Combo 450 N=192 n (%)	Encorafenib N=194 n (%)	Vemurafenib (N=191) n (%)
Any Therapy	158 (82.3)	161 (83.0)	165 (86.4)
Medication	62 (32.2)	63 (32.5)	59 (30.9)
Surgery	146 (76.0)	149 (76.8)	157 (82.2)
Radiotherapy	30 (15.6)	42 (21.6)	25 (13.1)
Medication: Setting at last treatment			
Adjuvant	52 (27.1)	46 (23.7)	46 (24.1)
Neoadjuvant	0	1 (0.5)	1 (0.5)
Therapeutic – Metastatic	10 (5.2)	16 (8.2)	12 (6.3)

Source: CSR COLUMBUS Part 1 Table 11 submitted to application June 30, 2017

Table 34: Prior Immunotherapy Any Setting: Columbus Part 1

	COLUMBUS Part 1		
	Combo 450 N=192 n (%)	Encorafenib N=194 n (%)	Vemurafenib (N=191) n (%)
Any Immunotherapy	57 (29.7)	58 (29.9)	57 (29.8)
Ipilimumab	7 (3.6)	10 (5.2)	7 (3.7)
Anti-PD1/PDL1	1 (0.5)	2 (1.0)	0
Interferons/Interleukins	51 (26.6)	51 (26.3)	52 (27.2)

Source: CSR COLUMBUS Part 1 Table 12 submitted to application June 30, 2017

Efficacy Results – Primary Endpoint

In the analyses that follow, cancer stage (IIIB + IIIC + IVM1a + IVM1b vs. IVM1c) and ECOG score (0 vs. 1) were specified as stratification factors. As discussed in “Protocol Amendments”, protocol v2 added prior first-line immunotherapy (yes vs. no) as a stratification factor for the primary analyses, and protocol v3 subsequently removed this stratification factor for the primary analyses, although it was retained as a stratification factor for randomization.

Table 35 presents the primary analysis of PFS for the Combo 450 arm compared with the vemurafenib arm. The Combo 450 arm demonstrated significant improvement in progression-free survival when compared to the vemurafenib arm, with a stratified log-rank test p-value of <0.0001.

The estimated median PFS times were 14.9 months (95% CI: [11.0, 18.5]) for the Combo 450 arm and 7.3 (95% CI: [5.6, 8.2]) for the vemurafenib arm. The stratified hazard ratio of PFS for the Combo 450 arm compared to the vemurafenib arm was 0.54 (95% CI: [0.41, 0.71]). Figure 12 shows the PFS curves, estimated using the Kaplan-Meier method. The curves diverge around 2 months and retain separation until about 24 months.

Table 35: Progression-Free Survival in the ITT Population for Part 1 of COLUMBUS (Combo 450 vs. Vemurafenib)

	Vemurafenib N = 191	Combo 450 N = 192
Number of events (%)	106 (55)	98 (51)
Censored (%)	85 (45)	94 (49)
Median PFS ¹ in months (95% CI)	7.3 (5.6, 8.2)	14.9 (11.0, 18.5)
Hazard Ratio (95% CI) ²	0.54 (0.41, 0.71)	
P-value ³	<0.0001	


Source: FDA Analysis

¹ BIRC central review

² Estimated with the Cox proportional hazards model stratified by cancer stage (IIIB + IIIC + IVM1a + IVM1b vs. IVM1c) and ECOG score (0 vs. 1).

³ Two-sided p-value estimated with the log-rank test stratified by cancer stage (IIIB + IIIC + IVM1a + IVM1b vs. IVM1c) and ECOG score (0 vs. 1).

Figure 12: Kaplan-Meier Plot of Progression-Free Survival in the ITT Population for Part 1 of COLUMBUS (Combo 450 vs. Vemurafenib)



Source: FDA Analysis

Follow-up time was similar across arms, with a median potential follow-up time for PFS of 14.4 months (95% CI: [10.1, 16.6]) in the vemurafenib arm and 16.7 months (range: [16.3, 18.4]) in the Combo 450 arm.

Efficacy Results – Key Secondary Endpoints

Table 36 presents the analysis of PFS for the Combo 450 arm compared with the encorafenib arm. The Combo 450 arm did not demonstrate a significant improvement in progression-free survival when compared to the encorafenib arm, with a two-sided stratified log-rank test p-value of 0.0513.

The estimated median PFS times were 14.9 months (95% CI: [11.0, 18.5]) for the Combo 450 arm and 9.6 (95% CI: [8.7, 14.8]) for the encorafenib arm. The stratified hazard ratio of PFS for the Combo 450 arm compared to the encorafenib arm was 0.75 (95% CI: [0.56, 1.00]). Figure 13 shows the PFS curves, estimated using the Kaplan-Meier method.

Table 36: Progression-Free Survival in the ITT Population for Part 1 of COLUMBUS (Combo 450 vs. Encorafenib)

	Encorafenib N = 191	Combo 450 N = 192
Number of events (%)	96 (50)	98 (51)
Censored (%)	95 (50)	94 (49)
Median PFS ¹ in months (95% CI)	9.6 (7.5, 14.8)	14.9 (11.0, 18.5)
Hazard Ratio (95% CI) ²	0.75 (0.56, 1.00)	
P-value ³	0.0513	


Source: FDA Analysis

¹ BIRC central review

² Estimated with the Cox proportional hazards model stratified by cancer stage (IIIB + IIIC + IVM1a + IVM1b vs. IVM1c) and ECOG score (0 vs. 1).

³ Two-sided p-value estimated with the log-rank test stratified by cancer stage (IIIB + IIIC + IVM1a + IVM1b vs. IVM1c) and ECOG score (0 vs. 1).

Figure 13: Kaplan-Meier Plot of Progression-Free Survival in the ITT Population for COLUMBUS (Combo 450 vs. Encorafenib)



Source: FDA Analysis

Follow-up time was similar across arms, with a median potential follow-up time for PFS of 16.6 months (95% CI: [14.8, 18.1]) in the encorafenib arm and 16.7 months (95% CI: [16.3, 18.4]) in the Combo 450 arm.

Due to the pre-specified hierarchical testing procedure, formal testing was stopped after the test of PFS for the Combo 450 arm compared with the encorafenib arm.

Efficacy Results – Other Endpoints

The pre-specified analysis of Test 3 is shown below. As discussed in “Protocol Amendments,” pooling of patients from Parts 1 and 2 may introduce bias into the analysis, as the parts were randomized separately and thus may yield imbalances in important patient characteristics. Patient baseline characteristics, demographics, and protocol deviations including the pooled encorafenib group can be found in Section 19.3.

Table 37 presents the analysis of PFS for the encorafenib (Parts 1 + 2) group compared with the Combo 300 arm. The Combo 300 arm exhibited a numerical improvement in progression-free survival when compared to the encorafenib (Parts 1 + 2) group, though no formal test was performed due to hierarchical testing rules.

The estimated median PFS times were 12.9 months (95% CI: [10.1, 14.0]) for the Combo 300 arm and 9.2 (95% CI: [7.4, 11.0]) in the encorafenib (Parts 1 + 2) group. The stratified hazard ratio of PFS for the Combo 300 arm compared to the encorafenib (Parts 1 + 2) group was 0.77 (95% CI: [0.61, 0.97]). Figure 14 shows the PFS curves, estimated using the Kaplan-Meier method.

Table 37: Progression-Free Survival in the ITT Population for COLUMBUS (Combo 300 vs. Pooled Encorafenib Group)


	Encorafenib 300 (Parts 1 + 2) N = 280	Combo 300 N = 258
Number of events (%)	160 (57)	133 (52)
Censored (%)	120 (43)	125 (48)
Median PFS ¹ in months (95% CI)	9.2 (7.4, 11.0)	12.9 (10.1, 14.0)
Hazard Ratio (95% CI) ²	0.77 (0.61, 0.97)	

Source: FDA Analysis

¹ BIRC central review

² Estimated with the Cox proportional hazards model stratified by cancer stage (IIIB + IIIC + IVM1a + IVM1b vs. IVM1c) and ECOG score (0 vs. 1).

Figure 14: Kaplan-Meier Plot of Progression-Free Survival in the ITT Population for COLUMBUS (Combo 300 vs. Pooled Encorafenib Group)



Source: FDA Analysis

Follow-up time was longer in the encorafenib (Parts 1 + 2) group, with a median potential follow-up time for PFS of 18.5 months (95% CI: [16.8, 22.0]) in the encorafenib (Parts 1 + 2) group and a median follow-up time of 13.9 months (range: [12.9, 14.7]) in the Combo 300 arm. This longer follow-up in the encorafenib (Parts 1 + 2) group is a result of randomization occurring later for Part 2 than for Part 1. Part 1 patients were randomized between December 30, 2013 and April 10, 2015 and Part 2 patients were randomized between March 19, 2015, and November 12, 2015. The median potential follow-up time for PFS for patients receiving encorafenib was 20.3 months (95% CI: [19.6, 23.3]) for patients in Part 1 and 14.8 months (95% CI: [14.7, 16.6]) for patients in Part 2.

Reviewer's comment: A sensitivity analysis that utilizes only patients from Part 2 for this analysis is presented in "Sensitivity Analyses." The sensitivity analysis is underpowered, as the trial was powered for the analysis of Test 3. The sensitivity analysis also shows a numerical trend of improved PFS in the Combo 300 arm.

Table 38 presents a preliminary analysis of OS for the Combo 450 arm compared with the vemurafenib arm. At the time of submission, Array was blinded to OS data. The data reviewed here was submitted by the DMC. The number of events required for an interim analysis (232) had not been reached at the time of data cut-off for Part 1. The analysis presented is based on 157 events.

The Combo 450 arm exhibited a numerical improvement in overall survival when compared to the vemurafenib arm, though no formal test was performed due to hierarchical testing rules.

The estimated median OS times were 26.0 months (95% CI: [23.4, NE]) for the Combo 450 arm and 16.9 months (95% CI: [14.6, NE]) for the vemurafenib arm. The hazard ratio of OS for the Combo 450 arm compared to the vemurafenib arm was 0.58 (95% CI: [0.42, 0.80]). Figure 15 shows the OS curves, estimated using the Kaplan-Meier method.

Table 38: Overall Survival, as Reported by the DMC, in the ITT Population for Part 1 of COLUMBUS (Combo 450 vs. Vemurafenib)


	Vemurafenib N = 191	Combo 450 N = 192
Number of events (%)	88 (46)	69 (36)
Censored (%)	103 (54)	123 (64)
Median OS in months (95% CI)	16.9 (14.6, NE ¹)	26.0 (23.4, NE ¹)
Hazard Ratio (95% CI) ²	0.58 (0.42, 0.80)	

Source: FDA Analysis

¹ NE: Not estimable.

² Estimated with the Cox proportional hazards model stratified by cancer stage (IIIB + IIIC + IVM1a + IVM1b vs. IVM1c) and ECOG score (0 vs. 1).

Figure 15: Kaplan-Meier Plot of Overall Survival in the ITT Population for Part 1 of COLUMBUS (Combo 450 vs. Vemurafenib)



Source: FDA Analysis

Follow-up time was similar across arms, with a median potential follow-up time for OS of 19.4 months (95% CI: [18.5, 20.5]) in the Combo 450 arm and 18.2 months (range: [17.4, 19.5]) in the vemurafenib arm.

Reviewer's comment: At the time of submission, Array was blinded to OS data. Consequently, this analysis was not included in the CSR. The above analysis is the product of the reviewer only and not a confirmation of sponsor analyses.

Durability of Response

Table 39 presents the confirmed ORR and DOR for each arm in Part 1 of COLUMBUS. ORR was defined as the proportion of patients with best objective response of complete response (CR) or partial response (PR). ORR had to be confirmed, as defined for CR and PR below:

- CR: at least two determinations of CR at least 4 weeks apart before progression
- PR: at least two determinations of PR or better at least 4 weeks apart before progression.

Table 39: Confirmed ORR and DOR Results from Part 1 of COLUMBUS

	Combo 450 N = 192	Encorafenib N = 194	Vemurafenib N = 191
ORR ¹	63%	51%	40%
(95% CI) ²	(56%, 70%)	(43%, 58%)	(33%, 48%)
CR	8%	5%	6%
PR	55%	45%	35%
Median DOR, months	16.6	14.9	12.3
(95% CI)	(12.2, 20.4)	(11.1, NE)	(6.9, 16.9)

Source: FDA Analysis

¹ BIRC central review

² Estimated using the Clopper-Pearson method

Table 40 presents the confirmed ORR and DOR for the groups in the Part 2 analysis of COLUMBUS.

Table 40: Confirmed ORR and DOR Results from Part 2 of COLUMBUS

	Combo 300 N = 258	Encorafenib (Part 2) N = 86
ORR ¹	66%	50%
(95% CI) ²	(60%, 72%)	(39%, 61%)
CR	8%	3%
PR	58%	47%
Median DOR, months	12.7	7.5
(95% CI)	(9.3, 15.1)	(5.6, 14.0)

Source: FDA Analysis

¹ BIRC central review

² Estimated using the Clopper-Pearson method

Table 41 shows the confirmed ORR and DOR by part for the encorafenib arms in COLUMBUS.

ORR seems to be similar between arms. DOR was longer in Part 1, with an estimated median DOR of 15.2 months (95% CI: [11.1, NE]) in part 1 and 7.5 months (95% CI: [5.6, 14.0]) in part 2. As stated above follow-up was longer for part 1.

Table 41: Confirmed ORR and DOR Results for the Encorafenib Arms in Parts 1 and 2 of COLUMBUS

	Encorafenib (Part 1) N = 194	Encorafenib (Part 2) N = 86
ORR ¹	51%	50%
(95% CI) ²	(43%, 58%)	(39%, 61%)
CR	6%	3%
PR	44%	47%
Median DOR, months (95% CI)	15.2 (11.1, NE)	7.5 (5.6, 14.0)

Source: FDA Analysis

¹ BIRC central review

² Estimated using the Clopper-Pearson method

Efficacy results for ORR and DOR which include the pooled encorafenib group may be found in Section 19.3.

Efficacy Results – Secondary or exploratory COA (PRO) endpoints

The following PRO analyses were pre-specified in the SAP. However, no type I error was allocated to any of the PRO analyses, and consequently these analyses are considered exploratory only.

In COLUMBUS, health quality of life data was collected via three instruments: the FACT-M, EQ-5D-5L, and EORTC QLQ-C30. The primary PRO analysis in COLUMBUS was to assess the difference in distribution of time to definitive 10% deterioration in the FACT-M melanoma subscale between the treatment arms in ITT population. The time to definitive 10% deterioration is defined as the time from the date of randomization to the date of event, which is defined as at least 10% relative to baseline worsening of the corresponding scale score with no later improvement above this threshold observed while on treatment or death due to any cause. The censoring rules were as follows:

- Patients who had definitive deterioration after more than twice the planned period between two assessments since the last assessment were censored at the date of their last available questionnaire.
- Patients receiving any further anti-neoplastic therapy before definitive deterioration were censored at the date of their last assessment before starting this therapy.
- Patients that had not worsened as of the cut-off date for the analysis were censored at the date of their last assessment before the cut-off.
- Patients with no baseline assessment or no postbaseline assessment performed were

censored at the randomization date.

Compliance was assessed as the percentage of patients who completed the full or part of the FACT-M questionnaire while on study. Compliance was calculated for patients still at risk. A patient was considered “at-risk” if they were still receiving treatment or were in post-treatment follow-up on the protocol-scheduled PRO assessment date. Compliance by cycle in Part 1 is shown in Table 42.

Table 42: FACT-M Compliance Summary by Time Window and Treatment (Part 1)

Visit	Combo 450		Encorafenib (Part 1)		Vemurafenib	
	Number of Patients Still on Study	Number of Patients Who Filled Out Instrument n (%) ¹	Number of Patients Still on Study	Number of Patients Who Filled Out Instrument n (%) ¹	Number of Patients Still on Study	Number of Patients Who Filled Out Instrument n (%) ¹
Baseline	192	165 (86)	194	159 (82)	191	160 (84)
Cycle 3 Day 1	185	168 (91)	186	168 (90)	181	160 (88)
Cycle 5 Day 1	174	153 (88)	157	145 (92)	145	128 (88)
Cycle 7 Day 1	161	143 (89)	132	120 (91)	110	101 (92)
Cycle 9 Day 1	139	122 (88)	100	88 (88)	87	80 (92)
Cycle 11 Day 1	121	109 (90)	86	79 (92)	63	56 (89)
Cycle 13 Day 1	104	94 (90)	77	71 (92)	49	48 (98)
Cycle 15 Day 1	94	83 (88)	72	62 (86)	40	36 (90)
Cycle 17 Day 1	83	76 (92)	62	53 (85)	34	30 (88)
Cycle 19 Day 1	66	56 (85)	47	44 (94)	29	25 (86)
Cycle 21 Day 1	46	39 (85)	36	33 (92)	22	20 (91)
Cycle 23 Day 1	31	26 (84)	20	20 (100)	16	15 (94)
Cycle 25 Day 1	22	18 (82)	11	9 (82)	11	10 (91)


Source: FDA Analysis

¹ Includes instruments fully or partially completed

Compliance was similar across arms for the first 25 cycles of treatment. At Cycle 25 Day 1, 22 patients were on study in the Combo 450 arm, 11 patients were on study in the encorafenib arm, and 11 patients were on study in the vemurafenib arm.

The estimated median time to definitive 10% deterioration (TTD) in the FACT-M subscale was not estimable (95% CI: [23.3, NE]) for the Combo 450 arm and 22.1 months (95% CI: [15.2, NE]) in the vemurafenib arm. The stratified hazard ratio of TTD for the Combo 450 arm compared to the vemurafenib arm was 0.46 (95% CI: [0.29, 0.72]). Figure 16 shows the TTD curves, estimated using the Kaplan-Meier method.


Figure 16: Time to Definitive 10% Deterioration in the FACT-M Subscale – Combo 450 vs. Vemurafenib (Part 1)



Source: FDA Analysis

The estimated median time to 10% deterioration (TTD) in the FACT-M subscale was not estimable (95% CI: [23.3, NE]) for the Combo 450 arm and 20.3 months (95% CI: [16.6, NE]) in the encorafenib arm. The stratified hazard ratio of TTD for the Combo 450 arm compared to the encorafenib arm was 0.48 (95% CI: [0.31, 0.75]). Figure 17 shows the TTD curves, estimated using the Kaplan-Meier method.

Figure 17: Time to Definitive 10% Deterioration in the FACT-M Subscale – Combo 450 vs. Encorafenib (Part 1)



Source: FDA Analysis

Compliance by cycle in Part 2 is shown in Table 43.

Table 43: FACT-M Compliance Summary by Time Window and Treatment (Part 2)

Visit	Combo 300		Encorafenib (Part 2)	
	Number of Patients Still on Study	Number of Patients Who Filled Out Instrument n (%) ¹	Number of Patients Still on Study	Number of Patients Who Filled Out Instrument n (%) ¹
Baseline	258	237 (92)	86	83 (97)
Cycle 3 Day 1	254	233 (92)	77	69 (90)
Cycle 5 Day 1	242	220 (91)	69	62 (90)
Cycle 7 Day 1	219	197 (90)	55	53 (96)
Cycle 9 Day 1	189	172 (91)	44	44 (100)
Cycle 11 Day 1	164	152 (93)	36	32 (89)
Cycle 13 Day 1	148	139 (94)	30	27 (90)
Cycle 15 Day 1	111	101 (91)	20	18 (90)
Cycle 17 Day 1	74	68 (92)	16	14 (88)
Cycle 19 Day 1	35	29 (83)	9	9 (100)
Cycle 21 Day 1	16	13 (81)	2	1 (50)

Source: FDA Analysis


¹ Includes instruments fully or partially completed

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

Compliance was similar across arms for the first 17 cycles of treatment. At Cycle 17 Day 1, 74 patients were on study in the Combo 300 arm, and 16 patients were on study in the encorafenib arm.

The estimated median time to 10% deterioration (TTD) in the FACT-M subscale was not estimable (95% CI: [NE, NE]) for the Combo 300 arm and not estimable (95% CI: [9.5, NE]) in the encorafenib arm. The stratified hazard ratio of TTD for the Combo 300 arm compared to the encorafenib arm was 0.32 (95% CI: [0.19, 0.54]). Figure 18 shows the TTD curves, estimated using the Kaplan-Meier method.

Figure 18: Time to Definitive 10% Deterioration in the FACT-M Subscale – Combo 300 vs. Encorafenib (Part 2)



Source: FDA Analysis

Compliance was similar for the EQ-5D-5L and EORTC QLQ-C30. Time to definitive deterioration was similar for the EORTC QLQ-C30. A mixed effect model for repeated measures (MMRM) was used to compare the treatment arms in terms of change from baseline the domain score over time (FACT-M melanoma subscale, index score of the EQ-5D-5L and global health status/QoL scale score). The results from the mixed effect model support the analyses results described above.

Other descriptive analyses of the FACT-M may be found in Section 19.3.

Additional Analyses Conducted on the Individual Trial

Sensitivity Analyses for Test 2

Array pre-specified a variety of sensitivity analyses for the PFS endpoints. Because test 2 failed

with a non-significant p-value, the superiority of Combo 450 to encorafenib in PFS was not clearly demonstrated. To assess the robustness of this result, we present a few pre-specified sensitivity analyses. Results of other pre-specified sensitivity analyses yield similar results. Array pre-specified a sensitivity analysis for PFS that would repeat the primary analysis with a censoring rule that backdates events occurring after one or more missing tumor assessments. Events were to be backdated to the assessment following the last adequate assessment: 8 weeks (or 12 weeks if the patient had been on treatment long enough) after the last adequate tumor assessment. Table 44 summarizes these results.

Table 44: Progression-Free Survival in the ITT for Part 1 of COLUMBUS using “Backdated” Assessments (Combo 450 vs. Encorafenib)

	Encorafenib N = 191	Combo 450 N = 192
Number of events (%)	102 (53)	102 (53)
Censored (%)	89 (47)	91 (47)
Median PFS in months (95% CI)	9.3 (7.4, 12.9)	14.1 (9.4, 18.0)
Hazard Ratio (95% CI) ¹	0.74 (0.56, 0.98)	

Source: FDA Analysis

¹ Estimated with the Cox proportional hazards model stratified by cancer stage (IIIB + IIIC + IVM1a + IVM1b vs. IVM1c) and ECOG score (0 vs. 1).

This analysis corrects for an imbalance in missed assessments between arms when the missed assessments are related to progression. If missed assessments are related to progression, the primary analysis may be biased, as patients who miss two or more assessments are censored at the last adequate assessment, even if they progress after the second missed assessment. In this scenario, the “backdated” analysis may more accurately measure the true treatment effect. In COLUMBUS, 6 patients had an event after two or more missed assessments on the encorafenib arm, and 4 patients on the Combo 450 arm.

Additional sensitivity analyses for Test 2 may be found in the Appendix.

Sensitivity Analysis for Test 3

Array also pre-specified a sensitivity analysis for test 3. As stated in the SAP v.4, “Stratified analyses for PFS (i.e. log-rank-test, Kaplan-Meier estimates and plots and Cox regression) will be repeated with data only for patients enrolled during Part 2 of the study. This will be performed separately for data assessed by BIRC and locally.” This analysis was intended to address the fact that the analysis of test 3 included patients randomized to encorafenib in Part 1, and thus were not randomized concurrently with patients in the Combo 300 arm. Table 45 summarizes the results of this analysis.

Table 45: Sensitivity Analysis for Progression-Free Survival in the ITT Population for Part 2 of COLUMBUS (Combo 300 vs. Encorafenib)

	Encorafenib N = 86	Combo 300 N = 258
Number of events (%)	96 (50)	133 (52)
Censored (%)	56 (65)	125 (48)
Median PFS in months (95% CI)	7.4 (5.6, 9.2)	12.9 (10.1, 14.0)
Hazard Ratio (95% CI) ¹	0.57 (0.41, 0.78)	

Source: FDA Analysis

¹ Estimated with the Cox proportional hazards model stratified by cancer stage (IIIB + IIIC + IVM1a + IVM1b vs. IVM1c) and ECOG score (0 vs. 1).

The estimated median PFS time for the encorafenib arm in Part 2 was 7.4 months (95% CI: [5.6, 9.2]). In Part 1, the estimated median PFS time for the encorafenib arm was 9.6 months (95% CI: [7.4, 14.8]). As discussed in the main efficacy results, follow-up time was longer in Part 1 than in Part 2. Additionally, the parts were randomized separately, yielding patient populations with slightly different demographics and baseline characteristics.

8.1.4. LOGIC2 – Study Results

Patient Disposition

Table 46 summarizes the disposition of patients who were naïve to treatment with BRAF inhibitors (Group A) in Part 1 of LOGIC2.

Table 46: Patient Disposition in Group A of Part 1 of LOGIC2

	Combo 450
	N = 75
	n (%)
Treatment received (%)	
YES	75 (100)
Primary reason for treatment discontinuation in Part 1 (%)	
ADVERSE EVENT	3 (4)
COMPLETED	0 (0)
DEATH	5 (7)
PHYSICIAN DECISION	1 (1)
PROGRESSIVE DISEASE	19 (25)
WITHDRAWAL BY PARENT/GUARDIAN	3 (4)
TREATMENT ONGOING	44 (59)
Treatment status at the end of Part 1 (%)	
TREATMENT ONGOING	44 (59)
TREATMENT DISCONTINUED	31 (41)

Source: FDA Analysis

Demographic Characteristics

Table 47 summarizes the patient demographics of patients who were naïve to treatment with BRAF inhibitors (Group A) in Part 1 of LOGIC2.

Table 47: Patient Demographics in Group A of Part 1 of LOGIC2

	Combo 450 N=75
Age (mean (sd))	55.3 (12.9)
Age Category (%)	
< 65	57 (76)
>= 65	18 (24)
Sex (%)	
F	28 (37)
M	47 (63)
Race (%)	
ASIAN	1 (1)
WHITE	74 (99)
ECOGBL (%)	
0	55 (73)
1	19 (25)
2	1 (1)
MISSING	0 (0)

Source: FDA Analysis

Baseline Disease Characteristics

Table 48 summarizes the patient and disease characteristics of patients who were naïve to treatment with BRAF inhibitors (Group A) in Part 1 of LOGIC2.

Table 48: Patient and Disease Characteristics in LOGIC2

	Combo 450 N = 75
Primary site of cancer (%)	
SKIN	62 (83)
UNKNOWN	5 (7)
OTHER	8 (11)
MISSING	0 (0)
Stage at time of study entry (%)	
STAGE IIIC	5 (7)
STAGE IV	60 (80)
STAGE IVA	2 (3)
STAGE IVB	8 (11)
MISSING	0 (0)
Number of organs involved at baseline (%)	
1	13 (17)
2	14 (19)
3	17 (23)
>3	31 (41)
Missing	0 (0)
LDH at baseline (%)	
<= ULN	21 (28)
> ULN	14 (19)
MISSING	40 (53)

Source: FDA Analysis

Efficacy Results – Primary Endpoint

As stated in “Study Endpoints,” a primary efficacy endpoint for Part 1 was not defined in the study protocol. ORR as determined by investigator is presented here, as it was the primary endpoint for Part 2.

Table 49 presents the confirmed ORR and DOR for Group A of Part 1 of LOGIC2. Confirmation of complete response (CR) or partial response (PR) had to be at least 4 weeks apart from the previous radiological assessment.

Table 49: Confirmed ORR and DOR Results for Group A of Part 1 of LOGIC2

	Combo 450 N = 75
ORR ¹	69%
(95% CI) ²	(58%, 80%)
CR	1%
PR	68%
Median DOR, months	8.5
(95% CI)	(6.7, 9.9)

Source: FDA Analysis

¹ Assessed by investigator

² Estimated using the Clopper-Pearson method

The median duration of potential follow-up time for confirmed ORR was 9.4 months (95% CI: [7.1, 10.6]) for patients naïve to BRAF inhibitors (Group A) of Part 1.

Efficacy Results – Other Endpoints

In LOGIC2, PFS was assessed by investigator. The estimated median PFS time for Group A of Part 1 was 9.5 months (95% CI: [8.0, 11.0]). The median duration of potential follow-up time for PFS was 9.4 months (95% CI: [7.1, 10.6]) for these patients.

As stated in “Primary Endpoints,” median DOR for ORR for Group A of Part 1 was 8.5 months (95% CI: [6.7, 9.9]).

8.1.5. Assessment of Efficacy Across Trials

Primary Endpoints

COLUMBUS demonstrated that Combo 450 had a statistically significant effect on PFS as assessed by BIRC when compared to vemurafenib. The estimated median PFS times were 14.9 months (95% CI: [11.0, 18.5]) for the Combo 450 arm and 7.3 months (95% CI: [5.6, 8.2]) in the vemurafenib arm. The hazard ratio of PFS for the Combo 450 arm compared to the vemurafenib arm was 0.54 (95% CI: [0.41, 0.71]).

While PFS was also measured in LOGIC2, time to event endpoints such as PFS are not interpretable in single arm studies. Furthermore, baseline differences in the study population and a shorter median follow-up time on the LOGIC2 study compared to the COLUMBUS study preclude cross-study observational comparisons with respect to PFS.

Secondary and Other Endpoints

COLUMBUS provided evidence on the treatment effect of Combo 450 on PFS when compared to encorafenib. The estimated median PFS times were 14.9 months (95% CI: [11.0, 18.5]) for the Combo 450 arm and 9.6 (95% CI: [8.7, 14.8]) in the encorafenib arm. The hazard ratio of PFS

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

for the Combo 450 arm compared to the encorafenib arm was 0.75 (95% CI: [0.56, 1.00]). This effect size was similar when estimated under various sensitivity analyses.

COLUMBUS also measured ORR. In COLUMBUS, the confirmed ORR for the Combo 450 arm was 63% (95% CI: [56%, 70%]) with an estimated median duration of response of 16.6 months (95% CI: [12.2, 20.4]) and 40% (95% CI: [33%, 48%]) with a duration of response 12.3 months (95% CI: [6.9, 16.9]) in the vemurafenib arm.

In LOGIC2, the ORR was assessed by investigator. The confirmed ORR for the BRAF inhibitor-naïve patients treated with Combo 450 was 69% (95% CI: [58%, 80%]) with a median duration of response of 8.5 months (95% CI: [6.7, 9.9]).

ORR in patients who were naïve to BRAF-inhibitors and treated with Combo 450 seems to be similar across trials. Differences in duration of response may be due to differences in length of follow-up or differences in patient populations.

Subpopulations

Tables for subgroup comparisons are shown in the figures below. Table 50 shows PFS comparisons of Combo 450 vs. vemurafenib from Part 1 by subgroup.

Multi-Disciplinary Review and Evaluation NDA 210496
 BRAFTOVI™ (encorafenib)

Table 50: Comparisons of Combo 450 vs. Vemurafenib in Part 1 by Subgroup

Subgroup	Combo 450: #Events/N	Vemurafenib: #Events/N	HR (95% CI)
Sex			
M	63/115	61/111	0.62 (0.44, 0.89)
F	35/77	45/80	0.5 (0.32, 0.79)
Disease Stage			
IVM1c	72/123	73/125	0.56 (0.4, 0.78)
IIIB, IIIC, IVM1a or IVM1b	26/69	33/66	0.56 (0.34, 0.94)
Prior 1st line Immunotherapy			
Y	5/8	4/7	0.4 (0.1, 1.64)
N	93/184	102/184	0.59 (0.44, 0.78)
ECOG			
1	37/55	33/51	0.67 (0.42, 1.08)
0	61/136	73/140	0.52 (0.37, 0.74)
BRAF Mutation			
V600K	8/22	15/23	0.27 (0.11, 0.68)
V600E	90/170	91/168	0.64 (0.48, 0.85)
Region			
Other	8/14	11/15	0.64 (0.26, 1.6)
North America	8/17	10/17	0.42 (0.16, 1.1)
Europe	80/156	83/153	0.58 (0.42, 0.79)
Australia	2/5	2/6	0.63 (0.06, 6.97)
Race			
Non-Caucasian	5/11	15/25	0.52 (0.19, 1.43)
Caucasian	93/181	91/166	0.59 (0.44, 0.79)
Baseline Brain Metastases			
Y	5/9	1/3	1.34 (0.15, 11.79)
N	93/183	105/188	0.57 (0.43, 0.75)
Age			
>=65	29/60	26/51	0.66 (0.39, 1.12)
<65	69/132	80/140	0.55 (0.4, 0.77)
Overall			
	98/192	106/191	0.58 (0.44, 0.77)

Source: FDA Analysis

Table 51 shows PFS comparisons of Combo 450 vs. encorafenib from Part 1 by subgroup.

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

Table 51: Comparisons of Combo 450 vs. Encorafenib in Part 1 by Subgroup

Subgroup	Combo 450: #Events/N	Encorafenib (Part 1): #Events/N	HR (95% CI)
Sex			
M	63/115	58/108	0.81 (0.56, 1.16)
F	35/77	38/86	0.8 (0.5, 1.26)
Disease Stage			
IVM1c	72/123	68/120	0.68 (0.49, 0.96)
IIIB, IIIC, IVM1a or IVM1b	26/69	28/74	0.95 (0.56, 1.63)
Prior 1st line Immunotherapy			
Y	5/8	5/11	0.81 (0.23, 2.83)
N	93/184	91/183	0.81 (0.6, 1.08)
ECOG			
1	37/55	31/53	0.79 (0.49, 1.28)
0	61/136	65/141	0.79 (0.56, 1.13)
BRAF Mutation			
V600K	8/22	8/19	0.53 (0.2, 1.44)
V600E	90/170	87/173	0.86 (0.64, 1.15)
Region			
Other	8/14	10/13	0.99 (0.39, 2.52)
North America	8/17	10/27	0.84 (0.33, 2.13)
Europe	80/156	74/150	0.8 (0.58, 1.09)
Australia	2/5	2/4	1.11 (0.15, 7.91)
Race			
Non-Caucasian	5/11	12/20	0.61 (0.21, 1.73)
Caucasian	93/181	84/174	0.84 (0.63, 1.13)
Baseline Brain Metastases			
Y	5/9	7/8	0.31 (0.09, 1.07)
N	93/183	89/186	0.84 (0.63, 1.12)
Age			
>=65	29/60	21/40	0.71 (0.4, 1.25)
<65	69/132	75/154	0.82 (0.59, 1.15)
Overall			
	98/192	96/194	0.81 (0.61, 1.07)

Source: FDA Analysis

Table 52 shows PFS comparisons of Combo 300 vs. encorafenib from Part 2.

Table 52: Comparisons of Combo 300 vs. Encorafenib in Part 2 by Subgroup

Subgroup	Combo 300: #Events/N	Encorafenib (Part 2): #Events/N	HR (95% CI)
Sex			
M	79/151	29/44	0.57 (0.37, 0.88)
F	54/107	27/42	0.55 (0.35, 0.88)
Disease Stage			
IVM1c	95/172	44/58	0.5 (0.35, 0.72)
IIIB, IIIC, IVM1a or IVM1b	38/86	12/28	0.8 (0.42, 1.55)
Prior 1st line Immunotherapy			
Y	7/18	3/5	0.19 (0.04, 0.83)
N	126/240	53/81	0.6 (0.43, 0.82)
ECOG			
1	39/70	18/23	0.43 (0.25, 0.77)
0	93/187	38/63	0.6 (0.41, 0.88)
BRAF Mutation			
V600K	23/34	3/6	2.36 (0.68, 8.2)
V600E	110/224	53/80	0.5 (0.36, 0.7)
Region			
Other	18/43	10/12	0.4 (0.19, 0.88)
North America	7/14	1/2	0.15 (0.01, 1.7)
Europe	108/201	45/71	0.62 (0.44, 0.88)
Australia	0/0	0/1	1 (1, 1)
Race			
Non-Caucasian	5/22	7/8	0.1 (0.03, 0.35)
Caucasian	128/236	49/78	0.64 (0.46, 0.9)
Baseline Brain Metastases			
Y	5/7	2/2	0.83 (0.13, 5.14)
N	128/251	54/84	0.56 (0.4, 0.76)
Age			
>=65	43/83	16/26	0.69 (0.39, 1.23)
<65	90/175	40/60	0.51 (0.35, 0.75)
Overall			
	133/258	56/86	0.56 (0.41, 0.77)

Source: FDA Analysis

The subgroup analyses do not show any outliers in the treatment effect across subgroups for any of the treatment comparisons.

8.1.6. Integrated Assessment of Effectiveness

The data from COLUMBUS showed a statistically significant improvement in PFS for Combo 450 when compared to vemurafenib. Data collected from other trials further characterize the efficacy of Combo 450, and support the observed ORR in COLUMBUS.

Supportive data for the contribution of binimetinib to the combination was collected in Parts 1 and 2 of COLUMBUS. Part 1 suggested a trend for improved PFS for the Combo 450 arm when compared to the encorafenib arm, though this comparison did not reach statistical significance. Part 2 suggested a trend for improved PFS for the Combo 300 arm when compared to the encorafenib arm.

CDTL Comment: Part 1 COLUMBUS Study met its primary endpoint, demonstrating that the combination of encorafenib (450 mg daily) and binimetinib (45 mg twice daily) was associated with a clinically and statistically significant improvement in PFS compared to vemurafenib as an

active control. However, per the FDA's Guidance for Industry: Codevelopment of Two or More New Investigational Drugs for Use in Combination, the development program must establish that each drug contributes to the overall treatment effect. As a class, MEK inhibitors have modest single agent activity in BRAF-mutated melanoma. For example, while trametinib (a MEK inhibitor) has approval as a single agent in unresectable or metastatic melanoma based on a randomized trial demonstrating an improvement in PFS compared to chemotherapy, trametinib is associated with an ORR of 22%, while dabrafenib (a BRAF inhibitor) yields an ORR of 51% and the combination of the two an ORR of 66% (trametinib USPI). The FDA thus did not consider it ethical to require the applicant to demonstrate the necessity of encorafenib to the observed treatment effect by including a binimetinib monotherapy control arm on COLUMBUS.

By contrast, given the high response rates and durability of responses that have been observed with BRAF inhibitors in BRAF-mutated melanoma as a class, the FDA considered it necessary for the applicant to demonstrate the necessity of binimetinib to the observed treatment effect by including an encorafenib monotherapy control arm. This was complicated by the inability to dose encorafenib monotherapy at more than 300 mg daily due to toxicities that are mitigated by the addition of binimetinib as described earlier in this review.

The Combo 450 arm demonstrated a numerical, but not statistically significant, improvement in PFS when compared to the encorafenib monotherapy arm, with a stratified hazard ratio of 0.75 (95% CI: [0.56, 1.00]), and a p-value of 0.0513. The marginal failure of this endpoint precluded further formal hypothesis testing due to hierarchical testing rules, including a comparison of the Combo 300 arm to encorafenib monotherapy on Part 2 of COLUMBUS. However, the Combo 300 arm exhibited a numerical improvement in PFS when compared to encorafenib monotherapy, with a stratified hazard ratio of 0.77 (95% CI: [0.61, 0.97]). Although it was not formally demonstrated, the consistency of these results across two trial stages provides a reasonable degree of confidence using a totality of the evidence approach that the addition of binimetinib to encorafenib prolongs PFS compared to encorafenib alone, and that both drugs are required to achieve the observed treatment effect.

8.2. Review of Safety

8.2.1. Safety Review Approach

Table 53 and Table 54 list the trials submitted to the NDA by the applicant contributing safety data to the analysis of the Combo 450 regimen. The primary trial characterizing the safety of this regimen was COLUMBUS Part 1. Seven patients who were randomized in Part 1 withdrew from the study prior to receiving any study treatment (5 patients in the vemurafenib arm and 2 in the encorafenib monotherapy arm). Only patients who received at least one dose of study drug are included in the safety analysis set. The safety analysis set for COLUMBUS Part 1 comprises 570 patients distributed as follows: 192 patients in the Combo 450 arm, 192 patients in the encorafenib monotherapy arm, and 186 patients in the vemurafenib arm.

The submission also included supportive safety data from Part 2 of COLUMBUS that compared a Combo 300 regimen with encorafenib monotherapy 300 mg. For the integrated safety analysis, the application specified a pooled safety set consisting of a total of 274 patients with BRAF+ melanoma who received the Combo 450 regimen (Combo 450 Pool) and a pooled safety set consisting of a total of 433 patients with BRAF+ disease who were treated with a regimen of encorafenib at a dose ≥ 400 mg QD given with binimetinib 45 mg BID (Combo ≥ 400 Pool). The trials contributing to these pooled sets are shown in Table 53. Two single agent pooled data sets were also analyzed for encorafenib and binimetinib. The trials contributing to these pooled data sets are shown in Table 54. The encorafenib monotherapy pooled dataset consists of 217 patients with BRAF+ melanoma who received 300 mg encorafenib daily (Enc 300 Pool). The patients for this data set are drawn primarily from COLUMBUS Part 1 encorafenib monotherapy arm. The binimetinib pooled dataset consists of 429 patients with NRA+ or BRAF+ melanoma who received 45 mg binimetinib twice daily (Bini 45 pool). The patients for this dataset are drawn primarily from CMEK162A2301, a randomized controlled study of binimetinib compared to dactinomycin in patients with NRAS+ melanoma.

This review focuses primarily on the safety data from COLUMBUS Part 1. Section 8.2.3 summarizes the tolerability and toxicities observed in patients in the Combo 450 arm of COLUMBUS Part 1 when compared to the vemurafenib control arm. This section also includes presentation of analyses for the encorafenib monotherapy arm. The analyses of adverse events in this section is based on preferred term (PT) and MedDRA groupings. Section 8.2.4 evaluates the toxicity of Combo 450 in terms of adverse drug reactions (ADRs) which are submission specific composite events terms formed from PT grouping and are based on the applicant's analysis of adverse events of special interests (AESI) and known class effects of BRAF and MEK inhibitors.

The largest pooled combination safety set for combination therapy (Combo ≥ 400 pool) was analyzed to assess for the presence of any rare but serious adverse events observed only in larger populations. No new or more serious safety signals not identified in the analysis of the Combo 450 arm were identified in this assessment.

Table 53: Trials Submitted in Support of Safety Assessment of Combo 450 Regimen

Trial	Population Description	Treatment Group	Number of Patients Treated	Included in Combo 450 Pool N= 274	Included in Combo ≥ 400 Pool N= 433	Trial (cutoff date)
CMEK162B2391 COLUMBUS PART 1	BRAF + Melanoma	Combo 450	192	Y	Y	19 May 2016
		Enc 300 Part 1	192	N/A	N/A	
		Vemurafenib	168	N/A	N/A	
CMEK162B2391 COLUMBUS Part 2	BRAF + Melanoma	Combo 300	257	N	N	09 Nov 2016
		Enc 300 Part 2	84	N/A	N/A	
CLGX818X2109 (LOGIC2)	BRAF/MEK-treatment Naïve Melanoma	Combo 450	75 (Part 1 Group A)	Y	Y	18 Feb 2016
	BRAF/MEK-treatment Non-naïve melanoma	Combo 450	83 (Part 1 Group B/C Run-in)	N	Y	
CMEK162X2110	BRAF V600 – dependent advanced solid tumors	Combo 400	4	N	Y	31 Aug 2015
		Combo 450	21	Y (7 BRAF inhibitor naïve melanoma)	Y	
		Combo 600	62	N	Y	

Source: Reviewer compiled from ISS Tables 1-1, 1-2, 1-3 (Submitted by Applicant to Module 5.3.5.3 June 30, 2017)

¹ Patients with diagnosis of melanoma who received encorafenib 450 mg QD with binimetinib 45 mg BID (267)

² Patients with diagnosis of melanoma who received encorafenib ≥ 400 mg QD with binimetinib 45 mg BID (350)

³ Encorafenib 450 mg QD with binimetinib 45 mg BID

⁴ Encorafenib monotherapy 300 mg QD

⁵ Vemurafenib monotherapy 960 mg BID

⁶ Encorafenib 300 mg QD with binimetinib 45 mg BID

Table 54: Trials Contributing to Pooled Single Agent Safety Data

Trial	Description	Patients	Trial (cutoff date)
Encorafenib 300 mg QD N=217			
CMEK162B2301 Enc 300 Part 1	BRAF + melanoma	192	19 May 2016
CMGX818X2101	BRAF + melanoma	10	18 Aug 2014
CLGX818X2102	BRAF V600+ melanoma	15	completed
Binimetinib 45 mg BID N=429			
CMEK162A2301	NRAS+ melanoma	269	18 Mar 2016
CMEK162X2201	BRAF+ melanoma	41	06 Nov 2015
	NRAS + melanoma	117	

Source: Reviewer compiled from ISS Table 1-3 (Submitted by Applicant to Module 5.3.5.3 June 30, 2017)

Safety Database Quality Assessment

The quality of the safety database submitted was assessed. The accurate representation of the data submitted by the Investigators in the AE dataset was evaluated through a spot check of 15 randomly selected patients enrolled in Part 1. Comparison was made between the CRFs and the AE dataset. No omissions or inaccuracies were detected. The validity of the coding of verbatim reported adverse event terms to the MedDRA lower level terms was assessed through a comparison of almost 16,000 adverse events (AETERM) submitted with COLUMBUS to the lowest coded level, AELLT. This assessment identified 12 AEs (<0.001%) that were incorrectly coded. An additional 8 AEs were identified as possibly an incorrect interpretation of the investigator’s intent, e.g., “hematoma of the left lower abdomen” coded as “abdominal hematoma” which subsequently becomes through the MedDRA dictionary “intra-abdominal hematoma.” Incorrect or sub optimally coded AEs were spread across all arms and were not clustered within particular PT(s) or other MedDRA level, potentially affecting the overall safety assessment. Summaries of events for patients who died within 30 days of last dose of study treatment were reviewed for agreement with the Applicants assessment of cause. No discrepancies were identified.

Overall Exposure

Statistics for the duration of exposure to study treatment for Part 1 of COLUMBUS are shown in Table 55.

The median duration of exposure in the Combo 450 arm was 51.2 weeks (51.2 weeks for encorafenib and 50.6 weeks for binimetinib). This was longer than the median duration of exposure in the encorafenib monotherapy arm (31.4 weeks) and the vemurafenib arm (27.1 weeks). More than half of patients in the Combo 450 arm (52.6%) received at least 48 weeks of study treatment. Less than half of the patients in the encorafenib monotherapy arm (39.1%) and the vemurafenib arm (25.3%) received at least 45 weeks of study treatment. The median relative dose intensity in the Combo 450 arm was 100% for encorafenib and 99.6% for binimetinib. The median relative dose intensity in the encorafenib monotherapy arm was 86.2% and in the vemurafenib arm was 94.5%. Exposure time in the Combo ≥ 400 pool was shorter

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

than observed in the COLUMBUS Part 1 Combo 450 arm, with only 36% of patients receiving more than 48 weeks of treatment. The actual and mean dose intensity, however, was similar between the Combo 450 arm from COLUMBUS Part 1 and the pooled Combo $\geq$ 400 data.

Table 55: Duration of Exposure to Study Treatment: COLUMBUS Part 1 and Combo ≥ 400

Time on Treatment (weeks)	COLUMBUS Part 1					Combo ≥ 400 Pool		
	Combo 450			Enc 30 N= 192	Vem N=186	Encorafenib N=433	Binimetinib N=433	Encorafenib + Binimetinib N=433
	Encorafenib N=192	Binimetinib N=192	Encorafenib + Binimetinib N= 192					
Mean (SD)	54.29 (30.9)	53.77 (31.3)	54.32 (30.9)	42.4 (31.2)	35.9 (29.5)	41.9 (30.7)	41.6 (30.7)	42.0 (30.6)
Median	51.21	50.64	51.2	31.4	27.1	34.0	33.3	34.0
Range (min-max)	0.4 - 116.0	0.4 - 116.0	0.4 - 116.0	0.1 - 113.3	0.9 - 121.6	0.1-132.9	0.1-132.9	0.1-132.9
Exposure Category (weeks) n (%)								
< 12	13 (6.8)	15 (7.8)	13 (6.8)	29 (15.1)	35 (18.9)	67 (15.5)	68 (15.7)	66 (15.2)
12 to < 24	21 (10.9)	20 (10.4)	20 (10.4)	42 (21.9)	45 (24.2)	86 (19.9)	86 (19.9)	85 (19.6)
24 to < 36	32 (16.7)	32 (16.7)	33 (17.2)	32 (16.7)	38 (20.4)	71 (16.4)	71 (16.4)	72 (16.6)
36 to ≤ 48	25 (13.0)	25 (13.0)	25 (13.0)	14 (7.3)	21 (11.3)	52 (12.0)	53 (12.2)	53 (12.2)
≥ 48	101 (52.6)	100 (52.1)	101 (52.6)	75 (39.1)	47 (25.3)	157 (36.3)	155 (35.8)	157 (36.3)
Actual Dose Intensity (mg/day)								
Mean (SD)	410.3 (70.2)	79.8 (16.5)		227.0 (77.5)	1613.4 (372.5)	426.6 (75.3)	81.6 (14.8)	
Median	450.0	89.6		256.6	1814.13	450.0	89.4	
Min-Max	150.0-450.6	6.3-90.0		44.4-300.5	325.0-1920.0	100.0 - 900.0	6.3 – 180.0	
Relative Dose Intensity (%)								
Mean (SD)	91.2 (15.6)	88.7 (18.3)		75.7 (25.8)	84.0 (19.4)	91.2 (15.3)	90.6 (16.4)	
Median	100	99.6		86.2	94.49	99.4	99.4	
Min-Max	33.3 - 100.1	6.9 - 100		14.8 – 100.2	16.9 - 100	20.4-200.0	6.9-200	

Source: ISS Tables 1-11 and 1-12 submitted to application 6/30/2017. COLUMBUS Part 1 data verified by Reviewer using COLUMBUS Part 1 SDTM.ex

Relevant characteristics of the safety population:

Demographic information for all patients randomized on COLUMBUS is found in Table 31, Section 8.1.1. The removal of the 7 patients who did not receive any study treatment from the full analysis did not significantly change the assessment.

Adequacy of the safety database:

The size of the safety database is adequate to provide a reasonable estimate of adverse reactions that may be observed with the Combo 450 regimen, and the duration of treatment is adequate to allow assessment of adverse reactions over time. The safety database represents the gender, age, and race consistent with that observed in the overall population of patients who are diagnosed with melanoma. The size of the Combo ≥ 400 pool and the duration of treatment for those patients is adequate to assess incidence of rare events that may only occur in larger population.

COLUMBUS Part 1 randomized the Combo 450 treatment against encorafenib 300 monotherapy and against vemurafenib monotherapy. In the absence of a placebo arm, contribution of the underlying disease to adverse reactions cannot be assessed. Since patients in all arms received a BRAF inhibitor and patients in the Combo 450 arm received a higher dose of encorafenib than in the encorafenib monotherapy arm, the ability to assess the contribution of each agent, encorafenib or binimetinib, to the safety assessment is limited.

8.2.2. Adequacy of Applicant's Clinical Safety Assessments

Issues Regarding Data Integrity and Submission Quality

The submission contained all required components of the eCTD. The overall quality and integrity of the application was adequate for substantive review to be completed.

Categorization of Adverse Event

AEs were reported by the Investigators in the CRF. All AEs reported for all trials contributing to pooled datasets including both the combination and monotherapy sets, were coded by the Applicant using the Medical Dictionary for Regulatory Activities (MedDRA) version 19.0.

For COLUMBUS, severity of AEs was coded by the Investigator according to NCI CTCAE V4.03 using Grade 1 to 4; CTCAE Grade 5 (death) was not to be used. All AEs and SAEs were collected after the main study informed consent was provided through 30 days after the last dose of study treatment. In addition, treatment-related SAEs were collected after 30 days. Progression of malignancy (including fatal outcome), if documented per RECIST, was not to be reported as an SAE. An abnormal laboratory value was recorded as an AE if considered by the Investigator to be clinically significant, induced clinical signs or symptoms, required concomitant therapy, or required change in study treatment. The Investigator AE reporting included an assessment of seriousness and relatedness along with action taken with the treatment. Treatment emergent AEs (TEAEs) were defined as an AE beginning between the day of the first exposure to study

drug(s) up to and including 30 days after the last dose of study drug(s). All trials contributing to pooled datasets followed similar guidelines for AE collection and any differences are assessed as not altering the overall analyses.

The COLUMBUS protocol defined an SAE as an AE that is fatal or life threatening, results in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, is medically significant, i.e., an event that jeopardizes the patient or may require medical or surgical intervention to prevent a serious event, or requires inpatient hospitalization or prolongation of existing hospitalization. Hospitalizations for routine treatment or monitoring of study indication and not associated with deterioration in condition, for elective or pre-planned treatment for a pre-existing condition that is unrelated to the indication under study and has not worsened, or social reasons/respite care in the absence of any deterioration on the patient's general condition are not considered SAEs.

The applicant performed an analysis based on ungrouped PT as well as standard MedDRA hierarchical groupings. The applicant also grouped PTs in their analysis of AEs of special interest (AESI) and their analysis of adverse drug reactions (ADRs). AESIs and ADRs are discussed in Section 8.2.4. This reviewer assessed the applicant's ADR groupings to adequately capture the reported adverse events in a clinically meaningful way and no additional safety signals were identified beyond those discussed below. The safety review presented here was performed on TEAEs regardless of Investigator's assessment of attribution.

Routine Clinical Assessments

For COLUMBUS, physical examinations, height and weight, performance status assessment, and vital signs were performed during screening (within 21 days of initiating study treatment), Day 1 of each cycle, at end of treatment (EOT), and at the 30-day safety follow-up visit. Vital signs included blood pressure, temperature, pulse, and respiratory rate measurements.

Routine laboratory assessments including hematology and clinical chemistries were performed during screening, Day 1 of each cycle, at EOT, and at 30-day safety follow up. Laboratory hematology assessments consisted of a complete blood count with platelets and differential. Routine clinical chemistry assessment consists of BUN/urea, uric acid, serum creatinine, sodium, potassium, magnesium, calcium, chloride, glucose, total protein, albumin, bicarbonate/CO₂, phosphate, AST, ALT, GGT, alkaline phosphate, and bilirubin (direct, indirect, and total).

Cardiac/muscle enzyme studies consisting of troponin and creatine phosphokinase (CPK) were measured pre-dose during screening, Day 1 of each cycle, at EOT, and at 30-day safety follow up.

Additional Clinical Assessments

Ophthalmologic examinations including slit lamp examination, best recorded visual acuity for distance testing, intraocular pressure (IOP), and fundoscopy were required for all patients enrolled in COLUMBUS. Patients on the Combo 450 and Combo 300 arms as well as patients on the encorafenib monotherapy and vemurafenib arms with baseline retinal abnormalities were

required to have ophthalmic examinations during screening, at each regulatory scheduled patient visit (Day 1 of each cycle), EOT, and at the 30-day safety follow-up (per Amendment 3).

Standard 12-lead Electrocardiograms (ECGs) were performed during screening, Day 1 Cycles 1,2, and 3, every 3 cycles thereafter (every 12 weeks), EOT, and at the 30-day safety follow-up.

Cardiac imaging with multiple gated acquisition scan (MUGA) or echocardiography (ECHO) scan or echocardiograph (ECHO) was obtained during screening, Day 1 of Cycles 2 and 3, every 3 cycles thereafter (every 12 weeks), EOT, and at the 30-dat safety follow up visit.

Skin evaluations were performed for all patients on day 1 of odd cycles (every 8 weeks starting Day 1 Cycle 1), EOT, and at the 30-day safety follow-up visit.

8.2.3. Safety Results

Deaths

Table 56 summarizes the primary cause of death for patients in COLUMBUS Part 1 who died while on therapy or within 30 days of the last dose of treatment (treatment emergent deaths). Based on disposition data, at the time of cutoff (9 May 2016), there were 17 treatment emergent deaths in the Combo 450 arm, 14 deaths in the encorafenib monotherapy arm, and 19 deaths in the vemurafenib arm. Of these deaths, 11/17 (65%) on the Combo 450 arm were attributed to underlying disease while 12/14 (86%) on the encorafenib monotherapy arm and 17/19 (89%) on the vemurafenib arm were attributed to underlying disease. Three of 17 deaths (18%) on the Combo 450 arm, 1/14 deaths (7%) on the encorafenib monotherapy arm, and 2/19 (11%) were attributed to adverse events. The Applicant provided detailed narratives for all patients on COLUMBUS Trial who died within 30 days of last exposure of study drug. A review of these narratives was performed. Table 57 below summaries these narratives for patients in Part 1 where cause of treatment emergent death was assessed as other than disease progression.

Table 56: Primary Cause of Treatment Emergent Deaths: COLUMBUS Part 1

Primary Cause of Death	COLUMBUS Part 1		
	Combo 450 N=192 n (%)	Enc 300 N=192 n (%)	Vem N=186 n (%)
All deaths prior to cutoff	69 (35.9)	74 (38.5)	88 (47.3)
Deaths on therapy or within 30 days of treatment discontinuation	17 (8.9)	14 (7.3)	19 (10.2)
Reason for Death			
Study Indication ¹	11 (5.7)	12 (6.3)	17 ² (9.1)
Adverse Event	3 (1.6)	1 (1.0)	2 (1.1)
Acute Myocardial Infarction		1 (0.5)	
Cerebral Hemorrhage	1 (0.5)		
Suicide	1 (0.5)		

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

Primary Cause of Death	COLUMBUS Part 1		
	Combo 450 N=192 n (%)	Enc 300 N=192 n (%)	Vem N=186 n (%)
Intestinal Sepsis			1 (0.5) ³
Lung Infection			1 (0.5) ⁴
Multiple Organ Dysfunction Syndrome	1 (0.5)		
Other	3 (1.6)	1 (0.5)	
Euthanasia	1 (0.5) ⁵		
Unknown	2 (1)	1 (0.5)	

Source: Reviewer generated table using COLUMBUS PART1: ADSL, (cutoff 9 May 2016, submitted by Applicant);

¹ Includes “malignant melanoma”, “study indication”, “metastases to CNS”

² Includes 1 patient for whom Investigator’s assessment for cause of death was progressive disease, but upon review, cannot definitely be determined and 1 patient who died of “general physical health deterioration” who had no post-baseline tumor assessments but for whom the Investigator considered disease progression as a possible cause of death,

³ Narrative notes patient also experienced Grade 5 pulmonary embolism concurrent with intestinal sepsis.

⁴ Narrative also notes cause as disease progression (malignant pleural effusion).

⁵ Narrative notes that prior to death, patient discontinued study treatment due to progressive disease, including hepatic metastases. Patient subsequently developed liver failure and reportedly opted for euthanasia.

Table 57: Summary of Applicant Narratives for Patients in COLUMBUS Part 1 Who Died ≤ 30 days of Treatment for Cause Other than Disease Progression

Patient	Treatment Arm	Reported Cause of death
(b) (6)	Combo 450	Unknown cause
The patient was a 51-year-old woman with a diagnosis of cutaneous melanoma, Stage IV M1c, with metastases to the bone, liver, lungs, skin, inguinal and other lymph nodes. Prior disease directed therapy included interferon. On study day 148, the patient died due to unknown reasons. The patient was found deceased at home with “no signs of suffering or vomiting, no rictus, no urine loss, and no missing drugs. No evidence of suicide was also noted.” The patient was reported by her husband as well without complains in the days prior to death. Adverse events reported as ongoing at the time of death were fatigue (Grade 1), upper abdominal pain (Grade 1), dysgeusia (Grade 1), and headache (Grade 2) since day 86. The most recent AE was pain in the left armpit scar (Grade 1) noted on Day 112. Concomitant medications at the time of death included alprazolam, paroxetine hydrochloride, quetiapine fumarate and zopiclone, all initiated prior to randomization, as well as cathartics and acetaminophen. Patients most recent ECG on day 140 was normal and last LVEF measured on day 142 was 55% (52% at screening). Except for Troponin, which was mildly elevated at 12.0 ng/mL (ULN < 10 ng/mL), all laboratory results from Day 140 were within normal limits. This reviewer agrees with the Applicant’s assessment that while a relationship between the event of death and the study drugs cannot be excluded, no clear relationship to study treatment is evident.		
(b) (6)	Combo 450	Multiple organ dysfunction syndrome
The patient was a 67-year-old gentleman with a diagnosis of cutaneous melanoma, Stage IV M1c with elevated LDH with metastases to the brain and axillary lymph nodes. Except for resection of brain metastasis, no prior disease directed therapy was reported. Relevant past medical conditions include atrial fibrillation. Active medical conditions at the time of randomization included hypertension and vertigo. On study Day 5, the patient was hospitalized with the SAE of epilepsy (Grade 3). On study Day 12, the patient experienced the SAE of pneumonia (Grade 3) and on study Day 14, the patient experienced the SAEs of gastric ulcer hemorrhage (Grade 2) and multiple organ dysfunction syndrome (Grade 4). No information on workup,		

Multi-Disciplinary Review and Evaluation NDA 210496

BRAFTOVI™ (encorafenib)

including culture, lung imaging, or gastroscopy, was provided. Concomitant medications at the time of the event included losartan with hydrochlorothiazide, sotalol hydrochloride, and betahistine hydrochloride. The patient was treated with amoxicillin with clavulanic acid (Days 12-37) for the event of pneumonia and aminomethyl benzoic acid and etamsylate (Days 14-37) for the event of gastric hemorrhage. The study drugs were interrupted starting on Day 15. On day 37, 22 days after the last dose of study drug, the patient died due to gastric ulcer hemorrhage and multiple organ failure.

The Applicant agreed with the Investigator’s assessment that there was no clear information to link death with study treatment. However, given the known association between hemorrhage and MEK inhibitors, in the absence of additional information, this reviewer concludes that the study drugs may have contributed to the cause of death, gastric hemorrhage, for this patient.

(b) (6)	Vemurafenib	Disease Progression (Unknown)
The patient was a 62-year-old gentleman with a diagnosis of cutaneous melanoma, Stage IV M1c with elevated LDH. Metastatic sites included lymph nodes, liver, spleen, lung, and adrenal gland. Prior disease directed therapy included lymphadenectomy and interferon. Relevant past medical conditions included cholecystectomy and thrombosis. The patient’s active medical conditions at the time of randomization included anemia, hypertension, type 2 DM, and hyperlipidemia. On study Day 57, the patient died. Abnormal laboratory results from study Day 28 included increased alkaline phosphatase (Grade 1, improving from baseline) and increased serum creatinine (Grade 1). LDH was WNL (elected at baseline). The last cardiac assessment performed on Day 32 showed a LVEF of 68% and normal ECG. There were no on-treatment tumor assessments. The Investigator reported the cause of death as disease progression. The Applicant concluded that based on the patient’s extensive disease burden and lack of evidence for alternative causes, disease progression as cause of death could not be excluded, the cause of death cannot be conclusively identified based on the information provided. This reviewer agrees with Applicant and would categorize cause of death as indeterminant.		

(b) (6)	Vemurafenib	Gastrointestinal sepsis
The patient was a 48-year-old gentleman diagnosed with cutaneous melanoma, Stage IV M1c with normal LDH. Metastatic sites included lymph nodes, liver, and skin. No prior disease directed therapy was reported. Relevant active medical conditions at the time of randomization included anemia, lymphopenia, sarcoidosis, and renal failure. On study Day 195, the patient experienced the SAE of increased GGT (Grade 4) and intestinal sepsis (Grade 4) and the non-serious AE of dyspnea (Grade 3). The patient was hospitalized with a gastrointestinal abscess and peritonitis complicated by septic shock. On Day 197, CT scan findings were consistent with right pulmonary embolism. The last day of study treatment was Day 195. On Day 206, 11 days after the last dose of study drug, the patient died due to the event of intestinal sepsis. The Investigator suspected a relationship between the event of GGT increased and the study drug but did not suspect a relationship between the events of lymphopenia, intestinal sepsis, pulmonary embolism and the study drug. The Applicant agreed with the Investigator’s assessment. This reviewer notes that the narrative grades the pulmonary embolism as fatal (Grade 5). This reviewer agrees with the Applicant’s assessment regarding the relationship between intestinal sepsis and study treatment.		

(b) (6)	Combo 450	Cerebral hemorrhage
The patient was a 54-year-old gentleman with a diagnosis of cutaneous melanoma, Stage IV M1c with normal LDH. Metastatic sites included extensive nodal disease, pleura, and lung. Prior disease directed therapy included excision of malignant lesions including lymphadenectomy. No prior antineoplastic medication or radiotherapy was reported. Relative active medical conditions at the time of randomization included hypertension (Grade 2 baseline). On study Day 231, MRI of the brain performed for a complaint of headache showed metastases. Study drugs were permanently discontinued due to disease progression. Radiation therapy for brain metastases was started		

Multi-Disciplinary Review and Evaluation NDA 210496

BRAFTOVI™ (encorafenib)

on Day 235. On Day 237, 7 days after the last dose of study drugs, the patient experienced a non-serious event of brain edema (Grade 3) and the SAE of cerebral hemorrhage (Grade 3). On Day 240, CT scan showed progressive bleeding (acute bleeding into disseminated cerebral metastasis of melanoma) and edema. The patient died due to cerebral hemorrhage on Day 246, 16 days after the last dose of study drugs.

The Investigator did not suspect a relationship between the events of brain edema and cerebral hemorrhage and the study drugs. The Applicant did not assess a relationship. This reviewer agrees with the Investigator that the cerebral hemorrhage, the identified cause of death, was most likely due to confirmed disseminated cerebral metastasis of melanoma; however, given the known association between BRAF/MEK inhibitors and hemorrhage, a contributory affect of study treatment to the hemorrhage cannot be ruled out.

(b) (6)	Combo 450	Unknown cause

The patient is a 35-year-old gentleman with a diagnosis of cutaneous melanoma, Stage IV M1c with elevated LDH. Metastatic sites included lymph nodes, vertebra, liver, pleura, retroperitoneum, and spleen. Prior disease directed therapy included excision of skin lesion and interferon. No relevant medical conditions at the time of randomization were reported.

On Day 77, the patient died in Russia (out of the country) due to unknown reasons. The cause of death was not reported on the death certificate. No further information was reported despite information requests by the Investigator of the patient's relative. Non-serious adverse events that were ongoing at the time of death were anemia (Grade 3) and neutropenia (Grade 3). There were no reported laboratory assessments in the 2 weeks prior to the death. The most recent tumor assessment performed (Day 56) showed partial response.

The Investigator did not suspect a relationship between the event of death and the study drugs. The Applicant did not provide an assessment. This reviewer concludes there is insufficient information to assess the cause of death.

(b) (6)	Encorafenib Monotherapy	Acute myocardial infarction

The patient was a 54-year-old gentleman with a diagnosis of cutaneous melanoma, Stage IV M1c with elevated LDH. Metastatic sites included axillary lymph nodes. Prior disease directed therapy included excision of melanoma on lower back. No prior antineoplastic medication or radiation was reported. Relevant active medical conditions at the time of randomization included muscular weakness and lymphedema.

On study Day 280, study drug was permanently discontinued due to disease progression. On Day 289, 9 days after the last dose of study drug, the patient experienced the serious adverse event of acute myocardial infarction. On Day 291, 11 days after the last dose of study drug, the patient died due to the event of acute myocardial infarction.

The Investigator did not suspect a relationship between the event of acute myocardial infarction and the study drug. The Applicant assessment was that the temporal relationship between the event and the study drug made a relationship with study drug improbable, citing the prolonged period on study drug preceding the event, and that the event of myocardial infarction occurred nearly 10 days after the last dose of study drug.

(b) (6)	Vemurafenib	Disease progression (General health deterioration)

The patient was a 68-year-old woman with a diagnosis of cutaneous melanoma, Stage IV M1c with normal LDH. Metastatic sites included bone, thoracic vertebrae, lymph nodes. No prior disease directed therapy was reported. The patient's relevant active medications at the time of randomization included atrial fibrillation, chronic obstructive pulmonary disease, diabetes mellitus, hemangioma of the liver, hypertension, and osteoporosis.

On study Day 28, the patient experienced the SAE of general physical health deterioration (Grade 4). No other AEs were reported and no laboratory results were provided. The patient did not have post-baseline tumor assessments. The patient received the last dose of study drug on Day 26. The patient is reported to have died due to the event of general physical health deterioration.

The Investigator did not suspect a relationship between the event of general physical health deterioration and the study drug and considered disease progression as a possible cause. The Applicant agreed.

Multi-Disciplinary Review and Evaluation NDA 210496

BRAFTOVI™ (encorafenib)

No post-baseline laboratory or cardiac assessments are available for the patient. Review of other patients treated at the same site demonstrates the Investigator regularly submitted AE reports for other patients suggesting the absence of other AEs for this patient likely accurately reflected the patient’s condition. Based on the patient’s multiple sites of disease at diagnosis and absence of other AEs reported, FDA agrees with the Applicant’s assessment.		
(b) (6)	Vemurafenib	Disease progression/ Lung infection
The patient was a 53-year-old gentleman with a diagnosis of cutaneous melanoma, Stage IV M1c with normal LDH. Metastatic sites included axillary lymph nodes and soft tissue. Prior disease directed therapy included radiation to axillary lymph nodes and right supraclavicular area. No prior antineoplastic medication was reported. The patient’s relevant active medical conditions at the time of randomization included hypertension, lower extremity neuropathy, and type 2 diabetes mellitus. On study Day 88. The patient was hospitalized due to a serious adverse event of pleural effusion (Grade 3) which was confirmed by CT scan. The pleural effusion was considered disease progression which was confirmed by the pathology report. On Day 89, the patient experienced a serious adverse event of lung infection (Grade 3). The patient was treated with penicillin. The patient underwent thoracostomies on Day 94 and Day 96. On Day 105, 16 days after the last dose of study drug, the patient died due to infection of the lung. The Investigator did not suspect a relationship between the events of pleural effusion/ lung infection and the study drug. The patient’s underlying disease was considered a possible contributory factor. The Applicant agreed with the Investigator’s assessment. This reviewer agrees with the Applicant’s assessment.		
(b) (6)	Encorafenib monotherapy	Unknown cause
The patient is a 64-year-old woman with a diagnosis of cutaneous melanoma, Stage IV M1b. Metastatic sites included lung and soft tissue. Prior disease directed therapy included surgery (skin excisions and lymphadenectomy) and radiation (lymph node and skin). The patient’s relevant medical conditions at the time of randomization included hypertension. On study Day 377, the patient died due to unknown cause. No autopsy was performed. The last dose of study drug was taken on the same day. AEs at the time of death included keratoacanthoma (Grade 2), palmoplantar keratoderma (Grade 2), The last laboratory results including chemistry, hematology, and cardiac enzymes evaluated on Day 365 were within normal limits. The patient had stable disease at the time of the most recent prior tumor assessment on Day 345. The Investigator did not suspect a relationship between the event of death and the study drug. The Applicant assessed the death as not related to study drug and more likely related to the underlying disease of melanoma. This reviewer concludes there is insufficient information upon which to draw a conclusion.		
(b) (6)	Combo 450	Suicide
The patient was a 73-year-old woman with a diagnosis of cutaneous melanoma, Stage IV M1a. Metastatic sites included skin. Prior disease directed therapy included excision of lesions including lymphadenectomy. No prior antineoplastic medication or radiation was reported. Relevant active medical conditions at the time of randomization included diabetes mellitus and hypercholesterolemia. The patient did not have reported previous psychiatric history. On study Day 8, the patient reported nausea and vomiting for the prior 48 hours. On Day 9, the event of nausea was considered Grade 3. The study drug was discontinued on Day 9. On Day 10, the patient experienced the SAEs of fatigue (Grade 3), general physical health deterioration (Grade 3), hyperkalemia (Grade 3), renal failure (Grade 3), and vomiting (Grade 3). Concurrent non-serious events included somnolence (Grade 1). The patient additionally reported persistent nausea and vomiting, poor general condition, and persistent exhaustion. The patient was admitted to the hospital. Over the next several days, the patient’s clinical condition improved. On Day 14, the patient reported feelings of depression with thoughts of hopelessness and death. According to the patient’s family, the patient did not have symptoms of depression prior to the start of treatment with study drugs and was living an active life style, walking 5 km daily, and being responsible for her home and farm animals. The patient’s family reported to have exhibited altered behavior due to depression since the beginning of treatment with study drugs. On Day 15, a psychological evaluation found the patient was alert and oriented without thought alterations although she did report apathy and weakness. No psychotic symptoms were observed and no psychopharmacological treatment was introduced. On Day 16, the patient was discharged from the hospital. At		

BRAFTOVI™ (encorafenib)

the time, the patient did not report thoughts of suicide or death and had no nausea and vomiting. The event of general physical health deterioration was considered resolved now. On Day 22, the patient reported depressed mood and poor appetite. On Day 24, 15 days after the last dose of study drug, the patient fell from the 16th floor of a building and died.

The Investigator suspected a relationship between the serious event of completed suicide and the study drugs. The Sponsor considered a causal relationship between study drug and the outcome of death by suicide possible. Given the significant change in the patient's activities and functioning that coincided with initiation of study treatment as well as a lack of prior psychiatric history, this reviewer agrees with the possible attribution of study drugs to this patient's death as a result of suicide.

(b) (6)	Combo 450	Euthanasia/ Liver failure
The patient was a 43-year-old gentleman with a diagnosis of cutaneous melanoma, Stage IV M1c with normal LDH. Metastatic sites included bone, lumbar vertebrae, and lung. Prior disease directed therapy included surgical excision of melanoma metastasis right parieto-temporal, radiation therapy to the bone. No prior antineoplastic medication was reported. No active medical conditions at the time of randomization were reported. On Day 258, the patient received the last dose of study drugs due to disease progression, confirmed by PET scan on Day 258, which showed increased uptake in the liver and bone consistent with metastases. On Day 264, 8 days after the last dose of study drug, the patient experienced a non-serious adverse event of hepatic failure (Grade 3). On day 268, the patient died. The patient's death certificated noted hepatic failure. It is also reported the patient opted for euthanasia. The investigator did not suspect a relationship between the event of hepatic failure and study drugs. The Applicant agreed with the Investigator's assessment. This reviewer agrees with the Applicant's assessment.		

Source: Reviewer synopses of Applicant provided summaries COLUMBUS Part 1 CSR

Based on the completed suicide by Patient (b) (6) this clinical reviewer performed a more extensive evaluation of depression, including suicidal ideation and suicide attempts. A thorough examination of the ISS-ADAE datafile revealed a total of three AEs that referenced suicide (2 in addition to Patient (b) (6) whose history is summarized above).

- Patient (b) (6) is a 49-year-old male randomized to the COMBO 450 arm in COLUMBUS Part 1. The reported event Grade 4 "depression suicidal" occurred on day 337 of treatment and was reported as recovered/resolved on day 338. On Day 338, the AE of Grade 2 "depression" was reported. At the time of data cutoff, there was no AE end date to the AE depression. The patient's medical history did not include any psychiatric disorder. *Reviewer Comment: It seems unlikely if the suicidal ideation reported was related to treatment, that it would have resolved within 1 day.*
- A non-treatment emergent case of completed suicide occurred in Patient (b) (6), a 71-year-old male with a diagnosis of melanoma enrolled on CLGX818X2109 and receiving COMBO 450 therapy. Per the ADSL dataset, the patient was taken off study 30 days after initiating treatment due to progressive disease. He committed suicide 31 days after coming off therapy. There were no reports of depression while on therapy. *Reviewer Comment: While this event just misses being defined as treatment emergent, the patient's progressive disease and discontinuation from therapy provides a plausible inciting event for his suicide.*

Table 58 summarizes for COLUMBUS Part 1 and the pooled datasets (monotherapy and Combo ≥ 400) the incidence of patient past medical history (prior to enrollment) of psychiatric

BRAFTOVI™ (encorafenib)

disorders and depression as well as the calculated incidence of psychiatric TEAEs at the SOC level (Psychiatric Disorder) and two reviewer generated composite terms for depression and suicidal ideation and/or attempt. As seen in the table, a history of psychiatric disorder was common in all populations with patients in the encorafenib monotherapy arm of COLUMBUS Part 1 having a higher incidence. The incidence of a history of depression was similar across populations. In COLUMBUS Part 1, the incidence of depression based on a reviewer defined pool of PTs in the Combo 450 arm was similar to that observed in the encorafenib monotherapy arm while slightly higher than that observed in the vemurafenib arm. Across all arms and in the pooled populations, the incidence of depression on therapy is similar or better than the incidence of a past medical history of depression.

A total of 2 patients in the Combo 450 arm had Grade 3-4 depression. These events were the AEs related to suicide detailed above. There were no additional reports of Grade 3-4 treatment emergent depression or reports involving suicide or suicidal ideation in any population. The largest pool for combination therapy is the Combo $\geq$ 400 set which consists of 433 patients. In this population, the overall incidence of depression is 3.2 and the overall incidence of grade 3-4 depression as well as AEs associated with suicide is 0.005%.

In summary, while depression was a fairly common TEAE in COLUMBUS Part 1, as it is in cancer patients in general, it was rarely greater than Grade 2, and the incidence was not greater than the percentage of patients with a history of depression prior to enrollment. The most concerning reports are those related to suicide. A small number of suicides is not uncommon in large cancer clinical trials, even in patients without a history of depression. Overall, there were three reports of suicide or suicidality in the ISS database. One was not treatment emergent and is more adequately explained as related to progressive disease rather than study drugs. One case lasted for only 1 day, being replaced in the setting of continued therapy by Grade 2 depression without mention of suicidality. The third case of completed suicide by a patient with no history of depression while on therapy may be related to study treatment; however, on the basis of this single event, there is insufficient evidence to suggest that either encorafenib or binimetinib may pose a risk of life-threatening depression.

Table 58: Incidence of Past Medical History of Psychiatric Disorders and Treatment Emergent Psychiatric Disorders and Depression: COLUMBUS Part 1 and Pooled Datasets

	COLUMBUS Part 1			Pooled Data Sets		
	Combo 450 N=192	Enc 300 N=192	Vem N=186	Combo $\geq$ 400 N=433	Bini 45 mg BID N=427	Enc 300 N=217
H/O psychiatric disorder n(%)	31 (16.1)	51 (26.6)	33 (17.7)	103 (23.8)	75 (17.6)	56 (25.8)
H/O depression n(%)	12 (6.3)	13 (6.8)	15 (8.1)	36 (8.3)	32 (7.5)	16 (7.4)
TEAE Psychiatric disorder						
All Grade n (%)	42 (21.9)	64 (33.3)	31 (16.7)	76 (17.6)	45 (10.5)	78 (35.9)
Grade 3-4 n (%)	3 (1.6)	6 (3.1)	0	7 (1.6)	3 (0.7)	8 (3.7)
TEAE Depression ¹						
All Grade n (%)	10 (5.2)	12 (6.3)	4 (2.1)	14 (3.2)	9 (2.1)	12 (5.5)
Grade 3-4 n (%)	2 (1.0)	0	0	2 (0.005)	0	0
TEAE Suicidal ²	2 (1.0)	0	0	2 (0.005)	0	0

BRAFTOVI™ (encorafenib)

Source: Reviewer generated from ISS Table 1.4.2 (Relevant Medical Histories) and ISS:ADAE (submitted by Applicant)

¹ Reviewer generated composite term comprising the PTs: completed suicide, depressed mood, depression, depression suicidal, persistent depressive disorder.

² Reviewer generated composite term comprising the PTs: completed suicide, depression suicidal.

Serious Adverse Events

Table 59 summarizes SAEs for COLUMBUS Part 1. The proportion of patients experiencing at least one SAE was similar across all arms in COLUMBUS Part 1, with slightly higher incidence of any SAE, non-fatal SAE, fatal SAE, or Grade 3-4 SAE observed in the vemurafenib arm.

Table 59: Serious Treatment Emergent Adverse Events: COLUMBUS Part 1 and Pooled Combination Dataset

	COLUMBUS Part 1			Combo ≥ 400 Pool N=433 n (%)
	Combo 450 N= 192 n (%)	Enc 300 N= 192 n (%)	Vem N=186 n (%)	
Any SAE	66 (34.3)	65 (33.9)	69 (37.1)	158 (36.5)
Non-Fatal	60 (31.3)	58 (30.2)	66 (35.5)	147 (33.9)
Fatal ¹	9 (4.7)	6 (3.1)	10 (5.4)	16 (3.7)
Grade 3-4 ²	57 (29.7)	54 (28.1)	60 (32.3)	142 (32.8)

Source: generated from SDTM.AE, STDM.DM (COLUMBUS Part 1 cutoff 9 May 2016) and ISS_ADADR (Combo ≥400 Pool)

¹ Fatal SAEs are defined as those that resulted in death (AEDTH=Y) since Grade 5 was not to be used in COLUMBUS.

² May include SAEs that resulted in death

For COLUMBUS Part 1, there were 31 TEAEs with a fatal outcome reported in 25 patients (11 AEs in 9 patients in the Combo 450 arm, 11 AEs in 10 patients in the encorafenib monotherapy arm, and 9 AEs in 6 patients in the vemurafenib arm). Table 60 summarizes TEAEs with an outcome of death that occurred within 30 days of receipt of study treatment and prior to cutoff date. Most notable is that 3 patients on the Combo 450 arm and 2 patients on the encorafenib monotherapy arm died as a result of cerebral hemorrhage, while no patients in the vemurafenib arm died as a result of cerebral hemorrhage. The event of cerebral hemorrhage was associated with brain metastases. While the difference may be the result of small numbers, it may also represent a greater risk of cerebral hemorrhage associated with encorafenib.

In the Combo ≥ 400 pool, there were 19 TEAEs with fatal outcome reported in 16 patients. Fatal events occurring in patients not included in Table 60 included myocardial infarction (1 patient), brain edema (1 patient), sepsis (1 patient), rectal hemorrhage (1 patient), epileptic seizure and aphagia (1 patient).

Table 60: Fatal Treatment Emergent Serious Adverse Events

	COLUMBUS Part 1		
	Combo 450 N=192 n (%)	Enc 300 N=192 n (%)	Vem N=186 n (%)
Patients with any AE with fatal outcome ¹	9 (4.6)	10 (5.2)	6 (3.1)
Cardiac disorders			
Acute myocardial infarction	0	1 (0.5)	0
Gastrointestinal disorders			
Abdominal pain upper	0	0	1 (0.5)
Ascites	0	0	1 (0.5)
Gastric ulcer hemorrhage	1 (0.5)	0	0
General disorders and administration site conditions			
Death	2 (1.0)	1 (0.5)	0
General physical health deterioration	1 (0.5)	0	2 (1.1)
Multi organ dysfunction syndrome	1 (0.5)	0	0
Non-cardiac chest pain	0	1 (0.5)	0
Metabolism and nutrition disorders			
Dehydration	0	0	1 (0.5)
Neoplasms benign, malignant and unspecified			
Metastases to central nervous system	0	3 (1.6)	0
Metastases to meninges	1 (0.5)	1 (0.5)	0
Nervous system disorders			
Brain stem syndrome	0	1 (0.5)	0
Cerebral hemorrhage	3 (1.6)	2 (1.0)	0
Coma	1 (0.5)	0	0
Hemiparesis	0	1 (0.5)	0
Nervous system disorder	0	0	1 (0.5)
Psychiatric disorders			
Suicide	1 (0.5)	0	0
Renal and urinary disorders			
Renal failure	0	0	1 (0.5)
Respiratory, thoracic, and mediastinal disorders			
Dyspnea	0	0	1 (0.5)
Pulmonary embolism	0	0	1 (0.5)

Source: Reviewer generated table using COLUMBUS Part 1 ADAE (cutoff 9 May 2016, submitted Applicant)

¹Based on reported outcome (AEDTH flag) and not AE toxicity grading

Table 61 shows the frequency of SAEs by PT (occurring in at least 2 patients ($\geq 1\%$) in the Combo 450 arm). Only the following terms occurred in more than 2% of patients in the Combo 450 arm: pyrexia (3.1%), anemia (2.1%), and abdominal pain (2.1%).

At the MedDRA higher level term (HLT) groupings, only the following terms occurred in more than 2% of patients in the Combo 450 arm: gastrointestinal disorders (3.1%), febrile disorders

BRAFTOVI™ (encorafenib)

(3.1), renal failure and impairment (2.6%), general signs and symptoms NEC (2.1%), nausea and vomiting symptoms (2.1%), and anemias NEC (2.1%).

At the MedDRA level of higher level group term (HLGT) only the following terms occurred in more than 2% of patients in the Combo 450 arm: infections – pathogen unspecified (6.3%), general system disorder NEC (4.7%), gastrointestinal signs and symptoms (4.7%), Neurological disorders NEC (3.1%), body temperature conditions (3.1%), renal disorders - excl nephropathies (2.6%), bacterial infectious disorders (2.6%), central nervous system vascular disorders (2.6%), and anemias nonhemolytic and marrow depression (2.1%).

The incidence of SAEs by the MedDRA Grouping SOC is shown in Table 62. At this level, only the following terms occurred in more than 5% of patients in the Combo 450 arm: gastrointestinal disorders (9.4%), infections and infestations (8.9%), general disorders and administration site conditions (8.3%) and nervous system disorders (7.3). For these terms, the incidence is higher in the Combo 450 arm than in the vemurafenib arm. Drilling down in the SOC nervous system disorders, the PTs occurring most often in the Combo 450 arm (≥ 2 patients) were: cerebral hemorrhage (3), balance disorder (2), dizziness (2), and transient ischemic attack (2). As noted previously, cerebral hemorrhage occurred in a slightly higher proportion of patients in the Combo 450 arm (1.5%) than in the vemurafenib arm (0.5%). No patients in the vemurafenib experienced balanced disorder or dizziness or transient ischemic attack.

Analysis of the Combo ≥ 400 pooled dataset did not identify any new SAEs of interest. At the PT level, the following SAEs occurred in $\geq 1\%$ of patients: vomiting (3.9%), nausea (3.5%), pyrexia (3.5%), abdominal pain (1.8%), anemia (1.8%), general physical health deterioration (1.8%), pneumonia, (1.6%), and diarrhea (1.4%). At the HLT level, the following groups occurred in $\geq 2\%$ of patients: nausea and vomiting symptoms (4.8%), febrile disorders (3.5%), gastrointestinal and abdominal pains (2.3%), and general signs and symptoms NEC (2.1%). At the HLGT level, the following groups occurred in $\geq 2\%$ of patients: gastrointestinal signs and symptoms (6.7%), infections – pathogen unspecified (5.3%), general system disorders NEC (4.6%), body temperature conditions (3.5%), and bacterial infectious disorders (2.1%). Incidence at the SOC level is included in Table 62. The incidence between the Combo 450 arm in the COLUMBUS trial and the pooled Combo ≥ 400 dataset are remarkably similar for both all grades and Grade 3-4 events at the SOC level.

Table 61: SAEs Occurring in at Least 2 patients (≥ 1%) in the Combo 450 Arm: COLUMBUS Part 1

Preferred Term	COLUMBUS Part 1		
	Combo 450 N=192 n (%)	Enc 300 N=192 n (%)	Vem N=186 n (%)
Pyrexia	6 (3.1)	3 (1.6)	2 (1.1)
Anemia	4 (2.1)	1 (0.5)	2 (1.1)
Abdominal pain	4 (2.1)	2 (1.0)	1 (0.5)
General physical health deterioration	3 (1.6)	2 (1.0)	6 (3.2)
Pulmonary embolism	3 (1.6)	0	2 (1.1)
Vomiting	3 (1.6)	6 (3.1)	2 (1.1)
Acute kidney injury	3 (1.6)	1 (0.5)	1 (0.5)
Cerebral hemorrhage	3 (1.6)	2 (1.0)	1 (0.5)
Pneumonia	3 (1.6)	0	0
Pleural effusion	2 (1.0)	1 (0.5)	2 (1.1)
Abdominal pain upper	2 (1.0)	2 (1.0)	1 (0.5)
Death	2 (1.0)	1 (0.5)	0
Erysipelas	2 (1.0)	1 (0.5)	0
Nausea	2 (1.0)	6 (3.1)	0
Non-cardiac chest pain	2 (1.0)	2 (1.0)	0
Balance disorder	2 (1.0)	0	0
Cellulitis	2 (1.0)	0	0
Colitis	2 (1.0)	0	0
Dizziness	2 (1.0)	0	0
Myocardial infarction	2 (1.0)	0	0
Transient ischemic attack	2 (1.0)	0	0
Urinary tract infection	2 (1.0)	0	0

Source: Reviewer generated table using COLUMBUS Part 1 ADAE (cutoff 9 May 2016, submitted Applicant)

Table 62: Incidence of Serious Adverse Event All Grades and Grades 3-4 by SOC: COLUMBUS Part 1 and Combo ≥400 Pool

SOC	COLUMBUS Part 1						Combo ≥ 400 Pool N=433 n (%)	
	Combo 450 N=192 n (%)		Enc 300 N=192 n (%)		Vem N=186 n (%)		All Grades	Grade 3-4
	All Grades	Grade 3-4	All Grades	Grade 3-4	All Grades	Grade 3-4	All Grades	Grade 3-4
Gastrointestinal disorders	18 (9.4)	15 (7.8)	15 (7.8)	13 (6.8)	10 (5.4)	9 (4.8)	52 (12.0)	43 (9.9)
Infections and infestations	17 (8.9)	16 (8.3)	5 (2.6)	4 (2.1)	9 (4.8)	7 (3.8)	32 (7.4)	28 (6.5)
General disorders and administration site conditions	16 (8.3)	14 (7.3)	13 (6.8)	12 (6.3)	11 (5.9)	8 (4.3)	34 (7.9)	27 (6.2)
Nervous system disorders	14 (7.3)	12 (6.3)	13 (6.8)	8 (4.2)	12 (6.5)	9 (4.8)	27 (6.2)	24 (5.5)
Respiratory, thoracic and mediastinal disorders	8 (4.2)	7 (3.6)	5 (2.6)	5 (2.6)	9 (4.8)	7 (3.8)	15 (3.5)	12 (2.8)
Renal and urinary disorders	6 (3.1)	4 (2.1)	3 (1.6)	3 (1.6)	6 (3.2)	5 (2.7)	10 (2.3)	8 (1.8)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	5 (2.6)	5 (2.6)	11 (5.7)	9 (4.7)	12 (6.5)	11 (5.9)	11 (2.5)	11 (2.5)
Blood and lymphatic system disorders	4 (2.1)	4 (2.1)	1 (0.5)	1 (0.5)	3 (1.6)	2 (1.1)	10 (2.3)	9 (2.1)
Cardiac disorders	4 (2.1)	2 (1.0)	4 (2.1)	2 (1.0)	4 (2.2)	3 (1.6)	8 (1.8)	6 (1.4)
Musculoskeletal and connective tissue disorders	4 (2.1)	3 (1.6)	13 (6.8)	11 (5.7)	8 (4.3)	6 (3.2)	10 (2.3)	8 (1.8)
Psychiatric disorders	3 (1.6)	3 (1.6)	0	0	1 (0.5)	0	5 (1.2)	5 (1.2)
Vascular disorders	3 (1.6)	1 (0.5)	0	0	0	0	5 (1.2)	3 (0.7)
Eye disorders	2 (1.0)	1 (0.5)	2 (1.0)	1 (0.5)	1 (0.5)	0	6 (1.4)	5 (1.2)
Injury, poisoning and procedural complications	2 (1.0)	2 (1.0)	2 (1.0)	2 (1.0)	2 (1.1)	2 (1.1)	6 (1.4)	4 (0.9)
Metabolism and nutrition disorders	2 (1.0)	2 (1.0)	4 (2.1)	4 (2.1)	5 (2.7)	4 (2.2)	10 (2.3)	9 (2.1)
Skin and subcutaneous tissue disorders	2 (1.0)	1 (0.5)	2 (1.0)	1 (0.5)	9 (4.8)	8 (4.3)	4 (0.9)	3 (0.7)
Hepatobiliary disorders	1 (0.5)	1 (0.5)	1 (0.5)	1 (0.5)	1 (0.5)	1 (0.5)	2 (0.5)	2 (0.5)
Investigations	1 (0.5)	0	3 (1.6)	2 (1.0)	5 (2.7)	2 (1.1)	8 (1.8)	7 (1.6)
Congenital, familial and genetic disorders	0	0	1 (0.5)	1 (0.5)	0	0	0	0
Immune system disorders	0	0	1 (0.5)	1 (0.5)	2 (1.1)	1 (0.5)	0	0
Product issues	0	0	1 (0.5)	1 (0.5)	0	0	0	0
Reproductive system and breast disorders	0	0	0	0	1 (0.5)	1 (0.5)	0	0

Source: Reviewer generated table using COLUMBUS Part 1 SDTM.AE (cutoff 9 May 2016, submitted Applicant) and ISS_ADAE (submitted by Applicant)

Dropouts and/or Discontinuations Due to Adverse Effects

With sponsor’s approval, patients were allowed to continue on study drug beyond locally determined disease progression confirmed by the BIRC. Of the 50 total on-treatment deaths, 8 patients were treated $\geq$ 30 days beyond progression per the BIRC (3 patients on the Combo 450 arm, 2 patients on the encorafenib monotherapy arm, 3 patients on the vemurafenib arm).

Table 63 summarizes study discontinuations for COLUMBUS Part 1 and the Combo $\geq$ 400 Pooled dataset. Based on information provided in the disposition dataset, as of Part 1 data cutoff, treatment was ongoing for 24.7% of patients across arms. A higher percentage of patients in the Combo 450 arm were ongoing (35.4%) compared to patients in the encorafenib monotherapy (24.0%) and vemurafenib (14.5%) arms. The most common reason for discontinuation from study treatment in all arms was progressive disease. The percentage of discontinuation due to progressive disease was higher in the vemurafenib arm compared to either of the other two arms in Part 1. A smaller percentage of patients discontinued treatment due to adverse events in the Combo 450 arm than in either of the two other arms in Part 1.

Further examination of discontinuations due to “Physician Decision” and “Subject/Guardian Decision” identified 23 additional discontinuations due to disease progression (7 in the Combo 450 arm, 10 in the encorafenib arm, 6 in the vemurafenib arm) and 13 additional discontinuations due to toxicities (2 in the Combo 450 arm, 8 in the encorafenib arm, and 3 in the vemurafenib arm). These additional cases are grouped under “Reviewer’s grouped reason for discontinuation” with progressive disease or toxicity, also shown in Table 63 for COLUMBUS Part 1 only. This information did not change the overall conclusion that a smaller percentage of patients in the Combo 450 arm discontinued treatment due to progressive disease or toxicity. The larger pooled dataset shows a pattern of discontinuations similar to that observed in the Combo 450 arm. Disposition in the Combo $\geq$ 400 pooled dataset and primary reason for discontinuation were similar to what was observed in the COLUMBUS Combo 450 arm.

Table 63: Discontinuations prior to cutoff by Investigator and Reviewer Assessed Reason: COLUMBUS Part 1 and Combo $\geq$ 400 Pool

	COLUMBUS Part 1			Combo $\geq$ 400 Pool N=433 n (%)
	Combo 450 N= 192 n (%)	Enc 300 N= 192 n (%)	Vem N=186 n (%)	
Treatment Ongoing at Cutoff date	68 (35.4)	46 (24.0)	27 (14.5)	149 (34.4)
Treatment Discontinued	124 (64.6)	146 (76.0)	159 (85.5)	284 (65.6)
Primary reason for discontinuation				
Adverse Event	16 (8.3)	24 (12.5)	26 (14)	31 (7.2)
Completed	0	0	0	4 (0.9)
Death	7 (3.6)	1 (0.5)	4 (2.2)	21 (4.8)
Lost to Follow-Up	1 (0.5)	1 (0.5)	0	1 (0.2)
Physician Decision	8 (4.2)	19 (9.9)	13 (7)	16 (3.7)
Progressive Disease	83 (43.2)	87 (45.3)	101 (54.3)	194 (44.8)

Multi-Disciplinary Review and Evaluation NDA 210496
 BRAFTOVI™ (encorafenib)

	COLUMBUS Part 1			Combo ≥ 400 Pool N=433 n (%)
	Combo 450 N= 192 n (%)	Enc 300 N= 192 n (%)	Vem N=186 n (%)	
Protocol Deviation	2 (1)	1 (0.5)	0	3 (0.7)
Withdrawn by Subject/Guardian	7 (3.6)	13 (6.8)	15 (8.1)	14 (3.2)
Reviewer Grouped Reason for Discontinuation				
Death	7 (3.6)	1 (0.5)	4 (2.2)	
Progressive Disease	90 (46.9)	98 (51.0)	107 (57.5)	
Toxicity	18 (9.4)	32 (16.7)	29 (15.6)	
Pursue other treatments	0	4 (2)	5 (2.7)	

Source: Reviewer generated table using COLUMBUS Part 1 SDTM.DS (cutoff 9 May 2016, submitted Applicant) and Combo ≥400 data from ISS Table 1-17

Based on the reported adverse event data, across all arms in COLUMBUS Part 1, 14% of patients (82/570) had an adverse event that led to permanent discontinuation of study treatment. The percentage of patients in the Combo 450 arm (12.5%) was lower than that observed in the encorafenib monotherapy arm (14.0%) and the vemurafenib arm (16.1%). The following AEs, by PT, led to discontinuation in at least 2 patients (≥1%) on the Combo 450 arm: alanine aminotransferase increased (2.6%), aspartate aminotransferase increased (2.6%), blood creatinine increased (1.0%), gamma-glutamyl transferase increased (1.0%), and headache (1.0%). These AEs occurred in a total of 8 patients. The AEs leading to discontinuation in ≥1% of patients in the Combo 450 arm were alanine aminotransferase increased (1.6%), aspartate aminotransferase increased (1.6%), blood creatinine increased (1.2%).

Table 64 summarizes at the SOC level TEAEs that led to discontinuation in at least 2 patients in the Combo 450 arm. Analysis at the SOC level of AEs leading to discontinuation shows results similar to those observed in the Combo 450 arm of COLUMBUS. No SOC group not shown in the table occurred in ≥ 1% of patients in the Combo ≥ 400 pool.

Table 64: TEAEs at the SOC Level Leading to Discontinuation ≥ 1% of patients in Combo 450 arm: COLUMBUS Part 1 and Combo ≥400 Pool

AESOC	Combo 450 N=192 n (%)	Enc 300 N=192 n (%)	Vem N=186 n (%)	Combo ≥ 400 Pool N=433 n (%)
Investigations	7 (3.6)	4 (2.1)	5 (2.7)	15 (3.5)
General disorders and administration site conditions	4 (2.1)	1 (0.5)	2 (1.1)	6 (1.4)
Gastrointestinal disorders	3 (1.6)	5 (2.6)	9 (4.8)	7 (1.6)
Neoplasms benign, malignant and unspecified	3 (1.6)	4 (2.1)	1 (0.5)	3 (0.7)
Nervous system disorders	3 (1.6)	4 (2.1)	3 (1.6)	6 (1.4)
Infections and infestations	2 (1.0)	0	1 (0.5)	2 (0.5)

Source: Reviewer generated table using COLUMBUS Part 1 SDTM.AE (cutoff 9 May 2016, submitted Applicant) and ISS_ADADR (Combo ≥400 pool)

Dose Interruptions and Reductions

Table 65 summarizes the frequency of adverse events leading to dose interruptions and reductions for COLUMBUS Part 1 and the Combo ≥ 400 pooled dataset. Across COLUMBUS Part 1 arms, 59.8% of patients had an adverse event that led to temporary interruption and/or dose reduction of study treatment. The percentage of patients in whom an AE led to dose interruption and/or reduction was lower in the Combo 450 arm (48%) than in the encorafenib monotherapy (70%) and the vemurafenib (61%) arms. This was also true for AEs leading to dose interruptions and to dose reductions when considered separately.

The specific AEs at the PT level that led to dose interruption and/or reduction in at least $\geq 2\%$ of patients in the Combo 450 arm are summarized in Table 66. The most common PT leading to dose interruption and/or reduction in at least 5% of patients are: nausea (8%), vomiting (7%) and ejection fraction decreased (5%). The proportion of patients with nausea leading to dose interruption and/or reduction was similar across arms in Part 1; however, the proportion of patients with vomiting leading to dose interruption and/or reduction was higher in the Combo 450 arm and the encorafenib monotherapy arm when compared to the vemurafenib arm. The AE of ejection fraction decreased leading to dose interruption and/or reduction was only observed in the Combo 450 arm.

In the Combo ≥ 400 pool, the most common AEs leading to dose interruption/reduction in $\geq 2\%$ of patients were ALT increased (5.3%), AST increased (4.4%), nausea (4.4%), lipase increased (3.2%), diarrhea (2.8%), vomiting (2.8%), GGT increased (2.5%), ejection fraction decreased (2.3%), pyrexia (2.3%), amylase increased (2.1%), and blood creatine phosphokinase increased (2.1%). These AEs are also seen in the list of AEs that lead to interruption/reduction in the Combo 450 arm of COLUMBUS. No new AEs that lead to dose reduction/interruption in $\geq 2\%$ of patients is identified in the Combo ≥ 400 pool.

Table 65: Frequency of Adverse Events leading to Dose interruptions/reductions: COLUMBUS Part 1

	COLUMBUS Part 1			Combo ≥ 400 Pool N=433 n (%) ¹
	C_450 N=192 n (%)	Enc 300 N=192 n (%)	Vem N=186 n (%)	
AE leading to dose interrupted	88 (45.8)	122 (63.5)	98 (53.7)	
Grade 3-4	62 (32.3)	77 (40.1)	64 (34.4)	
AE leading to dose reduction	22 (11.5)	52 (27.0)	42 (22.6)	
Grade 3-4	4 (2.1)	17 (8.9)	10 (5.4)	
AE leading to dose interruption and/or reduction	92 (47.9)	135 (70.3)	114 (61.3)	212 (49.0)
Grade 3-4	63 (32.8)	85 (44.3)	71 (38.2)	141 (32.6)

Source: Reviewer generated table using COLUMBUS Part 1 SDTM.AE (cutoff 9 May 2016, submitted Applicant) and ISS_ADADR (Combo ≥ 400 pool)

¹ Because of how some studies were coded, action taken in response to an AE, i.e., interruptions and reductions cannot be tabulated separately

Table 66: TEAEs by PT leading to dose interruption and/or dose reduction in ≥ 2% of patients in Combo 450 arm: COLUMBUS Part 1

PT	COLUMBUS Part 1		
	Combo 450 N=192 n (%)	Enc 300 N=192 n (%)	Vem N=186 n (%)
Nausea	16 (8.3)	17 (8.9)	14 (7.5)
Vomiting	13 (6.8)	10 (5.2)	4 (2.2)
Ejection fraction decreased	10 (5.2)	0	0
GGT increased	9 (4.7)	4 (2.1)	2 (1.1)
Pyrexia	8 (4.2)	5 (2.6)	14 (7.5)
ALT increased	7 (3.6)	4 (2.1)	4 (2.2)
Diarrhea	7 (3.6)	4 (2.1)	9 (4.8)
AST increased	6 (3.1)	2 (1.0)	3 (1.6)
Blood CPK	6 (3.1)	0	1(0.5)
Abdominal pain	5 (2.6)	3 (1.6)	2 (1.1)
Anemia	4 (2.1)	2 (1.0)	2 (1.1)
Arthralgia	4 (2.1)	24 (12.5)	16 (8.6)
Blood ALP	4 (2.1)	1 (0.5)	1 (0.5)
Blood creatinine increased	4 (2.1)	0	4(2.2)
Dizziness	4 (2.1)	0	0
Fatigue	4 (2.1)	4 (2.1)	7 (3.8)
Hyperkeratosis	4 (2.1)	10 (5.2)	2 (1.1)
Hypertension	4 (2.1)	1 (0.5)	2 (1.1)
Retinal detachment	4 (2.1)	1 (0.5)	1(0.5)

Source: Reviewer generated table using COLUMBUS Part 1 SDTM.AE (cutoff 9 May 2016, submitted by Applicant)

Abbreviations: ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; CPK = creatine phosphokinase; GGT = gamma-glutamyl transferase.

Significant Adverse Events

The ICH E3 guidance recommends that marked laboratory abnormalities not meeting the definition of SAEs also be considered significant AEs. Laboratory findings are discussed in a separate section below. In addition, the ICH E3 guidance considers other potentially important abnormalities, such as severe AEs (i.e., ≥ Grade 3 by CTCAE) that do not meet the definition of a serious AE as potentially significant.

Table 67 shows the incidence of Grade 3-4 TEAEs by PT occurring in ≥ 1 % of patient in the Combo 450 arm for COLUMBUS Part 1 arms. PTs which are not previously identified as SAEs occurring in at least 1% of patients in the Combo 450 arm (Table 61) are noted in bold. The only two AEs at the PT level that occur at Grade 3-4 severity in ≥ 1% of patients in the Combo ≥400 pool that does not also occur in ≥ 1% of patients in the Combo 450 arm of COLUMBUS are

hyponatremia which occurs in 1.6% of patients and arthralgia which occurred in 1.2% of patients in the Combo > 400 pool.

The incidence of Grade 3-4 TEAEs by SOC occurring in at least 2 patients (1%) in the Combo 450 arm, are shown in Table 68 for COLUMBUS Part 1. Analysis of the incidence of Grade 3-4 TEAEs at the SOC level in the Combo ≥400 pooled did not identify any SOC group occurring in ≥1% of patients not identified in the Combo 450 arm of COLUMBUS (Table 68).

Table 67: Incidence GRADE 3 and 4 TEAEs occurring in ≥ 1% of Patients in Combo 450 arm: COLUMBUS Part 1

PT	COLUMBUS Part 1		
	Combo 450 N=192 n (%)	Enc 300 N=192 n (%)	Vem N=186 n (%)
GGT increased	18 (9.4)	9 (4.7)	6 (3.2)
Blood CPK increased	13 (6.8)	0	0
Hypertension	11 (5.8)	6 (3.1)	6 (3.2)
ALT	10 (5.2)	2 (1)	3 (1.6)
Anemia	8 (4.2)	5 (2.6)	4 (2.2)
Pyrexia	7 (3.6)	2 (1.0)	0
Abdominal pain	5 (2.6)	4 (2.1)	1 (0.5)
Diarrhea	5 (2.6)	3 (1.6)	4 (2.2)
AST increased	4 (2.1)	1 (0.5)	3 (1.6)
Fatigue	4 (2.1)	1 (0.5)	4 (2.2)
Pleural effusion	4 (2.1)	2 (1.0)	1 (0.5)
Hyperglycemia	4 (2.1)	4 (2.1)	0
Abdominal pain upper	2 (1.0)	2 (1.0)	1 (0.5)
Acute kidney injury	2 (1.0)	1 (0.5)	1 (0.5)
Amylase increased	3 (1.6)	0	2 (1.1)
Asthenia	3 (1.6)	5 (2.6)	8 (4.3)
Cerebral hemorrhage	3 (1.6)	2 (1.0)	1 (0.5)
Dizziness	3 (1.6)	0	0
General physical health deterioration	3 (1.6)	3 (1.6)	8 (4.3)
Headache	3 (1.6)	6 (3.1)	1 (0.5)
Lipase increased	3 (1.6)	2 (1.0)	2 (1.1)
Nausea	3 (1.6)	8 (4.2)	3 (1.6)
Pneumonia	3 (1.6)	1 (0.5)	0
Vomiting	3 (1.6)	9 (4.7)	2 (1.1)
Balance disorder	2 (1.0)	0	0
Blood creatinine increased	2 (1.0)	0	1 (0.5)
Cellulitis	2 (1.0)	0	0
Cholestasis	2 (1.0)	1 (0.5)	0
Chorioretinopathy	2 (1.0)	0	0

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

PT	COLUMBUS Part 1		
	Combo 450 N=192 n (%)	Enc 300 N=192 n (%)	Vem N=186 n (%)
Colitis	2 (1.0)	0	0
Death	2 (1.0)	1 (0.5)	0
Diverticulitis	2 (1.0)	0	0
Ejection fraction decreased	2 (1.0)	2 (1.0)	0
Erysipelas	2 (1.0)	1 (0.5)	0
Gastroenteritis	2 (1.0)	1 (0.5)	1 (0.5)
Hyperkalemia	2 (1.0)	1 (0.5)	0
Hypophosphatasemia	2 (1.0)	0	2 (1.1)
Neutropenia	2 (1.0)	1 (0.5)	1 (0.5)
Non-cardiac chest pain	2 (1.0)	3 (1.6)	1 (0.5)
Edema peripheral	2 (1.0)	0	1 (0.5)
Pain in extremity	2 (1.0)	2 (1.0)	2 (1.1)
Pulmonary embolism	2 (1.0)	1 (0.5)	1 (0.5)
Rash	2 (1.0)	4 (2.1)	6 (3.2)
Renal failure	2 (1.0)	2 (1.0)	1 (0.5)
Urinary tract infection	2 (1.0)	0	0
Weight increased	2 (1.0)	0	0

Source: Reviewer generated table using COLUMBUS Part 1 SDTM.AE (cutoff 9 May 2016, submitted by Applicant)

Abbreviations: ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; CPK = creatine phosphokinase; GGT = gamma-glutamyl transferase.

Table 68: INCIDENCE OF GRADE 3 and 4 TEAEs by SOC occurring in >= 1% of Patients in Combo 450 arm: COLUMBUS Part 1

SOC	COLUMBUS Part 1		
	Combo 450 N=192 n (%)	Enc 300 N=192 n (%)	Vem N=1862 n (%)
Investigations	47 (24.5)	17 (8.9)	14 (7.5)
General disorders and administration site conditions	24 (12.5)	21 (10.9)	24 (13.0)
Gastrointestinal disorders	22 (11.5)	25 (13.0)	19 (10.2)
Infections and infestations	19 (10.0)	6 (3.1)	9 (4.8)
Nervous system disorders	18 (9.4)	18 (9.4)	14 (7.5)
Vascular disorders	12 (6.3)	7 (3.7)	6 (3.2)
Blood and lymphatic system disorders	11 (5.7)	9 (4.7)	9 (4.8)
Metabolism and nutrition disorders	10 (5.2)	14 (7.3)	10 (5.4)
Respiratory, thoracic and mediastinal disorders	8 (4.2)	10 (5.2)	8 (4.3)
Skin and subcutaneous tissue disorders	6 (3.1)	43 (22.4)	38 (20.4)

SOC	COLUMBUS Part 1		
	Combo 450 N=192 n (%)	Enc 300 N=192 n (%)	Vem N=1862 n (%)
Eye disorders	5 (2.6)	1 (0.5)	1 (0.5)
Musculoskeletal and connective tissue disorders	5 (2.6)	43 (22.4)	19 (10.2)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	5 (2.6)	11 (5.7)	22 (11.8)
Renal and urinary disorders	5 (2.6)	4 (2.1)	6 (3.2)
Hepatobiliary disorders	4 (2.1)	1 (0.5)	2 (1.1)
Psychiatric disorders	3 (1.6)	6 (3.1)	0
Cardiac disorders	2 (1.0)	4 (2.1)	5 (2.7)
Injury, poisoning and procedural complications	2 (1.0)	3 (1.6)	4 (2.2)

Source: Reviewer generated table using COLUMBUS Part 1 SDTM.AE (cutoff 9 May 2016, submitted by Applicant)

Treatment Emergent Adverse Events

The most commonly occurring TEAEs for the Combo 450 arm ($\geq 10\%$ all grades, $\geq 2\%$ Grade 3-4) by PT are shown in Table 69. The following common TEAEs were not identified in previous analyses of serious and significant AEs: arthralgia, headache, constipation, asthenia, vision blurred, rash, hypertension, ALT increased, and edema peripheral. These PTs in general represent common but rarely serious or significant adverse events.

Comparing the frequency of TEAEs in the Combo ≥ 400 pool dataset with the frequency in the Combo 450 arm reveals identified the single AE retinopathy as occurring in $\geq 10\%$ of patients in the Combo ≥ 400 pool but $< 10\%$ in the Combo 450 arm and where the difference in frequency between the two datasets is $\geq 5\%$. The frequency of retinopathy in the Combo 450 arm is 2.1% and in the Combo ≥ 400 pool is 10.6%. This represents a common event that is likely under-reported in the Combo 450 arm.

Comparing the Grade 3-4 TEAEs in the Combo ≥ 400 pool dataset with the frequency in the Combo 450 arm, two AEs, not previously identified in Table 69 have a frequency $\geq 2\%$ in the Combo ≥ 400 pool but $\leq 2\%$ in the Combo 450 arm: lipase increased and amylase increased. These are more adequately evaluated with laboratory assessments.

TEAEs occurring in $\geq 1\%$ of patients in the Combo ≥ 400 pool but in $\leq 1\%$ of patients in the Combo 450 arm included: detachment of retinal pigment epithelium (RPED) (Combo 450 arm: 0%, Combo ≥ 400 : 2.8%), hypocalcemia (Combo 450 arm: 0%, Combo ≥ 400 pool: 1.8%), hypokalemia (Combo 450 arm: 0.5%, Combo ≥ 400 pool: 1.8%), and electrocardiogram QT prolongation (Combo 450 arm: 0%, Combo ≥ 400 pool: 1.2%). These AEs represent rare but potentially serious events that are only observed in the larger pooled dataset. Hypokalemia, hypocalcemia, and QT prolongation are discussed with laboratory assessments and ECG monitoring later in this section of the review. RPED is a known toxicity associated with MEK inhibitors and is discussed further in Section 8.2.4.

Table 70 presents the incidence of TEAEs at the SOC level for COLUMBUS Part 1. The following SOC terms occur more frequently ($\geq 5\%$ increase) in the Combo 450 arm when compared to the vemurafenib arm (% increase): eye disorders (+21%), investigations (+12%), nervous system disorders (+8%), and psychiatric disorders (+5%). The following SOC terms occurred less frequently ($\geq 5\%$ decrease) in the Combo 450 arm when compared to the vemurafenib arm (% decrease): skin and subcutaneous tissue disorders (-26%), general disorders and administration site conditions (-6%), musculoskeletal and connective tissue disorders (-14%), and neoplasms benign, malignant and unspecified (-21%). These differences most likely represent the effect of adding the MEK inhibitor to a BRAF inhibitor. Analysis of TEAEs at the MedDRA levels Higher Level Term (HLT), Higher Level Group Term (HLGT) did not identify additional any safety signals.

Table 69: TEAE Occurring in $\geq 10\%$ All Grades or $\geq 2\%$ Grade 3-4 in Combo 450 Arm: COLUMBUS Part 1

Preferred Term	COLUMBUS Part 1					
	Combo 450 N=192 n (%)		Enc 300 N=192 n (%)		Vem N=1862 n (%)	
	All Grades	Grade 3-4	All Grades	Grade 3-4	All Grades	Grade 3-4
Nausea	79 (41.2)	3 (1.6)	74 (38.5)	8 (4.2)	63 (33.9)	3 (1.6)
Diarrhea	70 (36.5)	5 (2.6)	26 (13.5)	3 (1.6)	63 (33.9)	4 (2.2)
Vomiting	57 (29.7)	3 (1.6)	52 (27.1)	9 (4.7)	28 (15.1)	2 (1.1)
Fatigue	55 (28.7)	4 (2.1)	48 (25.0)	1 (0.5)	57 (30.7)	4 (2.2)
Arthralgia	49 (25.5)	1 (0.5)	84 (43.8)	18 (9.4)	83 (44.6)	11 (5.9)
Blood CPK	44 (22.9)	13 (6.8)	2 (1.0)	0	4 (2.2)	0
Headache	42 (21.9)	3 (1.6)	52 (27.1)	6 (3.1)	35 (18.8)	1 (0.5)
Constipation	42 (21.9)	0	27 (14.1)	0	12 (6.5)	1 (0.5)
Pyrexia	35 (18.2)	7 (3.7)	29 (15.1)	2 (1.0)	52 (28.0)	0
Asthenia	35 (18.2)	3 (1.6)	37 (19.3)	5 (2.6)	34 (18.3)	8 (4.3)
Abdominal pain	32 (16.7)	5 (2.6)	13 (6.8)	4 (2.1)	12 (6.5)	1 (0.5)
Vision blurred	30 (15.6)	0	4 (2.1)	0	4 (2.2)	0
GGT increased	29 (15.1)	18 (9.4)	21 (10.9)	9 (4.7)	21 (11.3)	6 (3.2)
Anemia	29 (15.1)	8 (4.2)	11 (5.7)	5 (2.6)	14 (7.5)	4 (2.2)
Rash	27 (14.1)	2 (1.0)	41 (21.4)	4 (2.1)	54 (29.0)	6 (3.2)
Hyperkeratosis	27 (14.1)	1 (0.5)	72 (37.5)	7 (3.7)	54 (29.0)	0
Dry skin	27 (14.1)	0	58 (30.2)	0	42 (22.6)	0
Myalgia	26 (13.5)	0	54 (28.1)	19 (9.9)	34 (18.3)	1 (0.5)
Alopecia	26 (13.5)	0	107 (55.7)	0	68 (36.6)	0
Dizziness	24 (12.5)	3 (1.6)	9 (4.7)	0	5 (2.7)	0
Abdominal pain upper	23 (12.0)	2 (1.0)	18 (9.4)	2 (1.0)	17 (9.1)	1 (0.5)
Hypertension	21 (10.9)	11 (5.7)	11 (5.7)	6 (3.1)	21 (11.3)	6 (3.2)
ALT increased	21 (10.9)	10 (5.2)	10 (5.2)	2 (1.0)	14 (7.5)	3 (1.6)
Pain in extremity	21 (10.9)	2 (1.0)	42 (21.9)	2 (1.0)	25 (13.4)	2 (1.1)
Pruritus	21 (10.9)	1 (0.5)	42 (21.9)	1 (0.5)	20 (10.8)	0
Edema peripheral	20 (10.4)	2 (1.0)	15 (7.8)	0	20 (10.8)	1 (0.5)

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

Preferred Term	COLUMBUS Part 1					
	Combo 450 N=192 n (%)		Enc 300 N=192 n (%)		Vem N=1862 n (%)	
	All Grades	Grade 3-4	All Grades	Grade 3-4	All Grades	Grade 3-4
Nasopharyngitis	20 (10.4)	0	11 (5.7)	0	18 (9.7)	0
AST increased	16 (8.3)	4 (2.1)	8 (4.2)	1 (0.5)	15 (8.1)	3 (1.6)
Hyperglycemia	9 (4.7)	4 (2.1)	6 (3.1)	4 (2.1)	0	0
Pleural effusion	4 (2.1)	4 (2.1)	3 (1.6)	2 (1.0)	2 (1.1)	1 (0.5)

Source: Reviewer generated table using COLUMBUS Part 1 SDTM.AE (cutoff 9 May 2016, submitted by Applicant)

Abbreviations: ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; CPK = creatine phosphokinase; GGT = gamma-glutamyl transferase.

Table 70: Incidence of TEAEs at the SOC level: COLUMBUS Part 1

	Combo 450 N=192 n (%)		Enc 300 N=192 n (%)		Vem N=1862 n (%)	
	All Grades	Grade 3-4	All Grades	Grade 3-4	All Grades	Grade 3-4
Gastrointestinal disorders	138 (71.9)	22 (11.5)	130 (67.7)	25 (13.0)	127 (68.3)	19 (10.2)
Skin and subcutaneous tissue disorders	125 (65.1)	6 (3.1)	184 (95.8)	43 (22.4)	170 (91.4)	38 (20.4)
General disorders and administration site conditions	122 (63.5)	24 (12.5)	123 (64.1)	21 (10.9)	130 (69.9)	24 (12.9)
Eye disorders	104 (54.2)	5 (2.6)	53 (27.6)	1 (0.5)	62 (33.3)	1 (0.5)
Investigations	103 (53.7)	47 (24.5)	71 (37.0)	17 (8.9)	77 (41.4)	14 (7.5)
Musculoskeletal and connective tissue disorders	102 (53.1)	5 (2.6)	149 (77.6)	43 (22.4)	125 (67.2)	19 (10.2)
Infections and infestations	97 (50.5)	19 (9.9)	82 (42.7)	6 (3.1)	92 (49.5)	9 (4.8)
Nervous system disorders	95 (49.5)	18 (9.4)	107 (55.7)	18 (9.4)	77 (41.4)	14 (7.5)
Respiratory, thoracic and mediastinal disorders	57 (29.7)	8 (4.2)	52 (27.1)	10 (5.2)	50 (26.9)	8 (4.3)
Metabolism and nutrition disorders	44 (22.9)	10 (5.2)	61 (31.8)	14 (7.3)	49 (26.3)	10 (5.4)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	44 (22.9)	5 (2.6)	72 (37.5)	11 (5.7)	82 (44.1)	22 (11.8)
Psychiatric disorders	42 (21.9)	3 (1.6)	64 (33.3)	6 (3.1)	31 (16.7)	0
Blood and lymphatic system disorders	40 (20.8)	11 (5.7)	20 (10.4)	9 (4.7)	30 (16.1)	9 (4.8)
Vascular disorders	36 (18.8)	12 (6.3)	36 (18.8)	7 (3.7)	36 (19.4)	6 (3.2)
Cardiac disorders	25 (13.0)	2 (1.0)	27 (14.1)	4 (2.1)	28 (15.1)	5 (2.7)
Injury, poisoning and procedural complications	25 (13.0)	2 (1.0)	16 (8.3)	3 (1.6)	28 (15.1)	4 (2.2)
Renal and urinary disorders	25 (13.0)	5 (2.6)	19 (9.9)	4 (2.1)	23 (12.4)	6 (3.2)
Reproductive system and breast disorders	19 (9.9)	0(0.0)	14 (7.3)	0	13 (7.0)	1 (0.5)
Ear and labyrinth disorders	12 (6.3)	0	11 (5.7)	1 (0.5)	8 (4.3)	0
Hepatobiliary disorders	7 (3.7)	4 (2.1)	3 (1.6)	1 (0.5)	9 (4.8)	2 (1.1)

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

Immune system disorders	6 (3.1)	0	12 (6.3)	2 (1.0)	8 (4.3)	1 (0.5)
Congenital, familial and genetic disorders	2 (1.0)	0	5 (2.6)	1 (0.5)	0	0
Endocrine disorders	2 (1.0)	0	4 (2.1)	0	3 (1.6)	0
Product issues	0		1 (0.5)	1 (0.5)	1 (0.5)	0
Social circumstances	0	0	1 (0.5)	0	0	0

Source: Reviewer generated table using COLUMBUS Part 1 SDTM.AE (cutoff 9 May 2016, submitted by Applicant)

Using FDA MAED Software, narrow scope MedDRA SMQs were analyzed to look for potential safety signals not identified through analysis of AEs by MedDRA system organ class, high level term, high level group term, or preferred term. The analysis did not identify any signals not previously identified.

Laboratory Findings

Table 71 summarizes the incidence of treatment emergent laboratory abnormalities occurring in $\geq 10\%$ (all grades) or $\geq 2\%$ (Grades 3-4) of patients in the Combo 450 arm of COLUMBUS Part 1. With the exception of CPK, overall, the laboratory abnormalities were similar among the arms given the expected differences due to chance and the longer exposure received in patients on the Combo 450 arm. In Part 1, patients in the Combo 450 arm experienced a significantly higher incidence of elevated CPK (58%) compared to the encorafenib monotherapy and vemurafenib arms (3% and 3.8% respectively). This is not unexpected with the addition of binimetinib as elevated CPK is a known class effect of MEK inhibitors.

Table 71: Incidence of Treatment-Emergent Laboratory Abnormalities (Changes from Baseline) Occurring in $\geq 10\%$ (All Grades) or $\geq 2\%$ (Grade 3-4) of Patients with Combo 450: COLUMBUS Part 1

Laboratory Test	Combo 450 N=192		Enc 300 N=192		Vem N=186	
	All Grades N (%)	Grade 3-4 ¹ N (%)	All Grades N (%)	Grade 3-4 ² n (%)	All Grades N (%)	Grade 3-4 ³ N (%)
Hematology						
Decreased hemoglobin	70 (36.5)	7 (3.6)	71 (37.0)	3 (1.6)	63 (33.9)	4 (2.2)
Decreased leukocytes	25 (13.0)	0	7 (3.6)	0	18 (9.7)	1 (0.5)
Decreased lymphocytes	25 (13.0)	4 (2.1)	29 (15.1)	2 (1.0)	56 (30.1)	12 (6.5)
Decreased neutrophils	25 (13.0)	6 (3.1)	9 (4.7)	2 (1.0)	9 (4.8)	1 (0.5)
Chemistry						
Increased ALT	56 (29.2)	11 (5.7)	29 (15.1)	3 (1.6)	50 (26.9)	4 (2.2)
Increased ALP	40 (20.8)	1 (0.5)	27 (14.1)	0	66 (35.5)	4 (2.2)
Increased AST	51 (26.6)	5 (2.6)	22 (11.5)	1 (0.5)	45 (24.2)	3 (1.6)
Increased CPK	111 (57.8)	10 (5.2)	6 (3.1)	0	7 (3.8)	0
Increased creatinine	178 (92.7)	7 (3.6)	147 (76.6)	1 (0.5)	171 (91.9)	2 (1.1)
Increased fasting glucose	53 (27.6)	10 (5.2)	52 (27.1)	8 (4.2)	37 (19.9)	5 (2.7)
Increased GGT	87 (45.3)	22 (11.5)	70 (36.5)	18 (9.4)	63 (33.9)	9 (4.8)

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

Laboratory Test	Combo 450 N=192		Enc 300 N=192		Vem N=186	
Increased magnesium	20 (10.4)	2 (1.0)	29 (15.1)	0	49 (26.3)	1 (0.5)
Decreased sodium	34 (17.7)	7 (3.6)	19 (9.9)	1 (0.5)	27 (14.5)	1 (0.5)

Source: Integrated Safety Summary Table 2-82 Submitted by Applicant June 30, 2017 (Reviewer confirmed underlying shift tables (ISS Table 3.1.4, 3.1.5) for Combo 450 arm using COLUMBUS Part 1 ADLB (cutoff 9 May 2016, submitted by Applicant).

Abbreviations: ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; CPK = creatine phosphokinase; GGT = gamma-glutamyl transferase;

Presented values represent new or worsening post-baseline abnormalities per National Cancer Institute CTCAE v4.03. Patients are counted only for the worst grade observed at post-baseline.

Baseline is defined as the last non-missing value prior to the first dose.

¹ Grade 4 laboratory test abnormalities limited to decreased neutrophils (n=2), increased creatine kinase (n=2) and increased fasting glucose (n = 1).

² Grade 4 laboratory test abnormalities limited to decreased neutrophils (n=1), increased fasting glucose (n=2) and increased GGT (n= 3).

³ Grade 4 laboratory test abnormalities limited to decreased lymphocytes (n=1), decreased neutrophils (n=1), increased fasting glucose (n=1), and increased GGT (n=2).

Vital Signs

For COLUMBUS, vital signs were obtained during screening (within 21 days of initiating study treatment), Day 1 of each cycle, at end of treatment (EOT), and at the 30-day safety follow-up visit. Vital signs included blood pressure, temperature, pulse, and respiratory rate measurements.

Table 72 summarizes the incidence of newly occurring abnormal vital signs for COLUMBUS Part 1. The vital signs where $\geq 5\%$ of patients in the Combo 450 experienced newly occurring abnormal value are: low body temperature, weight gain, high systolic blood pressure, and high diastolic blood pressure. The incidence of newly occurring high systolic BP in the Combo 450 arm was higher than that observed in the encorafenib monotherapy arm (15% versus 8%) but similar to that observed in the vemurafenib arm. The reason for the difference between the Combo 450 and encorafenib monotherapy arms is not clear. It may be due to the higher dose of encorafenib or increased duration of exposure. Based on adverse event reports of related PTs (hypertension, essential hypertension, hypertensive crisis, blood pressure increased, blood pressure systolic increased, hypertensive cardiomyopathy, orthostatic hypertension), which may include new, preexisting, and worsening hypertension, no patient in the Combo 450 arm discontinued therapy due to hypertension while only 5 patients (2.6%) required dose interruption and/or dose modification. Overall, while 15% of patients in the Combo 450 arm experienced newly occurring high systolic blood pressure, similar in incidence to the control arm, it was rarely severe enough to interfere with therapy.

Table 72: Patients with Newly Occurring Notably Abnormal Vital Signs by: COLUMBUS Part 1

Vital Sign Category	COLUMBUS Part 1		
	Combo 450 N=192 n/m (%) ¹	Enc 300 N=192 n/m (%)	Vem N=186 n/m (%)
Sitting pulse rate (bpm)²			
High	1/186 (0.5)	7/184 (3.8)	8/182 (4.4)
Low	3/185 (1.6)	8/181 (4.4)	2/182 (1.1)
Sitting systolic BP (mmHg)³			
High	27/177 (15.3)	14/177 (7.9)	31/172 (17.9)
Low	7/188 (3.7)	3/184 (1.6)	1/182 (0.5)
Sitting diastolic BP (mmHg)⁴			
High	23/182 (12.6)	5/183 (2.7)	13/181 (7.2)
Low	9/188 (4.8)	6/185 (3.2)	5/184 (2.7)
Weight (kg)⁵			
High	44/187 (23.5)	9/184 (4.9)	8/184 (4.3)
Low	2/187 (1.1)	8/184 (4.3)	13/184 (7.1)
Body temperature (°C)⁶			
High	19/185 (10.3)	11/176 (6.3)	17/181 (9.4)
Low	76/132 (57.6)	73/134 (54.5)	57/141 (40.4)

Source: Summary of Clinical Safety Table 4-1 submitted to Module 2.7.4, June 30, 2016. Reviewer confirmed for Combo 450 arm using COLUMBUS Part 1 ADVS (cutoff 9 May 2016, submitted Applicant)

Abbreviations: BP = blood pressure; bpm = beats per minute; °C = degree(s) Celsius; kg = kilogram(s); mg = milligram(s); mmHg = millimeter(s) of mercury;

¹ m = number of patients at risk for a specific category with a non-missing value at baseline and post-baseline, n = number of patients who met the criteria at least once.

² Low/high pulse rate [bpm]: ≤ 50 bpm with decrease from baseline of ≥ 15 bpm/≥ 120 bpm with increase from baseline of ≥ 15 bpm Low/high.

³ Low/high systolic BP [mmHg]: ≤ 90 mmHg with decrease from baseline of ≥ 20 mmHg/≥ 160 mmHg with increase from baseline of ≥ 20 mmHg.

⁴ Low/high diastolic BP [mmHg]: ≤ 50 mmHg with decrease from baseline of ≥ 15 mmHg/≥ 100 mmHg with increase from baseline of ≥ 15 mmHg.

⁵ Weight [kg]: ≥ 20% decrease from baseline/≥ 10% increase from baseline.

⁶ Low/high body temperature [°C]: ≤ 36°C/≥ 37.5°C.

Electrocardiograms (ECGs)

For patients enrolled on COLUMBUS, standard 12-lead Electrocardiograms (ECGs) were to be performed during screening, Day 1 Cycles 1, 2, and 3, every 3 cycles thereafter (every 12 weeks), EOT, and at the 30-day safety follow-up. Baseline measurements were based on the average of three screening ECGs performed in 5 minute intervals.

Table 73 summarizes the proportion of patients who demonstrated changes in QTcF for each arm in COLUMBUS Part 1 as well as the Combo 450, binimetinib 45 mg BID, and Encorafenib 300 mg monotherapy pools. A smaller proportion of patients demonstrated an increased > 30 ms from baseline in the Combo 450 arm (27%) compared to the vemurafenib arm (43%) while a similar proportion demonstrated an increased over 60 msec. A lower proportion of patients had a new QTcF > 450 ms in the Combo 450 arm (14%) compared to the encorafenib monotherapy arm (21%) and the vemurafenib arm (24%). The proportion of patients with new QTcF over 480 ms is low and similar among all arms.

No other notable ECG changes were identified. No patients on any arm experienced an increase in QRS more than 25% to a value above 110 ms.

Table 73: Patients with Notable ECG Value Changes: COLUMBUS Part 1

	COLUMBUS Part 1			Pooled Data Sets	
	Combo 450 N=192 n/m (%) ¹	Enc 300 N=192 n/m (%)	Vem N=186 n/m (%)	Bini 45 mg BID N=427 n/m (%)	Enc 300 N=217 n/m (%)
QTcF (ms) ²					
Increase from baseline > 30 ms	50/186 (26.9)	52/179 (29.1)	76 (179 (42.5)	82/412 (19.9)	65/204 (31.9)
Increase from baseline > 60 ms	10/186 (5.4)	7/179 (3.9)	10/179 (5.6)	11/412 (2.7)	7/204 (3.4)
New > 450 ms	25/178 (14.0)	36/171 (21.1)	42/174 (24.1)	11/412 (2.7)	7/204 (3.4)
New > 480 ms	7/186 (3.8)	7/177 (4.0)	5/179 (2.8)	51/384 (13.3)	44/194 (22.7)
New > 500 ms	1/186 (0.5)	5/178 (2.8)	3/179 (1.7)	15/411 (1.2)	5/203 (2.5)
QRS: Increase from baseline > 25% to a value > 110 ms	0	0	0	6/150 (4.0)	0

Source: Summary of Clinical Safety Table 4-2 submitted to Module 2.7.4, June 30, 2016, results from pooled Combo 450 arm confirmed by QT-IRT reviewer.

¹ m = number of patients at risk for a specific category with a non-missing value at baseline and post-baseline n = number of patients who met the criteria at least once.

² QTcF = QT interval corrected for heart rate using Frederica's formula.

QT

DOP2 requested consultations for evaluation of the encorafenib and binimetinib applications from the Interdisciplinary Review Team for QT Studies (QT-IRT). This section summarizes the findings from those consultations.

The Applicant did not conduct a dedicated QT study to evaluate QT prolongation for either binimetinib or encorafenib.

For the encorafenib and binimetinib applications, the Applicant submitted three cardiac studies:

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

- Study CP-16-002 is a cardiac safety analysis performed by the Applicant to evaluate the potential of binimetinib and its metabolite AA00426032 to delay cardiac repolarization as measured by QTc prolongation. The analysis is based on pooled ECG and PK data pooled from 7 clinical trials in healthy subjects and cancer patients (ARRY-162-0601, ARRY-162-0602, CMEK162A2101J, ARRAY-162-111, CMEKX2201, CMEK162X1101, and CMEK162A2301).
- Study CP-17-005 is a cardiac safety analysis performed by the Applicant to evaluate the potential of therapeutic concentrations of encorafenib to delay cardiac repolarization as measured by QT prolongation. The analysis was completed using encorafenib concentrations and ECG measurements from clinical trial CLGX818X2101, a dose escalation and expansion study in patients with metastatic melanoma and metastatic colorectal carcinoma conducted with expanded ECG monitoring.
- Study CP-17-006 is a cardiac safety analysis performed by the Applicant to evaluate the potential therapeutic concentrations of the combination of encorafenib and binimetinib that could delay cardiac repolarization as measured by QT prolongation. The analysis was completed using encorafenib concentrations and ECG measurements from clinical trials CMEK162X2110, CLGX818X2109, and CMEK162B2301.

The QT-IRT performed a review and analysis of the binimetinib data and study submitted with the application. The analysis utilized the same 7 clinical trials involving binimetinib monotherapy. The QT-IRT review concluded the following:

- In the pooled analysis across 7 clinical trials in subjects and patients receiving binimetinib, a relatively flat relationship between delta QTcF and concentrations of binimetinib or its metabolite AA00426032 was observed. Based on the observed concentration – delta QTcF relationship, no large QTc prolongation (20ms) is estimated following a dose of 45 mg BID.

No dose modifications for binimetinib for QT prolongation are recommended by QT-IRT. QT-IRT recommends modification of Section 12.2 of the label under Cardiac Electrophysiology to include a summary of the QTc prolongation assessment. This is described in Section 11 of this review.

The QT-IRT performed a review and analysis of the encorafenib monotherapy and encorafenib with binimetinib combination data and studies submitted with the application. The review concludes the following:

- Encorafenib is associated with dose-dependent QTc interval prolongation. The conclusion is based on data from studies CLGX818X2109 and CLGX818X20101 which showed an upper bound of the 2-sided 90% confidence interval > 20% for mean change in QTcF from baseline for encorafenib 450 mg once daily monotherapy and encorafenib 450 one daily in combination with binimetinib 45 mg twice daily.
- Although encorafenib shows a dose- and concentration- dependent QTc interval prolongation, there is a lack of direct relationship between concentrations of

encorafenib and QTc effects because of temporal increase in QTc effects. Therefore, a linear C-QTc model that assumes a direct relationship between plasma concentration and QTc cannot be used for analysis.

QT-IRT agreed with Array's proposed dose modifications for encorafenib to be included in the label which are summarized below:

- (b) (4) QTcF > 500 ms and (b) (4) ≤ (b) (4), withhold BRAFTOVI until QTcF (b) (4) 500 ms. (b) (4) discontinued if more than one recurrence
- (b) (4) QTcF > 500 ms and (b) (4) > 60 ms (b) (4), permanently discontinue BRAFTOVI.

QT-IRT recommended the addition of QT Prolongation as a new Warnings and Precautions with additional information provided in Section 12.2 under Cardiac Electrophysiology. Section 11 of this review presents the final agreed upon labeling language regarding QTc prolongation.

Echocardiograms and MUGA scans

COLUMBUS required patients have adequate cardiac function as measured by MUGA scan or echocardiogram with an LVEF ≥ 50%. Cardiac imaging was to be performed at screening, Day 1 of Cycles 2 and 3, and every 12 weeks (3 cycles) thereafter, at end of treatment, at 30-day safety follow up visit, and as clinically indicated during the treatment period. LVEF was summarized by treatment arm as change from baseline over time, worst change, and abnormalities.

Table 74 summarizes the incidence of worst post-baseline LVEF value based on CTCAE Grade for COLUMBUS Part 1. When compared to the encorafenib monotherapy or the vemurafenib arm, the Combo 450 regimen resulted in a higher proportion of patients experiencing a worsening of LVEF as measured by ECHO/MUGA. This increase is due to an increased in Grade 2 toxicity. In the Combo 450 arm, almost 31% of patients experienced a worsening of cardiac function (29.2% Grade 2, 1.6% Grade 3), while in the encorafenib monotherapy arm (Part 1), only 11% of patients experienced a worsening of cardiac function (9.4% Grade 2, 1.6% Grade 3).

Table 74: Incidence Worst Post-baseline LVEF Grade: COLUMBUS Part 1

Worst Post-baseline CTCAE Grade ¹	COLUMBUS Part 1		
	Combo 450 N= 192 n (%)	Enc 300 N= 192 n (%)	Vem N=186 n (%)
Grade 0	127 (66.1%)	161 (83.9)	161 (86.6)
Grade 2	56 (29.2)	18 (9.4)	16 (8.6)
Grade 3	3 (1.6)	3 (1.6)	2 (1.1)
Grade 4	0	0	0
Missing ²	6 (3.1)	10 (5.2)	7 (3.8)

Source: CSR COLUMBUS Part 1 Table 88 submitted to application June 30, 2017

¹ Grade 0: Non-missing value below Grade 2

Grade 2: LVEF between 40% and 50% or absolute reduction from baseline ≥ 10% and ≤ 20%

Grade 3: LVEF between 20% and 39% or absolute reduction from baseline $\geq$ 20%

Grade 4: LVEF below 20%

²Missing data were due to patients who died or withdrew consent prior to the first dose of study treatment. Patients were counted only for the worse grade observed post-baseline. Baseline % is based on N. Percentage for worst post-baseline value is based on Baseline n.

8.2.4. Analysis of Submission-Specific Safety Issues

Adverse Events of Special Interest

Based on preclinical data for binimetinib and encorafenib, data from earlier clinical trials, and known class effects for MEK and BRAF inhibitors, the applicant identified a set of adverse events of special interests (AESIs). The applicant derived the AESI groupings using standardized MedDRA queries or by modifying high level terms modified to remove PTs not felt to reflect the underlying pathology for the specific AESI group. Some AESIs were defined through use of a customized list or may comprise a single PT. The application considered the following AESIs:

- Ocular AESI groupings: retinopathy excluding RVO, RVO, uveitis-type events
- Liver-related AESI groupings: liver function test abnormalities, hepatic failure
- Myopathy/rhabdomyolysis-related AESI groupings: muscle enzyme/protein changes, myopathy, rhabdomyolysis
- Dermatologic-related AESI groupings: rash, photosensitivity, nail disorders, skin infections, severe cutaneous adverse reactions, PPE syndrome
- Cardiac related AESI groupings: bradycardia, tachycardia, left ventricular dysfunction
- Cutaneous malignancies AESI groupings: cutaneous squamous cell carcinoma (cuSCC), cutaneous non-squamous cell carcinoma, melanomas
- Additional AESI groupings: hypertension, peripheral edema, hemorrhage, pneumonitis, venous thromboembolism, tachycardia, acute renal failure, facial paresis

Table 75 shows the incidence of each AESI for all arms in COLUMBUS Part 1 for all grades and Grades 3-4 in order of decreasing frequency for Combo 450 arm.

The following AESIs occurred with greater frequency ($\geq$ 5% increase) in the Combo 450 arm when compared to the vemurafenib arm but with similar frequency between the encorafenib monotherapy and vemurafenib arm: retinopathy excluding RVO (+36%), muscle enzyme/protein changes (+21%), hemorrhage (+10%), and left ventricular dysfunction (+7%). For these AESIs, the increased toxicity observed in patients receiving Combo 450 compared to those receiving vemurafenib appears due to the addition of the MEK inhibitor binimetinib. These events have been previously associated with other MEK inhibitors.

The following AESIs, while not occurring with greater frequency ($\leq$ 5% difference), shows an increase in Grade 3-4 events ($\geq$ 2% increase) in the Combo 450 arm compared to the vemurafenib arm: liver function test abnormalities (+11%), hypertension (+3%), and skin infections (+2%). A similar increase in severity is not observed in patients in the encorafenib

monotherapy arm compared to patients in the vemurafenib arm, suggesting that the increased incidence in Grade 3-4 events observed in patients receiving Combo 450 compared to those receiving vemurafenib is due to the addition of the MEK inhibitor binimetinib. Hepatotoxicity is a known toxicity associated with other MEK inhibitors.

The following AESIs occurred with decreased frequency in the Combo 450 and in the encorafenib monotherapy arms ($\leq -5\%$) when compared to the vemurafenib arm: rash (-33% Combo 450, -10% encorafenib), photosensitivity (-33%, -33%), cutaneous squamous cell carcinoma (-14%, -9%). The decrease in the incidence in photosensitivity appears to be due to less BRAF inhibitor related toxicity, while the decrease in cutaneous squamous cell carcinoma and rash appears due to both less toxicity from the BRAF inhibitor encorafenib as well as from the addition of the MEK inhibitor binimetinib.

The following AESIs occur at a greater frequency ($\geq 5\%$ increase) in the encorafenib monotherapy arm when compared to the vemurafenib arm: palmar-plantar erythrodysesthesia syndrome (+37%), myopathy (11%), and facial palsy (7%). For these AESIs, the increase in incidence with encorafenib is negated by the addition of binimetinib. These events have been associated with other BRAF inhibitors.

Table 75: Incidence of AESI All Grades and Grades 3-4: Columbus Part 1

AESI	COLUMBUS Part 1		
	Combo 450 N=192 % All Grades (% Gr 3-4)	Enc 300 N=192 % All Grades (% Gr 3-4)	Vem N=186 % All Grades (% Gr 3-4)
Retinopathy excluding RVO	48.4 (2.6)	13.5 (0)	12.4 (0)
Rash	26.0 (1.0)	49.5 (5.2)	59.7 (13.4)
Liver Function Test Abnormalities	25.0 (14.6)	14.6 (5.7)	21 (3.8)
Muscle enzyme/ protein changes	22.9 (6.8)	1.6 (0)	2.2 (0)
Hemorrhage	18.2 (3.1)	12.5 (2.1)	8.1 (1.6)
Myopathy	16.7 (0)	31.3 (9.9)	19.9 (0.5)
Peripheral edema	12.5 (1.0)	9.9 (0)	11.8 (1.1)
Hypertension	11.5 (5.7)	6.3 (3.1)	11.3 (3.2)
Skin infections	11.5 (2.1)	12.0 (0.5)	14 (0)
Left ventricular dysfunction	7.8 (1.6)	2.1 (1.0)	1.1 (0)
PPES	6.8 (0)	51.0 (13.5)	14 (1.1)
Venous Thromboembolism	5.2 (1.0)	3.1 (1.0)	1.6 (0.5)
Photosensitivity	4.7 (0.5)	4.7 (0)	37.6 (1.6)
Acute renal failure	3.6 (2.6)	2.6 (1.6)	4.8 (1.6)
Uveitis type events	3.6 (0.5)	0.5 (0)	3.8 (0)
Cutaneous squamous cell carcinoma	2.6 (0)	7.8 (0)	16.7 (6.5)
Cutaneous non-squamous cell carcinoma	2.1 (0)	1.0 (0.5)	2.7 (0.5)
Nail disorders	1.6 (0)	3.1 (0)	0 (0)
Tachycardia	1.6 (0.5)	6.3 (1.0)	5.4 (0.5)

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

Bradycardia	1.0 (0)	0.5 (0)	1.1 (0.5)
Facial paresis	1.0 (0.5)	7.3 (1.6)	0.5 (0)
Hepatic failure	0.5 (0.5)	0 (0)	0 (0)
Pneumonitis	0.5 (0)	(1.0) (0)	0.5 (0.5)
Rhabdomyolysis	0.5 (0.5)	0 (0)	0 (0)
Severe Cutaneous Adverse Reactions	0.5 (0)	1.0 (0.5)	4.3 (2.7)
Melanomas	0 (0)	5.2 (1.6)	4.3 (3.2)
Retinal Vein Occlusion	0 (0)	0.5 (0.5)	0 (0)

Source: Reviewer generated table using ISS_ADAESI (cutoff 9 May 2016, submitted by Applicant)

Abbreviations: PPES = Palmar-plantar Erythrodysesthesia Syndrome

Adverse Drug Reactions

Based on all available safety data, the applicant identified a set of adverse drug reactions (ADRs). A complete list of the ADRs and associated PTs is shown in Table 76. Table 77 shows the incidence for each ADR for each arm of COLUMBUS Part 1.

Table 76: Adverse Drug Reactions Groupings

ADR Grouping	Preferred Terms
Abdominal pain	Abdominal discomfort, Abdominal pain, Abdominal pain lower, Abdominal pain upper, Epigastric discomfort, Gastrointestinal pain, Hepatic pain, Pelvic pain
Acneiform dermatitis	Acne, Acne pustular, Dermatitis acneiform
Alopecia	Alopecia, Alopecia totalis, Diffuse alopecia
Arthralgia	Arthralgia, Arthropathy, Joint Stiffness
Back pain	Back pain
Basal cell carcinoma	Basal cell carcinoma
Colitis	Colitis, Colitis ulcerative, Enterocolitis, Proctitis
Constipation	Constipation
Cutaneous squamous cell carcinoma	Keratoacanthoma, Lip squamous cell carcinoma, Squamous cell carcinoma, Squamous cell carcinoma of skin
Diarrhea	Diarrhea, Frequent bowel movements
Dizziness	Balance disorder, Dizziness, Vertigo
Drug hypersensitivity	Angioedema, Cutaneous vasculitis, Drug eruption, Drug hypersensitivity, Hypersensitivity, Hypersensitivity vasculitis, Urticaria, Vasculitis
Dry skin	Asteatosis, Dry skin, Xeroderma, Xerosis
Dysgeusia	Ageusia, Dysgeusia, Hypogeusia
Erythema	Erythema, Generalized erythema, Plantar erythema
Facial paresis	Facial nerve disorder, Facial paralysis, Facial paresis
Fatigue	Asthenia, Fatigue, Lethargy
Hemorrhage	Anal hemorrhage, Cerebral hemorrhage, Conjunctival hemorrhage, Diarrhea hemorrhagic, Epistaxis, Gastric hemorrhage, Gastric ulcer hemorrhage, Gastrointestinal hemorrhage, Hematemesis, Hematochezia, Hematospermia, Hematuria, Hemoptysis, Hemorrhage, Hemorrhagic cyst, Hemorrhoid hemorrhage, Intracranial tumor hemorrhage, Large intestinal hemorrhage, Lower gastrointestinal hemorrhage, Melena, Menorrhagia, Metrorrhagia, Mucosal hemorrhage, Occult blood, Polymenorrhagia, Postmenopausal hemorrhage, Post procedural hemorrhage, Pulmonary alveolar hemorrhage, Rectal hemorrhage, Retinal hemorrhage, Subdural hematoma, Tumor hemorrhage, Upper gastrointestinal hemorrhage, Uterine

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

	hemorrhage, Vaginal hemorrhage, Wound hemorrhage
Headache	Headache, Head discomfort, Migraine
Hyperkeratosis	Hyperkeratosis, Hyperkeratosis follicularis et parafollicularis, Keratosis pilaris, Lichenoid keratosis, Palmoplantar keratoderma, Parakeratosis, Skin hyperplasia
Hypertension	Blood pressure increased, Essential hypertension, Hypertension, Hypertensive cardiomyopathy, Hypertensive crisis, Orthostatic hypertension
Left ventricular dysfunction (Cardiomyopathy)	Cardiac failure, Ejection fraction abnormal, Ejection fraction decreased, Left ventricular dysfunction
Myopathy	Muscle injury, Muscle spasms, Muscular weakness, Myalgia, Myopathy, Myositis
Nausea	Nausea
Neuropathy	Dysesthesia, Hyperesthesia, Hypoesthesia, Neuralgia, Neuropathy peripheral, Paraneesthesia, Peripheral motor neuropathy, Peripheral sensorimotor neuropathy, Peripheral sensory neuropathy, Polyneuropathy, Sciatica, Sensory disturbance, Sensory loss
Pain in extremity	Pain in extremity
Palmar-plantar erythrodysesthesia syndrome	Palmar-plantar erythrodysesthesia syndrome
Pancreatitis	Pancreatitis, Pancreatitis acute
Panniculitis	Erythema nodosum, Panniculitis
Peripheral edema	Fluid retention, Generalized edema, Local swelling, Localized edema, Edema, Edema genital, Edema peripheral, Penile edema, Peripheral swelling, Scrotal edema
Pruritus	Pruritus, Pruritus generalized, Pruritus genital
Pyrexia	Body temperature increased, Hyperpyrexia, Hyperthermia, Pyrexia
Rash	Exfoliative rash, Rash, Rash erythematous, Rash follicular, Rash generalized, Rash macular, Rash maculo-papular, Rash maculovesicular, Rash papular, Rash pruritic, Rash vesicular
Serious retinopathy/Retinal pigment epithelial detachment (RPED)	Chorioretinitis, Chorioretinopathy, Cystoid macular edema, Detachment of macular retinal pigment epithelium, Detachment of retinal pigment epithelium, Exudative retinopathy, Macular detachment, Macular edema, Maculopathy, Metamorphopsia, Retinal detachment, Retinal disorder, Retinal exudates, Retinal edema, Retinal pigment epitheliopathy, Retinitis, Retinopathy, Subretinal fluid
Rhabdomyolysis	Rhabdomyolysis
Skin papilloma	Blepharal papilloma, Oral papilloma, Papilloma, Skin papilloma
Uveitis	Iritis, Iridocyclitis, Uveitis
Venous thromboembolism	Deep vein thrombosis, Embolism, Embolism venous, Mesenteric vein thrombosis, Pelvic venous thrombosis, Peripheral artery thrombosis, Phlebitis, Phlebitis superficial, Portal vein thrombosis, Pulmonary embolism, Thrombophlebitis, Thrombophlebitis superficial, Thrombosis, Venous thrombosis
Visual impairment	Vision blurred, Visual acuity reduced, Visual impairment
Vomiting	Retching, Vomiting

Source: ISS Study Report Table 2-78 (Submitted by Applicant)

Table 77: Incidence of ADR by General Organ System: COLUMBUS Part 1

ADR	Combo 450 (N=192) All Grades % (Gr 3-4 %)	Enc 300 (N=192) All Grades % (Gr 3-4 %)	Vem (N=186) All Grades % (Gr 3-4 %)
<i>General Disorders and administration site conditions</i>			
Fatigue	43.2 (3.1)	41.7 (3.1)	46.2 (6.5)

Multi-Disciplinary Review and Evaluation NDA 210496
 BRAFTOVI™ (encorafenib)

ADR	Combo 450 (N=192) All Grades % (Gr 3-4 %)	Enc 300 (N=192) All Grades % (Gr 3-4 %)	Vem (N=186) All Grades % (Gr 3-4 %)
Pyrexia	18.2 (4.2)	15.6 (1.0)	29.6 (0.0)
Peripheral edema	13.0 (1.0)	9.4 (0.0)	14.5 (1.1)
Drug hypersensitivity	3.6 (0.0)	4.7 (0.5)	4.8 (1.6)
<i>Gastrointestinal disorders</i>			
Nausea	41.1 (1.6)	38.5 (4.2)	33.9 (1.6)
Diarrhea	36.5 (2.6)	13.5 (1.6)	33.9 (2.2)
Vomiting	29.7 (1.6)	27.1 (4.7)	15.6 (1.1)
Abdominal pain	28.1 (3.6)	16.7 (3.1)	15.6 (1.1)
Constipation	21.9 (0.0)	14.1 (0.0)	6.5 (0.5)
Colitis	2.1 (1.0)	1.0 (0.0)	0.5 (0.0)
Pancreatitis	1.0 (1.0)	0.0 (0.0)	1.1 (0.5)
<i>Musculoskeletal and connective tissue disorders</i>			
Arthralgia	25.5 (0.5)	44.3 (9.4)	45.7 (5.9)
Myopathy	23.4 (0.0)	33.3 (9.9)	22.0 (0.5)
Pain in extremity	10.9 (1.0)	21.9 (1.0)	13.4 (1.1)
Back pain	9.4 (0.5)	15.1 (2.6)	5.9 (1.6)
Rhabdomyolysis	0.5 (0.5)	0.0 (0.0)	0.0 (0.0)
<i>Skin and subcutaneous tissue disorders</i>			
Hyperkeratosis	22.9 (0.5)	57.3 (4.7)	49.5 (1.1)
Rash	22.4 (1.0)	41.1 (4.2)	53.2 (13.4)
Dry skin	16.1 (0.0)	37.5 (0.0)	26.3 (0.0)
Pruritus	12.5 (0.5)	30.7 (0.5)	21.0 (1.1)
Alopecia	14.1 (0.0)	56.3 (0.0)	37.6 (0.0)
PPES	6.8 (0.0)	51.0 (13.5)	14.0 (1.1)
Erythema	7.3 (0.0)	15.6 (1.6)	17.2 (0.5)
Acneiform dermatitis	3.1 (0.0)	8.3 (0.0)	6.5 (0.0)
Panniculitis	1.6 (0.0)	0.5 (0.0)	3.2 (0.5)
<i>Nervous System Disorder</i>			
Headache	21.9 (1.6)	28.1 (3.6)	19.9 (0.5)
Dizziness	15.1 (2.6)	6.3 (0.5)	4.3 (0.0)
Neuropathy	12.0 (1.0)	21.9 (1.0)	13.4 (1.6)
Dysgeusia	5.7 (0.0)	13.0 (0.0)	10.2 (0.0)
Facial paresthesia	1.0 (0.5)	7.3 (1.6)	0.5 (0.0)
<i>Eye disorders</i>			
Visual impairment	20.3 (0.0)	5.7 (0.0)	4.3 (0.0)
RPED	19.8 (2.6)	2.1 (0.0)	1.6 (0.0)
Uveitis	3.6 (0.5)	0.5 (0.0)	3.8 (0.0)
<i>Cardiac and Vascular disorders</i>			
Hemorrhage	18.8 (3.1)	10.9 (2.1)	8.6 (1.6)
Hypertension	11.5 (5.7)	5.7 (3.1)	11.3 (3.2)

ADR	Combo 450 (N=192) All Grades % (Gr 3-4 %)	Enc 300 (N=192) All Grades % (Gr 3-4 %)	Vem (N=186) All Grades % (Gr 3-4 %)
Left ventricular dysfunction (Cardiomyopathy)	7.8 (1.6)	2.1 (1.0)	0.5 (0.0)
Venous thromboembolism	5.7 (1.6)	3.1 (1.0)	2.2 (0.5)
<i>Neoplasms benign, malignant, and unspecified</i>			
Skin papilloma	7.3 (0.0)	10.4 (0.0)	19.4 (0.0)
Cutaneous squamous cell carcinoma	2.6 (0.0)	7.8 (0.0)	17.2 (7.0)
Basal cell carcinoma	1.6 (0.0)	1.0 (0.5)	1.6 (0.5)
Source: Reviewer generated table using ISS_ADDR (cutoff 9 May 2016, submitted by Applicant)			
Abbreviations: PPES = palmar-plantar erythrodysesthesia; RPED = retinal pigment epithelial detachment.			

Combo 450 versus Vemurafenib Monotherapy

The following ADRs were observed more frequently ($\geq 5\%$ difference) in patients in the Combo 450 arm when compared to patients in the vemurafenib arm: RPED (+18.2), visual impairment (+16.0), constipation (+15.4), vomiting (+14.1), abdominal pain (+12.5), dizziness (+10.8), hemorrhage (+10.1), left ventricular dysfunction (+7.3), nausea (+7.3). With the exception of constipation and vomiting, a similar increase in frequency is not observed when comparing encorafenib to vemurafenib arms; therefore, the increased toxicity for these ADRs is due to the addition of binimetinib. These ADRs are consistent with toxicities known to be associated with MEK inhibitors.

The following ADRs were observed less frequently ($\geq 5\%$ difference) in patients in the Combo 450 arm when compared to patients in the vemurafenib arm: rash (-30.8), hyperkeratosis (-26.5), alopecia (-23.6), arthralgia (-20.2), cutaneous squamous cell carcinoma (-14.6), skin papilloma (-12.1), pyrexia (-11.3), dry skin (-10.2), erythema (-9.9), pruritus (-8.5), PPES (-7.2). Of these ADRs, a similar decrease is not observed when comparing encorafenib to vemurafenib arms for the following: hyperkeratosis, alopecia, arthralgia, dry skin, erythema, pruritus, and PPES. For these ADRs, the decrease in observed toxicity is due to the addition of binimetinib. For the following ADRs, a decrease is also observed when comparing encorafenib and vemurafenib arms: rash, cutaneous squamous cell carcinoma, skin papilloma, pyrexia. For these ADRs, the decrease in toxicity observed in the Combo 450 arm is due both to the comparative safety profile of encorafenib as well as to the addition of a MEK inhibitor to a BRAF inhibitor.

Encorafenib 300 monotherapy versus Vemurafenib Monotherapy

The following ADRs were observed more frequently ($\geq 5\%$ difference) in patients in the encorafenib monotherapy arm when compared to patients in the vemurafenib arm: PPES (+37.1), alopecia (+18.6), vomiting (+11.5), myopathy (+11.3), dry skin (+11.2), pruritus (+9.8), back pain (+9.2), neuropathy (+8.4), pain in extremity (+8.4), headache (+8.2), hyperkeratosis (+7.8), constipation (+7.6), facial palsy (+6.8). With the exception of vomiting and constipation, all of these ADRs were attenuated by the addition of binimetinib.

The following ADRs were observed less frequency ($\geq 5\%$ difference) in patients in the encorafenib monotherapy arm when compared to patients in the vemurafenib arm: diarrhea (-20.3), pyrexia (-13.9), rash (-12.1), cutaneous squamous cell carcinoma (-8.9), hypertension (-5.6), peripheral edema (-5.1).

Common ADRs associated with the Combo 450 regimen and Assessment of Contribution to Toxicity

The most common ADRs ($\geq 20\%$ all grades) for the combination 450 arm are: fatigue (43%), nausea (41%), diarrhea (36%), vomiting (30%), abdominal pain (28%), arthralgia (26%), myopathy (23%), hyperkeratosis (23%), rash (22%), headache (22%), constipation (22%), visual impairment (20%), and RPED (20%). Additionally, hypertension had a frequency of Grade 3-4 events $\geq 5\%$: hypertension (6%).

For the following common ADRs ($\geq 10\%$), there was less than a 5% difference (increase or decrease) in frequency between the combo 450 arm and the encorafenib monotherapy arm: peripheral edema (+3.6), vomiting (+2.6), pyrexia (+2.6), nausea (+2.6), fatigue (+1.6). For these ADRs, the increase in toxicity with addition of binimetinib and/or the higher dose of encorafenib is minimal.

For the following common ADRs, there was a $\geq 5\%$ increase in frequency from the encorafenib monotherapy arm to the Combo 450 arm indicating the addition of the binimetinib and/or the increase in encorafenib dose added to the overall toxicity in the Combo 450 arm: diarrhea (+22.9), RPED (+17.7), visual impairment (+14.6), abdominal pain (+11.5), dizziness (+8.9), hemorrhage (+7.8), constipation (+7.8), hypertension (+5.7). The low incidence of RPED (2.1%) in the encorafenib monotherapy arm indicates that the toxicity for this RPED observed in the combination 450 arm is due almost exclusively to the binimetinib.

For the remaining ADRs, the increase in frequency observed in the Combo 450 arm could be due to the higher dose of encorafenib and/or the addition of binimetinib. The results of an exploratory comparison of the incidence of ADRs between Combo 300 and Combo 450 is discussed below. It is noted here that of these ADRs, only diarrhea occurs more frequently ($\geq 5\%$) in the Combo 450 arm than in the Combo 300 arm. This suggests that, with the exception of diarrhea, the increase in frequency of ADRs observed in the Combo 450 is due primarily to the addition of binimetinib.

For the following common ADRs, there was a $\geq 5\%$ decrease in frequency from the encorafenib monotherapy arm to the Combo 450 arm: alopecia (-42.2%), hyperkeratosis (-34.4%), dry skin (-21.4), arthralgia (-18.8), rash (-18.7%), pruritus (-18.2%), pain in extremity (-10.9%), neuropathy (-9.9%), myopathy (-9.9%), headache (-6.3%). For these ADRs, the addition of binimetinib to encorafenib attenuated the toxicity associated with encorafenib. This phenomenon has been observed in other BRAF/MEK combination regimens although the set of ADRs in which this occurs appears broader with encorafenib and binimetinib. This is discussed in more detail below.

Treatment Modifications for ADRs

The COLUMBUS protocol specified detailed dose modifications (discontinuations, reductions, and/or interruptions) for anticipated toxicities. Depending on the toxicity, modifications were made to encorafenib and binimetinib, to encorafenib only, or to binimetinib only. Table 78 shows the frequency of treatment modifications for Combo 450 and encorafenib monotherapy arms in COLUMBUS Part 1. The frequency of discontinuations for any ADR is similar between arms while the frequency of reductions and interruptions is higher in the encorafenib monotherapy arm compared to the Combo 450 arm.

Table 78: Frequency of Treatment Discontinuations, Reductions, and Interruptions by Adverse Drug Reaction: COLUMBUS Part 1 COMBO 450 and Encorafenib Monotherapy

Adverse Drug Reaction	COLUMBUS Part 1					
	Combo 450 N=192			Enc 300 N=192		
	Discontinuations n (%)	Reductions n (%)	Interruptions n (%)	Discontinuations n (%)	Reductions n (%)	Interruptions n (%)
ANY ADR	15 (7.8)	20 (10.4)	74 (38.5)	17 (8.9)	47 (24.5)	104 (54.2)
Abdominal pain	1 (0.5)	1 (0.5)	6 (3.1)	0	1 (0.5)	6 (3.1)
Acneiform dermatitis	0	0	2 (1.0)	0	0	2 (1.0)
Alopecia	0	0	1 (0.5)	0	1 (0.5)	2 (1.0)
Amylase increased	1 (0.5)	1 (0.5)	2 (1.0)	0	0	0
Anemia	0	0	4 (2.1)	0	0	2 (1.0)
Arthralgia	0	1 (0.5)	3 (1.6)	1 (0.5)	8 (4.2)	16 (8.3)
Back pain	0	0	0	0	3 (1.6)	2 (1.0)
Basal cell carcinoma	0	0	1 (0.5)	0	0	0
ALP Increased	1 (0.5)	0	4 (2.1)	0	1 (0.5)	0
CPK Increase	1 (0.5)	0	6 (3.1)	0	0	0
Colitis	0	1 (0.5)	2 (1.0)	0	0	1 (0.5)
Constipation	0	0	1 (0.5)	0	1 (0.5)	0
Diarrhea	1 (0.5)	1 (0.5)	6 (3.1)	2 (1.0)	0	4 (2.1)
Dizziness	0	1 (0.5)	4 (2.1)	0	0	0
Drug hypersensitivity	0	0	0	2 (1.0)	2 (1.0)	3 (1.6)
Dry skin	0	1 (0.5)	0	0	1 (0.5)	1 (0.5)
Erythema	0	0	1 (0.5)	0	0	5 (2.6)
Facial paresis	0	0	1 (0.5)	2 (1.0)	1 (0.5)	6 (3.1)
Fatigue	1 (0.5)	2 (1.0)	4 (2.1)	0	4 (2.1)	9 (4.7)
Hemorrhage	3 (1.6)	0	2 (1.0)	0	0	2 (1.0)
Headache	2 (1.0)	1 (0.5)	1 (0.5)	2 (1.0)	2 (1.0)	11 (5.7)
Hyperkeratosis	0	2 (1.0)	4 (2.1)	2 (1.0)	8 (4.2)	9 (4.7)
Hypertension	0	1 (0.5)	4 (2.1)	0	0	1 (0.5)
LV dysfunction	0	0	12 (6.3)	2 (1.0)	0	0
Lipase increased	0	1 (0.5)	3 (1.6)	0	0	1 (0.5)
Myopathy	0	0	4 (2.1)	1 (0.5)	8 (4.2)	22 (11.5)
Nausea	0	2 (1.0)	14 (7.3)	0	6 (3.1)	11 (5.7)
Neuropathy	0	1 (0.5)	1 (0.5)	1 (0.5)	1 (0.5)	2 (1.0)
Pain in extremity	0	0	1 (0.5)	0	2 (1.0)	6 (3.1)
PPES	0	0	1 (0.5)	5 (2.6)	19 (9.9)	44 (22.9)
Pancreatitis	0	0	1 (0.5)	0	0	0
Peripheral edema	0	0	1 (0.5)	0	2 (1.0)	1 (0.5)
Pruritus	0	0	2 (1.0)	0	1 (0.5)	5 (2.6)
Pyrexia	1 (0.5)	1 (0.5)	8 (4.2)	0	0	5 (2.6)
Rash	1 (0.5)	1 (0.5)	2 (1.0)	1 (0.5)	2 (1.0)	15 (7.8)

Multi-Disciplinary Review and Evaluation NDA 210496
 BRAFTOVI™ (encorafenib)

RPED	0	5 (2.6)	8 (4.2)	0	0	1 (0.5)
Rhabdomyolysis	1 (0.5)	0	0	0	0	0
Transaminases increased	5 (2.6)	0	9 (4.7)	0	1 (0.5)	3 (1.6)
Uveitis	0	1 (0.5)	6 (3.1)	0	0	0
VTE	0	0	3 (1.6)	0	0	0
Visual impairment	0	0	3 (1.6)	0	0	0
Vomiting	0	0	13 (6.8)	3 (1.6)	1 (0.5)	9 (4.7)

Source: Reviewer generated table using ISS_ADADR (cutoff 9 May 2016, submitted by Applicant)

Abbreviations: ALP = alkaline phosphatase; CPK = creatine phosphokinase; LV= left ventricular; PPES = palmar-plantar erythrodysesthesia; RPED = retinal pigment epithelial detachment; VTE = venous thromboembolism

Adverse Reactions

The ADR and AESI analyses form the basis of the adverse reactions (ARs) identified by the applicant for inclusion in the labels for encorafenib and binimetinib. Table 79 summarizes the ARs associated with BRAF and MEK inhibitors currently labeled for use in patients with advanced or metastatic BRAF mutated melanoma. The BRAF inhibitors are: vemurafenib, which is approved as monotherapy and dabrafenib, which is approved as monotherapy or in combination with trametinib. The MEK inhibitors are cobimetinib, which is approved in combination with vemurafenib, and trametinib, which is approved as monotherapy or in combination with dabrafenib.

Table 80 summarizes the important safety signals for encorafenib and binimetinib as identified by the Applicant for inclusion in their proposed labels.

Individual ARs observed in COMBO 450 and/or other BRAF/MEK inhibitors that are considered “important,” “common,” and “otherwise clinically relevant” are discussed individually in more detail below. An “important” AR is one included in Section 5, Warnings and Precautions of a label; “common” ARs are those noted in Section 6.1 of a label and for COMBO 450 occurred in $\geq$ 25% of patients; “otherwise clinically relevant” ARs are also clinically notable but occur in $<$ 10% of patients and are also noted in Section 6.1 of a label. This discussion focuses on TEAEs reported in COLUMBUS Part 1 Combo 450 and encorafenib arms and to assist with assessing contribution by each drug to the event the binimetinib monotherapy pool. For rare events, the Combo > 400 pooled dataset is evaluated. All analyses are performed regardless of investigator or Applicant attribution to study drug(s).

Table 79: Important Safety Issues with Related Drugs in Patients with BRAF Mutated Melanoma

	Warnings/Precautions	Common Adverse Reactions	Clinically Relevant Adverse Reactions reported in < 10%
Vemurafenib (Zelboraf) ¹	New Primary Malignancies Cutaneous Malignancies Non-Cutaneous Squamous Cell Carcinoma Other Malignancies Tumor Promotion in BRAF Wild-Type Melanoma Hypersensitivity Reactions Dermatologic Reactions: severe dermatologic reactions including Stevens-Johnson Syndrome and toxic epidermal necrolysis QT Prolongation Hepatotoxicity Photosensitivity Ophthalmologic Reactions: uveitis, blurry vision, photophobia Embryo-Fetal Toxicity Radiation Sensitization and Radiation Recall Renal Failure: acute interstitial nephritis and acute tubular necrosis Dupuytren’s Contracture and Plantar Facial Fibromatosis	Arthralgia, rash, alopecia, fatigue, photosensitivity reaction, nausea, pruritus, and skin papilloma	Palmar-plantar erythrodysesthesia syndrome, keratosis pilaris, panniculitis, erythema nodosum, Steven-Johnson syndrome, toxic epidermal necrolysis, arthritis, Dupuytren’s contracture, neuropathy peripheral, VIIth nerve paralysis, basal cell carcinoma, oropharyngeal squamous cell carcinoma, folliculitis, retinal vein occlusion, vasculitis, atrial fibrillation
Dabrafenib (Tafinlar) ²	New Primary Cutaneous Malignancies Cutaneous Malignancies Non-Cutaneous Malignancies Tumor Promotion in BRAF Wild-Type Melanoma Hemorrhage Cardiomyopathy Uveitis Serious Febrile Reaction Serious Skin Toxicity Hyperglycemia G6PD Deficiency Embryo-Fetal Toxicity	<u>Single agent:</u> Hyperkeratosis, headache, pyrexia, arthralgia, papilloma, alopecia, and palmer-planter erythrodysesthesia syndrome <u>Given with trametinib</u> Pyrexia, rash, chills, headache, arthralgia, and cough	<u>Single agent:</u> Pancreatitis, hypersensitivity manifesting as bullous rash, interstitial nephritis <u>Given with trametinib</u> Pancreatitis, panniculitis,

Multi-Disciplinary Review and Evaluation NDA 210496
 BRAFTOVI™ (encorafenib)

	Warnings/Precautions	Common Adverse Reactions	Clinically Relevant Adverse Reactions reported in < 10%
Cobimetinib (Cotellic) ³	New Primary Cutaneous Malignancies Cutaneous Malignancies Non-Cutaneous Malignancies Hemorrhage Cardiomyopathy Severe Dermatologic Reactions Serous Retinopathy and Retinal Vein Occlusion Hepatotoxicity Rhabdomyolysis Severe Photosensitivity Embryo-Fetal Toxicity	Diarrhea, photosensitivity reaction, nausea, pyrexia, and vomiting	pneumonitis
Trametinib (Mekinist) ⁴	New Primary Cutaneous Malignancies Cutaneous Malignancies Non-Cutaneous Malignancies Hemorrhage Colitis and Gastrointestinal Perforation Venous Thromboembolism Cardiomyopathy Ocular Toxicities Renal Vein Occlusion Retinal Pigment Epithelial Detachment Interstitial Lung Disease Serious Febrile Reactions Serious Skin Toxicity Hyperglycemia Embryo-Fetal Toxicity	<u>Single agent:</u> rash, diarrhea, lymphedema <u>Given with Dabrafenib</u> Pyrexia, nausea, rash, chills, diarrhea, vomiting, hypertension, and peripheral edema	<u>Single agent:</u> Bradycardia, dry mouth, folliculitis, rash pustular, cellulitis, rhabdomyolysis, dizziness, dysgeusia, blurred vision, dry eye <u>Given with Dabrafenib</u> Bradycardia, rhabdomyolysis,

Table 80: Applicant Proposed Labeled Safety Issues: Encorafenib and Binimetinib

	Warnings/Precautions Section 5	Common Adverse Reactions (≥ 25%) Section 6.1	Clinically Relevant Adverse Reactions reported in < 10% Section 6.1	Drug Interaction
Encorafenib	New Primary Malignancies Cutaneous Malignancies Non-Cutaneous (b) (4) Hemorrhage (b) (4) uveitis Embryo-Fetal Toxicity	Fatigue, nausea, vomiting, arthralgias	Facial paresis, pancreatitis, panniculitis, drug hypersensitivity	Strong CYP3A4 Inhibitors Strong (b) (4) Inducers (b) (4)
Binimetinib	(b) (4) Cardiomyopathy Venous Thromboembolism Ocular Toxicities Serous retinopathy Retinal Vein Occlusion Uveitis Interstitial Lung Disease Hepatotoxicity Rhabdomyolysis Hemorrhage Embryo-Fetal Toxicities	Diarrhea, abdominal pain	Colitis, Drug hypersensitivity	(b) (4)

Source: Applicant proposed labels for encorafenib (BRATOVI) and binimetinib (MEKTOVI) submitted to the applications June 30, 2017.

Important ADRs and AESIs Identified in BRAF and MEK Inhibitors and in Combo 450

1. New Primary Malignancies

Cutaneous

Secondary skin neoplasms are a known class effect of BRAF inhibitors. They are not reported as a class effect for MEK inhibitors. The secondary skin neoplasms associated with BRAF inhibitors include cutaneous squamous cell carcinoma (cuSCC) and cutaneous non-squamous cell carcinomas.

The ADR cutaneous squamous cell carcinoma (CuSCC) comprises keratoacanthoma, lip squamous cell carcinoma, and squamous cell carcinoma. The incidence of cuSCC in the COLUMBUS Part 1 encorafenib monotherapy was 7.8%. The incidence in the COLUMBUS Part 1 Combo 450 arm was more than 5% lower, at an observed rate of 2.6%. The incidence was extremely low in patients who received binimetinib alone (0.2%). All events in the patients receiving encorafenib with or without binimetinib in COLUMBUS Part 1 were $\leq$ Grade 2, and no cases were categorized as serious. In COLUMBUS Part 1 Combo 450 arm or the encorafenib monotherapy arm, there were no events of cutaneous squamous cell carcinoma that led to treatment discontinuation, dose interruption, and/or reduction.

The decrease in observed frequency of CuSCC observed when binimetinib is added to encorafenib is consistent what is observed with other combination regimens involving BRAF and MEK inhibitors.

The AESI of cutaneous non-squamous cell carcinomas comprises the following PTs: basal cell, neoplasm skin, and dysplastic nevus syndrome. The incidence in COLUMBUS Part 1 Combo 450 arm was 2.1% (1.6% basal cell) and in the encorafenib monotherapy arm was 1% (1% basal cell). Thus, the decrease in incidence of CuSCC with the addition of binimetinib to encorafenib is not recapitulated with non-squamous cutaneous neoplasms. In COLUMBUS Part 1 Combo 450 arm or the encorafenib monotherapy arm, there were no events of cutaneous non-squamous cell carcinoma that led to treatment discontinuation, dose interruption, and/or reduction.

Non-cutaneous

To determine the incidence of non-cutaneous malignancies, this Reviewer defined a grouped term “non-cutaneous malignancy” using all AEs that were included in an AEHLGT containing the word “malignant,” with the exception of skin neoplasms. In Columbus Part 1, the incidence of non-cutaneous malignancy was 1.0% in the Combo 450 arm (2/192) and 1.6% in the encorafenib monotherapy arm (3/192). One of the cases in the Combo 450 arm was squamous cell carcinoma (0.5%) while all three observed in the encorafenib monotherapy arm were squamous cell carcinoma. Of note, 16 patients in the vemurafenib arm had a non-cutaneous malignancy (8.6%) with 12 of these patients (6.5%) having squamous cell carcinoma.

The ADR new primary malignancies, both cutaneous and non-cutaneous, is included in Warnings and Precautions for the vemurafenib, dabrafenib, cobimetinib, and trametinib labels.

^{(b) (4)} Although non-cutaneous malignancies in general, and non-cutaneous squamous cell carcinoma in particular, are rare in patients who received Combo 450 or encorafenib monotherapy in the COLUMBUS

Part 1 trial, the Applicant proposes the inclusion of non-cutaneous malignancies in Warnings and Precautions based on the mechanism of action of encorafenib and the general risk for it to promote the growth and development of malignancies associated with activation of RAS.

2. *Cardiomyopathy*

Cardiomyopathy is a known class effect associated with BRAF inhibitors and MEK inhibitors.

Based on AE reporting in COLUMBUS Part 1, the incidence of the ADR left ventricular dysfunction in the Combo 450 arm is 7.8% (1.6% Grade 3, 0% Grade 4) and in the encorafenib monotherapy arm is 2.1 % (1% Grade 3-4). No AEs were reported as serious.

The incidence of left ventricular dysfunction, however, is more accurately assessed based on ECHO/MUGA reporting. As discussed in Section 8.2.3 and shown in Table 74, the Combo 450 regimen resulted in a higher proportion of patients experiencing a worsening of LVEF as measured by ECHO/MUGA compared to the encorafenib monotherapy or vemurafenib arms. A similar increase in Grade 2 toxicity is observed when comparing the Combo 300 arm with the encorafenib 300 monotherapy arm in COLUMBUS Part 2. This data suggests that the increased toxicity observed in the Combo 450 arm is due to the addition of binimetinib rather than the increase in dose of encorafenib. In COLUMBUS Part 1, no patients in the Combo 450 arm and 2 patients in the encorafenib monotherapy arm (1%) discontinued treatment due to left ventricular dysfunction. Twelve patients in the Combo 450 arm (6.3%) and no patients in the encorafenib monotherapy arm interrupted treatment because of left ventricular dysfunction. No patient in either arm had a dose reduction for left ventricular dysfunction. Cardiomyopathy is labeled in Warnings and Precautions for dabrafenib, cobimetinib, and trametinib. It is not included in the label for vemurafenib (b) (4)

3. *Hepatotoxicity*

Hepatotoxicity, including elevation of hepatic enzymes, is a known class effect associated with BRAF and MEK inhibitors. Hepatotoxicity was identified as an AESI for binimetinib based on a case of fatal liver failure in Study CMEK162X2201 in which the patient developed acute liver failure after receiving a dose of binimetinib 60 mg BID.

Based on AE reporting, 13.5% of patients in Columbus Part 1 COMBO 450 arm and 6.8% of patients in the encorafenib monotherapy arm had a PT that fell under the Applicant-defined ADR Transaminase Increased¹. None of these events were serious. Five patients (2.6%) in the Combo 450 arm and 2 patients (1%) in the encorafenib monotherapy arm discontinued therapy due to increased transaminases. Nine patient (4.7%) in the Combo 450 arm and 3 patients (1.6%) in the encorafenib monotherapy arm had a dose interruption. No patients in the Combo 450 arm and 1 patient (0.5%) in the encorafenib monotherapy had a dose reduction for the ADR transaminase increased. In the Combo 450 arm, 13 patients (6.8%) had a Grade 3 event while in the encorafenib monotherapy arm, 3 patients (1.6%) had a Grade 3 event. No patient

¹ The ADR Transaminase Increased includes the PTs alanine aminotransferase increased, aspartate aminotransferase increased, hepatic enzyme increased, and transaminases increased.

on either arm had a Grade 4 event. In COLUMBUS Part 1, 5 patients in the Combo 450 arm (2.6%) and 4 patients in the encorafenib monotherapy arm (2.1%) discontinued treatment due to the ADR transaminases increased. No patients in the Combo 450 arm and 1 patient in the encorafenib monotherapy arm (0.5%) had a dose reduction for this ADR. There were 9 patients in the Combo 450 arm (4.7%) and 3 patients in the encorafenib monotherapy arm (1.6%) who had a dose interruption.

In the binimetinib monotherapy pooled dataset, the incidence of the ADR increased transaminase was 16.6% (71/427) with 3% of patients having a Grade 3 event. No Grade 4 events were reported. Only 2 patients (0.5%) had events that were reported as serious.

Hepatotoxicity may also be evaluated based laboratory assessments. As seen in Table 71, in COLUMBUS Part 1, significantly more patients in the Combo 450 arm experienced an increase in ALT (29%), AST (27%), ALP (21%), and GGT (45%) than in the encorafenib monotherapy arm (ALT: 15%, AST 12%, ALP: 14%, GGT: 37%). The majority of events for both arms were Grade 1 and 2. In the Combo 450 arm, 6% of patients had a Grade 3-4 increase in ALT, 2.6% a Grade 3-4 increase in AST, 0.5% a Grade 3-4 increase in ALP, and 12% a Grade 3-4 increase in GGT. In the encorafenib monotherapy arm, 1.6% experienced a Grade 3-4 increase in ALT, 0.5% a Grade 3-4 increase in AST, 0% a Grade 3-4 increase ALP, and 9.4% of patients a Grade 3-4 increase in GGT. There were no cases meeting the criteria for Hy's law in the Combo 450 or Part 1 encorafenib monotherapy arms.

While a significant portion of patients in the Combo 450 arm experienced increases in transaminases, the increase was usually mild ($\leq$ Grade 2) and did not lead to a serious AE. Both encorafenib and binimetinib appear to contribute to the hepatotoxicity observed with Combo 450; however, based on the totality of the data, the contribution of binimetinib appears greater.

Hepatotoxicity is listed in Warnings and Precautions in the vemurafenib (as liver injury) and cobimetinib (as liver laboratory abnormalities) but not the dabrafenib or trametinib product labels. (b) (4)

4. Hemorrhage

Hemorrhage is a known class effect associated with MEK inhibitors.

In COLUMBUS Part 1, hemorrhage occurred in 18.8% of patients in the Combo 450 arm (13% Grade 1, 2.6% Grade 2, 1.6% Grade 3, and 1.6% Grade 4) and in 10.9% of patients in the encorafenib monotherapy arm (7.3% Grade 1, 1.6% Grade 2, and 1.0% Grade 3, and 1.0% Grade 4). In the Combo 450 arm, the most frequent hemorrhagic events were gastrointestinal (4.2%), hematochezia (3.1%), and hemorrhoidal hemorrhage (1%). In COLUMBUS Part 1, 3 patients in the Combo 450 arm (1.6%) and no patients in the encorafenib monotherapy arm discontinued treatment due to the ADR hemorrhage. No patients in either the Combo 450 or encorafenib monotherapy arm had a dose reduction, while 2 patients in the Combo 450 arm (1.0%) and 2 patients in the encorafenib monotherapy arm (1.0%) had an event that led to treatment interruption.

In the binimetinib pooled population, hemorrhage was reported in 9.8% of patients.

Hemorrhage includes the PT cerebral hemorrhage. In the Combo 450 arm, 1.6% (3/193) had a fatal cerebral hemorrhage. One additional patient in the Combo 450 arm was reported as having intracranial tumor hemorrhage (0.5%). In Part 1 encorafenib arm, 2 patients (1.0%) had a fatal intracranial hemorrhage. Although these events were considered related to new cerebral metastasis, COLUMBUS does not provide information that allows assessment if Combo 450 or encorafenib monotherapy increases this risk.

Hemorrhage is included in Warnings and Precautions in the dabrafenib but not the vemurafenib label and in the cobimetinib and trametinib labels. The Applicant proposes the inclusion of hemorrhage in Warnings and Precautions of the encorafenib and the binimetinib labels.

5. Ocular Toxicities

After Amendment 3 to the COLUMBUS protocol, ophthalmic examinations including slit lamp examination, visual acuity, intraocular pressure (IOP), and fundoscopy were required for all enrolled patients. Patients on the Combo 450 and Combo 300 arms as well as patients on the encorafenib monotherapy and vemurafenib arms with baseline retinal abnormalities had ophthalmic examinations during screening, at each regulatory scheduled patient visit (Day 1 of each cycle), EOT, and at the 30-day safety follow-up. Ophthalmic Coherence T (OCT) (for non-vascular abnormalities) and/or fluorescein angiography (for vascular abnormalities) examinations were required for patient with clinical findings indicative of retinal abnormalities.

(b) (4)

DOP 2 requested an ophthalmology consult from the Division of Transplant and Ophthalmology Products (DTOP) to review the risks of ocular events in patients receiving binimetinib in combination with encorafenib. Three ocular events were reviewed based on known class effects of BRAF and MEK inhibitors: retinopathy excluding retinal vein occlusion (RVO), RVO, and uveitis.

Retinopathy is a known class effect of MEK inhibitors. Clinical findings are characterized by serous retinal detachment. In COLUMBUS Part 1, retinopathy, excluding RVO events, was reported in a higher percentage of patients in the Combo 450 arm (48.4%) as compared with the encorafenib monotherapy (13.5%) and vemurafenib arms (12.4, %). This was true for all PTs included in the term retinopathy.

The incidence of the narrower ADR RPED for Columbus Part 1 Combo 450 arm was 19.8% (38/192) and in the encorafenib monotherapy arm was 2.1% (6/192). In the Combo 450 arm, symptomatic RPED (Grade ≥ 2 in the Applicant's grading system) was noted in 15 patients (7.8%) and in 1 patient in the encorafenib monotherapy arm (0.5%). For 38 patients in the Combo 450 arm (19.8%) and 6 patients in the encorafenib monotherapy arm (3.1%) the event was serious. No patients on either arm discontinued treatment due to RPED. In the Combo 450 arm, 5 patients (2.6%) and no patients in the encorafenib arm required dose reduction. There were 8 patients in the Combo 450 arm (4.2%) and 1 patient in the encorafenib monotherapy arm (0.5%) who interrupted treatment due to RPED.

The incidence of RPED in the pooled binimetinib monotherapy arm was 35.4%. Based on the data, the serous retinopathy observed in patients who receive Combo 450 is due to the binimetinib.

Retinopathy is included Warnings and Precautions in the cobimetinib label as serous retinopathy and the trametinib label as RPED. Retinopathy is not included in the vemurafenib or dabrafenib labels. The Applicant proposes the inclusion of serous retinopathy in Warnings and Precautions of the binimetinib label.

Retinal vein occlusion is a known class effect of MEK inhibitors. Based on the low frequency, the Applicant does not include it as a separate ADR. It was, however, evaluated as an AESI. In COLUMBUS Part 1, no RVO events were reported in any patient in the Combo 450 or in the larger pooled dataset COMBO > 400. One patient in the Columbus Part 1 encorafenib monotherapy arm (0.5%) experienced RVO. The event was grade 3 and no action was taken with treatment.

In the binimetinib monotherapy pooled dataset, 9 patients experienced RVO for an incidence of 2.1%. Five patients (1.2%) had Grade 3-4 events. Seven of the patients (1.6%) discontinued treatment due to RVO. One of the 7 patients had previously had a dose adjustment or interruption for Grade 1 event that subsequently progressed to Grade 2 before discontinuation.

Although not observed in patients receiving binimetinib with encorafenib, based on the single agent binimetinib data along with experience with other MEK inhibitors, the Applicant considers RVO an adverse reaction associated with binimetinib.

RVO is included in Warnings and Precautions in the cobimetinib and trametinib labels only. The Applicant proposes the inclusion of serous retinopathy in Warnings and Precautions of the binimetinib label.

Uveitis is a known class effect of BRAF inhibitors. In COLUMBUS Part 1, the ADR uveitis occurred in 3.6% of patients in the Combo 450 arm and only 0.5% of patients in the encorafenib monotherapy arm. Uveitis did not lead to discontinuation in any patients in COLUMBUS Part 1. Uveitis led to dose reduction in 1 patient (0.5%) and dose interruption in 6 patients (3.1%) in the Combo 450 arm while no patients in the encorafenib monotherapy arm had a dose interruption or reduction due to uveitis.

Uveitis is generally associated with BRAF inhibitors rather than MEK inhibitors. In the vemurafenib arm from Part 1 of Columbus, the incidence was 3.8%. The data from COLUMBUS in which the incidence of uveitis in patients receiving encorafenib monotherapy was low (0.7% across Parts 1 and 2) but was higher in patients receiving encorafenib with binimetinib (3.6% in the Combo 450, 3.9% in Combo 300) suggests that the primary contributor to toxicity is binimetinib. This is, however, inconsistent with the incidence of uveitis in the binimetinib monotherapy pooled dataset where the incidence was 0.2%. There is no clear explanation for the low rate of uveitis observed in the encorafenib monotherapy arm. One might postulate that it is artifact due to closer ophthalmologic monitoring required for patients receiving combination therapy; however, the incidence in the vemurafenib arm was 3.8%. One might postulate that it is related to the lower dose of encorafenib in the monotherapy arm; however, the incidence of uveitis in COLUMBUS Part 2 Combo 300 arm (3.9%) was similar to that

observed in the Combo 450 arm. Overall, based on the data, uveitis is assessed as related to both encorafenib and binimetinib.

Uveitis is included Warnings and Precautions in the vemurafenib and dabrafenib labels only and not included in the cobimetinib and trametinib labels. The Applicant proposes the inclusion of uveitis to Warnings and Precautions of the encorafenib and binimetinib labels.

6. *Venous Thromboembolism*

Venous thromboembolism (VTE) is a known class effect of MEK inhibitors. In COLUMBUS, the ADR VTE occurred in 5.7% (11/192) of patients in the Combo 450 arm (1.6% Grade 3-4) and in 3.1% of patients in the encorafenib monotherapy arm (1% Grade 3-4). In the Combo 450 arm, 3.1% of the patients had a serious VTE event. No patients in the encorafenib monotherapy arm had a serious VTE event. No patients in the Combo 450 arm discontinued therapy due to the event of VTE while 1 patient (0.5%) required a dose reduction and 6 patients (3.1%) required dose interruption. No patient in the encorafenib monotherapy arm discontinued, reduced, or interrupted therapy due to VTE. The ADR VTE occurred in 4.4% of patients in the binimetinib monotherapy pooled dataset.

Based on the data, VTE is assessed as related to the binimetinib in the Combo 450 regimen.

Venous thromboembolism is included Warnings and Precautions in the trametinib label. The Applicant proposes the inclusion of venous thromboembolism to Warnings and Precautions of the binimetinib label.

7. *Interstitial Lung Disease (ILD)*

Interstitial lung disease/pneumonitis is a known class effect associated with MEK inhibitors. The AESI pneumonitis, used by the Applicant, comprises the PT Interstitial lung disease, lung infiltration, and pneumonitis. In COLUMBUS 0.5% of patients in the Combo 450 arm and 1% of patients in the encorafenib monotherapy arm experienced ILD. No additional cases were observed in the Combo $\geq$ 400 pooled dataset (0.2%). In the binimetinib monotherapy pooled dataset there were 6 patients with ILD (1.4%), with 2 of the patients having Grade 3 events (0.5) (no Grade 4 events), and 3 patients having events categorized as serious.

ILD is rare in patients receiving Combo 450. ILD is included in Warnings and Precautions in the trametinib label. It is noted in other clinical experience in the cobimetinib label (pneumonitis). The Applicant proposes inclusion of the ADR interstitial lung disease in Warnings and Precautions of the binimetinib label.

8. *Rhabdomyolysis*

Elevation of serum CPK is a known class effect associated with MEK inhibitors. It may be associated with muscular symptoms. Rhabdomyolysis is not included in the label for vemurafenib or dabrafenib. It is included in Warnings and Precautions in the cobimetinib label. It is included with other clinically important adverse reactions (Section 6.1) in the trametinib label.

A higher percentage of patients in the Combo 450 arm (58%) compared with the encorafenib monotherapy part 1 arm (3%) and the vemurafenib arm (3.8%) had elevated laboratory value of

CPK. In the Combo 450 arm, 5% of patients had Grade 3 laboratory CPK elevation (all Grade 3) while no patients on the encorafenib monotherapy arm had Grade 3-4 laboratory CPK elevation. No patients in either arm had Grade 4 toxicity.

Despite the high number of patients who experienced Grade 1-2 CPK elevation, rhabdomyolysis was reported in only 1 patient in the Combo 450 arm (0.5%). No additional cases were observed in the Combo $\geq$ 400 pool (0.2%).

Based on AE reporting, 1 patient on the Combo 450 arm discontinued treatment due to elevated CPK with 6 patients (3.1%) requiring treatment interruption. No patients in the encorafenib monotherapy arm discontinued, reduced, or interrupted treatment due to elevated CPK or rhabdomyolysis.

The incidence in the binimetinib monotherapy pooled safety set was 0.5% (2 patients). All cases were Grade 3-4. No cases of rhabdomyolysis were reported in the encorafenib monotherapy part 1 or the vemurafenib arms.

The applicant reports that in the Combo 450 arm, of the patients who had an elevation of laboratory values of serum CPK, seven (6.3%) had at least one temporally associated muscle-related AE reported. The patient who experienced rhabdomyolysis had Grade 4 laboratory CPK elevation, muscle symptoms, and renal dysfunction.

Rhabdomyolysis is included in Warnings and Precautions in the cobimetinib label. It is noted with other clinically important adverse reactions under Clinical Experience in the trametinib label. Rhabdomyolysis is not included in the vemurafenib or dabrafenib labels. The Applicant proposes inclusion of rhabdomyolysis in the binimetinib label but not the encorafenib label.

9. QT prolongation

As seen in Table 73 from Section 8.2.3, while 27% of patients in the Combo 450 arm and 29% in of patients in the encorafenib monotherapy arm have an increased in QTcF more than 30 ms, few patients have a more significant increased of more than 60 ms with only 5.4% patients in the Combo 450 arm and 3.9% of patient in the encorafenib monotherapy arm experiencing such a change. Similarly, while 14% of patients in the Combo 450 arm have a new QTcF > 450 ms (21 % in the encorafenib monotherapy arm), a new QTcF > 500ms was rare in the Combo 450 arm with only 0.5% of patients having such an event (2.8% in the encorafenib monotherapy arm. Thus, mild increases were common, a larger, more serious increases, were rare. No patients discontinued treatment because of QT prolongation.

QT prolongation is included in Warnings and Precautions for the vemurafenib label. It is noted in the dabrafenib label under Pharmacodynamics that “no large changes in the mean QT interval (i.e., > 20 ms) were detected with dabrafenib 300 mg administered twice daily (two times the recommended dosage).” QT prolongation is not included in the cobimetinib or the trametinib labels.

As discussed in Section 8.2.3, QT-IRT found no large QTc prolongation (20 ms) is expected following a dose of 45 mg BID for binimetinib while a dose dependent QTc interval prolongation is associated with encorafenib.

The Applicant did not include QTc as an adverse reaction in either the encorafenib or binimetinib label; however, based on the QT-IRT, FDA believes QTc prolongation should be included in Warnings and Precautions in the encorafenib label. This is consistent with the safety analysis as well as the Applicant's proposed dose modifications for prolonged QTc, and is discussed further in Section 11.

Additional Common (≥ 25%) ADRs Observed in Combo 450

10. Fatigue

The ADR fatigue is commonly reported for patients on all arms in the Columbus Trial. In part 1, 43.2% of patients in the Combo 450 arm (3.1% Grade 3-4) and 41.7% of patients in the encorafenib monotherapy arm (3.1% Grade 3-4) experienced fatigue. Despite its frequency, only 2 patients (1%) in the Combo 450 arm and in the encorafenib monotherapy arm had events that were categorized as serious. One patient in the Combo 450 arm (0.5%) and no patients in the encorafenib monotherapy arm discontinued therapy because of fatigue. In the Combo 450 arm, 4 patients (2.1%) required treatment interruption while 2 patients (1.0%) required dose reduction. In the encorafenib monotherapy arm, 9 patients (4.7%) required treatment interruption and 4 patients (2.1%) required treatment reduction.

The addition of binimetinib in the Combo 450 arm did not increase the incidence of fatigue, although the incidence of fatigue in the binimetinib pooled dataset was 40%.

11. Nausea

The ADR nausea is commonly reported for patients on all arms in the Columbus Trial. In part 1, 41.1% of patients in the Combo 450 arm (1.6% Grade 3-4) and 38.5% of patients in the encorafenib monotherapy arm (4.2% Grade 3-4) experienced nausea. Despite its frequency, only 2 patients (1%) in the Combo 450 arm and 6 patients (3%) in the encorafenib monotherapy arm had events that were categorized as serious. No patients in either arm discontinued therapy because of nausea. In the Combo 450 arm, 14 patients (7.3%) required treatment interruption because of nausea while 2 patients (0.5%) required dose reduction. In the encorafenib monotherapy arm, 11 patients (5.7%) required treatment interruption and 6 patients (3.1%) required treatment reduction.

The addition of binimetinib in the Combo 450 arm did not increase the incidence of nausea, although the incidence of nausea in the binimetinib pooled dataset was 30%.

12. Vomiting

The ADR vomiting is commonly reported for patients on all arms in the Columbus Trial. In Part 1, 29.7% of patients in the Combo 450 arm (1.6% Grade 3-4) and 27.1% of patients in the encorafenib monotherapy arm (4.7% Grade 3-4) experienced vomiting. Despite its frequency, only 3 patients (1.6%) in the Combo 450 arm and 6 patients (3%) in the encorafenib monotherapy arm had events that were categorized as serious. No patients in the Combo 450 arm and 3 patients (1.6%) in the encorafenib monotherapy arm discontinued therapy because of vomiting. In the Combo 450 arm, 13 patients (6.8%) required treatment interruption because

of vomiting and no patients required dose reduction. In the encorafenib monotherapy arm, 9 patients (4.7%) required dose interruption and 1 patient (0.5%) required treatment reduction.

The addition of binimetinib in the Combo 450 arm did not increase the incidence of vomiting, although the incidence in the binimetinib monotherapy pooled dataset was 19.7%.

13. Arthralgias

The ADR arthralgias is commonly reported for patients on all arms in the Columbus Trial. In Part 1, 25.5% of patients in the Combo 450 arm (0.5% Grade 3-4) and 44.3% of patients in the encorafenib monotherapy arm (9.4% Grade 3-4) experienced arthralgias. Despite its frequency, no patients in the Combo 450 arm and only 1 patient (0.5%) in the encorafenib monotherapy arm had events that were categorized as serious. No patients in the Combo 450 arm and 1 patient (0.5%) in the encorafenib monotherapy arm discontinued therapy because of arthralgias. In the Combo 450 arm, 3 patients (1.6%) required treatment interruption because of arthralgias with 1 (0.5%) patients requiring dose reduction. In the encorafenib monotherapy arm, 16 patients (8.3%) required dose interruption and 8 patients (4.2%) required treatment reduction.

Although the incidence of arthralgias in the binimetinib monotherapy pooled dataset was 7.5%, the addition of binimetinib to encorafenib decreases the incidence in the Combo 450 arm. This is consistent with what is observed in other MEK/BRAF regimens and suggests some of the arthralgia observed with encorafenib is related to activation of the RAS pathway.

14. Diarrhea

The ADR diarrhea is frequently reported for patients on all arms in the Columbus Trial. In Part 1, 36.5% of patients in the Combo 450 arm (2.6% Grade 3-4) while only 13.5% of patients in the encorafenib monotherapy arm (1.6% Grade 3-4) experienced diarrhea. Despite the frequency of diarrhea AEs, only 1 patient (0.5%) in the Combo 450 arm and in the encorafenib monotherapy arm had an event that was categorized as serious. One patient in the Combo 450 arm (0.5%) and 2 patients (1.0%) in the encorafenib monotherapy arm discontinued therapy because of diarrhea. In the Combo 450 arm, 6 patients (3.1%) required treatment interruption and 1 patient (0.5%) requiring dose reduction for diarrhea. In the encorafenib monotherapy arm, 4 patients (2.1%) required dose interruption and no patients required dose reduction.

The incidence of diarrhea in the binimetinib monotherapy pooled dataset was 42.6%. The addition of binimetinib to encorafenib in the Combo 450 arm increases the incidence of diarrhea, although serious events and events leading to discontinuation or dose reduction remain rare.

15. Abdominal Pain

The ADR abdominal pain is frequently reported for patients on all arms in the Columbus Trial. In Part 1, 28.2% of patients in the Combo 450 arm (3.6% Grade 3-4) while only 16.7% of patients in the encorafenib monotherapy arm (3.1% Grade 3-4) experienced abdominal pain. It is notable that 6 patients (3.1%) in the Combo 450 arm and 4 patients (2.1%) in the encorafenib monotherapy arm had an event that was categorized as serious.

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

In the Combo 450 arm 6 patients (3.1%) and 4 patients (1.0%) in the encorafenib monotherapy arm discontinued therapy because of abdominal pain. In the Combo 450 arm, 6 patients (3.1%) required treatment interruption and 1 patient (0.5%) requiring dose reduction for abdominal pain. In the encorafenib monotherapy arm, 6 patients (3.2%) required dose interruption and 1 patient (0.5%) patient required dose reduction.

The incidence of abdominal pain in the binimetinib monotherapy pooled dataset was 15.9%. The addition of binimetinib to encorafenib in the Combo 450 arm increases the incidence of abdominal pain, and in both the Combo 450 and the encorafenib monotherapy arms, a relatively high number of patients discontinued therapy because of this ADR.

Clinically Relevant Adverse Reactions Reported in < 10% COMBO 450

16. Facial Paresis

Facial paresis has been reported in patients receiving BRAF inhibitors. In COLUMBUS Part 1, the incidence of facial paresis in the Combo 450 arm and vemurafenib arms was 1.0%. In the encorafenib arm, the incidence was 7.3% (1.6% Grade 3-4). In the encorafenib monotherapy arm, facial paresis was reported as an SAE for 2.6% of patients, led to discontinuation in 1% of patients, and required dose interruption and/or change in 3.6% of patients. Facial paresis was not reported in any patients in the binimetinib pooled dataset. The addition of binimetinib effectively eliminates this toxicity in patients receiving Combo 450.

Facial paresis has been observed in patients receiving vemurafenib. The vemurafenib label notes VIIth nerve paralysis under clinically relevant adverse reactions (Section 6.1) reported in < 10% of patients. Similarly, the Applicant proposed label for encorafenib includes the AR facial paresis in Section 6.1 under clinically relevant adverse reactions reported in < 10% Combo 450.

17. Pancreatitis

Pancreatitis is a known class effect associated with BRAF inhibitors. In the Combo 450 arm Grade 3-4 AEs of amylase and lipase elevations were reported in 1.6% and 1.6% of patients. The Applicant reports that a clinical review showed in 4 patients in the Combo 450 arm elevation was associated with abdominal pain, two of whom were diagnosed with acute pancreatitis. While the ADR pancreatitis occurred in 2 patients in the Combo 450 arm (1%), there were no patients in the encorafenib monotherapy arm with the ADR pancreatitis. There were 2 cases of pancreatitis in the Combo 450 arm that were categorized as serious. No patients discontinued or reduced treatment for pancreatitis. One patient (0.5%) interrupted treatment because of pancreatitis.

In the binimetinib monotherapy pooled population, there were no cases of pancreatitis.

Pancreatitis is included in the dabrafenib label under clinically relevant adverse reactions (Section 6.1) reported in < 10% of patients. The Applicant proposed label for encorafenib includes the AR pancreatitis in Section 6.1 under clinically relevant adverse reactions reported in < 10% Combo 450.

18. Panniculitis

Panniculitis is associated with use of BRAF and MEK inhibitors. In COLUMBUS Part 1, the ADR panniculitis occurred in 1.6% of patients (0% Grade 3-4) in the Combo 450 arm and 0.5% of patients in the encorafenib monotherapy arm. No patient in the Combo 450 or encorafenib arms discontinued, reduced, or interrupted therapy due to panniculitis. In the binimetinib monotherapy pooled dataset, panniculitis occurred in 0.2% of patients.

Panniculitis is included in the vemurafenib and dabrafenib labels under clinically relevant adverse reactions (Section 6.1) reported in < 10% of patients. The Applicant proposed label for encorafenib includes the AR panniculitis in Section 6.1 under clinically relevant adverse reactions reported in < 10% Combo 450.

19. *Drug Hypersensitivity*

The ADR drug hypersensitivity comprises the events urticaria, angioedema, hypersensitivity, hypersensitivity vasculitis, cutaneous vasculitis, vasculitis, and drug eruptions. In COLUMBUS Part 1, The ADR drug hypersensitivity occurred in 3.6% of patients in the Combo 450 arm (0% Grade 3-4) and in 4.7% of patients in the encorafenib monotherapy arm (0.5% Grade 3-4). One patient in the Combo 450 a5m (0.5%) and 1 patient in the encorafenib monotherapy arm (0.5%) had a drug hypersensitivity event that was classified as serious. No patients in the Combo 450 arm discontinued, reduced, or interrupted therapy due to drug hypersensitivity event. In the encorafenib monotherapy arm, 2 patients (1%) discontinued, 2 patients (1%) reduced, and 3 patients (1.6%) interrupted therapy due to drug hypersensitivity.

In the binimetinib monotherapy pooled population, 1.2% of patients had a drug hypersensitivity event.

Drug hypersensitivity is in Warnings and Precautions of the vemurafenib label and under clinically relevant adverse reactions (Section 6.1) reported in < 10% of patients in the dabrafenib label. The Applicant proposed labels for encorafenib and binimetinib include the AR drug hypersensitivity in Section 6.1 under clinically relevant adverse reactions reported in < 10% Combo 450.

20. *Colitis*

The ADR colitis comprises the events colitis, colitis ulcerative, enterocolitis, proctitis.

In COLUMBUS Part 1, the ADR colitis occurred in 2.1% of patients (1% Grade 3-4) in the Combo 450 arm and 1.0% of patients in the encorafenib monotherapy arm (0% Grade 3-4). Two patients in the Combo 450 arm (1%) had events that were classified as serious. No patients in the encorafenib arm had events classified as serious. No patient in the Combo 450 arm or the encorafenib monotherapy arm discontinued treatment due to colitis. In the Combo 450 arm, 1 patient (0.5%) reduced treatment while 2 patients (1%) interrupted treatment due to colitis. In the encorafenib monotherapy arm, no patients reduced treatment and 1 patient (0.5%) interrupted treatment due to colitis. There were no reports of intestinal perforation in the Combo 450 or encorafenib arms.

In the binimetinib monotherapy pooled dataset, there were no patients with the ADR colitis reported.

Colitis and Intestinal Perforation is included in Warnings and Precaution for the trametinib label. The Applicants proposed label for binimetinib include the AR colitis in Section 6.1 under clinically relevant adverse reactions reported in < 10% Combo 450.

Important ARs Identified in BRAF and MEK Inhibitors but not included in the proposed binimetinib or encorafenib labels

21. Severe Cutaneous Reactions

Serious cutaneous reactions are known to occur with BRAF and MEK inhibitors. Severe or serious dermatologic reactions are included in Warnings and Precautions in the vemurafenib, dabrafenib, cobimetinib, and trametinib labels. The Applicant did not include Severe Cutaneous Reactions in the set of ADRs due to the low frequency in the Combo 450 arm (1 patient), but did assess the events as an AESI.

The incidence in patients receiving encorafenib and/or binimetinib is low. All cases reported in COLUMBUS Part 1 were reported under the PT exfoliative dermatitis. Across the pooled combination dataset, there was one additional patient with an event of toxic skin eruption. In the pooled binimetinib dataset, 5 patients (1.2%) had a serious cutaneous reaction.

No AEs of Stevens Johnson Syndrome or toxic epidermal necrolysis occurred in the Combo $\geq$ 400, binimetinib monotherapy, or encorafenib monotherapy datasets.

The Applicant does not propose inclusion of serious cutaneous reactions in Warnings and Precautions for the binimetinib label.

22. Photosensitivity

Photosensitivity is an adverse drug reaction known to be associated with vemurafenib and is included in Warnings and Precautions in the vemurafenib and cobimetinib labels.

The AESI photosensitivity comprises the PTs of photosensitivity reaction, solar dermatitis, and dermatitis. In COLUMBUS Part 1, 5.2% of patients (10/192) in the Combo 450 arm, 4.7% of patients in the encorafenib monotherapy arm, and 37.6% of patients (70/186) in the vemurafenib arm had the AE of photosensitivity. The majority of events in patients receiving encorafenib with or without binimetinib were Grade 1 or 2. In the larger Combo $\geq$ 400 pooled dataset, 3.5% of patients experienced a photosensitivity event. The risk of photosensitivity associated with encorafenib or Combo 450 regimen is low.

The Applicant does not propose inclusion of photosensitivity in the labels for binimetinib or encorafenib.

23. Radiation Sensitization and Radiation Recall

Radiation sensitization and radiation recall has been observed in patients taking vemurafenib and based on post marketing experience was added as a Warnings and Precaution to the label. In the ISS dataset submitted to binimetinib and encorafenib applications, there were no reports of radiation sensitization or radiation recall. In COLUMBUS Part 1, there was only 1 report of radiation injury in the Combo 450 arm (0.5%).

The applicant does not propose inclusion of radiation sensitization and/or recall in the labels for binimetinib or encorafenib.

24. Renal Failure

Renal Failure has been associated with use of BRAF inhibitors. It is included in Warnings and Precautions in the Vemurafenib label and as interstitial nephritis with other clinically important adverse reactions in Section 6.1 of the dabrafenib label.

The AESI acute renal failure includes the following PTs: acute kidney injury, renal failure, renal impairment, and oliguria. In COLUMBUS Part 1, 3.6% of patients in the Combo 450 arm (2.6% Grade 3-4), 2.6% of patients in the encorafenib monotherapy arm (1.6% Grade 3-4), and 4.8% of patients in the vemurafenib arm (1.6% Grade 3-4) had an AE classified as acute renal failure. Acute renal failure led to discontinuation of therapy in no patients in the Combo 450 arm and in 2 patients (1.0%) in the encorafenib monotherapy arm. The incidence of the AESI acute renal failure in the Combo $\geq$ 400 pooled dataset was 3.5% (2.1% Grade 3-4), similar to the that observed in the combination arm in COLUMBUS Part 1.

Considering laboratory measurement of creatinine as a marker of renal impairment, in COLUMBUS Part 1, 92.7% of patients in the Combo 450 arm (3.6% Grade 3-4) and 76.6% of patient in the encorafenib monotherapy arm (0.5% Grade 3-4) had a post baseline abnormal creatinine measure. Therefore, it appears that the addition of binimetinib or the increased dose of encorafenib may have increased the incidence of creatinine increases slightly in the Combo 450 patients; however, this may also be due to the longer exposure observed in the Combo 450 arm. Mild increases in creatinine can occur in cancer patients in the absence of drug therapy. In the absence of a placebo control arm, it is difficult to determine drug effect based on Grade 1 elevations. In summary, while increased creatinine was common in the COLUMBUS trial, Grade 3-4 increases were not.

The applicant does not propose inclusion of acute renal failure or any renal related AR in the binimetinib or encorafenib labels.

25. Dupuytren's Contracture and Plantar Facial Fibromatosis

Dupuytren's contracture, also known as plantar facial fibromatosis, is slowly progressive fibrosis of the palmar fascia, has been observed in patients who have received vemurafenib and is postulated as an adverse reaction associated with the BRAF inhibitor. Although not included in the original label for vemurafenib, Dupuytren's contracture was subsequently added. In the ISS dataset submitted to binimetinib and encorafenib applications, there were no reports of Dupuytren's contracture or plantar fascial fibromatosis. This reviewer examined all TEAEs classified in the SOC Musculoskeletal and connective tissue disorders to identify possible case with none found.

The applicant does not propose inclusion of Dupuytren's Contracture and Plantar Facial Fibromatosis in the binimetinib or encorafenib labels.

26. Serious Febrile Reaction

Serious febrile reactions have been observed in patients treated with dabrafenib as a single agent or administered with trametinib and is included in Warnings and Precautions for both

labels. The ADR pyrexia comprises the PTs body temperature increased, hyperpyrexia, hyperthermia, and pyrexia. In COLUMBUS Part 1, 18.2% of patients in the Combo 450 arm (4.2% Grade 3-4), 15.6% of patients in the encorafenib monotherapy arm (1% Grade 3-4), and 29.6% of patients in the vemurafenib arm (0% Grade 3-4) had an event classified as the ADR pyrexia. In the Combo 450 arm, there were no Grade 4 events. Pyrexia led to discontinuation of treatment in 0.5% and interruption or reduction of dose in 4.2%.

The PT pyrexia was the most commonly reported SAE in Combo 450 arm of COLUMBUS occurring in 6 patients (3.1%). Review of the narratives for these patients reveals that 2 patients developed an SAE of pyrexia after discontinuation of treatment due to progressive disease. Pyrexia resolved in both patients. Two patients developed an SAE of pyrexia associated with concurrent infections. One patient developed an SAE of pyrexia which resolved the next day without intervention. One patient had multiple episodes of pyrexia, one of which was classified as an SAE. No infectious etiology was identified and the events were not associated with concurrent AEs associated with infections. In summary 4 of the 6 patients had concurrent factors which may have contributed to the pyrexia, resulting in 2 patients in the Combo 450 arm (1%) having the AE pyrexia considered serious for which there is not an identifiable cause other than study drug.

The applicant does not propose inclusion of serious febrile reaction in the binimetinib or encorafenib labels.

27. Hyperglycemia

Hyperglycemia is included in Warnings and Precautions for the dabrafenib and trametinib labels.

In COLUMBUS Part 1, the incidence of the PT blood glucose increased was 1.6% in the Combo 450 arm (0.5% Grade 3-4) and 0% in the encorafenib monotherapy arm. None of the events were categorized as serious and no events required treatment discontinuation, interruption, or reduction. In the binimetinib monotherapy pooled dataset, there was only 1 patients (0.2%).

For hyperglycemia based on laboratory assessment, 27.6% of patients in the Combo 450 arm (5.2% Grade 3-4) and 27.1% of patients in the encorafenib monotherapy Part 1 arm (4.2%) had an increased fasting glucose (change from baseline).

The applicant does not propose inclusion of hyperglycemia in the binimetinib or encorafenib labels.

28. G6PD Deficiency

G6PD deficiency is included in Warnings and Precautions for the dabrafenib label. Encorafenib contains a sulfonamide moiety; however, the applicant does not include this potential risk in Warnings and Precautions in the proposed label. In response to an IR from FDA (dated 2/2/2008), the applicant provided an assessment of risk of hemolytic anemia for patients with G6PD. Key points are copied from the submission (SDN0024 submitted 2/5/2018) below:

- *Risk assessment for hemolytic anemia in patients with G6PD deficiency is based on ADME data showing that despite the sulfonamide moiety in the molecule,*

metabolism of encorafenib does not produce reactive metabolites associated with hemolysis in patients with G6PD and clinical data from across the clinical program for encorafenib did not show any cases of hemolytic anemia.

- *In vitro and in vivo ADME data from monkeys and humans confirm that encorafenib metabolism does not produce glutathione adducts of N-acetyl cysteine adducts. Thus, the hallmarks of reactive metabolites are not present following administration of encorafenib to humans and non-human primates.*

Attenuation of encorafenib associated ADRs by binimetinib

Table 81 shows the ADRs in which the frequency was a least 5% lower in the COMBO 450 compared to the encorafenib monotherapy arm. The attenuation of BRAF toxicities with the addition of a MEK inhibitor has been observed in other regimens that use BRAF and MEK inhibitors together. It is postulated that these toxicities are the result of a paradoxical activation of MAP kinase signally in BRAF wild-type cells by the BRAF inhibitor while the MEK inhibitor blocks this effect. In other BRAF/MEK combination regimens, this effect has been observed primarily in skin associated toxicities including hyperkeratosis, cuSCC, alopecia, and PPES. The list of ADRs in which the combination therapy is less toxic than encorafenib monotherapy include several toxicities not reported for other BRAF/MEK combination regimens.

The label for encorafenib should indicate the increased risk for these ADRs if a patient must discontinue binimetinib. Further, based on dose finding trials, the dose of encorafenib should be decreased to 300 mg once daily.

Table 81: ADRs Decreased (≥5%) in Combo 450 arm compared to Encorafenib monotherapy arm: COLUMBUS Part 1

ADR	Combo 450 N=192 All grades % (Grade 3-4 %)	Enc 300 N=192 All grades % (Grade 3-4 %)	Combo 450-Enc 300 Δ Incidence All Grades (Grade 3-4)
PPES	6.8 (0)	51 (13.5)	-44.3 (-13.5)
Alopecia	14.1 (-)	56.3 (-)	-42.2 (-)
Hyperkeratosis	22.9 (0.5)	57.3 (4.7)	-34.4 (-4.2)
Dry skin	16.1 (-)	37.5 (-)	-21.4 (-)
Arthralgia	25.5 (0.5)	44.3 (9.4)	-18.8 (-8.9)
Rash	22.4 (1.0)	41.1 (4.2)	-18.7 (-3.1)
Pruritus	12.5 (0.5)	30.7 (0.5)	-18.2 (0)
Pain in extremity	10.9 (1.0)	21.9 (1.0)	-10.9 (9)
Neuropathy	12 (1.0)	21.9 (1.0)	-9.9 (0)
Myopathy	23.4 (0)	33.3 (9.9)	-9.9 (-9.9)
Erythema	7.3 (0)	15.6 (1.6)	-8.3 (-1.6)
Dysgeusia	5.7 (-)	13 (-)	-7.3 (-)

ADR	Combo 450 N=192 All grades % (Grade 3-4 %)	Enc 300 N=192 All grades % (Grade 3-4 %)	Combo 450-Enc 300 Δ Incidence All Grades (Grade 3-4)
Facial paresis	1 (0.5)	7.3 (1.6)	-6.3 (-1.0)
Headache	21.9 (1.6)	28.1 (3.6)	-6.3 (-2.1)
Back pain	9.4 (0.5)	15.1 (2.6)	-5.7 (-2.1)
CuSCC	2.6 (0)	7.8 (0)	-5.2 (0)
Acneiform dermatitis	3.1 (0)	8.3 (0)	-5.2 (0)

Source: Reviewer generated table using ISS_ADADR (cutoff 9 May 2016, submitted by Applicant)
Abbreviations: cuSCC = cutaneous squamous cell carcinoma, PPES = palmar-plantar erythrodysesthesia.

Combo 450 versus Combo 300

In COLUMBUS Part 2, patients were randomized to received Combo 300 or encorafenib 300mg monotherapy. Although Part 1 and Part 2 were randomized at separate times, the demographics and baseline characteristics between the groups are similar, allowing an exploratory comparison of safety. Table 82 provides a comparison of overall safety between the Combo 450 and Combo 300 arm in COLUMBUS. Overall, the two arms are similar in: median exposure, on treatment deaths, and incidence of adverse events with the following exceptions: patients in the Combo 450 arm had a higher incidence of Grade 3-4 AEs (58%) compared to patients in the Combo 300 arm (47%), patients in the Combo 450 arm had a higher incidence of serious AEs (34%) compared to patients in the Combo 300 arm (29%), and patient in the Combo 450 arm had a higher incidence of Grade 3-4 AEs requiring dose interruption (33%) compared to patients in the Combo 300 arm (23%). For other parameters, the difference in incidence was < 5% between the two arms.

Table 83 lists ADRs that occur with increased frequency (≥5%) in the Combo 450 arm when compared to the Combo 300 arm.

In summary, the increased dose of encorafenib used in the Combo 450 arm compared to the Combo 300 arm results in a slight increase in toxicity, but this increase in toxicity does not lead to greater number of on treatment deaths or discontinuations. It does lead to slight increase in severity of adverse events.

Table 82: Summary of Deaths and Adverse Events Combo 450 versus Combo 300: COLUMBUS

	Combo 450 N=192		Combo 300 N=257	
	Median duration of exposure 51.21 weeks		Median duration of exposure 52.14 weeks	
	All Grades n (%)	Grade 3-4 n (%)	All Grades n (%)	Grade 3-4 n (%)
On-treatment deaths (≤ 30 days EOT)	17 (8.9)	----	25 (9.7)	---

Adverse Events	189 (98.4)	111 (57.8)	252 (98.1)	120 (46.7)
Serious AEs	66 (34.4)	57 (29.7)	75 (29.2)	65 (25.3)
AEs leading to discontinuation	24 (12.5)	22 (11.5)	32 (12.5)	23 (8.9)
AE requiring dose interruption/reduction	92 (47.9)	63 (32.8)	115 (44.7)	59 (23.0)

Source: CSR COLUMBUS Part 1 Table 35, CSR COLUMBUS Part 2 Initial Table 24.

Table 83: ADRs increased (≥5%) in Combo 450 arm versus Combo 300 arm: COLUMBUS

ADR	Combo 450 N=192 % All Grades (% Gr 3-4)	Combo 300 N=257 % All Grades (% Gr 3-4)
Nausea	43.2 (1.6)	27.2 (1.6)
Vomiting	30.2 (1.6)	15.2 (0.4)
Hemorrhage	19.3 (3.6)	6.6 (1.6)
Fatigue	45.3 (3.1)	33.5 (1.6)
Headache	22.9 (1.6)	12.1 (0.4)
Rash	22.9 (1.0)	14 (0.8)
Diarrhea	37.0 (2.6)	28.4 (1.6)

Source: Reviewer generated table using ISS_ ADADR (Submitted with 4-month safety update 10/27/2018)

8.2.5. Clinical Outcome Assessment (COA) Analyses Informing Safety/Tolerability

There were no COA analyses performed informing safety and tolerability. Patient reported outcomes are not included in the label. An analysis of COA as a secondary or exploratory endpoint is discussed in Section 8.1.2.

8.2.6. Safety Analyses by Demographic Subgroups

TEAES by Age

Table 84 summarizes AEs by age group for COLUMBUS Part 1. Patients were categorized as < 65 years of age or ≥ 65 years of age. In the COMBO 450 arm, a higher proportion of older patients (≥ 65 years) experienced Grade 3-4 TEAEs and SAEs and this translated into higher proportion of patients having a TEAE leading to reduction and/or interruption of treatment. Analysis comparing the frequency of individual ADRs in patients < 65 years of age to the frequency in patients ≥ 65 years of age identified some minor differences; however, some differences are to be expected due to chance alone, and given the limited number of patients in each group, a true interaction between gender and these differences could not be concluded. While adverse events occur more frequently in patients ≥ 65 years, this is observed across all treatment arms and is unlikely to be treatment-specific. Furthermore, age ≥ 65 does not result in an increased

frequency of treatment interruption or discontinuation. Therefore, no age specific labeling is indicated.

Table 84: Overall Summary of Adverse Events by Age Group: COLUMBUS Part 1

Event	COLUMBUS Part 1					
	Combo 450		Enc 300		Vem	
	<65 N= 132 n (%)	≥65 N= 60 n (%)	<65 N= 153 n (%)	≥65 N= 39 n (%)	<65 N= 136 n (%)	≥65 N=50 n (%)
Any TEAE	129 (97.7)	60 (100)	153 (100)	38 (97.4)	135 (99.3)	50 (100)
Grade 3-4 TEAE	73 (55.3)	38 (63.3)	99 (64.7)	28 (71.8)	83 (61.0)	35 (70)
Any SAE	42 (31.9)	24 (40.0)	51(33.3)	14 (35.9)	53 (39.0)	16 (32.0)
Grade 3-4 SAE	36 (27.3)	21 (35.0)	43 (28.1)	11 (28.2)	46 (33.8)	14 (28.0)
TEAE leading to discontinuation	16 (12.1)	8 (13.3)	21 (13.7)	6 (15.4)	18 (13.2)	13 (26.0)
TEAE leading to interruption	59 (44.8)	29 (48.3)	98 (64.0)	24 (61.5)	71 (52.2)	27 (54.0)
TEAE leading to reduction	11 (0.8)	11 (18.3)	42 (27.4)	10 (25.6)	26 (19.1)	16 (32.0)
TEAE leading to interruption/reduction	60 (45.5)	32 (53.3)	109 (71.2)	26 (66.7)	80 (58.8)	34 (68.0)

Source: Reviewer generate table ISS_ADAE (cutoff 9 May 2016, submitted by applicant)

TEAES by Gender

Table 85 summarizes the adverse events by sex for COLUMBUS Part 1. Across all stages, 60% of patients diagnosed with melanoma will be male. This ratio was maintained generally across arms in the trial. The incidence for each event e.g., Grade 3-4 TEAE, is similar ($\leq 10\%$ difference) between male and female patients for each arm. Analysis comparing the frequency of individual ADRs in males to the frequency in females did identify some minor differences; however, given the limited number of patients in each group, a true interaction between gender and these differences could not be concluded. Therefore, no gender specific labeling is indicated.

Table 85: Overall Summary of Adverse Events by Sex: COLUMBUS Part 1

Event	COLUMBUS Part 1					
	Combo 450		Enc 300		Vem	
	Male N= 115 n (%)	Female N= 77 n (%)	Male N= 106 n (%)	Female N= 86 n (%)	Male N= 108 n (%)	Female N= 78 n (%)
Any TEAE	112 (97.4)	77 (100)	105 (99.1)	86 (100)	107 99.1)	78 (100)
Grade 3-4 TEAE	65 (56.6)	46 (59.7)	73 (68.9)	54 (62.8)	67 (62.0)	51 (65.4)

Event	COLUMBUS Part 1					
	Combo 450		Enc 300		Vem	
	Male N= 115 n (%)	Female N= 77 n (%)	Male N= 106 n (%)	Female N= 86 n (%)	Male N= 108 n (%)	Female N= 78 n (%)
Any SAE	42 (36.5)	24 (31.2)	43 (40.6)	22 (25.6)	41 (38.0)	28 (35.9)
Grade 3-4 SAE	37 (32.3)	20 (26.0)	33 (31.1)	21 (24.4)	34 (31.5)	26 (33.3)
TEAE leading to discontinuation	9 (7.8)	5 (6.5)	5 (4.7)	5 (5.8)	7 (6.5)	4 (5.1)
TEAE leading to interruption	20 (17.4)	7 (9.1)	20 (18.9)	13 (15.1)	14 (13.0)	11 (14.1)
TEAE leading to reduction	3 (2.6)	0	0	1 (1.2)	2 (1.9)	0
TEAE leading to interruption/reduction	22 (19.1)	7 (9.1)	20 (18.9)	14 (16.3)	15 (13.9)	11 (14.1)

Source: Reviewer generate table ISS_ADAE (cutoff 9 May 2016, submitted by applicant)

8.2.7. Specific Safety Studies/Clinical Trials

No clinical trials were conducted to evaluate a specific safety concern. As covered in Section 8.2.3 with the discussion of QT, while a dedicated QT trial was not performed, three cardiac studies were submitted.

8.2.8. Additional Safety Explorations

Human Carcinogenicity or Tumor Development

See Section 5.5.3.

Human Reproduction and Pregnancy

There were no reported exposures to encorafenib or binimetinib in pregnant or lactating women.

Pediatrics and Assessment of Effects on Growth

Not applicable.

Overdose, Drug Abuse Potential, Withdrawal, and Rebound

No AEs of overdose have been reported for patients receiving single-agent encorafenib or single agent binimetinib. One SAE report of an overdose of binimetinib was reported for a patient receiving binimetinib given with encorafenib. The patient was prescribed to take 45 mg twice daily of binimetinib along with 300 mg once daily of encorafenib. Approximately 6.5 months after starting treatment, the patient took a one time 135 mg dose of binimetinib while omitting the encorafenib dose. No AEs were reported with the overdose event. The event was considered resolved after 5 days.

In dose escalation trials of encorafenib to be given with a fixed dose of 45 mg twice daily of binimetinib, patients received encorafenib 600 mg QD (68 patients) and 800 mg (6 patients). Per the Applicant, the most commonly reported AEs in patients receiving doses $\geq$ 600 mg were nausea, diarrhea, fatigue, constipation, abdominal pain, vomiting, headache, and arthralgia. In addition, 21% of patients receiving doses $\geq$ 600 mg had events of renal dysfunction (Grade 3 hypercreatinemia).

8.2.9. Safety in the Postmarket Setting

Safety Concerns Identified Through Postmarket Experience

Not applicable.

Expectations on Safety in the Postmarket Setting

Safety in the postmarket setting is expected to be similar to that observed on the clinical trials reviewed in this application. Safety with long-term use of encorafenib and binimetinib when used together will need to be monitored closely given the risk of secondary malignancies associated with RAS pathway activation by encorafenib.

8.2.10. Integrated Assessment of Safety

The evaluation of the safety of the Combo 450 regimen in patients with locally advanced or metastatic melanoma with a BRAF V600 E/K mutation was based primarily on the 570 patients randomized in COLUMBUS Part 1 who received at least one dose of study drug(s). Part 1 of COLUMBUS was a randomized, open label, multi-center, controlled trial comparing the efficacy and safety of encorafenib plus binimetinib versus vemurafenib versus encorafenib monotherapy in patients with locally advanced unresectable or metastatic melanoma with BRAF V600 mutation. Of the 570 patients, 192 received encorafenib plus binimetinib (Combo 450), 192 patients received encorafenib monotherapy, and 186 patients received vemurafenib.

The review also included analysis of a pooled dataset of 433 patients who received encorafenib $\geq$ 400 mg QD in conjunction with binimetinib 45 mg BID. This pooled dataset was considered adequate to detect serious but rare events associated with the regimen.

COLUMBUS excluded patients that were at increased risk of adverse reactions from the known toxicity of kinase inhibitors of BRAF and/or MEK. Such inclusion criteria included the following:

- History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO (e.g. uncontrolled glaucoma or ocular hypertension, history of hyper viscosity or hypercoagulability syndromes);
- Impaired cardiovascular function or clinically significant cardiovascular diseases, including history of acute coronary syndromes (including myocardial infarction, unstable angina, CABG, coronary angioplasty, or stenting) <6 months prior to screening, symptomatic chronic heart failure, history or current evidence of clinically significant cardiac arrhythmia and/or conduction abnormality <6 months prior to screening;

- Uncontrolled hypertension despite medical treatment;
- Patients who have neuromuscular disorders that are associated with elevated CPK (e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy).

In COLUMBUS, the median duration of exposure to Combo 450 regimen was 51.2 weeks (range 0.4 weeks to 116 weeks) with 52.6% of patients receiving the combination treatment for at least 48 months. Table 86 summarizes the overall safety profile of the Combo 450 regimen as observed in COLUMBUS Part 1. Overall the Combo 450 regimen was generally better tolerated than vemurafenib with lower incidence of Grade 3-4 TEAEs, SAEs, AEs leading to discontinuations and lower incidence of AEs leading to reductions or interruptions, despite a longer median exposure in the Combo 450. Tolerability of Combo 450 was similar to that observed in the encorafenib monotherapy arm.

Table 86: Summary of Safety Events: COLUMBUS Part 1

Category	Combo 450 N=192 n (%)	Enc 300 N=192 n (%)	Vemurafenib N=186 n (%)
Median Exposure (weeks)	51.2	31.4	27.1
On-treatment deaths ¹	17 (8.9)	14 (7.3)	19 (10.2)
Adverse Event	189 (98.4)	191 (99.5)	185 (99.5)
Grade 3-4	111 (57.8)	127 (66.1)	118 (63.4)
Serious Adverse Event	66 (33.4)	65 (33.9)	69 (37.1)
Grade 3-4	57 (29.7)	54 (28.1)	60 (32.3)
AE → discontinuation	24 (12.5)	27 (14.1)	31 (16.7)
Grade 3-4	22 (11.5)	21 (10.9)	18 (9.7)
AE → dose interruption/ change	92 (47.9)	135 (70.3)	114 (61.3)
Grade 3-4	63 (32.8)	85 (44.3)	71 (38.2)

¹ Includes deaths due to disease progression

Source: Reviewer generated table – summarizing Review Tables

The most common adverse drug reactions observed in the Combo 450 arm, occurring in at least 20% of patients, were: fatigue, nausea, diarrhea, vomiting, abdominal pain, arthralgias, myopathy, hyperkeratosis, headache, rash constipation, RPED, and visual impairment. In addition, Grade 3-4 laboratory abnormalities observed in at least 5% of patients in the Combo 450 arm were increased ALT, increased AST, increased fasting glucose, and increased GGT. Other serious but rare adverse drugs reactions include: new cutaneous malignancies such as squamous cell cutaneous squamous cell carcinoma, left ventricular dysfunction, hemorrhage with a risk of cerebral hemorrhage associated with brain metastases, retinal pigment epithelial detachment, uveitis, retinal vein occlusion, venous thromboembolism, interstitial lung disease, rhabdomyolysis, and QT prolongation.

Overall, the safety profile of the Combo 450 regimen is similar to that observed with other BRAF/MEK inhibitor regimens, including the commonly observed adverse drug reactions as well as the rare but serious toxicities. No new safety signals were identified in the course of this review. As with other BRAF/MEK regimens, there is a risk of several toxicities, including secondary malignancies, associated with RAS pathway activation due to a BRAF inhibitor, specifically encorafenib. As with other BRAF/MEK regimens, this toxicity is attenuated by the addition of a MEK inhibitor, specifically binimetinib. With Combo 450, however, this attenuation effect appears to apply to a larger set of toxicities than observed in other BRAF/MEK inhibitor combinations, for example arthralgias and myalgias/myopathy.

The safety profile of the Combo 450 regimen for the treatment of patients with advanced or metastatic BRAF V600 mutant melanoma is acceptable with adverse reactions typically managed through temporary treatment discontinuation or dose reduction.

SUMMARY AND CONCLUSIONS

8.3. Statistical Issues

COLUMBUS was not adequately designed to demonstrate that the efficacy of Combo 450 is superior to Combo 300 for any endpoint. Because Part 1 and Part 2 were randomized at different times, comparisons of Combo 450 to Combo 300 may not be meaningful. However, results from Parts 1 and 2 do not suggest any detrimental effect of Combo 450 vs. Combo 300 on key efficacy endpoints.

COLUMBUS failed to demonstrate a statistically meaningful difference in PFS between Combo 450 and encorafenib. However, estimates of the treatment effect suggest Combo 450 may increase PFS when compared to encorafenib. This comparison does not account for differences in dosing. Part 2 of COLUMBUS was designed to isolate the effect of binimetinib, as encorafenib was given at 300mg in both arms. Estimates from Part 2 of the treatment effect of Combo 300 vs. encorafenib on PFS suggest that Combo 300 increases PFS, although this comparison was not pre-specified as the primary analysis of this comparison. The test pre-specified to assess this comparison, Test 3, utilized patients from both Parts 1 and 2, and consequently may be biased. However, the results from Test 3 also suggest a treatment effect of Combo 300 on PFS when compared to encorafenib.

8.4. Conclusions and Recommendations

COLUMBUS demonstrated that the combination regimen of encorafenib 450 mg once daily given with binimetinib 45 mg twice daily had a statistically significant effect on PFS when compared to vemurafenib, with estimated median PFS times of 14.9 months (95% CI: [11.0, 18.5]) for the Combo 450 arm and 7.3 months (95% CI: [5.6, 8.2]) for the vemurafenib arm, along with an associated hazard ratio of 0.54 (95% CI: [0.41, 0.71]). The risks identified with the use of the combination regimen were consistent with other BRAF/MEK inhibitor regimens and are manageable by medical oncologists.

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

Based on the favorable risk: benefit profile, the clinical and statistical reviewers recommend approval for binimetinib and encorafenib when given together for patients with advanced or metastatic melanoma harboring a BRAF V600 mutation.

Jonathan Vallejo, PhD
Primary Statistical Reviewer

Lisa Rodriguez, PhD
Statistical Team Leader

Margaret Thompson, MD, PhD
Primary Clinical Reviewer

Ashley Ward, MD
Clinical Team Leader

9 Advisory Committee Meeting and Other External Consultations

No advisory committee meeting was held for this NDA.

10 Pediatrics

Encorafenib and binimetinib were not studied in pediatric patients. Encorafenib with binimetinib was granted orphan designation status for the treatment of Stage IIB-IV melanoma positive for the BRAF mutation on 11/19/2013 (Orphan Designation Number 13-4116).

11 Labeling Recommendations

11.1 Prescription Drug Labeling

Encorafenib (BRAFTOVI)

The following are recommended major changes to the BRAFTOVI (encorafenib) prescribing information proposed by the applicant based on this review:

- **1 INDICATIONS AND USAGE:**

Add Limitation of Use stating that BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma as required per 21 CFR 201.57, which states that if evidence is available to support the safety and effectiveness of the drug or biological product only in selected subgroups of the larger population (e.g., patients with mild disease or patients in a special age group), include a succinct description of the limitations of usefulness of the drug.

- **2 DOSAGE AND ADMINISTRATION:**

Modify Dosage Modifications for Adverse Reactions as follows:

- Include exceptions to dose modifications of BRAFTOVI for those ARS associated with binimetinib as a footnote to Table 2.

- Remove (b) (4).
(b) (4).

Add Section 2.4 Dose Modifications for Coadministration of Strong or Moderate CYP3A4 Inhibitors providing the recommended dose reductions for patient who cannot avoid concomitant use of these drugs.

- **5 WARNINGS AND PRECAUTIONS (W&P)**

- In general:

- Except for rare events of those attenuated by the addition of binimetinib, a W&P should include only the incidence for encorafenib given with binimetinib. (b) (4)

- Add new W&P Tumor Promotion in BRAF Wild-Type Tumors as this serious effect has been shown with other BRAF inhibitors. (b) (4)

Add "QTc Prolongation" as a new W&P based on the observed QTc changes in patients in the COLUMBUS trial and the assessment that this toxicity is due to encorafenib. Array disagreed with FDA's proposal to add QTc prolongation to W&P, presenting their argument in a letter submitted to the NDA on 5/25/2018 (SDN 34). A teleconference subsequently occurred between Array and FDA on June 6, 2018 to discuss this disagreement.

In their letter, Array argued that the observed effect in terms of central tendency is best described by data from the Week 2 Day 1 time point or from an average of all time points that encompass the steady-state data, both of which showed an upper-bound 90% CI < 20 ms for mean QTc change. They stated that the former represents the steady-state value with the lowest variability, and the latter incorporates all available data. This is in contrast to FDA, whose assessment used 6-week data and is consistent with the intersection-union test recommended in the context of thorough studies in the ICH E14 guidance.

Array further stated that the absence of any clinical signal and the low observed rate of clinically relevant QTc prolongations > 500 ms suggests a limited potential for clinically meaningful arrhythmogenic effects. While Array acknowledged a signal for concentration-dependent QTc prolongation, they maintain that the effect is below the threshold that would warrant inclusion in W&P.

At the teleconference, Array restated their belief that the inter-subject variability of QTC effect is high, and the effect of encorafenib on mean QTc change is less than 20 ms at encorafenib steady-state exposure.

FDA disagreed, considering the effect size as derived in the review by QT-IRT to be robust with similar effect size to that observed in another study with encorafenib monotherapy. FDA cited ICH E14, which states that a warning/precautionary statement should be recommended for drugs that prolong the QT/QTc interval (prolongation exceeds 5 ms as evidenced by an upper bound of the two sided 90% CI around 10 ms), and noted its general position, in the absence of a “definitive” QT study that can exclude a large QTc prolongation signal, is to require a QT prolongation Warnings and Precaution for an oncology drug based on the totality of evidence. It is the standard practice for FDA to base labeling recommendations on the largest upper bound of the two sided 90% CI for the by-time (central tendency) analysis.

With this additional explanation, Array agreed to include the W&P, and FDA agreed that only patients at high risk of QT prolongation at baseline needed to be monitored with serial ECG.

- Add “Risks associated with BRAFTOVI as a Single Agent” as a new W&P to warn that BRAFTOVI when used as a single agent is associated with an increased risk of certain adverse reactions compared to when BRAFTOVI is used in combination with binimetinib.
- Add “Risks associated with Combination Treatment” as a new W&P to refer the clinician to the binimetinib label.

○ **6 ADVERSE REACTIONS**

- In Table 3, delete (b) (4) and add information about adverse reactions that are observed at a higher rate in patients receiving BRAFTOVI alone compared to those receiving it in combination with binimetinib. During labeling negotiations, Array provided adequate justification for exclusion from Table 3 of AEs that could reasonably be attributed primarily or exclusively to binimetinib.
- In Table 4, remove (b) (4). During labeling negotiations, Array provided adequate justification (b) (4)

○ **8 USE IN SPECIFIC POPULATIONS**

- As per 21 CFR 21.57(c)9(v) remove data regarding geriatric use given clinical studies of encorafenib did not include sufficient number of patients aged 65 and older to determine whether they respond differently from younger patients.

● **12 CLINICAL PHARMACOLOGY**

- **12.2 Pharmacodynamics:** Replace Array's proposal with the following text:
Cardiac Electrophysiology
A dedicated study to evaluate the QT prolongation potential of BRAFTOVI has not been conducted. BRAFTOVI is associated with dose-dependent QTc interval prolongation. Following administration of the recommended dose of BRAFTOVI in combination with binimetinib, based on a central tendency analysis of QTc in a study of adult patients with melanoma, the largest mean (90% CI) QTcF change from baseline (Δ QTcF) was 18 (14 to 22) ms [see Warnings and Precaution (5.5)].

● **14 CLINICAL STUDIES**

- Remove (b) (4).
- In Table 5, remove (b) (4) add information for progressive disease and deaths, and calculate DOR for confirmed responses only.

Binimetinib (MEKTOVI)

The following are recommended major changes to the MEKTOVI (binimetinib) prescribing information proposed by the applicant based on this review:

● **2 DOSAGE AND ADMINISTRATION:**

Modify Dosage Modifications for Adverse Reactions as follows:

- Remove (b) (4).
- Add dose modifications for uveitis given its inclusion in W&P Add Section 2.3 Dose Modifications for Moderate or Severe Hepatic Impairment

○ **5 WARNINGS AND PRECAUTIONS (W&P)**

- Remove (b) (4)
(b) (4)
- **6 ADVERSE REACTIONS**
 - In Table 3, delete (b) (4)
(b) (4). During labeling negotiations, Array provided adequate justification (b) (4)
 - In Table 4, remove (b) (4)
(b) (4) During labeling negotiations, Array provided adequate justification (b) (4)
(b) (4) FDA agreed that Table 4 does not need to be identical in the labels for BRAFTOVI and MEKTOVI.
- **8 USE IN SPECIFIC POPULATIONS**
 - As per 21 CFR 21.57(c)9(v) remove data regarding geriatric use given clinical studies of encorafenib did not include sufficient number of patients aged 65 and older to determine whether they respond differently from younger patients.
- **14 CLINICAL STUDIES**
 - Remove (b) (4)
 - In Table 5, remove (b) (4)
(b) (4)

CDTL Comment: During labeling negotiations with the applicant, it was agreed that the rare but serious events of Retinal Vein Occlusion and Interstitial Lung Disease should be included in the Warnings & Precautions section of the binimetinib label (see rationale provided in Section 8.2.4 of this review). As these events were not observed in the primary safety pool (n=192 who received Combo 450 regimen on COLUMBUS), the applicant and the FDA agreed to use a pool of n=690 patients with BRAF V600 mutation positive melanoma who were exposed to binimetinib at a dose of 45 mg twice daily in combination with encorafenib at doses between 300 mg and 600 mg once daily across multiple clinical trials (COLUMBUS Parts 1 and 2, LOGIC2, and patients on Study CMEK162X2110 who received either the Combo 450 or the Combo 600 regimen) to describe the frequency of these events.

To ensure that patients are adequately informed of the risks of encorafenib and binimetinib and when to seek medical attention, the FDA requested that Array provide a Patient Medication Guide for encorafenib and a Patient Package Insert (PPI) for binimetinib. The FDA determined that a Patient Medication Guide was warranted for encorafenib due to the risk of new primary malignancies and the need for ongoing surveillance. The FDA determined that a PPI was sufficient to communicate the risks of binimetinib.

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

Carton and Container Labeling was reviewed per FDA standard practice. Numerous minor modifications were recommended to improve clarity and usability. See CMC, OPDP, DMEPA, and Patient Labeling review for details.

12 Risk Evaluation and Mitigation Strategies (REMS)

There are no safety issues identified that require Risk Evaluation and Mitigation Strategies (REMS).

13 Postmarketing Requirements and Commitment

A clinical postmarketing commitment was requested to provide mature overall survival data from COLUMBUS for the purposes of updating the product label. See action letter for final wording and milestone dates.

Two clinical pharmacology postmarketing commitments were requested to generate additional management guidelines with respect to drug-drug interactions. See action letter for final wording and milestone dates.

14 Division Director (DHOT)

John Leighton, PhD

15 Division Director (OCP)

Nam Atiqur Rahman, PhD

16 Division Director (OB)

Rajeshwari Sridhara, PhD

17 Associate Division Director (Clinical)

Steven Lemery, MD, MHS

18 Office Director

Richard Pazdur, MD

19 Appendices

19.1. Financial Disclosure

Covered Clinical Study (Name and/or Number): CMEK162B2301

Was a list of clinical investigators provided:	Yes ☒	No ☐ (Request list from Applicant)
Total number of investigators identified: <u>2146</u>		
Number of investigators who are Sponsor employees (including both full-time and part-time employees): <u>0</u>		
Number of investigators with disclosable financial interests/arrangements (Form FDA 3455): <u>0</u>		
If there are investigators with disclosable financial interests/arrangements, identify the number of investigators with interests/arrangements in each category (as defined in 21 CFR 54.2(a), (b), (c) and (f)): Compensation to the investigator for conducting the study where the value could be influenced by the outcome of the study: _____ Significant payments of other sorts: _____ Proprietary interest in the product tested held by investigator: _____ Significant equity interest held by investigator in Sponsor of covered study: _____		
Is an attachment provided with details of the disclosable financial interests/arrangements:	Yes ☐	No ☐ (Request details from Applicant)
Is a description of the steps taken to minimize potential bias provided:	Yes ☐	No ☐ (Request information from Applicant)
Number of investigators with certification of due diligence (Form FDA 3454, box 3) <u>0</u>		
Is an attachment provided with the reason:	Yes ☐	No ☐ (Request explanation from Applicant)

Covered Clinical Study (Name and/or Number): CLGX818X2109

Was a list of clinical investigators provided:	Yes ☒	No ☐ (Request list from Applicant)
Total number of investigators identified: <u>243</u>		
Number of investigators who are Sponsor employees (including both full-time and part-time		

Multi-Disciplinary Review and Evaluation NDA 210496
 BRAFTOVI™ (encorafenib)

employees): <u>0</u>		
Number of investigators with disclosable financial interests/arrangements (Form FDA 3455): <u>0</u>		
If there are investigators with disclosable financial interests/arrangements, identify the number of investigators with interests/arrangements in each category (as defined in 21 CFR 54.2(a), (b), (c) and (f)): Compensation to the investigator for conducting the study where the value could be influenced by the outcome of the study: _____ Significant payments of other sorts: _____ Proprietary interest in the product tested held by investigator: _____ Significant equity interest held by investigator in Sponsor of covered study: _____		
Is an attachment provided with details of the disclosable financial interests/arrangements:	Yes ☐	No ☐ (Request details from Applicant)
Is a description of the steps taken to minimize potential bias provided:	Yes ☐	No ☐ (Request information from Applicant)
Number of investigators with certification of due diligence (Form FDA 3454, box 3) <u>0</u>		
Is an attachment provided with the reason:	Yes ☐	No ☐ (Request explanation from Applicant)

Covered Clinical Study (Name and/or Number): CLGC818X2101

Was a list of clinical investigators provided:	Yes ☒	No ☐ (Request list from Applicant)
Total number of investigators identified: <u>194</u>		
Number of investigators who are Sponsor employees (including both full-time and part-time employees): <u>0</u>		
Number of investigators with disclosable financial interests/arrangements (Form FDA 3455): <u>0</u>		
If there are investigators with disclosable financial interests/arrangements, identify the number of investigators with interests/arrangements in each category (as defined in 21 CFR 54.2(a), (b), (c) and (f)): Compensation to the investigator for conducting the study where the value could be influenced by the outcome of the study: _____ Significant payments of other sorts: _____		

Proprietary interest in the product tested held by investigator: _____		
Significant equity interest held by investigator in Sponsor of covered study: _____		
Is an attachment provided with details of the disclosable financial interests/arrangements:	Yes ☐	No ☐ (Request details from Applicant)
Is a description of the steps taken to minimize potential bias provided:	Yes ☐	No ☐ (Request information from Applicant)
Number of investigators with certification of due diligence (Form FDA 3454, box 3) <u>0</u>		
Is an attachment provided with the reason:	Yes ☐	No ☐ (Request explanation from Applicant)

19.2. OCP Appendices (Technical documents supporting OCP recommendations)

19.2.1. Population PK Analysis

The goal of population PK analysis (popPK) in this submission is to develop a population pharmacokinetic (PK) model to assess sources of variability (intrinsic and extrinsic covariates) and predict exposures to binimetinib, AR00426032 (active metabolite) and encorafenib. PopPK analyses were conducted by the applicant with Phoenix WinNonlin. Independent popPK analyses were conducted by the reviewer to confirm and reproduce the results using NONMEN 7.3.

19.2.1.1 Encorafenib

The popPK analysis included 701 patients contributing a total of 5325 encorafenib concentrations, among whom 383 (54.6%) and 146 (20.8%) were cancer patients enrolled in the COLUMBUS Part 1 and LOGIC 2 trials. The majority of the encorafenib concentrations were collected at cycle 1 day 1 (37.7%) and cycle 1 day 15 (20.9%).

A two-compartment model with first-order absorption was found to best describe the PK profile of encorafenib. An Emax function to describe the time-varying CL was incorporated into this model to evaluate the potential magnitude and time-dependent effect of enzyme auto-induction. Interim population PK analysis was first conducted based on rich concentration-time profiles in study ARRAY-162-105, CLGX818X2101 and CMEK162X2110. Two approaches were employed to evaluate the adequacy of the model fitting: simulation-based predictive checks and diagnostic plots comparing the predicted and observed concentrations. No signs of model misspecification were identified in the goodness-of-fit plots of base model (Figure 19). The prediction-corrected visual predictive check (Figure 20) showed the model provided satisfactory prediction of the central tendency and variability of the observed data in both cycle 1 day 1 and cycle 1 day 15.

Same base model was applied to all studies including sparse sampling in CMEK162B2301 part 1 after fixing typical value of E_{max} and T_{50} to the estimates obtained in the interim analysis. Covariates were initially screened using visual inspection, and the most relevant covariates were formally evaluated within the population PK model using a full model approach. The full covariate model included the following covariates effects: time effect, disease status (healthy subjects), hepatic impairment (NCI criteria), ECOG status, strong and moderate CYP3A4 inhibitors, potent CYP3A inducer and combination therapy as categorical covariates, and eGFR (as a measure of renal function), total protein, bilirubin, LDH, body weight, age and dose as continuous variable on CL/F, and age and body weight as continuous variable on V/F. The final population PK parameters of encorafenib derived with the full covariate model were presented in Table 87. An E_{max} function successfully describes the time-varying CL which was estimated to increase 1.34-fold at steady state with T_{50} at 60.1 hours.

The effect of evaluated covariates on PK parameters were illustrated in the forest plot (Figure 22). A comparative popPK analysis showed that encorafenib exposures were similar between 59 patients with mild hepatic impairment (total bilirubin within upper limit of normal [ULN] and AST greater than ULN or total bilirubin greater than 1 and up to 1.5 times ULN and any AST) and 640 patients with normal hepatic function (total bilirubin and AST within ULN) according to NCI criteria. Encorafenib exposures were similar among 159 patients with mild (CLcr 60 to less than 90 mL/min) renal impairment, 33 patients with moderate renal impairment (CLcr 30 to less than 60 mL/min), and 508 patients with normal renal function (greater than or equal to 90 mL/min). No dose adjustment is necessary in patients with mild hepatic impairment and in patients with mild and moderate renal impairment. Dedicated studies in patients with severe organ impairment will not be requested as PMRs to be consistent with advice that has been provided for other approved BRAF inhibitors (i.e., vemurafenib and dabrafenib). Based on a popPK analysis, age (19 to 89 years), sex, body weight (41.9 to 167.9 kg), mild hepatic impairment (Child-Pugh Class A), and mild or moderate renal impairment (CLcr 30 to 90 mL/min) do not have a clinically meaningful effect on the PK of encorafenib; therefore, dose adjustments based on these intrinsic factors are not necessary. The effects of race/ethnicity, moderate or severe hepatic impairment (Child-Pugh Class B or C), and severe renal impairment (CLcr $\leq$ 29 mL/min) on encorafenib PK have not been studied.

Evaluable PK data in patients in part 2 of study CMEK162B2301 was also added to the analysis dataset in order to obtain accurate post-hoc PK parameters to calculate predicted exposure metrics. The goodness-of-fit (GOF) plots derived with full model without patients in part 2 of study CMEK162B2301 were provided in Figure 21. The GOF plots in patients enrolled in part 1 and part 2 of study CMEK162B2301 were provided in Figure 23. The prediction-corrected visual predictive check for encorafenib PK profile in study CMEK162B2301 (Figure 24) confirms that model captured the observed PK profile of encorafenib and can be used to derive exposure metrics for the subsequent exposure-response analyses.

Final population PK models were used to derive rich concentration-time profiles at steady state and exposure metrics were derived according to the randomized dose of patients enrolled in

the study. Summary of exposure metrics of encorafenib in patients enrolled in the COLUMBUS study Part 1 and Part 2 were presented in Table 88.


Table 87: Final Population PK Parameters of Full model of Encorafenib.

Parameter	Estimate	Bootstrap Median	CV	95% CI
CL	15.4	15.9	5.88	(15, 17.7)
VC	19.9	17.4	13.16	(14.3, 21.3)
Q	7.56	6.83	20.5	(3.92, 7.68)
VP	35.9	34.8	8.5	(27.8, 37.1)
KA	0.513	0.503	6.33	(0.441, 0.532)
Lag Time	0.417	0.428	3.43	(0.401, 0.45)
Emax	-1.34 FIX			
T50	60.1 FIX			
Additive Error	0.003	0.003	20.75	(0.002, 0.004)
Proportional Error	-0.477	-0.465	-3.84	(-0.491, -0.438)
Covariate Effects				
CL_WT	0.357	0.38	21.32	(0.268, 0.539)
CL_Age	-0.177	-0.254	-37.58	(-0.432, -0.165)
CL_Combo	0.0397	-0.05	-124.76	(-0.19, 0.04)
CL_Strong CYP3A Inducer	0.0738	0.12	187.15	(-0.353, 2.09)
CL_Dose	0.0516	0.074	64.76	(0.01, 0.182)
CL_Bilirubin	-0.19	-0.179	-25.78	(-0.245, -0.101)
CL_Strong CYP3A Inhibitor	-0.0703	-0.075	-93.45	(-0.26, 0.023)
CL_Moderate CYP3A Inhibitor	-0.187	-0.263	-230.48	(-0.72, 0.714)
CL_Healthy Subjects	0.147	0.165	49.95	(0.049, 0.285)
CL_ECOG 1	-0.156	-0.076	-73.7	(-0.156, 0.016)
CL_ECOG 2	0.07	-0.035	-386	(-0.356, 0.228)
CL_EGFR	0.072	0.025	430.64	(-0.085, 0.124)
CL_LDH	-0.313	-0.129	-72.1	(-0.305, 0.046)
CL_Total Protein	0.05	0.048	37.53	(0.018, 0.076)
Mild Hepatic Impairment	0.241	0.123	77.41	(-0.026, 0.29)
Moderate Hepatic Impairment	0.127	0.243	76.42	(-0.043, 0.484)
V_Age	-0.132	-0.418	-63.36	(-0.943, -0.132)
V_WT	1.01	1.08	25.3	(0.637, 1.54)
Random Effects				
ω^2 - CL [-]	0.221	0.2	15.64	(0.151, 0.246)
ω^2 - VC [-]	1.1	1.11	14.13	(0.895, 1.39)
ω^2 - VP [-]	0.13	0.129	56.51	(0.072, 0.197)
ω^2 - Alag [-]	0.0135	0.014	40.1	(0.008, 0.028)
ω^2 - Emax [-]	0.0002	0.0002	163.71	(0, 0.438)
ω^2 - Ka [-]	0.08	0.015	104.98	(0, 0.08)
ω^2 - Q [-]	0.077	0.066	158.21	(0, 0.111)

ω^2 - T50 [-]	0.103	0.302	127.67	(0.103, 4.95)

Source: Reviewer's analysis based on popPK dataset "allpkdat.xpt"


Figure 19: Goodness-of-fit Plots of Encorafenib in Patients with Rich PK Profile in Study ARRAY-162-105, CLGX818X2101 and CMEK162X2110



DV: Observations; PRED: Population Predictions; IPRED: Individual Predictions; CWRES: Conditional Weighted Residuals. Red solid line: Smooth regression through data. Orange solid line: Linear regression through data.

Source: Reviewer's analysis based on popPK dataset "allpkdat.xpt"


Figure 20: Prediction corrected Visual Predictive Check for Encorafenib PK profile at Cycle 1 Day 1 and Cycle 1 Day 15 in Study CLGX818X2101 and CMEK 162X2110



Red solid lines are median percentiles for observed data. Red dashed lines are 5th and 95th percentiles for observed data. Light orange and blue areas are the 95% confidence interval (CI) around the simulated median, 5th and 95th percentiles.

Source: Reviewer's analysis based on popPK dataset "allpkdat.xpt"


Figure 21: Goodness-of-fit Plots of Encorafenib in All Patients in Study ARRAY-162-105, CLGX818X2101, CMEK162X2110, CLGX818X2109 and CMEK162B2301 Part 1.



DV: Observations; PRED: Population Predictions; IPRED: Individual Predictions; CWRES: Conditional Weighted Residuals. Red solid line: Smooth regression through data. Orange solid line: Linear regression through data.

Source: Reviewer's analysis based on popPK dataset "allpkdat.xpt"


Figure 22: Covariate Effects on Encorafenib PK Parameters



Reference: Weight 75 kg, Age 53 yrs, Total Protein 70 g/L, Bilirubin 0.47 mg/dL, LDH 327 U/L, EGFR 111.6 mL/min/1.73 m²

Source: Reviewer's analysis based on popPK dataset "allpkdat.xpt"


Figure 23: Goodness-of-fit Plots of Encorafenib in Patients from Part 1 and Part 2 in Study CMEK162B2301



DV: Observations; PRED: Population Predictions; IPRED: Individual Predictions; CWRES: Conditional Weighted Residuals. Red solid line: Smooth regression through data. Orange solid line: Linear regression through data.

Source: Reviewer's analysis based on popPK dataset "allpkdat.xpt"

Figure 24: Prediction-corrected Visual Predictive Check for Encorafenib PK profile in Study CMEK162B2301



Black solid lines are 5th, median and 95th percentiles for observed data. Orange and blue solid lines are 5th, median and 95th percentiles for simulated data. Light orange and blue areas are the 95% confidence interval (CI) around the simulated median, 5th and 95th percentiles.

Source: Reviewer's analysis based on popPK dataset "allpkdat.xpt"

Table 88: Summary of Steady-State Exposure Metrics of Encorafenib Administered as Monotherapy or in Combination with Binimetinib in COLUMBUS study.

ARM	PARA	Geom_Mean	CV	Min	Max
Combo MEK162 at 45 mg LGX818 at 300 mg	AUCinf	10.952	133.23	2.56	152.25
Combo MEK162 at 45 mg LGX818 at 450 mg	AUCinf	16.716	191.46	4.71	594.46
Monotherapy LGX818 at 300 mg (Part 1)	AUCinf	8.559	134.57	2.74	125.72
Monotherapy LGX818 at 300 mg (Part 2)	AUCinf	9.598	112.51	3.58	98.81
Combo MEK162 at 45 mg LGX818 at 300 mg	Cmax	2.545	47.57	0.8	10.44
Combo MEK162 at 45 mg LGX818 at 450 mg	Cmax	3.775	66.86	0.91	26.73
Monotherapy LGX818 at 300 mg (Part 1)	Cmax	2.17	46.19	0.47	9.64
Monotherapy LGX818 at 300 mg (Part 2)	Cmax	2.24	45.21	0.54	7.58
Combo MEK162 at 45 mg LGX818 at 300 mg	Half.life	3.959	50.59	2.53	16.99

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

Combo MEK162 at 45 mg LGX818 at 450 mg	Half.life	4.075	65.82	2.73	23.78
Monotherapy LGX818 at 300 mg (Part 1)	Half.life	3.662	46.25	2.79	16.48
Monotherapy LGX818 at 300 mg (Part 2)	Half.life	3.813	58.08	2.9	20
Combo MEK162 at 45 mg LGX818 at 300 mg	Cmin	0.015	308.57	0.001	2.373
Combo MEK162 at 45 mg LGX818 at 450 mg	Cmin	0.023	320.08	0.002	8.277
Monotherapy LGX818 at 300 mg (Part 1)	Cmin	0.009	391.67	0.001	1.937
Monotherapy LGX818 at 300 mg (Part 2)	Cmin	0.012	338.1	0.002	1.415

* units of exposure metrics are mcg/mL

Source: Reviewer's analysis based on popPK dataset "allpkdat.xpt"

19.2.1.2 Binimetinib

The popPK models for binimetinib and its active metabolite AR00426032 were developed sequentially. The parent drug model was developed first and extended to active metabolite by fixing individual post-hoc binimetinib PK parameters estimates. This review will focus on the parent drug model because abundance of the equipotent active metabolite is substantially lower than (<20%) that of the parent drug and hence is not considered the driving factor for efficacy or safety.

The popPK analysis included 428 patients contributing a total of 3128 binimetinib concentrations, among whom 192 (54.6%) were cancer patients enrolled in the part 1 of the COLUMBUS trial. The majority of the binimetinib concentrations were collected at cycle 1 day 1 (35.6%) and cycle 1 day 15 (21.0%).

A two-compartment model with first-order absorption was found to best describe the PK profile of binimetinib. An Emax function to describe the time-varying CL was incorporated into this model to evaluate the potential magnitude and time-dependent effect of enzyme auto-induction. Interim population PK analysis was first conducted based on rich concentration-time profiles in study ARRAY-162-105 and CMEK162X2110. Same base model was applied to all studies including sparse sampling in CMEK162B2301 part 1 after fixing typical value of Emax and T50 to the estimates obtained in the interim analysis. Covariates were initially screened using visual inspection, and the most relevant covariates were formally evaluated within the population PK model using a full model approach. The full covariate model included the following covariates effects: time effect, gender, disease status (healthy subjects), hepatic impairment (NCI criteria), ECOG status, phase of clinical trial and combination therapy as categorical covariates, and creatinine clearance, albumin, bilirubin, body weight and age as continuous variables on CL/F, and age, body weight and albumin as continuous variable and gender and disease status as categorical variables on V/F. The final population PK parameters of binimetinib derived with the full covariate model were presented in Table 89. No signs of model misspecification were identified in the goodness-of-fit plots of full covariate model (Figure 26). The prediction-corrected visual predictive check (Figure 27) showed the model provided satisfactory prediction of the central tendency and variability of the observed data in both cycle 1 day 1 and cycle 1 day 15. An Emax function successfully describes the time-varying CL which was estimated to increase 0.84-fold at steady state with T50 at 81.3 hours.

The effect of evaluated covariates on binimetinib PK parameters were illustrated in the forest plot (Figure 25). Covariate effects indicate that extreme body weight values (5th and 95th percentiles) of approximately 52 and 111 kg were associated with within 20% differences in CL/F relative to a typical patient (78 kg). Consistent with the assumption that patients would exhibit relatively poor hepatic function compared to healthy subjects, CL/F was approximately 44% lower in patients relative to healthy subjects. Bilirubin levels, a marker for hepatic function, suggest an inverse relationship whereby the CL/F of binimetinib decreased with higher bilirubin levels, which was aligned with the results shown in the dedicated study. Patients with moderate or severe hepatic impairment should reduce the dose to 30 mg BID.

Evaluable binimetinib PK data in patients in part 2 of study CMEK162B2301 was also added to the analysis dataset in order to obtain accurate post-hoc PK parameters to calculate predicted exposure metrics. The GOF plots in patients enrolled in Part 1 and Part 2 of study CMEK162B2301 were provided in Figure 28. The prediction-corrected visual predictive check for binimetinib PK profile in study CMEK162B2301 (Figure 29) confirms that model captured the observed PK profile of binimetinib and can be used to derive exposure metrics for the subsequent exposure-response analyses.

Final population PK models were used to derive rich concentration-time profiles at steady state and exposure metrics were derived according to the randomized dose of patients enrolled in the study. Summary of exposure metrics of binimetinib in patients enrolled in the COLUMBUS study Part 1 and Part 2 were presented in Table 90.

Table 89: Final Population PK Parameters of Full model of Binimetinib.


Parameter	Estimate	Bootstrap Median	CV	95% CI
CL	19	19	4.99	(17.4, 20.2)
VC	14.9	14.9	39.01	(13.1, 20.8)
Q	7.8	7.8	4.6	(7.11, 8.26)
VP	185	185	9.18	(160, 216)
KA	0.423	0.422	4.76	(0.383, 0.443)
Lag Time	0.217	0.223	4.99	(0.208, 0.248)
Additive Error	-0.481	-0.467	-4.54	(-0.502, -0.439)
Emax	-0.842 FIX			
T50	81.3 FIX			
CL_Age	-0.176	-0.149	-41.58	(-0.21, -0.042)
CL_WT	0.36	0.314	28.45	(0.148, 0.434)
CL_Albumin	-0.266	-0.277	-35.38	(-0.505, -0.119)
CL_Bilirubin	-0.196	-0.203	-12.9	(-0.261, -0.162)
CL_Combo	-0.06	-0.056	824.78	(-0.067, 0.361)
CL_Creatinine CL	0.138	0.146	36.59	(0.076, 0.297)
CL_Disease State	-0.576	-0.595	-48.91	(-1.02, -0.547)
CL_ECOG 1	0.0001	0	6257.97	(-0.002, 0.003)
CL_ECOG 2	-0.0695	-0.118	-143.34	(-0.387, 0.125)

Multi-Disciplinary Review and Evaluation NDA 210496
 BRAFTOVI™ (encorafenib)

CL_Mild Hepatic Impairment	-0.0165	-0.016	-338.35	(-0.074, 0.056)
CL_Moderate Hepatic Impairment	0.138	0.156	70.12	(-0.005, 0.394)
CL_Phase 3	-0.00162	0.005	151.1	(-0.004, 0.066)
CL_Sex	0.171	0.168	17.03	(0.129, 0.223)
V_Age	-0.358	-0.358	-46.8	(-0.674, -0.069)
V_Albumin	-1.97	-2.03	-17.36	(-2.71, -1.54)
V_Disease State	-0.109	-0.134	-118.23	(-0.65, -0.092)
V_Sex	-0.0213	-0.017	595.5	(-0.037, 0.214)
V_WT	0.809	0.768	30.69	(0.367, 1.02)
ω^2 - CL [-]	0.056	0.054	12.81	(0.041, 0.056)
ω^2 - Q [-]	0.139	0.139	20.18	(0.102, 0.191)
ω^2 - VP [-]	0.645	0.642	15.67	(0.384, 0.773)
ω^2 - Ka [-]	0.199	0.197	22.52	(0.123, 0.225)
ω^2 - VC [-]	0.31	0.312	34.07	(0.283, 0.628)
ω^2 - Alag [-]	0.288	0.282	12.06	(0.207, 0.304)
ω^2 - Emax [-]	0.029	0.029	111.49	(0.024, 0.046)


Source: Reviewer's analysis based on popPK dataset "allpkdat.xpt"

Figure 25: Covariate Effects on Binimetinib PK Parameters




Source: Reviewer's analysis based on popPK dataset "allpkdat.xpt"

Figure 26: Goodness-of-fit Plots of Binimetinib in All Patients in Study ARRAY-162-105, CMEK162X2110, CLGX818X2109 and CMEK162B2301 Part 1.




Source: Reviewer's analysis based on popPK dataset "allpkdat.xpt"

Figure 27: Prediction-corrected Visual Predictive Check for Binimetinib PK profile at Cycle 1 Day 1 and Cycle 1 Day 15.




Source: Reviewer's analysis based on popPK dataset "allpkdat.xpt"

Figure 28: Goodness-of-fit Plots of Binimetinib in Patients from Part 1 and Part 2 in Study CMEK162B2301



Source: Reviewer's analysis based on popPK dataset "allpkdat.xpt"

Figure 29: Prediction-corrected Visual Predictive Check for Binimetinib PK profile in Study CMEK162B2301



Source: Reviewer’s analysis based on popPK dataset “allpkdat.xpt”

Table 90: Summary of Exposure Metrics of Binimetinib Administered in Combination with Encorafenib in COLUMBUS study.

ARM	PARA	Geom_Mean	CV	Min	Max
Combo MEK162 at 45 mg LGX818 at 300 mg	AUCinf	2490.764	31.52	937.47	6326.11
Combo MEK162 at 45 mg LGX818 at 450 mg	AUCinf	2573.254	35.49	1118.46	9217.85
Combo MEK162 at 45 mg LGX818 at 300 mg	Cmax	466.13	25.56	156.87	865.67
Combo MEK162 at 45 mg LGX818 at 450 mg	Cmax	486.911	26.93	148.35	1179.92
Combo MEK162 at 45 mg LGX818 at 300 mg	Half.life	4.822	26.39	2.23	12.78
Combo MEK162 at 45 mg LGX818 at 450 mg	Half.life	4.715	23.87	2.58	10.08
Combo MEK162 at 45 mg LGX818 at 300 mg	Cmin	51.614	45.01	10.063	167.018
Combo MEK162 at 45 mg LGX818 at 450 mg	Cmin	53.323	49.18	13.469	233.457

Source: Reviewer’s analysis based on popPK dataset “allpkdat.xpt”

19.2.2. Dose-Response Analyses

Study CMEK162B2301 is an ongoing 2-part, multicenter, randomized, open label, Phase 3 study comparing the efficacy and safety of encorafenib plus binimetinib to vemurafenib and encorafenib monotherapy in patients with locally advanced unresectable or metastatic melanoma with BRAF V600 mutation. Part 1 of the study was designed to evaluate the activity of encorafenib 450 mg QD plus binimetinib 45 mg BID (Combo 450) vs. vemurafenib. Part 2 was designed to further define and characterize the contribution of binimetinib to the combination using the same encorafenib dose, 300 mg QD, in the combination (Combo 300) and the single-agent encorafenib arm (Mono 300). The summary of baseline covariates in Combo 450 and Mono 300 in part 1 and Combo 300 and Mono 300 in part 2 were provided in Table 91. The distribution of age and ECOG status were similar across treatment groups in Part 1 and 2. However, the median LDH value in monotherapy part 2 appears to be higher than the Combo 450 in part 2 and both monotherapy and combination treatment groups in part 1. A higher percentage of patients (~10%) in monotherapy part 2 have stage IV M1C with elevated LDH compared to other treatment groups.

One of the key clinical pharmacology review question is whether the encorafenib 450mg QD in combination with binimetinib 45mg BID can provide better benefit-risk profile than encorafenib 300mg QD in combination with the same dose of binimetinib. The independent dose/exposure-response analyses were conducted to help address this question. As Combo 450 arm and Combo 300 arm were not randomized groups and evaluated in different time, we will use encorafenib monotherapy which were tested in both parts as comparator in comparing these two doses. A direct comparison between these two doses were also conducted after controlling for the baseline covariates.

Table 91: Baseline Characteristics in Part 1 and Part 2 of Study CMEK162B2301.

Baseline Characteristics	Monotherapy (Part 1) (n=191)	Monotherapy (Part 2) (n=84)	Combo 450 (Part 1) (n=192)	Combo 300 (Part 2) (n=257)	Overall (n=724)
Age (years)					
Mean (CV%)	54.5 (23.2%)	56.2 (26.0%)	56.2 (24.2%)	57.4 (24.4%)	56.2 (24.3%)
Median [Min, Max]	54.0 [23.0, 88.0]	57.5 [19.0, 81.0]	57.0 [20.0, 89.0]	58.0 [20.0, 94.0]	56.5 [19.0, 94.0]
LDH (U/L)					
Mean (CV%)	267 (94.7%)	342 (109%)	299 (124%)	301 (106%)	296 (110%)
Median [Min, Max]	189 [75.0, 1890]	221 [115, 2100]	173 [76.0, 3590]	201 [103, 3100]	192 [75.0, 3590]
≤270 U/L (ULN)	151 (79.1%)	55 (65.5%)	142 (74.0%)	185 (72.0%)	533 (73.6%)
>270 U/L (ULN)	40 (20.9%)	29 (34.5%)	80 (26.0%)	72 (28.0%)	191 (26.4%)
Sex					
Female	86 (45.0%)	42 (50.0%)	77 (40.1%)	107 (41.6%)	312 (43.1%)
Male	105 (55.0%)	42 (50.0%)	115 (59.9%)	150 (58.4%)	412 (56.9%)
Race					
White	171 (89.5%)	77 (91.7%)	181 (94.3%)	236 (91.8%)	665 (91.9%)
Black or African American	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	1 (0.1%)
Asian	6 (3.1%)	7 (8.3%)	5 (2.6%)	15 (5.8%)	33 (4.6%)
Other	2 (1.0%)	0 (0.0%)	3 (1.6%)	2 (0.8%)	7 (1.0%)
Unknown	9 (4.7%)	0 (0.0%)	2 (1.0%)	3 (1.2%)	14 (1.9%)
American Indian or Alaska Native	2 (1.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)
Missing	1 (0.5%)	0 (0.0%)	1 (0.5%)	0 (0.0%)	2 (0.3%)
ECOG n (%)					
ECOG=0	138 (72.3%)	60 (71.4%)	136 (70.8%)	189 (73.5%)	523 (72.2%)
ECOG=1	53 (27.7%)	24 (28.6%)	56 (29.2%)	68 (26.5%)	201 (27.8%)
Cancer Stage					
Stage IIIB	2 (1.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.3%)
Stage IIIC	4 (2.1%)	5 (6.0%)	9 (4.7%)	8 (3.1%)	26 (3.6%)
Stage IV M1A	29 (15.2%)	12 (14.3%)	26 (13.5%)	31 (12.1%)	98 (13.5%)
Stage IV M1B	38 (19.9%)	10 (11.9%)	34 (17.7%)	47 (18.3%)	129 (17.8%)
Stage IV M1C with elevated LDH	50 (26.2%)	32 (38.1%)	50 (26.0%)	72 (28.0%)	204 (28.2%)
Stage IV M1C with normal LDH	68 (35.6%)	25 (29.8%)	73 (38.0%)	99 (38.5%)	265 (36.6%)

CV= Coefficient of variation; ECOG= Eastern Cooperative Oncology Group; Max= Maximum; Min= Minimum; n= Number of subjects; ULN= Upper limit of normal

Note: A total of 6 subjects did not have concentrations of binimetinib or encorafenib. Only subjects included in the PK analysis were retained for the descriptive statistics.

Source: Applicant's Pop-PK report amendment, Table 2, Page 17

19.2.2.1 Dose-Response Analyses for Efficacy

Multiple efficacy endpoints including ORR, PFS and OS were compared between Combo 300 and Combo 450. The results of confirmed ORR by BIRC were first compared. The confirmed ORR appears to be comparable between Combo 450 (63.0 (95% CI: 55.8, 69.9)) and Combo 300 (65.9 (95% CI: 59.8, 71.7)), and ORR in 2 monotherapy arms in part 1 (50.5%) and part2 (50.4%) are also comparable.


The Kaplan-Meier (KM) curve of PFS for monotherapy and combination therapy in each part of study CMEK162B2301 were presented in Figure 30. The median time to PFS is 15.5 months for Combo 450 and 9.56 months for Mono 300 in part 1, and 12.88 months for Combo 300 and 7.36 months for Mono 300 in part 2, respectively. The numerical increase in median PFS

comparing combination therapy to its randomized monotherapy is comparable (5.94 months vs 5.52 months). The difference in time to PFS between different treatment groups were characterized by a Cox proportional-hazards (CPH) model. A full model approach was first applied to incorporate all the known risk factors. The covariates with p-value larger than 0.05 were removed from the full model after backward elimination. The risk factors included in the full model include: Age, Gender, Body weight, Race, Region, Primary tumor site, Metastatic disease, Cancer stage at baseline per IWRS, Brain Metastases, Baseline LDH, ECOG score, BRAF mutation status and Number of organs.

The HRs obtained from final cox regression characterizing direct comparison of time to PFS of Combo 450 versus Mono 300 in part 1, Combo 300 versus Mono 300 in part 2 and cross-part comparison of Combo 450 versus Combo 300 and Mono 300 in part 1 versus part 2 were provided in Table 92. Both combination doses showed a statistically significant improvement in PFS compared to its randomized monotherapy after adjusting for baseline covariates. The HR comparing Combo 300 to Mono 300 in part 2, 0.56 (95% CI: 0.41, 0.77), is numerically lower than the HR comparing Combo 450 to Mono 300 in part 1, 0.75 (95% CI: 0.56, 0.99).

Time to PFS was also compared between two encorafenib monotherapies in part 1 and part 2 to evaluate whether efficacy results between Part 1 and Part 2 are comparable. Based on cox regression after adjusting for significant baseline covariates, patients receiving Mono 300 in Part 2 had a trend of higher risk of progression or death compared to patients receiving Mono 300 in Part 1 (HR: 1.29, 95% CI: 0.92, 1.82).

Figure 30: The Kaplan-Meier (KM) Curve of PFS for Monotherapy and Combination Therapy in Part 1 and Part 2 of Study CMEK162B2301.



Source: Reviewer's analysis based on dataset "adtte.xpt"

Table 92: HRs of Dose Comparison and Significant Baseline Covariates of Final D-R Model of PFS.

Covariate	HR	Lower 95% CI	Upper 95% CI	P-value
Combo 450 vs Mono 300(P1)	0.747	0.564	0.99	0.0427
STAGE IV M1A	1.93	0.444	8.34	0.381
STAGE IV M1B	4.33	1.04	18	0.0435
STAGE IV M1C WITH ELEVATED LDH	3.07	0.721	13.1	0.129
STAGE IV M1C WITH NORMAL LDH	3.37	0.825	13.8	0.0906
ECOG Score:1	1.48	1.09	2.02	0.0132
Male vs Female	1.37	1.03	1.83	0.0305
Log(Baseline LDH)	2.93	2.1	4.09	2.85E-10
Combo 300 vs Mono 300(P2)	0.559	0.407	0.769	0.000355
ECOG Score:1	1.53	1.11	2.12	0.0102
Number of Organs>3	1.65	1.08	2.5	0.0196

Multi-Disciplinary Review and Evaluation NDA 210496
 BRAFTOVI™ (encorafenib)

Number of Organs=2	0.882	0.572	1.36	0.571
Number of Organs=3	1.22	0.794	1.88	0.363
Male vs Female	1.43	1.06	1.94	0.0204
Log(Baseline LDH)	2.26	1.76	2.89	1.59E-10
Combo 450 vs Combo 300	0.836	0.634	1.1	0.202
ECOG Score:1	1.46	1.1	1.94	0.00864
Male vs Female	1.45	1.11	1.9	0.00607
Log(Baseline LDH)	2.75	2.25	3.37	0
Mono 300(P2) vs Mono 300(P1)	1.29	0.918	1.82	0.142
STAGE IV M1A	0.0517	0.00717	0.374	0.00332
STAGE IV M1B	0.116	0.0168	0.804	0.0292
STAGE IV M1C WITH ELEVATED LDH	0.112	0.0163	0.776	0.0266
STAGE IV M1C WITH NORMAL LDH	0.134	0.0197	0.916	0.0404
ECOG Score:1	1.72	1.22	2.42	0.00203
Metastatic Disease	28.1	2.02	392	0.013
Log(Baseline LDH)	2.41	1.7	3.42	7.00E-07

Source: Reviewer's analysis based on dataset "adtte.xpt"


The overall survival (OS) data is still premature to conduct formal analysis. Per study protocol, the interim analysis will be conducted when approximately 232 OS events have occurred in the Combo 450 and vemurafenib arms combined. An independent OS analysis was conducted by the reviewer based on the data pertaining to dates of deaths and survival follow-up status as of 09 November 2016. There is a total of 81 events out of 192 patients treated with Combo 450, 86 events out of 258 patients treated with Combo 300 and 98 events out of 191 patients treated with vemurafenib based on the data in applicant's original submission. In addition, there are 94 events out of 194 patients and 29 events out of 86 patients in the Mono 300 in Part 1 and 2, respectively.

The Kaplan-Meier (KM) curve of OS for monotherapy and combination therapy in each part of study CMEK162B2301 were presented in Figure 31. The median time to OS is 31.2 months for Combo 450, and 23.1 and 19.5 months for Mono 300 in Part 1 and Part 2, respectively. The median OS is not reached for Combo 300 based on available data. The median follow-up is 10 months shorter in Combo 300 (15 months) compared to Combo 450 (25 months) The difference in time to OS between different treatment groups were characterized by a Cox proportional-hazards (CPH) model. Stepwise selection was conducted to screen significant covariates to be included in the final model. The model selection and the covariates included in the full model were same as those in the cox analysis for PFS. The HRs obtained from final cox regression characterizing randomized comparison of Combo 450 versus Mono 300 in Part 1, Combo 300 versus Mono 300 in Part 2 and cross-part comparison of Combo 450 versus Combo 300 and Mono 300 Part 1 versus Part 2 were provided in Table 93.

The patients treated with Combo 450 had a statistically significantly lower risk of death compared to its randomized monotherapy after adjusting for baseline covariates, and the HR

comparing Combo 450 to Mono 300 in Part 1 is numerically lower than the HR comparing Combo 300 to Mono 300 in Part 2 (0.658 (95% CI: 0.486, 0.892) vs. 0.824 (0.537, 1.26)). The cross-part comparison between two combination therapies showed that patients treated with Combo 450 had a trend of lower risk of death compared to Combo 300 with HR estimated to be 0.729 (95% CI: 0.519, 1.02). In addition, no strong difference in risks of death were found between patients receiving Mono 300 in Part 1 and Part 2 (HR: 0.973, 95% CI: 0.616, 1.54, although the median OS in part 2 is 3.6 months shorter). The results from dose response analyses for OS are preliminary and should be interpreted with caution as it is important to note that both arms are immature, especially considering patients treated in Part 2 are followed approximately 10 months shorter than the patients in Part 1.

Figure 31: The Kaplan-Meier (KM) Curve of Preliminary OS for Monotherapy and Combination Therapy in Part 1 and Part 2 of Study CMEK162B2301.



Source: Reviewer's analysis based on dataset "adsl.xpt"

Table 93: HRs of Dose Comparison and Significant Baseline Covariates of Final D-R Model of OS.

Covariate	HR	Lower 95% CI	Upper 95% CI	P-value
Combo 450 vs Mono 300(P1)	0.658	0.486	0.892	0.00702
Male vs Female	1.46	1.07	2	0.0165
STAGE IV M1A	0.378	0.199	0.72	0.00307
STAGE IV M1B	1.09	0.713	1.67	0.688
STAGE IV M1C WITH ELEVATED LDH	0.78	0.466	1.31	0.344
Log(Baseline LDH)	3.56	2.49	5.09	3.74E-12
Combo 300 vs Mono 300(P2)	0.824	0.537	1.26	0.376
ECOG Score:1	2.39	1.63	3.51	9.28E-06
Non-Caucasian vs Caucasian	0.216	0.0676	0.689	0.00963
STAGE IIIC	0.168	0.0229	1.23	0.0793
STAGE IV M1A	0.441	0.186	1.04	0.0623
STAGE IV M1B	0.605	0.316	1.16	0.128
STAGE IV M1C WITH ELEVATED LDH	0.695	0.415	1.16	0.167
Log(Baseline LDH)	2.88	2.07	4.01	4.02E-10
Combo 450 vs Combo 300	0.729	0.519	1.02	0.0675
ECOG Score:1	1.69	1.22	2.34	0.00147
Number of Organs>3	1.64	1.03	2.63	0.038
Number of Organs=2	0.948	0.584	1.54	0.828
Number of Organs=3	1.35	0.842	2.15	0.215
Primary Site: Unknown	0.364	0.115	1.15	0.0859
Log(Baseline LDH)	2.74	2.18	3.44	0
Mono 300(P2) vs Mono 300(P1)	0.973	0.616	1.54	0.906
Age	0.983	0.968	0.998	0.0299
ECOG Score:1	1.71	1.16	2.52	0.00641
Male vs Female	1.5	1.03	2.18	0.0365
STAGE IV M1A	0.193	0.0762	0.489	0.00053
STAGE IV M1B	0.924	0.538	1.59	0.775
STAGE IV M1C WITH ELEVATED LDH	0.784	0.441	1.39	0.406
Log(Baseline LDH)	3.06	2.02	4.65	1.51E-07

Source: Reviewer's analysis based on dataset "adsl.xpt"

19.2.2.2 Dose-Response Analyses for Safety


The safety profile between Combo 450 and Combo 300 were also compared. Time to general safety event or time to safety event of special interest were compared between two combo doses using cox proportional analysis. The HR of time to evaluated safety event of combination therapy (Combo 450 or Combo 300) relative to its randomized monotherapy in each part was

estimated and compared. A cross-part comparison between two combo doses was also conducted using cox proportional hazard model.

For general safety profiles, time to occurrence of first AE leading to drug discontinuation, first safety event of special interest of encorafenib, first dose adjustment/reduction, first grade 3/4 AE and first SAE were compared between treatment groups in study CMEK162B2301. The Kaplan-Meier (KM) curve of time to general safety events of interest in each part of study CMEK162B2301 were presented in Figure 32. The combination therapy appears to have a better safety profile than monotherapy and vemurafenib arm. In general median time to safety event also appears to be longer in Combo 300 than Combo 450.

The HRs obtained from final cox regression comparing time to general safety events of interest of Combo 450 to Mono 300 in Part 1, Combo 300 to Mono 300 in Part 2 and Combo 450 to Combo 300 were provided in Table 94. It was also visualized in the forest plot shown in Figure 8. The HR comparing Combo 300 to Mono 300 in Part 2 is numerically lower than the HR comparing Combo 450 to Mono 300 in Part 1 for time to first safety event of special interest of encorafenib, first dose adjustment/reduction, first grade 3/4 AE and first SAE. Cross-part comparison shows patients in Combo 450 had a statistically significantly higher risk of having special interest of encorafenib and grade 3/4 AE compared to Combo 300 with HR estimated to be 1.47 (95% CI: 1.14, 1.91) and 1.46 (95% CI: 1.12, 1.9), respectively. Patients in Combo 450 also tend to have higher risks of experiencing SAE and dose adjustment/reduction compared to Combo 300, but the difference is not statistically significant. For the time to first AE leading to discontinuation, there appears to be no difference between Combo 450 and Combo 300.

Figure 32: The Kaplan-Meier (KM) Curve of Time to Evaluated General Safety Event in Part 1 and Part 2 of Study CMEK162B2301.



Source: Reviewer's analysis based on dataset "adttes.xpt"

Table 94: Parameter Estimates of Final D-R Model of General Safety Events Comparing Combo 450 to Mono (P1), Combo 400 to Mono (P2) and Combo 450 to Combo 300.

Covariate	HR	Lower 95% CI	Upper 95% CI	P-value
Time to first AE requiring dose discontinuation				
Age	1.03	1.01	1.06	0.00162
Europe	0.217	0.0651	0.726	0.0131
North America	0.727	0.202	2.62	0.626
Other	0.163	0.027	0.983	0.0478
Male vs Female	0.575	0.336	0.985	0.0439
Combo 450 vs Mono 300(P1)	0.822	0.485	1.39	0.465
ECOG Score:1	2.07	1.08	3.95	0.0282
Combo 300 vs Mono 300(P2)	0.986	0.452	2.15	0.973
Age	1.03	1.01	1.05	0.00436
Combo 450 vs Combo 300	0.993	0.579	1.7	0.978
Time to first AE of special interest of encorafenib				
ECOG Score:1	0.666	0.498	0.89	0.00605
Europe	0.737	0.346	1.57	0.428
North America	1.96	0.87	4.43	0.104
Other	0.691	0.284	1.68	0.414
Combo 450 vs Mono 300(P1)	0.76	0.592	0.975	0.031


Multi-Disciplinary Review and Evaluation NDA 210496
 BRAFTOVI™ (encorafenib)

Combo 300 vs Mono 300(P2)	0.614	0.439	0.858	0.00429
ECOG Score:1	0.632	0.462	0.863	0.00396
Europe	0.531	0.195	1.44	0.214
North America	1.14	0.391	3.35	0.806
Other	0.501	0.171	1.47	0.208
Combo 450 vs Combo 300	1.47	1.14	1.91	0.00331
Time to first Grade 3/4 AE				
Age	1.02	1.01	1.03	0.00013
Combo 450 vs Mono 300(P1)	0.589	0.455	0.763	6.17E-05
Combo 300 vs Mono 300(P2)	0.551	0.39	0.779	0.000737
Log(Baseline LDH)	1.41	1.1	1.81	0.00732
Age	1.01	1	1.02	0.00384
Combo 450 vs Combo 300	1.46	1.12	1.9	0.00456
Log(Baseline LDH)	1.33	1.08	1.63	0.00754
Time to first serious AE				
Age	1.02	1.01	1.03	0.00745
Male vs Female	1.5	1.04	2.15	0.0285
Combo 450 vs Mono 300(P1)	0.764	0.538	1.08	0.131
Log(Baseline LDH)	1.92	1.49	2.49	6.47E-07
Age	1.02	1	1.03	0.0376
Combo 300 vs Mono 300(P2)	0.69	0.436	1.09	0.112
Log(Baseline LDH)	1.89	1.4	2.55	3.64E-05
Age	1.02	1.01	1.03	0.00445
Combo 450 vs Combo 300	1.31	0.927	1.85	0.126
Log(Baseline LDH)	1.88	1.47	2.4	3.71E-07
Time to first dose adjustment/reduction				
Age	1.01	1	1.02	0.0172
BRAF:V600E	0.621	0.421	0.914	0.0157
Non-Caucasian	1.67	1.03	2.7	0.037
Europe	0.402	0.176	0.919	0.0308
North America	0.626	0.258	1.52	0.3
Other	0.425	0.163	1.11	0.0805
STAGE IIIC	1.43	0.779	2.61	0.25
STAGE IV M1A	1.46	1.01	2.11	0.0428
STAGE IV M1B	1.01	0.71	1.43	0.957
STAGE IV M1C WITH ELEVATED LDH	0.687	0.486	0.971	0.0334
Combo 450 vs Mono 300(P1)	0.531	0.41	0.687	1.45E-06
Combo 300 vs Mono 300(P2)	0.517	0.376	0.709	4.44E-05
BRAF: V600E	0.603	0.431	0.845	0.00325
Combo 450 vs Combo 300	1.27	0.99	1.63	0.0595

Source: Reviewer's analysis based on dataset "adttes.xpt"

Time to event analysis were also conducted using Cox regression analysis with same methodology for safety events of special interest which include: AST > 5x ULN or ALT > 5x ULN, Grade 2 or above Hemorrhage, Grade 2 or above Myopathy, Grade 2 or above Hand-Foot Syndrome, Grade 2 or above Rash, Grade 1 or above Retinopathy Excluding RVO, Grade 2 or above Skin Infections, definitive deterioration in LVEF, first QTcF increase from baseline > 30 ms and first new QTcF > 450 ms. The HRs obtained from final cox regression comparing time to special safety events of interest of Combo 450 to Mono 300 in Part 1, Combo 300 to Mono 300 in Part 2 and Combo 450 to Combo 300 were visualized in Figure 33. Based on the Cox regression analysis, patients in the combination therapy had significantly lower risks of developing grade 2+ myopathy, grade 2+ hand-foot syndrome, grade 2+ rash compared to patients in the monotherapy. On the other hand, they have significantly higher risks of experiencing definite deterioration in LVEF and grade 1+ retinopathy excluding RVO compared to patients in the monotherapy. No difference in time to occurrence was detected between Combo 450 and Combo 300 in the cross-part comparison except for grade 1+ retinopathy excluding RVO. Patients treated with Combo 450 had significantly higher risks of developing grade 1+ retinopathy excluding RVO compared to patients in the Combo 300 group. The risks of developing liver toxicity or grade 2+ hemorrhage also appear to be higher in patients treated with combination therapy compared to monotherapy and in patients treated with Combo 450 compared to Combo 300, but the difference is not statistically significant. For the time to first QTcF increase from baseline > 30 ms and first new QTcF > 450 ms, there appears to be no difference between Combo 450 and Combo 300.

Figure 33: The HRs Comparing Combination Therapy to the Randomized Monotherapy and HR Comparing Combo 450 to Combo 300 after Adjusting for Baseline Covariates for Evaluated Special Safety Event of Interest in Study CMEK162B2301.



*ASTALT: Time to AST > 5x ULN or ALT > 5x ULN; FHEMORR: Time to First Grade 2 or above Hemorrhage; FMYOPA: Time to First Grade 2 or above Myopathy; FPALMAR: Time to First Grade 2 or above Hand-Foot Syndrome; FRASH: Time to First Grade 2 or above Rash; FRERVO: Time to First Grade 1 or above Retinopathy Excluding RVO; FSKINFE: Time to First Grade 2 or above Skin Infections; LVEF: Time to Definitive Deterioration in LVEF; QTCF1: Time to First QTcF Increase from baseline > 30 ms; QTCF3: Time to First new QTcF > 450 ms

Source: Reviewer's analysis based on dataset "adttes.xpt"

19.2.3. Exposure Response Analyses

The population of ER analysis between encorafenib exposure and efficacy and safety endpoints includes a total of 449 patients among whom 192 patients were treated with Combo 450 in part 1 and 257 patients were treated with Combo 300 in Part 2. Model-predicted steady-state exposure metrics (SS Cavg, SS Ctrough and SS AUC) at day 15 were selected for the primary analyses of E-R. Pre-specified baseline covariates tested in dose-response analyses listed in section 19.4.2.1 were first added to the full models to adjust for potential confounding effects. The covariates with p-value larger than 0.05 were removed from the full model after backward elimination.

19.2.3.1 Encorafenib Exposure and Efficacy

The relationship between encorafenib exposure and objective response rate was characterized using logistic regression. The parameter estimates of the final logistic regression relating predicted steady state exposure metrics as continuous variable to ORR was provided in Table 95. The crude rates of objective response rates (ORRs) were also compared among patients in different exposure quartiles (Table 96). Overall, no associations were found between encorafenib exposure and ORR in 449 patients in study CMEK162B2301. Crude rates of ORR are found comparable between patients with low encorafenib exposure and patients with high encorafenib exposure.

Table 95: Parameter Estimates of Final Encorafenib E-R Model of ORR.

Covariate	Estimate	Lower 95% CI	Higher 95% CI	P-value
Intercept	5.17	2.619	7.84	0
Age	-0.017	-0.032	-0.003	0.021
AUCinf	0.001	-0.004	0.006	0.804
STAGE IIIC	-0.325	-1.373	0.811	0.552
STAGE IV M1A	-0.893	-1.519	-0.272	0.005
STAGE IV M1B	-0.041	-0.621	0.555	0.892
STAGE IV M1C WITH ELEVATED LDH	0.251	-0.41	0.931	0.462
Log(Baseline LDH)	-0.642	-1.122	-0.181	0.007
Intercept	5.182	2.629	7.851	0
Age	-0.017	-0.032	-0.003	0.021
CMIN	0.079	-0.253	0.457	0.648
STAGE IIIC	-0.339	-1.382	0.791	0.534
STAGE IV M1A	-0.891	-1.517	-0.27	0.005
STAGE IV M1B	-0.042	-0.622	0.554	0.889
STAGE IV M1C WITH ELEVATED LDH	0.251	-0.409	0.931	0.462
Log(Baseline LDH)	-0.644	-1.124	-0.183	0.007
Intercept	5.161	2.611	7.828	0
Age	-0.017	-0.032	-0.002	0.028
CMAX	-0.017	-0.108	0.074	0.701
STAGE IIIC	-0.261	-1.317	0.887	0.636

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

STAGE IV M1A	-0.893	-1.519	-0.272	0.005
STAGE IV M1B	-0.036	-0.616	0.56	0.905
STAGE IV M1C WITH ELEVATED LDH	0.255	-0.405	0.936	0.454
Log(Baseline LDH)	-0.633	-1.114	-0.173	0.008

Source: Reviewer's analysis based on dataset "adtte.xpt"

Table 96: Crude ORR Rates in Patients with Different Encorafenib Exposure Quartiles.

Exposure	Group	N	Responders (95% CI) (%)	HR (95% CI)	P-value
AUC	<Median	225	69.3 (62.8, 75.2)	1.30 (0.86, 1.96)	0.211
	>Median	224	60.3 (53.5, 66.7)		
CMIN	<Median	224	69.2 (62.6, 75.1)	1.31 (0.87, 1.97)	0.198
	>Median	225	60.4 (53.7, 66.8)		
CMAX	<Median	224	67.4 (60.8, 73.4)	1.12 (0.75, 1.68)	0.587
	>Median	225	62.2 (55.5, 68.5)		

Source: Reviewer's analysis based on dataset "adtte.xpt"

In addition, the relationship between encorafenib exposure and PFS was characterized using cox proportional hazard models. The final parameter estimates for relationship between encorafenib exposure as continuous variable and time to PFS were provided in Table 97 separately for each evaluated exposure metric. The baseline covariates retained in the final model after backward elimination were also provided in Table 97. No statistically significant relationship was found between encorafenib exposure and time to PFS.

The effect of encorafenib exposure on PFS was also examined via Kaplan-Meier curves stratified by predicted SS encorafenib exposure quartiles (Figure 34). After adjusting for significant covariate effects, the patients with low encorafenib exposure were estimated to have similar risks of progression or death compared to patients with high encorafenib exposure, although the median PFS is numerically longer in patients with low exposure (14.9 months vs 11.1 months).


Table 97: Parameter Estimates of Final Encorafenib E-R Model of Time to PFS.

Covariate	HR	Lower 95% CI	Upper 95% CI	P-value
ECOG Score: 1	1.42	1.07	1.89	0.0145
Male vs Female	1.46	1.11	1.9	0.00589
AUCinf	0.999	0.996	1	0.53
Log(Baseline LDH)	2.81	2.3	3.44	0
ECOG Score: 1	1.42	1.07	1.89	0.0145
Male vs Female	1.46	1.12	1.9	0.00574
Cmin	0.937	0.771	1.14	0.515
Log(Baseline LDH)	2.81	2.3	3.44	0
ECOG Score: 1	1.42	1.07	1.88	0.0156
Male vs Female	1.45	1.11	1.9	0.00614
Cmax	0.99	0.94	1.04	0.692

Log(Baseline LDH)	2.82	2.3	3.45	0

Source: Reviewer's analysis based on dataset "adtte.xpt"

Figure 34: The Kaplan-Meier (KM) Curve of Time to PFS Stratified by Predicted Encorafenib Exposure Metrics.



Source: Reviewer's analysis based on dataset "adtte.xpt"

Similarly, the association between encorafenib exposure and OS was evaluated with cox proportional hazard models. The final parameter estimates for relationship between encorafenib exposure as continuous variable and time to OS were provided in Table 98 separately for each evaluated exposure metric. No statistically significant relationship was found between encorafenib exposure and time to OS. The Kaplan-Meier curves of time to OS in patients with low and high encorafenib exposure were provided in Figure 35. After adjusting for significant covariate effects, patients with low encorafenib exposure were estimated to have

Multi-Disciplinary Review and Evaluation NDA 210496
 BRAFTOVI™ (encorafenib)


similar risk of death compared to patients with high encorafenib exposure, although the median OS is numerically longer in patients with low exposure (31.2 months vs 26.5 months).

Table 98: Parameter Estimates of Final Encorafenib E-R Model of Time to OS.

Covariate	HR	Lower 95% CI	Upper 95% CI	P-value
ECOG Score: 1	1.7	1.23	2.34	0.00137
AUCinf	1	0.996	1	0.904
STAGE IIIC	0.14	0.019	1.03	0.0538
STAGE IV M1A	0.62	0.333	1.15	0.132
STAGE IV M1B	0.98	0.606	1.58	0.933
STAGE IV M1C WITH ELEVATED LDH	0.756	0.478	1.2	0.232
Log(Baseline LDH)	3.12	2.33	4.18	2.04E-14
ECOG Score: 1	1.7	1.23	2.35	0.00131
CMIN	0.965	0.747	1.25	0.785
STAGE IIIC	0.143	0.0195	1.04	0.055
STAGE IV M1A	0.619	0.332	1.15	0.131
STAGE IV M1B	0.981	0.607	1.58	0.937
STAGE IV M1C WITH ELEVATED LDH	0.757	0.479	1.2	0.234
Log(Baseline LDH)	3.13	2.34	4.19	1.72E-14
ECOG Score: 1	1.69	1.22	2.33	0.00162
CMAX	1.01	0.95	1.08	0.737
STAGE IIIC	0.131	0.0178	0.97	0.0466
STAGE IV M1A	0.62	0.333	1.15	0.132
STAGE IV M1B	0.974	0.603	1.57	0.915
STAGE IV M1C WITH ELEVATED LDH	0.752	0.475	1.19	0.225
Log(Baseline LDH)	3.1	2.31	4.16	4.53E-14

Source: Reviewer's analysis based on dataset "adsl.xpt"

Figure 35: The Kaplan-Meier (KM) Curve of Time to OS Stratified by Predicted Encorafenib Exposure Metrics.



Source: Reviewer's analysis based on dataset "adsl.xpt"

19.2.3.2 Encorafenib Exposure and Safety

The relationship between encorafenib exposure and time to safety endpoints was characterized using cox proportional hazard models. The general safety endpoints and safety events of special interest were same as those evaluated in the dose-response analyses. The final parameter estimates for relationship between encorafenib AUC as continuous variable and time to safety endpoints were provided in Table 99 for general safety endpoints and in Table 100 for safety events of special interest. The ER analyses also evaluated the effect of encorafenib exposure quartiles on safety risks. Table 101 contains the rates of evaluated safety events in patients with encorafenib exposure below median and above median, as well as the HRs in safety risks comparing patients with low exposure to patients with high exposure.

Overall, no statistically significant relationship was found between encorafenib AUC as continuous variable and time to evaluated safety events. The HRs in safety risks comparing patients with low encorafenib exposure to patients with high encorafenib exposure in the combination therapy were consistent with dose response analyses. Based on the cox regression analysis, patients with low encorafenib exposure had significantly lower risks of having grade ¾ AE, safety event of special interest for encorafenib and grade 1+ retinopathy compared to patients with high encorafenib exposure. The risks of developing other safety events such as AE leading to discontinuation, liver toxicity, grade 2+ hemorrhage, grade 2+ rash and definitive deterioration in LVEF also appear to be lower in patients with low encorafenib exposure compared to patients with high encorafenib exposure, but their differences are not statistically significant.

Table 99: Parameter Estimates of Final Encorafenib E-R Model of Time to Evaluated General Safety Event.

Covariate	HR	Lower 95% CI	Upper 95% CI	P-value
Time to first AE leading to discontinuation				
Age	1.03	1.01	1.05	0.00292
AUCInf	0.992	0.98	1	0.189
Time to first safety event of special interest for Encorafenib				
ECOG Score:1	0.66	0.483	0.903	0.00941
Europe	0.385	0.142	1.05	0.0613
North America	0.852	0.294	2.47	0.768
Other	0.312	0.107	0.912	0.0332
Male vs Female	1.33	1	1.77	0.0468
AUCInf	1	0.997	1	0.944
Weight	0.992	0.984	1	0.0492
Time to first Grade 3/4 AE				
Age	1.01	1	1.02	0.00523
AUCInf	0.999	0.996	1	0.573
Log(Baseline LDH)	1.32	1.07	1.63	0.0102
Time to first SAE				
Age	1.02	1.01	1.03	0.00466
AUCInf	0.998	0.993	1	0.305
Log(Baseline LDH)	1.89	1.47	2.41	4.48E-07
Time to first dose adjustment/reduction				
BRAF:V600E	0.62	0.443	0.866	0.00515
AUCInf	1	0.997	1	0.922

Source: Reviewer's analysis based on dataset "adtttes.xpt"

Table 100: Parameter Estimates of Final Encorafenib E-R Model of Time to Evaluated Safety Event of Special Interest.

Covariate	HR	Lower 95% CI	Upper 95% CI	P-value
Time to AST > 5x ULN or ALT > 5x ULN				
BRAF:V600E	0.251	0.101	0.624	0.00292
Europe	0.0426	0.0088	0.206	8.75E-05
North America	0.124	0.0188	0.817	0.03
Other	0.152	0.0278	0.837	0.0304
AUCinf	1	0.991	1.01	0.938
STAGE IIIC	1.64	0.349	7.75	0.53
STAGE IV M1A	0.976	0.3	3.17	0.968
STAGE IV M1B	0.838	0.285	2.47	0.749
STAGE IV M1C WITH ELEVATED LDH	0.0319	0.0032	0.319	0.00336
Log(Baseline LDH)	3.03	1.34	6.82	0.00762
Time to First Grade 2 or above Hemorrhage				
AUCinf	0.998	0.986	1.01	0.782
Log(Baseline LDH)	3.8	2.04	7.09	2.61E-05
Time to First Grade 2 or above Myopathy				
AUCinf	0.998	0.988	1.01	0.757
Time to First Grade 2 or above Hand-Foot Syndrome				
AUCinf	0.974	0.92	1.03	0.359
Time to First Grade 2 or above Rash				
AUCinf	1	0.991	1.01	0.984
Time to First Grade 1 or above Retinopathy Excluding RVO				
ECOG Score: 1	0.606	0.413	0.89	0.0107
Europe	0.398	0.126	1.26	0.117
North America	0.891	0.261	3.04	0.853
Other	0.277	0.079	0.969	0.0446
Male vs Female	1.45	1.03	2.04	0.0313
AUCinf	0.999	0.995	1	0.765
Weight	0.986	0.976	0.996	0.00587
Time to First Grade 2 or above Skin Infections				
Metastatic Disease	0.178	0.052	0.611	0.00606
AUCinf	0.992	0.978	1.01	0.317
Log(Baseline LDH)	2.25	1.33	3.8	0.00254
Time to Definitive Deterioration in LVEF				
AUCinf	1	1	1.01	0.0519
Weight	1.01	1	1.02	0.0431
Time to First QTcF Increase from baseline > 30 ms				
Age	1.02	1.01	1.04	0.00522
AUCinf	1	0.996	1	0.804
STAGE IIIC	1.56	0.592	4.14	0.367
STAGE IV M1A	2.04	1.13	3.68	0.0177

STAGE IV M1B	1.83	1.05	3.2	0.0323
STAGE IV M1C WITH ELEVATED LDH	2.43	1.49	3.97	0.000391
Time to First new QTcF > 450 ms				
Age	1.03	1.01	1.05	0.00271
Metastatic Disease	0.0109	0.00222	0.0533	2.47E-08
AUCinf	1	0.997	1.01	0.387
STAGE IIIC	0.00351	0.000227	0.0544	5.25E-05
STAGE IV M1A	0.997	0.442	2.25	0.995
STAGE IV M1B	0.888	0.414	1.9	0.76
STAGE IV M1C WITH ELEVATED LDH	1.82	1.01	3.28	0.0451

Source: Reviewer's analysis based on dataset "adtttes.xpt"

Table 101: The Rates of Evaluated Safety Events in Patients with Low or High Encorafenib Exposure and the HR in Risks Comparing Patients with Low Exposure to Patients with High Exposure.

Evaluated Time-to-Event	Rates		HR (Below Median vs Above Median)
	AUC Below Median N=225, n(%)	AUC Above Median N=224, n(%)	
Overall Safety			
AE Leading to Discontinuation	24 (10.7)	35 (15.6)	0.73 (0.43, 1.2)
Special Interest of Encorafenib	113 (50.2)	133 (59.4)	0.72 (0.56, 0.93)
Grade 3/4 AE	104 (46.2)	126 (56.2)	0.73 (0.56, 0.96)
SAE	62 (27.6)	73 (32.6)	0.93 (0.65, 1.3)
First Dose Adjustment/Reduction	123 (54.7)	132 (58.9)	0.84 (0.65, 1.1)
Safety of Special Interest			
AST/ALT > 5x ULN	9 (4.1)	16 (7.3)	0.48 (0.2, 1.2)
Grade 2+ Myopathy	14 (6.2)	10 (4.5)	1.4 (0.6, 3.1)
Grade 2+ Hemorrhage	4 (1.8)	11 (4.9)	0.44 (0.14, 1.4)
Grade 2+ Hand-Foot Syndrome	9 (4.0)	4 (1.8)	2.2 (0.68, 7.3)
Grade 2+ Rash	12 (5.3)	16 (7.1)	0.67 (0.32, 1.4)
Grade 1+ Retinopathy Excluding RVO	78 (34.7)	95 (42.4)	0.76 (0.56, 1.0)
Grade 2+ Skin Infections	15 (6.7)	15 (6.7)	1.2 (0.57, 2.6)
Definitive Deterioration in LVEF	60 (27.1)	70 (31.8)	0.74 (0.52, 1.1)
First QTcF Increase from baseline>30ms	50 (22.4)	61 (28.6)	0.81 (0.55, 1.2)
First new QTcF>450ms	26 (12.4)	39 (18.7)	0.71 (0.42, 1.2)

Source: Reviewer's analysis based on dataset "adtttes.xpt"

19.2.3.3 Binimetinib Exposure and Efficacy

The relationship between binimetinib exposure and objective response rate was characterized using logistic regression. The parameter estimates of the final logistic regression relating predicted steady state exposure metrics as continuous variable to ORR was provided in Table 102. The crude rates of objective response rates (ORRs) were also compared among patients in

different exposure quartiles (Table 103). Overall, no associations were found between binimetinib exposure and ORR in 449 patients in study CMEK162B2301. And crude rates of ORR were found comparable between patients with low binimetinib exposure and patients with high binimetinib exposure.

Table 102: Parameter Estimates of Final Binimetinib E-R Model of ORR.

Covariate	Estimate	P-value	Lower 95% CI	Higher 95% CI
Intercept	5.036	0	2.441	7.748
Age	-0.018	0.02	-0.034	-0.003
AUCinf	0.059	0.627	-0.176	0.302
STAGE IIIC	-0.338	0.535	-1.38	0.791
STAGE IV M1A	-0.898	0.005	-1.525	-0.277
STAGE IV M1B	-0.041	0.891	-0.621	0.555
STAGE IV M1C WITH ELEVATED LDH	0.246	0.471	-0.415	0.926
Log(Baseline LDH)	-0.632	0.008	-1.113	-0.172
Intercept	5.052	0	2.493	7.726
Age	-0.019	0.015	-0.034	-0.004
CMIN	3.643	0.36	-4.006	11.679
STAGE IIIC	-0.361	0.507	-1.403	0.765
STAGE IV M1A	-0.906	0.004	-1.533	-0.284
STAGE IV M1B	-0.035	0.908	-0.615	0.562
STAGE IV M1C WITH ELEVATED LDH	0.247	0.468	-0.413	0.928
Log(Baseline LDH)	-0.639	0.007	-1.118	-0.179
Intercept	5.321	0	2.607	8.166
Age	-0.016	0.04	-0.032	-0.001
CMAx	-0.284	0.737	-1.95	1.383
STAGE IIIC	-0.28	0.608	-1.323	0.851
STAGE IV M1A	-0.894	0.005	-1.521	-0.274
STAGE IV M1B	-0.031	0.917	-0.613	0.566
STAGE IV M1C WITH ELEVATED LDH	0.261	0.446	-0.402	0.945
Log(Baseline LDH)	-0.653	0.007	-1.141	-0.186

Source: Reviewer's analysis based on dataset "adtte.xpt"

Table 103: Crude ORR Rates in Patients with Different Binimetinib Exposure Quartiles.

Exposure	Group	N	Responders (95% CI) (%)	HR (95% CI)	P-value
AUC	<Median	225	64.9 (58.2, 71.0)	0.9 (0.6, 1.36)	0.622
	>Median	224	64.7 (58.0, 70.9)		
Cmin	<Median	224	67 (60.3, 73.0)	1.23 (0.81, 1.86)	0.341
	>Median	225	62.7 (56.0, 68.9)		
Cmax	<Median	224	67.4 (60.8, 73.4)	1.12 (0.74, 1.69)	0.579
	>Median	225	62.2 (55.5, 68.5)		

Source: Reviewer's analysis based on dataset "adtte.xpt"

In addition, the relationship between binimetinib exposure and PFS was characterized using cox proportional hazard models. The final parameter estimates for relationship between binimetinib exposure as continuous variable and time to PFS were provided in Table 104 separately for each evaluated exposure metric. The baseline covariates retained in the final model after backward elimination were also provided in Table 104. No statistically significant relationship was found between binimetinib exposure and time to PFS.


The effect of binimetinib exposure on PFS was also examined via Kaplan-Meier curves stratified by predicted SS binimetinib exposure quartile (Figure 36). After adjusting for significant covariate effects, the patients with low binimetinib exposure were estimated to have similar risk of progression or death compared to patients with high binimetinib exposure.

Table 104: Parameter Estimates of Final Binimetinib E-R Model of Time to PFS.

Covariate	HR	Lower 95% CI	Upper 95% CI	P-value
ECOG Score: 1	1.41	1.07	1.87	0.0162
Male vs Female	1.4	1.06	1.84	0.018
AUCinf	0.922	0.797	1.07	0.276
Log(Baseline LDH)	2.79	2.28	3.41	0
ECOG Score: 1	1.41	1.07	1.87	0.016
Male vs Female	1.41	1.07	1.85	0.0138
Cmin	0.0869	0.000814	9.26	0.305
Log(Baseline LDH)	2.8	2.29	3.42	0
ECOG Score: 1	1.4	1.06	1.86	0.0187
Male vs Female	1.41	1.06	1.86	0.0165
Cmax	0.68	0.249	1.86	0.451
Log(Baseline LDH)	2.77	2.26	3.39	0

Source: Reviewer's analysis based on dataset "adtte.xpt"

Figure 36: The Kaplan-Meier (KM) Curve of Time to PFS Stratified by Predicted Binimetinib Exposure Metrics.



Source: Reviewer's analysis based on dataset "adtte.xpt"


Similarly, the association between binimetinib exposure and OS was evaluated with cox proportional hazard models. The final parameter estimates for relationship between binimetinib exposure as continuous variable and time to OS were provided in Table 105 separately for each evaluated exposure metric. A statistically significant relationship was found between time to OS and binimetinib Cmax, but such relationships were not observed on Cmin and AUC. The Kaplan-Meier curves of time to OS in patients with low and high binimetinib exposure were provided in Figure 37. After adjusting for significant covariate effects, patients with low binimetinib exposure were estimated to have similar risks of death compared to patients with high binimetinib exposure, although the median OS is numerically longer in patients with high AUC or Cmax (Not reached vs 26 months).

Table 105: Parameter Estimates of Final Binimetinib E-R Model of Time to OS.

Covariate	HR	Lower 95% CI	Upper 95% CI	P-value
ECOG Score: 1	1.64	1.19	2.25	0.00255
AUCinf	0.879	0.734	1.05	0.158
Log(Baseline LDH)	2.91	2.35	3.6	0
ECOG Score: 1	1.69	1.22	2.33	0.00149
CMIN	0.24	0.000615	93.6	0.639
STAGE IIIC	0.144	0.0198	1.05	0.0554
STAGE IV M1A	0.622	0.334	1.16	0.134
STAGE IV M1B	0.975	0.604	1.57	0.918
STAGE IV M1C WITH ELEVATED LDH	0.76	0.48	1.2	0.24
Log(Baseline LDH)	3.1	2.32	4.16	2.88E-14
ECOG Score: 1	1.6	1.16	2.21	0.00426
CMAX	0.287	0.0869	0.946	0.0402
Log(Baseline LDH)	2.85	2.3	3.54	0

Source: Reviewer's analysis based on dataset "adsl.xpt"

Figure 37: The Kaplan-Meier (KM) Curve of Time to OS Stratified by Predicted Binimetinib Exposure Metrics.



Source: Reviewer's analysis based on dataset "adsl.xpt"

19.2.3.4 Binimetinib Exposure and Safety

The relationship between binimetinib exposure and time to safety endpoints was characterized using cox proportional hazard models. The general safety endpoints and safety events of special interest were same as those evaluated in the dose-response analyses. The final parameter estimates for relationship between binimetinib AUC as continuous variable and time to safety endpoints were provided in Table 106 for general safety endpoints and in Table 107 for safety events of special interest. In general, no statistically significant relationship was found between binimetinib AUC as continuous variable and time to evaluated safety events except for time to first dose adjustment/reduction. Patients with higher binimetinib exposure were more likely to experience dose adjustment/reduction based on the analysis.

The ER analyses also evaluated the effect of binimetinib exposure quartile on safety risks. Table 108 contains the rates of evaluated safety events in patients with binimetinib exposure below median and above median, as well as the HRs in safety risks comparing patients with low exposure to patients with high exposure. Based on the cox regression analysis, patients with low binimetinib exposure had significantly lower risks of experiencing dose adjustment/reduction compared to patients with high binimetinib exposure. On the other hand, they have significantly higher risks of experiencing serious adverse events and grade 2+ hand-foot syndrome compared to patients with high binimetinib exposure.

The risks of developing other safety events such as grade 2+ hemorrhage, grade 2+ rash, grade 2+ skin infections and QTcF > 450ms appear to be higher in patients with low binimetinib exposure, and the risks of developing liver toxicity and grade 1+ retinopathy excluding RVO appear to be higher in patients with high exposure, but their differences are not statistically significant.

Table 106: Parameter Estimates of Final Binimetinib E-R Model of Time to Evaluated General Safety Event.

Covariate	HR	Lower 95% CI	Upper 95% CI	P-value
Time to first AE leading to discontinuation				
Age	1.03	1.01	1.06	0.00213
AUCinf	0.831	0.61	1.13	0.24
Time to first safety event of special interest for Encorafenib				
ECOG Score:1	0.662	0.485	0.904	0.00952
Europe	0.421	0.156	1.14	0.089
North America	0.874	0.301	2.54	0.804
Other	0.362	0.125	1.05	0.061
AUCinf	1.03	0.907	1.18	0.624
Time to first Grade 3/4 AE				
Age	1.01	1	1.02	0.0148
AUCinf	1.04	0.913	1.2	0.523
Log(Baseline LDH)	1.32	1.07	1.63	0.0102
Time to first SAE				
Age	1.02	1.01	1.03	0.00524
AUCinf	0.948	0.777	1.16	0.595
Log(Baseline LDH)	1.86	1.45	2.37	7.87E-07
Time to first dose adjustment/reduction				
BRAF:V600E	0.632	0.452	0.885	0.00745
AUCinf	1.14	1.01	1.27	0.0292

Source: Reviewer's analysis based on dataset "adtttes.xpt"

Table 107: Parameter Estimates of Final Binimetinib E-R Model of Time to Evaluated Safety Event of Special Interest.

Covariate	HR	Lower 95% CI	Upper 95% CI	P-value
Time to AST > 5x ULN or ALT > 5x ULN				
BRAF:V600E	0.251	0.101	0.624	0.00292
Europe	0.0426	0.0088	0.206	8.75E-05
North America	0.124	0.0188	0.817	0.03
Other	0.152	0.0278	0.837	0.0304
AUCinf	1	0.991	1.01	0.938
STAGE IIIC	1.64	0.349	7.75	0.53
STAGE IV M1A	0.976	0.3	3.17	0.968
STAGE IV M1B	0.838	0.285	2.47	0.749
STAGE IV M1C WITH ELEVATED LDH	0.0319	0.0032	0.319	0.00336
Log(Baseline LDH)	3.03	1.34	6.82	0.00762
Time to First Grade 2 or above Hemorrhage				
AUCinf	0.998	0.986	1.01	0.782
Log(Baseline LDH)	3.8	2.04	7.09	2.61E-05
Time to First Grade 2 or above Myopathy				
AUCinf	0.998	0.988	1.01	0.757
Time to First Grade 2 or above Hand-Foot Syndrome				
AUCinf	0.974	0.92	1.03	0.359
Time to First Grade 2 or above Rash				
Non-Caucasian vs Caucasian	3.64E-08	0	Inf	0.996
AUCinf	1	0.991	1.01	0.984
Time to First Grade 1 or above Retinopathy Excluding RVO				
ECOG Score: 1	0.606	0.413	0.89	0.0107
Europe	0.398	0.126	1.26	0.117
North America	0.891	0.261	3.04	0.853
Other	0.277	0.079	0.969	0.0446
Male vs Female	1.45	1.03	2.04	0.0313
AUCinf	0.999	0.995	1	0.765
Weight	0.986	0.976	0.996	0.00587
Time to First Grade 2 or above Skin Infections				
Metastatic Disease	0.178	0.052	0.611	0.00606
Primary Site: Unknown	3.58E-08	0	Inf	0.996
AUCinf	0.992	0.978	1.01	0.317
Log(Baseline LDH)	2.25	1.33	3.8	0.00254
Time to Definitive Deterioration in LVEF				
AUCinf	1	1	1.01	0.0519
Weight	1.01	1	1.02	0.0431
Time to First QTcF Increase from baseline > 30 ms				
Age	1.02	1.01	1.04	0.00522
AUCinf	1	0.996	1	0.804

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

STAGE IIIC	1.56	0.592	4.14	0.367
STAGE IV M1A	2.04	1.13	3.68	0.0177
STAGE IV M1B	1.83	1.05	3.2	0.0323
STAGE IV M1C WITH ELEVATED LDH	2.43	1.49	3.97	0.000391
Time to First new QTcF>450 ms				
Age	1.03	1.01	1.05	0.00271
Metastatic Disease	0.0109	0.00222	0.0533	2.47E-08
AUCinf	1	0.997	1.01	0.387
STAGE IIIC	0.00351	0.000227	0.0544	5.25E-05
STAGE IV M1A	0.997	0.442	2.25	0.995
STAGE IV M1B	0.888	0.414	1.9	0.76
STAGE IV M1C WITH ELEVATED LDH	1.82	1.01	3.28	0.0451

Source: Reviewer's analysis based on dataset "adttes.xpt"

Table 108: The Rates of Evaluated Safety Events in Patients with Low or High Binimetinib Exposure and the HR in Risks Comparing Patients with Low Exposure to Patients with High Exposure.

Evaluated Time-to-Event	Rates		HR (Below Median vs Above Median)
	AUC Below Median N=225, n(%)	AUC Above Median N=224, n(%)	
Overall Safety			
AE Leading to Discontinuation	29 (12.9)	30 (13.4)	1.3 (0.74, 2.2)
Special Interest of Encorafenib	119 (52.9)	127 (56.7)	0.9 (0.7, 1.2)
Grade 3/4 AE	116 (51.6)	114 (50.9)	1.0 (0.8, 1.4)
SAE	74 (32.9)	61 (27.2)	1.5 (1.0, 2.1)
First Dose Adjustment/Reduction	112 (49.8)	143 (63.8)	0.73 (0.57, 0.93)
Safety of Special Interest			
AST/ALT > 5x ULN	10 (4.52)	15 (6.79)	0.71 (0.31, 1.6)
Grade 2+ Myopathy	12 (5.33)	12 (5.36)	1.1 (0.48, 2.4)
Grade 2+ Hemorrhage	9 (4.0)	6 (2.68)	1.6 (0.55, 4.4)
Grade 2+ Hand-Foot Syndrome	11 (4.89)	2 (0.89)	5.9 (1.3, 27)
Grade 2+ Rash	17 (7.56)	11 (4.91)	1.5 (0.7, 3.2)
Grade 1+ Retinopathy Excluding RVO	80 (35.6)	93 (41.5)	0.87 (0.63, 1.2)
Grade 2+ Skin Infections	19 (8.44)	11 (4.91)	1.8 (0.87, 3.9)
Definitive Deterioration in LVEF	67 (30.3)	63 (28.6)	1.2 (0.82, 1.6)
First QTcF Increase from baseline>30ms	60 (27.0)	51 (23.8)	1.4 (0.95, 2.1)
First new QTcF>450ms	34 (16.3)	31 (14.8)	1.5 (0.88, 2.5)

Source: Reviewer's analysis based on dataset "adttes.xpt"

In summary, DR relationships for efficacy suggest that encorafenib 450mg and 300mg QD in combination therapy have a comparable ORR and PFS. However, OS appears to be better in encorafenib dosing regimen 450mg QD compared to 300mg QD in combination with

binimetinib based on preliminary analyses. Therefore, there is insufficient evidence that Combo 300 is as effective as Combo 450. Cross-part comparison of safety profile between Combo 300 and Combo 450 did not indicate a clinically significant safety concern for Combo 450 relative to Combo 300 which would outweigh the potential for improved efficacy in higher dose. The ER relationships were consistent with DR relationships, and they both support the use of the proposed encorafenib dose of 450 mg QD with dose modification in the event of adverse reactions to the lowest dose of 200 mg.

19.2.4. **Physiological-based Pharmacokinetic Modeling Review**

19.2.4.1. Objectives

To evaluate the adequacy of applicant's physiologically-based pharmacokinetic (PBPK) model to predict the steady state drug-drug interaction (DDI) between posaconazole or itraconazole (two strong CYP3A inhibitors) and encorafenib (a CYP3A substrate) at the therapeutic dose levels in cancer patients.

19.2.4.2. Background

Encorafenib is a selective BRAF kinase inhibitor that is primarily eliminated by CYP3A4 metabolism. In vitro data suggested that encorafenib is both a time-dependent inhibitor and an inducer of CYP3A4. In Study CMEK162X2110, the geometric mean ratios on encorafenib C_{max} and AUC between Day 15 and Day 1 values were 0.63 and 0.45, respectively, suggesting a net effect of auto-induction on CYP3A4 across the dose range of 50 and 600 mg QD. In Study ARRAY-818-105, co-administration of strong (posaconazole) and moderate (diltiazem) CYP3A4 inhibitors with a single dose of 50 mg encorafenib resulted in 3- and 2-fold increase in AUC and 1.7 and 1.5-fold increase in C_{max}. Even though encorafenib is a P-gp substrate, the contribution of P-gp inhibition by posaconazole and diltiazem was difficult to assess in Study ARRAY-818-105. The T_{max} values in different treatment arms in the study were similar, suggesting that the observed DDIs were not due to differences in absorption rates, but due to inhibition of CYP3A4 metabolism. Study ARRAY-818-102 indicated a lack of food effect on the extent of exposure to encorafenib following a single oral 100 mg dose. The applicant developed an encorafenib PBPK model to describe the PK profiles of encorafenib based on in silico, in vitro, and clinical PK data.

On November 3 and November 22, 2017, two information requests (IRs) were issued, requesting a revision of the submitted PBPK model to better describe the observed encorafenib exposure after repeated doses of encorafenib between 200 and 550 mg dose level, to conduct the DDI simulations with posaconazole and itraconazole in fed condition, and to improve model performance in predicting the food effect on encorafenib.

This review evaluates the adequacy of the applicant's final PBPK model to predict the steady state DDI effect of CYP3A inhibitors on encorafenib at 450 mg QD levels in cancer patients.

19.2.4.3. Method

Summary of Clinical Studies Used in Encorafenib Model Development and Verification

Study	N*	Relevant Study Features
CLGX818A2101	4	ADME study: Single oral dose of 100 mg [¹⁴ C]encorafenib given as a micro-emulsion
ARRAY-162-105	15	DDI study: Single dose of 300 mg encorafenib alone, and single dose of 100 mg encorafenib alone or in combination with 20 mg rabeprazole. PK data from single agent encorafenib treatments were used.
CLGX818X2101	54	Phase 1, dose-escalation study in patients: Oral encorafenib administered as micro-emulsion solution or as capsules. PK data for capsules were used.
ARRAY-818-102	31	Food effect: Single dose of 100 mg encorafenib under fasted and fed conditions
ARRAY-818-105	32	DDI study: Single dose of 50 mg encorafenib alone or in combination with posaconazole or diltiazem. Only encorafenib PK data were collected in the study.

* N refers to the number of patients in the study with encorafenib PK data; for Study CLGX818X2101 it refers to patients with PK data in the dose escalation phase although there was also PK data in the dose expansion phase.

Source: adapted from cp17-002-a3-report-body.pdf, Table 2

Reviewer's Comment: In model verification, the sponsor compared the PBPK predicted steady state exposure to the population PK (popPK) predicted steady state C_{max} and AUC for the 300 mg QD and 450 mg QD treatments in Study CMEK162B2301. Comparison to popPK model prediction is not considered a valid qualification especially when the encorafenib PBPK model was developed and refined based on popPK model estimates. Simulation results for Study CMEK162B2301 will not be discussed in this review.

Software

GastroPlus™ (Version 9.0) was used to develop the PBPK model. The ADMET Predictor™ module was used to obtain in silico estimates of physicochemical and biopharmaceutical properties from structure if experimentally determined values were not available, or to provide an objective alternative to experimental data. The PBPKPlus™ module was used to simulate the pharmacokinetic distribution and systemic clearance of encorafenib. The Parameter Sensitivity Analysis mode was used to assess the importance of a variety of parameters in predicting absorption and pharmacokinetics. The DDI module was used to predict the effect of encorafenib auto induction of CYP3A4 on its own PK and to predict the effect of CYP3A inhibitors on encorafenib.

Encorafenib Model Development

The Advanced Compartmental Absorption and Transit (ACAT™) model was used to describe the drug disposition in each region of the intestinal tract. The default Johnson model was used to model drug dissolution. Intestinal absorption was modeled as passive diffusion. The human jejunal P_{eff} was optimized to match clinical observation. The absorption rate coefficients in individual intestinal compartments are calculated from P_{eff} and absorption scale factors (ASFs). The intestinal first-pass metabolism of encorafenib by CYP2C19 and CYP3A4 enzymes was modeled using Michaelis-Menten kinetics with the same K_m and V_{max} values for liver metabolism (described below).

A PBPK model was developed with all perfusion-limited tissues. Human organ weights, volumes, and blood perfusion rates specific to subjects in each study (gender, age, and body

weight) were generated by GastroPlus internal Population Estimates for Age-Related (PEAR) Physiology™ Module. Drug tissue:plasma partition coefficients (Kps) were estimated using the Lukacova method using drug-specific and system-specific parameters. Kps were further adjusted by using a lower logP value to better match the shape of PK profiles in Study ARRAY-818-102. An adjusted Fup, 12.76%, instead of the in-vitro reported value 13.9%, was used in the PBPK model to account for possible drug binding to plasma lipids as may occur with more lipophilic compounds.

Systemic clearance of encorafenib was limited to CYP2C19 and CYP3A4 metabolism using Michaelis-Menten kinetics. In the initial model, Km were set to in-vitro measurements and Vmax values were fitted to in vivo plasma concentration-time profiles for 100 mg doses in healthy subjects and 50-700 mg doses in cancer patients in the fasted state. In model refinement, sponsor conducted sensitivity analysis on CYP3A4 Km to improve model prediction of food effect. For each Km value, Vmax was fitted to match observed fasted AUC for a single 100 mg dose from the ARRAY-818-102 study, and subsequently used to simulate exposure for a single 100 mg dose in fed state. A CYP3A4 Km, 213.9 µg/mL, 10-fold higher than reported in-vitro Km was used in the final PBPK model. Vmax values in patient population were lower to 88.6% of those in healthy subjects based on differences between the two populations from the encorafenib population PK model.

To account for changes in encorafenib metabolism after multiple doses, the effect of encorafenib on CYP3A4 activity was modeled as a concentration-independent induction with parameters EC50 and Emax fitted to clinical observations in Studies CLGX818X2101 and ARRAY-818-102. Time-dependent inhibition, as evident in in vitro assays, was not included in the final PBPK model.

Table 112 in Appendix provides a summary of drug-specific parameters in the encorafenib model.

Reviewer's comment:

- a. *Sponsor's encorafenib PBPK model was developed based on the following assumptions: 1) Tissue distribution of encorafenib was limited by blood flow to tissues; 2) Encorafenib permeability is through the passive route only; and 3) the effect of P-gp on absorption was negligible. These assumptions were supported by the high logP and hence high permeability.*
- b. *Sponsor's encorafenib PBPK model was developed based on the assumption that 1) the metabolism of encorafenib was limited to CYP3A4 and CYP2C19; and 2) renal elimination of encorafenib was minimal. These assumptions were supported by data from Study CLGX818A2101.*
- c. *It should be noted that the effect of encorafenib as a CYP3A4 modulator has not been qualified with any probe drug for CYP3A substrate. The prediction of DDI potential between encorafenib and a modulator drug which is also a CYP3A substrate should be interpreted with caution.*

Encorafenib Model Verification

When simulating PK data from clinical studies for model verification, the mean age of subjects, mean weight of subjects, gender of the majority of the study population, disease state (healthy or cancer patient), and the fed or fasted state specified in clinical protocol were matched in the PBPK model. Male PBPK model was used for studies where the group of subjects included an equal number of males and females. The IR: Capsule formulation was selected in all simulations. Stomach transit time was set to 0.1 hours in fasted state, 1 hour in fed, and 0.5 hour in non-fasted state. Unless specified, all simulations were conducted with encorafenib auto-induction of CYP3A4 in the DDI module. Verification simulations included:

1. Prediction of encorafenib PK in healthy subjects after single doses of 50, 100, or 300 mg encorafenib as micro-emulsion or capsule. (Studies CLGX818A2101, ARRAY-818-105, and ARRAY-162-105)
2. Prediction of encorafenib PK in cancer patients receiving 50 to 550 QD doses in Study CLGX818X2101.
3. Prediction of food effect in healthy subjects receiving a single dose of 100 mg encorafenib in the fasted and fed status (Study ARRAY-818-102).
4. Prediction of DDI with posaconazole in healthy subjects receiving a single dose of 50 mg encorafenib (Study ARRAY-818-105). The DDI simulation was conducted such that 400 mg posaconazole was given twice daily from Day 1-9 in the fed condition excepted for the first dose on Day 7, when it was administered with a single dose of 50 mg encorafenib in the fasted state. The baseline condition is a single dose of 50 me encorafenib in the fasted state.

Reviewer conducted a simulation to predict DDI with diltiazem in healthy subjects receiving a single dose of 50 mg encorafenib in the fasted condition. Reviewer's analysis was conducted with GastroPlus Version 9.5.

Encorafenib Model Application

The encorafenib PBPK model was used to predict the DDI effect of posaconazole (400 mg BID) and itraconazole (200 mg QD) on encorafenib at 450 mg QD and 300 mg QD dose levels in cancer patients. Itraconazole model from the standard GastroPlus database (simplified to include only parent compound and the first metabolite, OH-itraconazole) was used in the simulations. The physiology for was parameterized for a 59.3-year-old, 79.8 kg man. The simulations were conducted in the fed condition.

Reviewer's Comment: In addition to DDI simulation with posaconazole and itraconazole, the applicant conducted a DDI simulation to evaluate the effect of rifampin (a strong CYP3A inducer) on encorafenib steady state exposure. Because the DDI module does not allow simultaneous fitting of two induction effects (one from rifampin and one from encorafenib in this case), the simulation only included the effects of rifampicin on CYP3A4 expression. The simulation was based on the assumptions that induction in the gut was at a maximum from rifampin and the induction in the liver was driven by rifampicin. However, there were no

adequate clinical data to verify these assumptions. The PBPK analysis was not adequate to predict DDI potential between encorafenib and rifampin.

Posaconazole and Diltiazem Models

Sponsor developed a posaconazole and a diltiazem PBPK model using clinical data from literature. The posaconazole-midazolam DDI simulation settings and the diltiazem-midazolam DDI simulation settings were not submitted. Based on the summary of model predictions, the posaconazole and diltiazem PBPK models appear adequate in terms of their capacity to predict posaconazole / diltiazem PK as a single agent and to predict their effect as a strong or moderate CYP3A inhibitor on midazolam PK (Table 113 and Table 114 in Appendix).


19.2.4.4. Result

Can PBPK model capture encorafenib exposure under different dosing scenario as a single agent?

Yes. Sponsor's PBPK model were developed, refined, and verified based on results of: (1) single-dose PK data on encorafenib in healthy subjects from Studies CLGX818A2101, ARRAY-818-105, and ARRAY-162-105 (Figure 38); (2) single- and multiple-dose PK data on encorafenib in cancer patients in Study CLGX818X2101 (Figure 39); and (3) food effect on a single-dose of 100 mg encorafenib in healthy subjects in Study ARRAY-818-102 (Figure 40). The prediction errors in C_{max} and AUC, across all doses in healthy volunteers and in cancer patients (on both days), are within 2-fold in all the simulations, except for the first day treatment with 50 mg encorafenib in Study CLGX818X2101. The C_{max} and AUC after a single dose of 50 mg encorafenib in cancer patients were under-predicted with a predicted / simulated AUC ratio (AUCR) of 0.44 and C_{max} ratio (C_{max}R) of 0.46. Only one subject provided PK data in the 50 mg treatment group in Study CLGX818X2101. Consistent with minimal food effect observed in Study ARRAY-818-102, the final model predicted a 4% decrease in AUC_{inf} when a single dose of 100 mg encorafenib was administered in the fed state than in a fasted state. Model performance in capturing encorafenib exposure when encorafenib was administered alone is acceptable.


It is noted that the simulated Day 15/Day 1 AUC ratios (between 0.66-0.71) are higher than that based on observation (approximately 0.5). There does not appear to be a correlation between dose and the Day 15/Day 1 AUC ratio in the range of 50-550 mg, based on either simulation or observation.

Figure 38. Observed (points) and PBPK-predicted (lines) plasma-time profiles of encorafenib in healthy subjects taking a single dose of encorafenib.




Source: PBPK report (cp17-002-a3-report-body.pdf), Figure 6 -9

Figure 39. Observed (points) and PBPK-predicted (lines) plasma-time profiles of encorafenib in cancer patients receiving QD doses of encorafenib as capsule.



Source: PBPK report (cp17-002-a3-report-body.pdf), Figure 10-17

Figure 40. Observed (points) and PBPK-predicted (lines) plasma-time profiles of encorafenib in healthy subjects taking a single dose of 100 mg encorafenib the fasted (left) and fed (right) status.




Source: PBPK report (cp17-002-a3-report-body.pdf), Figure 2 and 3

Can PBPK model capture encorafenib exposure under the effect of posaconazole, a strong CYP3A inhibitor?

Yes. Sponsor’s encorafenib PBPK model was verified based on the results of single-dose PK data (Figure 41) and fold change (Table 109) in encorafenib exposure in Study ARRAY-818-105 with posaconazole.

Figure 41. Observed (points) and PBPK-predicted (lines) plasma-time profiles of encorafenib in healthy subjects taking a single dose of 50 mg encorafenib with posaconazole.



Source: PBPK report (cp17-002-a3-report-body.pdf), Figure 19

Table 109. Summary of the predicted vs. observed AUC and Cmax ratios with or without the presence of posaconazole, a strong CYP3A4 inhibitor. PE: prediction error.

	Cmax (ng/mL)			AUC _{inf} (ng-h/mL)		
	Observed	Simulated ^b	PE	Observed	Simulated	PE
Single-agent encorafenib ^a	460.2	380.8	0.83	2006	1891	0.94
Combination encorafenib/diltiazem ^a	872.5	1098.0	1.26	5775	6232	1.08
Ratio [combination/single-agent]	1.90	2.88	1.52	2.88	3.30	1.14

^a The PK data are for encorafenib when administered as a single oral dose of 50 mg administered on Day 1 or for the same dose co-administered with posaconazole (oral suspension).

^b PBPK model representing an average subject in the study (42-year-old male, 77kg) was used in simulation.

Source: adapted from PBPK report (cp17-002-a3-report-body.pdf), Table 6

Can PBPK model capture encorafenib exposure under the effect of diltiazem, a moderate CYP3A inhibitor?

No. The encorafenib-diltiazem PBPK model significantly under-estimated the DDI effect by diltiazem on encorafenib exposure after a single dose of encorafenib (Table 110).

Removing encorafenib auto-induction from the encorafenib-diltiazem DDI simulation would increase encorafenib AUC by 123% (without vs with auto induction AUCR=2.23) and increase diltiazem AUC by 26% (AUCR=1.26). Removing encorafenib auto-induction from the simulation of encorafenib as a single agent would increase the predicted (steady state) AUC by approximately 40% (AUCR=1.41) at the same dose level. The impact of auto-induction is significantly higher in the DDI simulations, suggesting that a 26% increase in diltiazem exposure is clinically relevant in terms of inhibitory effect on CYP3A4 and on encorafenib PK.

Table 110. Summary of the predicted vs. observed AUC and Cmax ratios with or without the presence of diltiazem, a moderate CYP3A4 inhibitor. PE: prediction error.

	Cmax (ng/mL)			AUC _{inf} (ng-h/mL)		
	Observed	Simulated	PE	Observed	Simulated	PE
Single-agent encorafenib	482	381	0.79	1882	1892	1.01
Combination encorafenib/diltiazem	698	411	0.59	3511	2054	0.59
Ratio [combination/single-agent]	1.45	1.08	0.74	1.87	1.09	0.58

Source: Reviewer's analysis using sponsor's diltiazem and encorafenib PBPK models.

Can PBPK model predict encorafenib exposure change when the drug is co-administered with strong CYP3A inhibitors, posaconazole and itraconazole, at the 300 mg QD or 450 mg QD dose levels?

PBPK model can be used to predict posaconazole effect on 450 mg QD doses of encorafenib. The encorafenib PBPK model was verified using clinical DDI study with posaconazole, a strong CYP3A inhibitor. While encorafenib parameters on CYP3A metabolism, inhibition, and induction were fitted to clinical observations, PK data from the encorafenib-posaconazole treatment in the DDI study was not used in encorafenib model building. The model predicted a 2.8-fold and 3.6-fold increase in single day and steady state AUC, when 450 mg QD encorafenib is co-administered with 400 mg BID posaconazole (Table 111).

The predicted DDI effect by itraconazole on encorafenib is associated with uncertainty. The encorafenib PBPK model has not been verified for its induction/inhibitory effect on a probe drug for CYP3A4 substrate (such as midazolam). Itraconazole is primarily eliminated by CYP3A4. The effect of encorafenib auto-induction and competitive inhibition on itraconazole exposure and consequently, itraconazole effect on encorafenib exposure may not be predicted with confidence.

Table 111. Predicted effect of CYP3A4 inhibitors on encorafenib exposures in cancer patients

	Day 1		Steady State	
	CmaxR	AUCR	CmaxR	AUCR
Posaconazole (400 mg BID)	2.60	2.77	3.27	3.60
Itraconazole (200 mg QD)	2.60	2.79	3.19	3.47

Source: adapted from PBPK report (cp17-002-a3-report-body.pdf), Table 7

19.2.4.5. Conclusion

The applicant's PBPK model for encorafenib can be used to predict encorafenib PK after single- and multiple- doses of encorafenib as a single agent. The model can be used for the prediction of DDI effect between posaconazole (a strong CYP3A inhibitor) and encorafenib at the therapeutic dose level. Encorafenib AUC at 450 mg QD level is predicted to increase by 2.8-fold after a single dose and 3.6-fold at steady state, with co-administration with posaconazole at 400 mg BID.

19.2.4.6. Information Requests

November 3, 2017:

1. Your encorafenib model significantly over-predicts encorafenib exposure after repeated doses of encorafenib between 200 and 550 mg dose level. Please improve your encorafenib model and justify changes made in the model parameters.
2. The tablet formula was used in 'encorafenib-Healthy-baseline model.mdb' for the assessment of model performance in healthy subjects. Rationalize your choice of tablet formula and use the capsule formulation to simulate the exposure of encorafenib following repeated oral doses in the healthy subjects.
3. Using the updated encorafenib model, simulate the effects of posaconazole and itraconazole on the PK of encorafenib in the fed condition. Summarize the predicted DDI effects on the PK of encorafenib (such as R_AUC and R_Cmax) after a single dose and after multiple doses of encorafenib.

November 22, 2017:

1. Your encorafenib PBPK model predicts significant food effects with approximately 50% reduction in AUC after a single dose of encorafenib. This is not consistent with conclusions from the dedicated food effect study (Study ARRAY-818-102). Please improve the encorafenib PBPK model in terms of food effect and justify changes made to the model parameters.
2. Using the updated encorafenib model, simulate the effects of posaconazole and itraconazole on the PK of encorafenib in the fed condition. Summarize the predicted DDI effects on the PK of encorafenib (such as R_AUC and R_Cmax) after a single dose and after multiple doses of encorafenib.

19.2.4.7. Appendix

Table 112. Key physicochemical and biopharmaceutical parameters for encorafenib used in GastroPlus simulations

Parameter	Value	Reference
logP	2.59 ^a	Measured
logD	1.8 at pH 6.8	Measured
Diffusion coefficient	0.55 x 10 ⁻⁵ cm/s ²	ADMET Predictor

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

pKa	Base: 4.53, Acid: 6.97	Measured
Reference solubility	0.01 mg/mL @ pH 6.8	Measured
Solubility Factor	1000	Fitted to in vitro data
FaSSIF solubility	0.15 mg/mL	Measured
FeSSIF solubility	0.73 mg/mL	Measured
Bile salt solubilization ratio	127 000	Fitted to in vitro data ^b
Human effective permeability (P _{eff})	3.01 x 10 ⁻⁴ cm/s	Fitted to in vivo data
Particle radius	5 μm	6003359_RD01_P1_C_975
Precipitate radius	1 μm	GastroPlus default value
Drug particle density	1.2 g/mL	GastroPlus default value
Mean precipitation time	90000 s	Fitted value ^c
Blood:plasma concentration ratio (R _{bp})	0.75	DMPK R1000210
Plasma protein binding (F _{up})	13.9 % unbound	DMPK R1000210
Adjusted F _{up}	12.76 % unbound	GastroPlus algorithm ^d
Metabolism^e		
CYP 3A4 Km	213.9 μg/mL	Fitted to in vivo data ^f
CYP 3A4 Vmax	9.45 x 10 ⁻² mg/s/mg-enzyme	Fitted to in vivo data
CYP 2C19 Km	7.51 μg/mL	DMPK R1100629
CYP 2C19 Vmax	5.04 x 10 ⁻³ mg/s/mg-enzyme	Fitted to in vivo data
Interaction		
<i>Competitive inhibition</i>		
CYP1A2 IC50 unbound	16.5 μM	DMPK R1000039
CYP2B6 IC50 unbound	0.943 μM	DMPK R1000039
CYP2C8 IC50 unbound	22.5 μM	DMPK R1000039
CYP2C9 IC50 unbound	4.86 μM	DMPK R1000039
CYP2C19 IC50 unbound	37.6 μM	DMPK R1000039
CYP2D6 IC50 unbound	23.6 μM	DMPK R1000039
CYP3A4 IC50 unbound	7.77 μM	DMPK R1000039
UGT1A1 IC50 unbound	5.929 μM ^g	DMPK R1100758
<i>Time-dependent inhibition</i>		
CYP3A4 k _{inact}	Not Included	
CYP3A4 Ki irreversible unbound	Not Included	
<i>Induction</i>		
CYP3A4 EC50	0.0001 μM	Fitted to in vivo data ^h
CYP3A4 Emax	0.4 (fold-change)	Fitted to in vivo data ^h
CYP1A2 EC50	34.8 μM	DMPK R1200539 ⁱ
CYP1A2 Emax	25.1 (fold-change)	DMPK R1200539 ⁱ
CYP2C9 EC50	3.3 μM	DMPK R1200539 ⁱ
CYP2C9 Emax	3.6 (fold-change)	DMPK R1200539 ⁱ
CYP2B6 EC50	2.0 μM	DMPK R1200539 ⁱ
CYP2B6 Emax	8.9 (fold-change)	DMPK R1200539 ⁱ

^a The measured logP = 2.59 was used in simulations but the tissue/plasma partition coefficients were calculated using logP = 2.15 for better matching of the PK profiles across studies

^b The bile salt solubilization ratio is calculated from FaSSIF, FeSSIF and aqueous solubility.

^c Precipitation time was increased from GastroPlus default value of 900 s to decrease precipitation potential since PK data are consistent with drug staying in solution.

^d Adjusted F_{up} was calculated from experimental F_{up} and logD @ pH = 7.4 using the default GastroPlus equation. The adjusted F_{up} was used in simulations and the K_p calculations in place of F_{up}.

^e Vmax values shown are representative of healthy subjects. Vmax values for both CYP enzymes were lower by 0.886 in cancer patients based on population PK analysis.

Multi-Disciplinary Review and Evaluation NDA 210496
BRAFTOVI™ (encorafenib)

^f The Km was set to higher value to eliminate food effect due to saturable metabolism at a 100 mg dose in healthy volunteers and the Vmax value was fitted using in vivo data.

^g IC50 (total) value of 7 µM was corrected for microsomal protein binding based on unbound fractions of 0.847 for 0.25 mg/mL human liver microsome protein.

^h The EC50 was set to a low value to simulate concentration-independent induction.

ⁱ The induction parameters were calculated from the data in the referenced report for use in DDI simulations..

Source: PBPK report (cp17-002-a3-report-body.pdf), Table 1

Table 113. Predicted versus observed DDI effects of posaconazole on midazolam.

Dose, mg		Observed DDI*		Predicted DDI	
Posaconazole	Midazolam	AUCR	CmaxR	AUCR	CmaxR
200 BID	2 (PO)	4.98	2.2	3.0	2.65
200 BID	0.4 (IV)	4.42	1.3	2.63	1.08

* Clinical data from *Clin Ther.* 2009;31(2):286-298.

Source: PBPK report, cp17002-report-body.pdf, Table A1.4.

Table 114. Predicted versus observed DDI effects of diltiazem on midazolam.

Dose, mg		Observed DDI*		Predicted DDI	
Diltiazem	Midazolam	AUCR	CmaxR	AUCR	CmaxR
120mg sustained release PO BID for 6 days	0.05 mg/kg IV infusion over 2 min on day 6 of diltiazem administration	1.72	1.29	1.80	1.31
60mg PO TID, total of 5 doses	15mg PO, 1 hr after the 4th dose of diltiazem	3.75	2.05	3.93	2.32

* Clinical data from *Drug Metab Dispos.* 2009;37:1587-1597 and *Clin Pharmacol.* 1994;37:221-225.

Source: PBPK report, cp17002-report-body.pdf, Table A2.7.

19.3. Statistical Appendix

Patient Disposition

The encorafenib (Part 1) arm had 17% of patients with treatment ongoing, compared to 26% ongoing in the encorafenib (Part 2) arm and 39% in the Combo 300 arm. However, patients in Part 1 also had a longer duration of follow up, as discussed in “Other Endpoints”. Table 115 shows the patient disposition of Part 2, including the pooled Encorafenib group.

Table 115: Patient Disposition in Part 2 of COLUMBUS, including pooled Encorafenib Group

	Encorafenib (Part 1)	Encorafenib (Part 2)	Encorafenib (Parts 1 + 2)	Encorafenib 300mg + Binimetinib
N	194	86	280	258
Treatment received (%)				
YES	192 (99)	84 (98)	276 (99)	257 (100)
NO	2 (1)	2 (2)	4 (1)	1 (0)
Primary reason for treatment discontinuation (%)				
ADVERSE EVENT	26 (13)	6 (7)	32 (11)	22 (9)
DEATH	1 (1)	1 (1)	2 (1)	8 (3)
LOST TO FOLLOW-UP	0 (0)	1 (1)	1 (0)	0 (0)
PHYSICIAN DECISION	21 (11)	8 (9)	29 (10)	22 (9)
PROGRESSIVE DISEASE	95 (49)	39 (45)	134 (48)	96 (37)
PROTOCOL DEVIATION	1 (1)	0 (0)	1 (0)	0 (0)
SUBJECT/GUARDIAN DECISION	15 (8)	7 (8)	22 (8)	8 (3)
UNTREATED	2 (1)	2 (2)	4 (1)	1 (0)
TREATMENT ONGOING	33 (17)	22 (26)	55 (20)	101 (39)
Treatment ongoing (%)				
YES	33 (17)	22 (26)	55 (20)	101 (39)
NO	159 (82)	62 (72)	221 (79)	156 (60)
UNTREATED	2 (1)	2 (2)	4 (1)	1 (0)

Source: FDA Analysis

Demographics

Table 116 shows the patient demographics in the analysis set used for Test 3 of COLUMBUS, which includes patients randomized to encorafenib in Part 1. Due to the addition of patients from the encorafenib arm in Part 1, the encorafenib (Parts 1 + 2) group had a lower percentage of patients aged 65 and older (24%) than the Combo 300 arm (32%). There was also a higher percentage of women (46%) in the encorafenib (Parts 1 + 2) group than in the Combo 300 arm (41%). Otherwise, the demographics appear to be generally balanced over the two arms.

Table 116: Patient Demographics in Part 2 of COLUMBUS, including Pooled Encorafenib Group

	Encorafenib (Part 1)	Encorafenib (Part 2)	Encorafenib (Parts 1 + 2)	Combo 300
N	194	86	280	258
Age (mean (sd))	54.6 (12.6)	55.8 (14.7)	55.0 (13.3)	57.4 (14.0)
Age Category (%)				
<65	154 (79)	60 (70)	214 (76)	175 (68)
>=65	40 (21)	26 (30)	66 (24)	83 (32)
Sex (%)				
F	86 (44)	42 (49)	128 (46)	107 (41)
M	108 (56)	44 (51)	152 (54)	151 (59)
Race (%)				
MISSING	1 (1)	1 (1)	2 (1)	0 (0)
AMERICAN INDIAN OR ALASKA NATIVE	2 (1)	0 (0)	2 (1)	0 (0)
ASIAN	6 (3)	7 (8)	13 (5)	15 (6)
BLACK OR AFRICAN AMERICAN	0 (0)	0 (0)	0 (0)	1 (0)
OTHER	2 (1)	0 (0)	2 (1)	2 (1)
UNKNOWN	9 (5)	0 (0)	9 (3)	4 (2)
WHITE	174 (90)	78 (91)	252 (90)	236 (91)
ECOG (%)				
0	143 (74)	62 (72)	205 (73)	191 (74)
1	51 (26)	24 (28)	75 (27)	67 (26)

Source: FDA Analysis

Protocol Deviations

Table 117 shows the protocol deviations in the analysis set used for Test 3 of COLUMBUS, which includes patients randomized to encorafenib in Part 1.

Table 117: Protocol Deviations in Part 2 of COLUMBUS, including pooled Encorafenib Group

Reason	Encorafenib (Part 1)	Encorafenib (Part 2)	Encorafenib (Parts 1 + 2)	Combo 300
N	192	194	191	
Patient did not receive at least one dose of study medication	2 (1)	2 (2)	4 (1)	1 (0)
No histologically confirmed diagnosis of unresectable or metastatic cutaneous melanoma or unknown primary melanoma (stage IIIb, IIIC to IV per AJCC)	1 (1)	0 (0)	1 (0)	0 (0)
Not positive for <i>BRAF V600</i> mutation	2 (1)	0 (0)	2 (1)	0 (0)
Prior treatment for unresectable or metastatic cutaneous melanoma other than immunotherapy	0 (0)	0 (0)	0 (0)	2 (1)
Prior treatment with a RAF and/or MEK inhibitor	1 (1)	0 (0)	1 (0)	0 (0)
New anti-neoplastic therapy administered after start of study treatment and prior to first tumor assessment	4 (2)	0 (0)	4 (1)	0 (0)

Source: FDA Analysis

Durability of Response

Table 118: Confirmed ORR and DOR Results from Part 2 of COLUMBUS (Combo 450 vs. Pooled Encorafenib Group)

	Combo 300 N = 258	Encorafenib (Parts 1 + 2) N = 280
ORR ¹	66%	50%
(95% CI) ²	(60%, 72%)	(44%, 56%)
CR	8%	5%
PR	58%	45%
Median DOR, months	12.7	12.9
(95% CI)	(9.3, 15.1)	(8.9, 15.5)

Source: FDA Analysis

¹ BIRC central review

² Estimated using the Clopper-Pearson method

Additional Exploratory Analyses Conducted on the Individual Trial

Array pre-specified a sensitivity analysis for PFS that would repeat the primary analysis using the BIRC data on the Per Protocol set. Table 119 summarizes these results in the Combo 450 vs. encorafenib comparison.

Table 119: Progression-Free Survival in the Per-Protocol Population for Part 1 of COLUMBUS (Combo 450 vs. Encorafenib)

	Encorafenib N = 184	Combo 450 N = 188
Number of events (%)	95 (52)	95 (51)
Censored (%)	89 (48)	93 (49)
Median PFS in months (95% CI)	9.6 (7.5, 14.8)	15.5 (11.0, 18.7)
Hazard Ratio (95% CI) ¹	0.73 (0.54, 0.97)	


Source: FDA Analysis

¹ Estimated with the Cox proportional hazards model stratified by cancer stage (IIIB + IIIC + IVM1a + IVM1b vs. IVM1c) and ECOG score (0 vs. 1).

Secondary or Exploratory COA (PRO) Endpoints

The mean FACT-M overall score by treatment arm and visit in Part 1 is shown in Figure 42.

Figure 42: Mean FACT-M Overall Score by Treatment Arm and Visit in Part 1




Source: FDA Analysis

Figure 43 and Source: FDA Analysis.


Figure 44 show these means for Combo 450 vs. vemurafenib and Combo 450 vs. encorafenib. A 95% confidence interval for each visit is plotted about the mean.

Figure 43: Mean FACT-M Overall Score by Treatment Arm and Visit in Part 1 (Combo 450 vs. Vemurafenib)



Source: FDA Analysis.


Figure 44: Mean FACT-M Overall Score by Treatment Arm and Visit in Part 1 (Combo 450 vs. Encorafenib)



Source: FDA Analysis

The mean change from baseline in FACT-M overall score by treatment arm and visit in Part 1 is shown in Figure 45.

Figure 45: Mean Change from Baseline FACT-M Overall Score by Treatment Arm and Visit in Part 1




Source: FDA Analysis

Figure 46 and Source: FDA Analysis


Figure 47 show these means for Combo 450 vs. vemurafenib and Combo 450 vs. encorafenib. A 95% confidence interval for each visit is plotted about the mean.

Figure 46: Mean Change from Baseline FACT-M Overall Score by Treatment Arm and Visit in Part 1 (Combo 450 vs. Vemurafenib)



Source: FDA Analysis


Figure 47: Mean Change from Baseline FACT-M Overall Score by Treatment Arm and Visit in Part 1 (Combo 450 vs. Encorafenib)



Source: FDA Analysis

The mean FACT-M overall score by treatment arm and visit in Part 2 is shown in Figure 48.


Figure 48: Mean FACT-M Overall Score by Treatment Arm and Visit in Part 2 (Combo 300 vs. Encorafenib)



Source: FDA Analysis


The mean change from baseline in FACT-M overall score by treatment arm and visit in Part 2 is shown in Figure 49.

Figure 49: Mean Change from Baseline FACT-M Overall Score by Treatment Arm and Visit in Part 2 (Combo 300 vs. Encorafenib)




Source: FDA Analysis

Figure 50: FACT-M Compliance Summary by Time Window and Treatment (Part 1)



Source: FDA Analysis

Figure 51: FACT-M Compliance Summary by Time Window and Treatment (Part 2)



Source: FDA Analysis

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ANUJA PATEL
06/25/2018

RUBY LEONG
06/25/2018

YOUWEI N BI
06/25/2018

JIANG LIU
06/25/2018

JINGYU YU on behalf of NAN ZHENG
06/25/2018
on behalf of NAN ZHENG

YUCHING N YANG
06/25/2018

HONG ZHAO
06/25/2018
I concur.

QI LIU
06/25/2018

STEPHANIE L AUNGST
06/25/2018

WHITNEY S HELMS
06/25/2018

JOHN K LEIGHTON
06/25/2018

LISA R RODRIGUEZ on behalf of JONATHON J VALLEJO
06/25/2018

LISA R RODRIGUEZ
06/25/2018

RAJESHWARI SRIDHARA
06/25/2018